HEARING DATES: June 1, 2017; June 8, 2017; June 9, 2017; June 13, 2017

SUBJECT MATTER OF PROPOSED REGULATIONS: Medical Cannabis Regulation

SECTIONS AFFECTED: §5000, 5004, 5006, 5008, 5010, 5012, 5014, 5016, 5017, 5018, 5020, 5022, 5024, 5026, 5028, 5030, 5032, 5033, 5036, 5039, 5042, 5045, 5048, 5050, 5051, 5054, 5056, 5058, 5060, 5062, 5064, 5066, 5068, 5070, 5072, 5074, 5076, 5080, 5082, 5084, 5086, 5088, 5090, 5092, 5094, 5096, 5098, 5100, 5102, 5104, 5106, 5108, 5110, 5112, 5114, 5116, 5118, 5122, 5124, 5126, 5128, 5130, 5132, 5136, 5138, 5140, 5142, 5145, 5148, 5151, 5154, 5157, 5160, 5163, 5166, 5172, 5175, 5178, 5181, 5184, 5187, 5190, 5193, 5196, 5199, 5202, 5205, 5208, 5211, 5214, 5217, 5220, 5223, 5226, 5229, 5232, and 5235.

BACKGROUND

The Medical Cannabis Regulation and Safety Act (MCRSA or Act) provides a statutory framework for the licensing of commercial cannabis businesses within the State of California. The MCRSA established the Bureau of Medical Cannabis Regulation, which, through the passage of proposition 64, was renamed the Bureau of Marijuana Control (bureau) within the Department of Consumer Affairs (DCA). The bureau was created to license and regulate dispensaries, distributors, transporters, and testing laboratories under the MCRSA. Until now, the state has not comprehensively regulated the medical cannabis industry. The bureau’s proposed regulations address the specific implementation for the license types to be regulated by the bureau pursuant to the MCRSA including, distributors, transporters, and dispensaries. Regulations for testing laboratories will be proposed by the bureau at a later date. Manufacturer licenses will be issued and regulated by the California Department of Public Health and cultivator licenses will be issued and regulated by the California Department of Food and Agriculture. While developing these regulations, all three licensing authorities worked cooperatively to strive for consistency in areas of overlap and to create a state system that allows for reasonable regulation of the industry as a whole.

REQUIREMENTS APPLICABLE TO ALL APPLICANTS AND LICENSEES

STATEMENT OF PURPOSE, PROBLEM, RATIONALE, AND BENEFITS

With the passage of the MCRSA, the bureau was established to create a comprehensive and coherent regulatory framework for an established industry that had not been comprehensively regulated by the state. While the MCRSA provides guidance on the larger macro issues, much of the implementation specifics and clarification of terms was left to the bureau. There are many terms and phrases that will apply to all applicants and licensees regardless of license type. These
proposed regulations will help the applicant and licensee better understand: (1) the applicable meaning of key statutory and other terms related to the bureau’s licensing program; (2) what documents and information are required in an application; and (3) specific clarification of prohibitions, requirements, or conditions for compliance with the MCRSA statute.

First, the proposed regulations seek to make clear the applicable meaning of key statutory terms and other terms used within the regulations. These terms include those relevant to requirements of applicants, such as “owner,” “priority review,” “beginning date of operation,” and “good standing.” Within MCRSA, the Legislature recognized the current medical cannabis goods marketplace and required the forthcoming regulatory system to prioritize the review of applications for businesses that were in operation before January 1, 2016, and are in good standing with the local authority. The proposed regulations will further explain, specifically, what will be required to demonstrate these pre-conditions for priority review. The primary goal of these proposed regulations is to clearly set out who qualifies as an owner, who is entitled to priority review, and to define crucial words in the MCRSA so that applicants understand what information they need to supply to the bureau for efficient processing of their application.

Second, the proposed regulations clarify what documents and information are required to complete an application for all license types. The MCRSA expressly requires an applicant to provide certain information to the bureau for processing, including proof of property owner approval for commercial cannabis activity, proof of the local jurisdictions approval of the commercial cannabis activity, a premises diagram, proof of bond, proof of insurance (for distributors and transporters), proof of a labor peace agreement if applicable, proof of fingerprint submission to the Department of Justice, and a waiver of sovereign immunity if applicable. The proposed regulations will specify what must be submitted to the bureau related to these items. The regulations also provide that the bureau may request additional information from the applicant so that the bureau will have all of the necessary information to appropriately evaluate the application for licensure. The regulations clarify that incomplete applications are abandoned after a specified length of time, that applications may be withdrawn before the bureau issues or denies a license, and the requirements for license surrender. The requirements for renewal are also included in these regulations so that licensees understand what is necessary to renew a license and when the renewal information is due to the bureau. The regulations also clarify when the bureau must be notified of a change in the information previously provided to the bureau and when those changes require a new application, approval by the bureau, or just notification to the bureau. This prevents licensees from subverting license requirements by making changes after licensure that would have led to denial of licensure.

Third, the proposed regulations provide clarification of special terms, prohibitions, requirements, or conditions set forth in the MCRSA that apply to all license types. Specifically, the regulations include a prohibition that no bureau staff or law enforcement officers charged with enforcement of the MCRSA have any financial interest in a related commercial cannabis business. Without a clear prohibition, law enforcement and employees of the bureau or the state who are tasked with
enforcement of the ACT could legally own or hold an interest in commercial cannabis businesses. This proposed regulation is necessary to ensure that the those tasked with enforcing the ACT and criminal laws execute their duties and obligations in a fair and objective manner on behalf of the State of California. Additionally, the regulations contain a provision that a license may be denied for a prior conviction that is substantially related to the qualifications, functions, or duties of the business for which licensure is sought. The regulations further provide criteria for the bureau to consider in determining whether or not an applicant that has been convicted of a crime that is substantially related to the qualifications, functions, or duties of the business for which licensure is sought has been sufficiently rehabilitated and is therefore suitable for licensure. These criteria include the nature of the offense, a person’s criminal record as a whole, compliance with terms set by the court, any act that would allow discipline of a license, whether the activity would have been legal if committed at the time of application, dismissal of a conviction, certificate of rehabilitation, whether the person’s conduct would be legal if it has engaged in at the time of application, and any other evidence submitted. This allows the bureau to review the applicant’s criminal history and rehabilitation fully to ensure applicants are appropriate for licensure while not barring licensure due to a conviction without considering other factors.

The requirements for record keeping, entry into the track and trace system, and security have been clearly explained and apply to all licensees for consistency purposes. These requirements will assist in preventing theft, diversion into the illegal or unregulated market of medical cannabis goods, increased public safety through video surveillance, alarms, locks, limited-access areas, tracking of movement of medical cannabis goods, and notifications to the bureau and law enforcement for inventory discrepancies. The regulations also have requirements for destruction of medical cannabis goods to ensure that the products that fail testing or are discarded do not end up in the illegal or unregulated market, or are accessible to children and non-patients to protect the public safety.

The regulations also provide that a licensee is responsible for acts of an agent or employee to ensure that licensees do not violate the MCRSA or regulations by allowing others to act for them. Grounds for disciplinary action against a licensee, in addition to those in MCRSA, are included to prevent changes to the premises without bureau approval, denying access to the premises for inspection, and impeding investigations.

**DISTRIBUTION**

**STATEMENT OF PURPOSE, PROBLEM, RATIONALE, AND BENEFITS**

Distributors play a pivotal role in the commercial cannabis supply chain. Ensuring a seamless transition from the cultivation and manufacturing of the product through the distribution process is key to a well-regulated market. Prior to the MCRSA, there was no state regulatory process for the operation of commercial cannabis distributors or distribution centers. The proposed distributor regulations are designed with three main goals: (1) to design a regulated system that
provides the emerging industry the flexibility to properly provide medical cannabis goods in a safe and secure method, (2) to ensure the medical cannabis goods are properly stored, handled, packaged, and tested, and (3) to ensure distributors keep and maintain records that are adequate to effectively track and trace the medical cannabis goods thereby helping to prevent entry of untested medical cannabis goods into the legal market, and diversion of medical cannabis goods into the illegal or unregulated market. With these goals in mind, the overall purpose of the proposed regulations is to lay out the minimum requirements for holding a state distributor license.

First, the proposed regulations will permit the distributor to take title to medical cannabis goods after harvest, but before manufacturing. This proposed regulation provides statutory clarity and provides a distributor with the flexibility to purchase medical cannabis goods wholesale before processing or after. By requiring the holder of legal title to be the actual seller of the product and permitting distributor-to-distributor sales, the proposed regulations allow for more than one business model; therefore, allowing for licensees to tailor their services based on the needs and demands of different regions of the state. By permitting distributors to conduct destruction of their own medical cannabis goods and medical cannabis goods from other licensees, it creates a uniform and standard destruction process.

Second, the proposed regulations are designed to ensure that medical cannabis goods are properly stored, handled, packaged, and tested. The ability of a distributor to package, re-package, and label medical cannabis goods for a licensee will allow for more efficient and easier flow of medical cannabis goods through the distribution chain. However, the proposed regulations prohibit a distributor from accepting medical cannabis goods that have not already been packaged by the manufacturer who manufactured the products. The bureau and the State Department of Public Health agree this provision is necessary to ensure the quality and safety of manufactured medical cannabis goods. It ensures packaging takes place in an environment most conducive to good manufacturing practices for packaging. The proposed regulations will also clarify the proper procedures for taking a reliable and representative sample of the medical cannabis goods for testing and clarifies the quality assurance and testing standards applicable to distributors including harvest batch testing samples do not exceed 10 pounds. Because laboratory testing is one of the integral parts of quality assurance for medical cannabis goods it is critical to the industry that the regulations be clear and concise. Therefore, the bureau proposes distributors witness sampling in person and that it be recorded on video. These requirements would allow the bureau to verify the sampling process. This requirement helps to prevent situations of nonexistent or improper sampling, intentional tampering with medical cannabis goods during sampling, and helps to resolve any disputes between licensees that may arise regarding procedures used to sample. To allow for a smooth transition to the state regulatory system a grace period has been provided for such that licensees have 180 days after licensure before product must be tested and labeled as required by MCRSA and the regulations.
Finally, the proposed regulations are designed to ensure the distributors keep and maintain records adequate to effectively track and trace the medical cannabis goods, helping to prevent untested product from entering the marketplace and prevent diversion of product into the illegal or unregulated market. These proposed regulations enumerate what information and data a distributor must enter into the track and trace system. The data includes information about the licensee from whom the goods were received, the type and amount of goods received, the party who holds title to the goods, and the unique identifiers or lot number of the goods. Information required to be tracked would include the testing laboratory’s name and license number, name of the testing-laboratory sampling agent or agents, weight of the sample taken, date, information related to the sale of the medical cannabis goods, such as the date of contract for sale, type of goods purchased, and the date title passes. Last, the proposed regulations would require the distributor to disclose when it uses its own transporter license to transport the medical cannabis goods to one or more dispensaries and enter that transport event into the track and trace database. This information would include the transporter license number, amount of goods transported, vehicle information, and date of transport. Requiring distributors to keep and maintain a record of these specific data points and information helps prevent untested product from entering the market and diversion of product into the illegal or unregulated market.

**TRANSPORTERS**

**STATEMENT OF PURPOSE, PROBLEM, RATIONALE, AND BENEFITS**

Properly regulating and licensing the transportation of medical cannabis goods is vital to an effective commercial cannabis industry containing a supply chain that is designed to identify and prevent entry of untested medical cannabis goods and diversion of medical cannabis goods into the illegal or unregulated market. Prior to the passage of MCRSA, the transportation of medical cannabis goods had no restrictions, safety requirements, security safeguards, or generalized standards. The MCRSA created a licensing structure for the bureau to promulgate clarifying rules and regulations to ensure the safe and secure transport of medical cannabis goods. When medical cannabis goods are transported from one location to another, there is an increased potential for the medical cannabis goods to be diverted into the illegal market, for untested product to enter into the medical cannabis market, or theft. The overarching goals of the regulations are to ensure that medical cannabis goods are transported in a safe and secure manner.

First, the regulations will prevent a transport licensee from holding title to the medical cannabis goods, require that medical cannabis goods are not visible or identifiable during transport, permit transport by roadway only, require medical cannabis goods to be in a secure locked box within the interior of the vehicle, require all transport vehicles to be equipped with alarm systems, and require the vehicle to be attended at all times in residential neighborhoods. Without a prohibition on the licensed transporter from holding title, the demarcation of licensed activity is not clear. Prohibiting the transporter from holding title clarifies existing ambiguity by clearly...
denoting the permitted licensed activity. Limiting transport to roadways and requiring that medical cannabis goods not be visible are requirements that were selected by the bureau to mitigate intersections with federal law and regulation and will reduce the probability of theft of shipments. Securely locking the product in a box within the interior of the vehicle, requiring alarm systems, and not permitting the vehicle to be left unattended in a residential neighborhood is required in order to discourage theft and other crimes that may threaten public safety. Transporters may not transport nonmedical cannabis goods with medical cannabis goods. However, a transporter may transport medical cannabis goods from multiple licensees at the same time.

Second, the minimum age for drivers and passengers of licensed transport vehicles is 21 years old. The legal age for a person without a physician recommendation to possess cannabis goods is 21. This requirement helps to ensure that persons who have dominion and control over medical cannabis goods during transport meet that age requirement. This provision assists in limiting children’s access to medical cannabis goods. Permitting only a licensee’s employees to be present during transport provides the bureau with the ability to take appropriate action against a license for improper activity or malfeasance during transport, helping to discourage diversion and theft.

Finally, the transport of medical cannabis goods will require thorough and proper record keeping. A transport licensee will be required to keep and maintain a load specific shipping manifest, business records, and maintain full integration with the track and trace database. These requirements ensure the medical cannabis goods stay within the regulated market, preventing untested and potentially unsafe medical cannabis goods from entering into the system or product being diverted into illegal or unregulated markets. Under the MCRSA every transport of medical cannabis goods must be accompanied by a correlative manifest, however MCRSA does not specify what must be in the manifest. If a shipping manifest is incomplete or does not have specific information of the medical cannabis goods being shipped or the intended destination, an enforcement officer would have a difficult time determining the legality and validity of the shipment. These proposed regulations are necessary to ensure medical cannabis goods stay within the regulated market. By clearly stating the information transport licensees are required to have on their shipping manifest, the regulations allow for uniformity of records across transport licensees and increase the speed and effectiveness of bureau enforcement investigations. Uniform manifests amongst the licensees allow the bureau to better train enforcement personnel on what to expect and how to inspect a shipment. Lastly, the proposed regulations specify the events that a transporter must enter into the track and trace system.

**DISPENSARIES**

**STATEMENT OF PURPOSE, PROBLEM, RATIONALE, AND BENEFITS**

Dispensaries provide medical cannabis goods to medical cannabis patients who are the end users of the product. Prior to the MCRSA, there was no state regulatory process for the operation of
dispensaries. Under the MCRSA, the bureau is responsible for establishing rules for the operation of medical cannabis dispensaries. Without the regulations developed by the bureau, there is no set of rules that would apply to all the dispensaries across the state. The overall purpose of the proposed regulations is to lay out the minimum requirements for holding a state license to operate a medical cannabis dispensary. The proposed dispensary regulations are designed with three main goals.

First, the regulations are designed to ensure that dispensaries follow the MCRSA supply chain requirements. The regulations are designed to require that dispensaries purchase their medical cannabis goods from licensed distributors and have the medical cannabis goods delivered by licensed transporters. Additionally, the proposed regulations require that dispensaries use the track and trace system to monitor activity. The proposed regulations will also require that the dispensaries ensure that they only provide medical cannabis goods to individuals who are legally allowed to purchase them. This is achieved by requiring that all potential customers provide the dispensary with identification, a physician’s recommendation, and, in the case of primary caregivers, documentation of the authorization for them to act as a primary caregiver. The proposed regulations also ensure that patients will have access to medical cannabis by setting requirements for delivery to patients. The regulations also set forth the requirements for a producing dispensary license, thereby clarifying the licenses that can be held to ensure there is no violation of the cross-licensure restrictions within the MCRSA.

Second, the regulations are designed to protect public health and safety. The proposed regulations require that dispensaries only sell medical cannabis goods that have undergone required testing procedures. The proposed regulations also prohibit a dispensary from packaging medical cannabis goods on-site, which leads to a reduction in the risk of contamination or adulteration after the mandated state testing process. A grace period is provided to allow a smooth transition to the state regulatory system; dispensaries can sell medical cannabis goods that have not been tested as required by MCRSA for 180 days after licensure if a label is affixed to the package with the date of sale and the phrase “This product has not been tested under the Medical Cannabis Regulation and Safety Act.” During this period, dispensaries may also package loose dried flower to sell. This will provide the public with critical health and safety information while allowing medical cannabis goods to be available during the transition. The regulations prohibit the consumption of medical cannabis goods by delivery employees while they are performing deliveries. The proposed regulations also require that medical cannabis goods be stored in a manner to prevent spoilage or degradation. The proposed regulations prevent a dispensary from reselling any medical cannabis goods that have been returned by a customer. Additionally, the proposed regulations require that medical cannabis goods be placed in an exit package after sale. The exit packaging will make it more difficult for young children to gain access to the medical cannabis goods. Limits on daily sales to an individual medical cannabis patient reflect the limits under the Health and Safety Code so that a dispensary does not allow a person to purchase more than the amount he or she can legally possess.
Third, the proposed regulations are designed to limit the risk of diversion. The proposed regulations have strict security requirements regarding who may access the dispensary premises. The proposed regulations limit the amount and placement of medical cannabis goods used for display. The proposed regulations require that dispensaries only be open for sales between the hours of 6:00 a.m. to 9:00 p.m. in order to reduce the increased risk of robbery and other crimes. The proposed regulations impose rules on who can perform deliveries, the time during which deliveries can be made, and how deliveries are to be performed to reduce the risk of crime. Under the proposed regulations, dispensaries are required to closely monitor their inventory of medical cannabis goods by doing inventory reconciliation every week and keeping detailed records of all activities. Additionally, the proposed regulations require dispensaries to report significant losses in inventory and theft or other crimes to law enforcement and the bureau. Samples may not be provided free of charge.

**SPECIFIC PURPOSE, NECESSITY, AND RATIONALE FOR EACH ADOPTION**

The bureau proposes to add sections §5000, 5004, 5006, 5008, 5010, 5012, 5014, 5016, 5017, 5018, 5020, 5022, 5024, 5026, 5028, 5030, 5032, 5033, 5036, 5039, 5042, 5045, 5048, 5050, 5051, 5054, 5056, 5058, 5060, 5062, 5064, 5066, 5068, 5070, 5072, 5074, 5076, 5080, 5082, 5084, 5086, 5088, 5090, 5092, 5094, 5096, 5098, 5100, 5102, 5104, 5106, 5108, 5110, 5112, 5114, 5116, 5118, 5122, 5124, 5126, 5128, 5130, 5132, 5136, 5138, 5140, 5142, 5145, 5148, 5151, 5154, 5157, 5160, 5163, 5166, 5172, 5175, 5178, 5181, 5184, 5187, 5190, 5193, 5196, 5199, 5202, 5205, 5208, 5211, 5214, 5217, 5220, 5223, 5226, 5229, 5232, and 5235 of Division 42 of Title 16 of the California Code of Regulations, as follows.

The following sections are proposed for numbering purposes only and possible future rulemaking. They are not proposed in this rulemaking to contain any regulatory language, but are included for clarity for the reader.

§5001, 5002, 5003, 5005, 5007, 5009, 5011, 5013, 5015, 5019, 5021, 5023, 5025, 5027, 5029, 5031, 5034, 5035, 5037, 5038, 5040, 5041, 5043, 5044, 5046, 5047, 5049, 5052, 5053, 5055, 5057, 5059, 5061, 5063, 5065, 5067, 5069, 5071, 5073, 5075, 5077, 5078, 5079, 5081, 5083, 5085, 5087, 5089, 5091, 5093, 5095, 5097, 5099, 5101, 5103, 5105, 5107, 5109, 5111, 5113, 5115, 5117, 5119, 5120, 5121, 5123, 5125, 5127, 5129, 5131, 5133, 5134, 5135, 5137, 5139, 5141, 5143, 5144, 5146, 5147, 5149, 5150, 5152, 5153, 5155, 5156, 5158, 5159, 5161, 5162, 5164, 5165, 5167, 5168, 5169, 5170, 5171, 5173, 5174, 5176, 5177, 5179, 5180, 5182, 5183, 5185, 5186, 5188, 5189, 5191, 5192, 5194, 5195, 5197, 5198, 5200, 5201, 5203, 5204, 5206, 5207, 5209, 5210, 5212, 5213, 5215, 5216, 5218, 5219, 5221, 5222, 5224, 5225, 5227, 5228, 5230, 5231, 5233, 5234, and 5236.

**§ 5000. Definitions**

Subsection (a) defines “Act” as the Medical Cannabis Regulation and Safety Act. This is necessary because “Act” is used throughout the regulations.
Subsection (b) defines “address of record” as the permanent address of an individual or organization. This is necessary because the bureau must have a permanent address for all licensees.

Subsection (c) defines bureau as the Bureau of Marijuana Control. The bureau was previously named the Bureau of Medical Marijuana Regulation in the Medical Marijuana Regulation and Safety Act, then the Bureau of Medical Cannabis Regulation through the Medical Cannabis Regulation and Safety Act, and most recently the Bureau of Marijuana Control within Proposition 64 passed in 2016. This is necessary because “bureau” is used throughout the regulations.

Subsection (d) defines “cannabis waste” as waste that is not hazardous waste, as defined in Public Resources Code section 40191, that contains cannabis and that has been made unusable and unrecognizable in the manner prescribed in section 5080 of this division. This definition is necessary to clarify under what circumstances medical cannabis goods are considered “cannabis waste” and must be handled accordingly.

Subsection (e) defines “commercial vehicle” as a vehicle that is used or maintained for the transportation of persons for hire, compensation, or profit or designed, used, or maintained primarily for the transportation of property as defined in Vehicle Code Section 260. This definition is necessary to delineate the classification of vehicle used during transport. This definition is commonly used in the industry and is based on Vehicle Code Section 260. Keeping this commonly used definition will allow the transportation industry to seamlessly adjust to this newly created market.

Subsection (f) defines “delivery employee” as an individual employed by a licensed dispensary who delivers medical cannabis goods from the licensed dispensary premises to a qualified patient or primary caregiver at a physical address. The term delivery employee requires a definition because delivery employees need to be differentiated from the other employees of the licensee. There are a number of regulations that only apply to delivery employees but not all employees due to the unique duties of an employee who delivers medical cannabis goods. In order to avoid confusion with employees who do not preform deliveries, the term delivery employee is used throughout the regulations.

Subsection (g) defines “display” as medical cannabis goods that are stored in the licensed dispensary’s retail area during the hours of operation. As used in the proposed regulations, the term display is used to describe medical cannabis goods that are stored in the dispensary retail area for the purpose of allowing customers to view the product before purchasing it. The term display requires a definition because in the proposed regulations, display refers specifically to the display of medical cannabis goods rather than any other kind of display.

Subsection (h) defines “display case” as the container in the licensed dispensary retail area where medical cannabis goods are stored and visible to customers. As used in the proposed regulations,
display case describes a container for storing medical cannabis goods for the purpose of display. The term display case requires a definition because in the proposed regulations, display case refers specifically to a container holding medical cannabis goods rather than any other kind of case that might be used for display.

Subsection (i) defines “free sample” as any amount of medical cannabis goods provided to a medical cannabis patient or primary caregiver without cost or payment. The term free sample requires a definition because the term refers specifically to a sample from a dispensary to a medical cannabis patient in order to induce the medical cannabis patient to purchase the product. This is not to be confused with a sample from a licensed distributor to a licensed dispensary for the purpose of determining whether or not the licensed dispensary will sell the product.

Subsection (j) defines “limited-access area” as an area in which medical cannabis goods are stored and is only accessible to a licensee and a licensee’s employees and contractors. This term is necessary to clearly delineate higher security areas on a licensed premises.

Subsection (k) defines “lot number” or “batch number” as a distinctive group of numbers, letters, or symbols or any combination of these that is unique to the lot of medical cannabis goods. This term is necessary to identify the lot or batch from which a medical cannabis goods sample was taken for purposes of laboratory testing.

Subsection (l) defines “medical cannabis goods” as medical cannabis, including dried flower, and manufactured medical cannabis products. This is necessary to provide a means to refer to medical cannabis, dried flower, and manufactured medical cannabis products in a short and succinct way.

Subsection (m) defines “medical cannabis patient” as a person whose physician has recommended the use of cannabis to treat a serious illness, including cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma, arthritis, migraine, or any other illness for which cannabis provides relief. This definition was adapted from the guidelines for the security and non-diversion of marijuana grown for medical use written by then Attorney General Edmund G. Brown Jr. dated August 2008. The term medical cannabis patient was not defined by the MCRSA. Health and Safety Code section 11362.7, subsection (f) defines the term “qualified patient” for purposes of the state Medical Marijuana Identification Card program, but excludes from the scope of the term patients who have a Medical Marijuana Program Identification card. These proposed regulations utilize the expanded term “medical cannabis patient” to include “qualified patients” as well as patients with a Medical Marijuana Program Identification card.

Subsection (n) defines “nonvolatile solvent” as any solvent used in the extraction process that is not a volatile solvent and includes carbon dioxide used for extraction. This definition was developed in coordination with proposed regulations promulgated by the California Department of Public Health and is being adopted here for consistency.
Subsection (o) defines “operating hours” as the hours within a day in which the licensed dispensary may allow medical cannabis patients and primary caregivers to enter the dispensary premises and purchase medical cannabis goods. The term operating hours requires a definition in order to differentiate operating hours from other parts of the day, or non-operating hours. The proposed regulations impose specific duties on a licensee during operating hours and other duties outside of operating hours. In order to allow licensees to clearly understand when they are permitted to allow customers onto the premises and sell product, this definition is required.

Subsection (p) defines “ownership interest” as an interest held by a person who is an owner as defined in section 5004 of these regulations. This is necessary because owners are determined by meeting certain thresholds as set out in section 5004. This also differentiates an ownership interest from a mere financial interest.

Subsection (q) defines “package” and “packaging” as any container or wrapper that may be used for enclosing or containing any medical cannabis goods for final retail sale. This definition specifies that “package” and “packaging” do not include a shipping container or outer wrapping used solely for the transport of medical cannabis goods in bulk quantity to a licensee. This definition is necessary because “package” and “packaging” are reoccurring terms within the regulations. There is no definition of packaging in the statute.

Subsection (r) defines “pest” as an undesired insect, rodent, nematode, fungus, bird, vertebrae, invertebrate, weed, virus, bacteria, or other microorganism that is injurious to human health. This definition was developed in coordination with proposed regulations promulgated by the California Department of Public Health and is being adopted here for consistency.

Subsection (s) defines “pre-roll” as dried cannabis flower rolled in paper prior to retail sale. This definition was developed in coordination with proposed regulations promulgated by the California Department of Food and Agriculture and is being adopted here for consistency.

Subsection (t) defines “proprietary private security officer” as having has the same meaning as that term is defined in Business and Professions Code section 7574.01. The term proprietary private security officer requires a definition in order to specify the specific requirements for the security personnel required. This definition was taken from Business and Professions code section 7574.01.

Subsection (u) defines “publicly owned land” as any building or real property that is owned or leased by a city, county, state, federal, or other government entity. The term publicly owned land is used in the proposed regulations in the context of forbidding licensed dispensaries from delivering to publicly owned or leased land. This definition is necessary to specify that the term applies to land owned or leased by any government. It is vital that licensees fully understand which properties are considered to be publicly owned and which are not in order to be aware of where they are allowed to make deliveries of medical cannabis goods.
Subsection (v) defines “purchase” as obtaining medical cannabis goods in exchange for consideration. This definition is necessary to provide clarity and consistency with other terms including “purchaser,” “sell,” “sale,” and “to sell.”

Subsection (w) defines “purchaser” as a person who is engaged in a transaction with a licensee for purposes of obtaining medical cannabis goods. This definition was adapted from the definition for “purchaser” in the Adult Use of Marijuana Act. (Bus. & Prof. Code, § 26001, subsection (z).) This is necessary to minimize confusion between MCRSA and AUMA.

Subsection (x) defines “quarantine” as the storage or identification of medical cannabis goods, to prevent distribution or transfer of the medical goods, in a physically separate area clearly identified for such use. Medical cannabis goods must be held in an area for 72 hours before they are destroyed in order to allow the bureau time to inspect them. This term is necessary to label the area the medical cannabis goods must be held in.

Subsection (y) defines “residential area” as an area that is within 600 feet of any single-family or multifamily residence, other than commercial hotels, motels and similar establishments for temporary lodging. This definition is necessary to delineate the scope of area qualified as residential area. This definition is an amalgamation of local ordinances and Section 11362.768 of the Health and Safety Code. This is necessary for public safety and to ensure consistency with other rules related to regulated substances.

Subsection (z) defines “retail area” as a building, room, or other area upon the licensed dispensary premises in which medical cannabis goods are sold or displayed. This term requires a definition in order it differentiate it from other areas of the licensed premises. The proposed regulations impose specific rules that apply to the retail area. This definition allows a licensed dispensary to clearly identify these areas within their facility.

Subsection (aa) defines the term “security monitoring.” This definition is required in order to clarify what is considered “security monitoring” as required by the proposed regulations. The definition specifies that security monitoring must be uninterrupted attention to potential alarm signals. Thus, it is clear to all licensees that any monitoring system that does not meet the definition in this proposed subsection would not be considered to be proper “security monitoring” as required in the proposed regulations.

Subsection (bb) defines “sell,” “sale,” and “to sell” as including any transaction whereby, for consideration, title to medical cannabis goods are transferred from one person to another, and includes the delivery of medical cannabis goods pursuant to an order placed for the purchase of the same and soliciting or receiving an order for the same, but does not include the return of medical cannabis goods by a licensee to the licensee from whom such medical cannabis goods were purchased. This definition was adapted from the definition in the Adult Use of Marijuana Act (Bus. & Prof. Code, § 26001, subsection (aa)).
Subsection (cc) defines “sublet” as to lease or rent all or part of a leased or rented property. The proposed regulations do not allow a dispensary operator to sublet any portion of the licensed premises. In order to clarify what is meant by the term sublet, this definition is required. This definition was taken from the dictionary definition of the word sublet.

Subsection (dd) defines “vehicle alarm system” as a device or series of devices installed to discourage theft of the vehicle or its contents and is intended to summon general attention or to summon law enforcement as a result of an indication of an attempted breach of the commercial vehicle. The MCRSA requires the safe and secure transport and handling of medical cannabis goods. This definition clarifies and helps licensees to better understand the level of security that is required on their vehicles. The enumerated safety measures were selected based on their level of security, availability to the market and associated cost. The definitional type and kind of security measures are in-line with other jurisdictions regulating the sale and transport of medical cannabis goods.

Subsection (ee) defines “wholesale” as the sale of medical cannabis goods to a distributor for resale to one or more dispensaries. This definition is necessary for the differentiation of retail sale and sales to a licensee who will sell goods at retail. Distributors may, through a sale contract, buy medical cannabis goods and sell the goods to a dispensary. The dispensary will then sell the goods at retail.

§ 5004. Owner
All applicants for a commercial cannabis activity license must electronically submit to the Department of Justice fingerprint images as part of a criminal background check. (Bus. & Prof. Code, § 19323.) Business and Professions Code section 19300.5(b) generally defines an applicant as an “owner.” Specifically, it defines an applicant as the following: 1) the owner or owners of the proposed premises, including all persons having an ownership interest; 2) each person participating in the direction, control, or management of, or having a financial interest in the proposed premises, if the owner is an entity; and 3) if the applicant is a publicly traded company, the chief executive officer and any person or entity with an aggregate ownership interest of five percent or more.

The regulation clarifies that individuals with a noncontrolling ownership interest do not need to submit the information listed in the application for individual owners nor do they need to submit to a background check. A five percent aggregate ownership threshold is set for publicly traded companies, but there are no thresholds in the MCRSA for other types of business organizations. The bureau must set thresholds of ownership to determine who must submit an application and receive a background check. Without thresholds anyone with any financial interest in the commercial cannabis business or ownership interest in the premises, no matter how small of an interest or how limited their involvement in the commercial cannabis business, would have to receive background checks; this would place a significant burden on the bureau and investors in the commercial cannabis industry.
The regulation provides for a threshold of ownership of 20 percent for all business organizations aside from publicly traded companies. The regulation requires persons that have significant ownership or control of the business to provide specified information and have a background check while eliminating the need for passive investors to do so. The regulation ensures that the bureau’s resources are utilized by conducting background checks on persons that are in control of the commercial cannabis business and not wasted by conducting background checks on passive investors that have no control over the business. This regulation also benefits the commercial cannabis industry by eliminating the burden of undergoing a background check for small investors.

Proposed subsection (a) is a restatement of the statutory language for publicly traded companies and is included for clarity.

Proposed subsection (b) defines an owner for all business organizations except publicly traded companies. Subsection (b)(1) defines an owner as an individual that has a 20 percent ownership threshold. Subsection (b)(2) defines an owner as the chief executive officer and all members of the board of directors of an entity when that entity has a twenty percent ownership threshold. Subsection (b)(3) defines an owner as an individual that will be participating in the direction, control, or management of the licensed commercial cannabis business. At pre-regulation meetings, the public provided feedback on various threshold percentages that the bureau presented. Feedback from the public supported having the same threshold for all business organizations however, the public largely felt that the five percent threshold in statute for publicly traded companies was too low and would impede investment because of the requirement of background checks for all owners. The bureau determined that a 20 percent threshold or participation in the direction, control, or management of the licensed medical cannabis business would capture persons that would be responsible for running the business and ensuring that they were licensed and therefore responsible for complying with the MCRSA and regulations. Twenty percent is also consistent with the Adult Use of Marijuana Act (AUMA). (Bus. & Prof. Code, § 26000 et seq.)

Proposed subsection (c) clarifies that any person holding a community property interest in the commercial cannabis business but not participating in the direction, control, or management of the business does not need to submit the information required of individual owners with the application for licensure. This subsection is necessary because owner identification is a fundamental and critical threshold issue for all licensing. It is imperative an applicant or licensee fully disclose all relevant and applicable information in regards to business owners so the bureau can assess their qualifications. Cannabis licenses are unique and individualized to the owner of that particular business. The MCRSA has ownership restrictions based on license type. Under California law, without a signed written agreement transmuting property, property acquired by married persons, during marriage while domiciled in the state is presumed to be community property. Not requiring applicants or existing licensees to disclose persons with a community property interest would potentially allow for hidden ownership.
This proposed subsection also bars a person holding a community property interest in a revoked or denied license from applying for or holding a commercial cannabis license for the same period the previous license was revoked or denied. Under the operation of California’s community property laws describe above, permitting a non-named community property interest holder to apply or hold a license, outside of the revoked or denied timeframe, would allow the revoked or denied party to potentially circumvent the disciplinary or denial action.

Proposed subsection (d) clarifies that banks and other financial institutions that provide loans are not owners. This is necessary to ensure that it is clear that lenders are not owners and therefore not required to apply for the license and submit to background checks.

Proposed subsection (e) defines individuals with noncontrolling interests and clarifies that they do not need to submit the information required of individual owners in the application. This section is necessary so that all individuals with an interest in a commercial cannabis business are accounted for while clarifying that those with noncontrolling interests need not submit to the background check.

§ 5006. Application Requirements
In order to obtain a license an application must first be submitted to the bureau. The purpose of this section is to specify what information must be provided by the applicant in the application. Proposed subsections (a) and (b) (1) through (b)(26) specify information disclosures required by an applicant at the time of application submission for licensure. Business and Professions Code section 19322 enumerates specific, yet limited information an applicant is required to include in the application. Subsection (a)(8) specifically permits the licensing authority to clarify and further list information it may need from an applicant in order to make its licensing determination. Additionally, MCRSA places specific limitations on which licenses can be held by a single licensee, therefore the proposed regulation includes information that will be necessary in order for the bureau to determine that an individual or entity is not obtaining licenses that the applicant is not eligible to have.

Proposed subsection (a) is necessary for application processing. Permitting online submission provides flexibility for the applicant to submit the application from anywhere in the state. The State of California is very large and requiring an applicant to physically turn in printed copies in person in Sacramento would be tremendously burdensome on the applicant and the burgeoning industry. Permitting applicants to submit electronically also helps the bureau process the applications in an effectively and timely fashion.

In order for the bureau to conduct a thorough and effective evaluation of an application and to ensure the applicant is a bona fide and qualified applicant under the law, the bureau must receive specific information from the applicant. The information contained in proposed subsections (b)(1), (b)(2), (b)(7) through (b)(13) is elicited for the purpose of allowing the bureau to accurately determine and verify the true identity of the applicant. Proposed subsections (b)(14)
through (b)(18) are necessary to determine how the commercial cannabis business will be organized and to ensure that all owners as defined in proposed section 5004 are identified.

Proposed subsection (b)(4) clarifies that Business and Professions Code section 115.4 applies to applicants that are individuals. If an applicant is an individual that has been honorably discharged from active duty from the Armed Forces of the United States then that applicant may voluntarily disclose his or her military service and will be eligible for expedited licensing.

In order for the bureau to conduct a thorough and effective evaluation of an applicant’s submission, to ensure the applicant is a bona fide and qualified applicant under the law, the bureau must receive specific information. The information contained in proposed subsection (b)(3) and (b)(5) is elicited for the purpose of allowing the bureau to accurately determine and verify whether the applicant is duly qualified under the law. Understanding the type of license they are applying, if they currently hold a commercial cannabis license and if they have been previously denied a license by the bureau is important because if they already hold a license the second requested license may be barred by law and if they were previously denied a license the bureau will want to ensure the malady had been remedied if possible.

Under Business and Professions code section 19321, the bureau is required to give priority application review to commercial cannabis businesses that were in operation before January 1, 2016. Proposed subsections (19) and (20) are necessary to help the bureau determine the date the applicant began operating. These two subsections require the applicant to state and support with evidence the operational start date.

In order for the bureau to ensure that all individuals with a interest in the commercial cannabis business are accounted for and to determine that there are no hidden owners that must receive the background check required under Business and Professions Code sections 144, 19322, subsection (a)(1), and 19323 subsection (b)(4), the bureau must have a list of all individuals with a noncontrolling interest. Proposed subsection (b)(21) requires that the applicant list all individuals with a noncontrolling interest as defined in proposed section 5004 of this division.

In order for the bureau to conduct a thorough and effective evaluation of an applicant’s submission to ensure the applicant is a bona fide and qualified applicant under the law, the bureau must receive specific information from the applicant. The information contained in proposed subsection (b)(22)(A) through (b)(22)(L) are necessary for the bureau to accurately determine and verify the true identity of individual owners as defined in proposed section 5004, and to establish if an owner has interests in another license that would be a ban to the license applied for.

Under Business and Professions Code sections 144; 19322, subsection (a)(1); and 19323 (b)(4) the bureau is required to request and conduct criminal history record checks on all applicants. The information contained in proposed subsection (b)(22)(M) – (N) clarifies what information is needed by the bureau in order to gather all pertinent criminal history information in order to
properly conduct the statutorily mandated checks. The information required provides the bureau with detailed information necessary to evaluate the circumstance of the conviction and any subsequent rehabilitation.

This proposed subsection (b)(22)(O) requires the applicant to attest all of the information supplied in the application is true and accurate and clearly states repercussions for misstatements. Misrepresenting any fact on an application subverts the bureau’s ability to accurately evaluate the suitability of the applicant. Requiring an attestation and clarifying potential repercussions seeks to ensure and clarify the importance of truthfulness in the application. It is imperative an applicant only include accurate and truthful information so the bureau can accurately assess their qualifications.

Proposed subsection (b)(22)(P) requires an applicant to disclose any individual that holds a community property interest in the commercial cannabis business. Under California law, without a signed written agreement transmuting property, all property acquired by a married person during a marriage while domiciled in the state is presumed to be community property. Not requiring applicants to disclose persons with a community property interest would potentially allow for hidden ownership. Owner identification is a fundamental and critical threshold issue for licensing. It is imperative an applicant fully disclose all relevant and applicable information in regards to business owners. Under MCRSA, ownership of multiple licenses may be restricted based on license type. Subsections (b)(22)(P)(i) through (b)(22)(P)(vi) require specific identifying information including name, date of birth, social security number or individual taxpayer identification number, mailing address, and the phone number of the community property interest holder so that the bureau can sufficiently identify individuals with an interest in the commercial cannabis business and ensure that there are no hidden owners or any license type combinations in violation of MCRSA.

Proposed subsection (b)(23) is necessary to ensure applicants provide the statutorily mandated information. Proposed subsection (b)(23) is enumerated in Business and Professions Code sections 19328, subsection (c)(1)(B) and 19322, subsection (a)(3) respectively. Reiterating these requirements will help the bureau gather all required documents and process the application in a timely fashion.

Proposed subsection (b)(24) is specifically enumerated and required by Business and Professions Code section 19322(a)(7). Including this regulatory section will ensure the prospective applicant will supply information demonstrating compliance with the statutory requirement to have the legal right to occupy and use the location of the proposed premises.

Proposed subsections (b)(25)-(b)(26) are specifically enumerated and required by Business and Professions Code section 19322(a)(4) for the 600-foot radius requirement and Business and Professions Code section 19322(a)(6) for the labor peace agreement requirements. Including
these regulatory sections will ensure the prospective applicant will supply information demonstrating compliance with the statutory requirements.

Proposed subsection (b)(27) requires that the applicant provide a valid seller’s permit number issued by the California State Board of Equalization. (Bus. & Prof. Code, § 19322, subd. (a)(7).) This requirement is included in the MCRSA and included here to promote clarity to ensure that applicants are aware of the application requirement.

Without a detailed, thorough and legible description of the proposed premises the bureau is unable to ensure the proposed premises meets all statutory limitations and requirements for the proposed activity. Under current law the statute does not specify what premises specific information is required to be included at time of application for licensure. Proposed subsection (b)(28) is necessary to clarify what premises information is required at time of application. By requiring a scaled, thorough and legible diagram in the application process, the bureau will be able to appropriately and within a reasonable timeframe, evaluate the applicant’s application for compliance with law. Including the premises information will allow for more effective and less disruptive site visits and investigations by bureau officers.

Under the MCRSA all commercial cannabis licensees are required to carry a bond, however the statute does not clarify at what level. In order to grant a license the bureau must verify that the applicant has obtained the bond in the amount required by the bureau in proposed section 5016, and therefore necessitates the inclusion of proposed subsection (b)(29) in the application.

The purpose of proposed subsections (b)(30) through (b)(32) is to clarify the requirements of Business and Professions Code section 19322, subsection (b), which requires applicants seeking licensure to cultivate, distribute, manufacture, test, or dispense medical cannabis or medical cannabis products, to include with their application a detailed description of the applicant’s operating procedures for cultivation, extraction and infusion methods, the transportation process, inventory procedures, quality control procedures, and security procedures as required by the licensing authority.

The statute does not specify which operating procedures are required for applicants of each license type and allows the licensing authority to decide. Additionally, the statute does not provide any guidance as to what specific information is required in the operating procedures. These subsections clarify the requirements of the statute by indicating that an applicant for a distributor or a dispensary license must provide operating procedures for inventory procedures, quality control procedures, and security procedures. These sections also indicate that an applicant for a transporter license must provide operating procedures for the transportation process and security protocols. In addition, these sections specify specific information that must be included in each operating procedure that is submitted as part of the application process.

The benefit of these subsections is added clarity and a decrease in the risk of confusion from applicants who are preparing license applications. From these subsections, an applicant will be
able to determine which operating procedures must be included with their application as well as what specific information must be contained in those operation procedures.

Proposed subsection (b)(33) requires tribal government applicants and licensees renewing an existing license to execute and include a waiver of sovereign immunity when submitting their application or renewal request. This subsection is necessary to ensure all licensees comply with the statutory and regulatory rules related to the licensing of commercial cannabis activity. Since tribal governments enjoy limited sovereign immunity from certain state laws and regulations, this waiver is critical to the application of these rules and regulations. The bureau seeks to implement regulations that make clear the statutory intent of regulating a fair and efficient cannabis industry. It also seeks to clarify potential conflict of laws, specifying which regulations are applicable to a tribal government eliminating business and enforcement uncertainty. It also clarifies the applicable law, legal claims, and rights afforded to the parties.

§ 5008. Law Enforcement Personnel Not to Hold Licenses
This section describes the prohibition of all persons that have within their professional duties any duty that involves the enforcement of the MCRSA or any other legal provisions regarding the sale, use, possession, transportation, distribution, testing, manufacturing, or cultivation of medical cannabis goods from holding a license issued by the bureau.

Without a clear prohibition of ownership by persons involved in the enforcement of the MCRSA, law enforcement and certain employees of DCA could legally own or hold an interest in commercial cannabis businesses. This would create either the appearance of a conflict or an actual conflict of interest. This section is necessary to ensure DCA staff and law enforcement personnel execute their duties and obligations in a fair and objective manner on behalf of the State of California.

§ 5010. Premises
The MCRSA requires that each premises upon which commercial cannabis activity is conducted be licensed. The MCRSA does not, however define the term “premises.” Proposed subsection (a) defines premises and by doing so ensures that applicants know how many licenses they will need for the areas upon which they will conduct their commercial cannabis activity and the requirements for the each location. The premises on which commercial cannabis activity is conducted is subject to numerous requirements and inspection by the bureau, therefore, one contiguous area which is occupied by one licensee, as clarified in proposed subsection (b), only allows the bureau to effectively inspect the area and allows for one responsible licensee who must ensure compliance with license conditions.

§ 5012. Premises Diagram
This section requires an applicant to submit a premises diagram that describes the application requirements for the diagram of the proposed premises. Without a detailed, thorough, and legible description of the proposed premises the bureau is unable to ensure the proposed premises meets
all statutory limitations and requirements for the proposed commercial cannabis activity. Under
current law the statute does not specify what premises-specific information is required to be
included with the application.

Proposed subsections (a)-(d) are necessary to clarify what premises-specific information is
required to be included with the application. By requiring a scaled, thorough, and legible
diagram in the application process it will allow the bureau, to appropriately, and within a
reasonable timeframe, evaluate the application for compliance with law. Including the premises
information will allow for more effective and less disruptive site visits and investigations by
bureau employees. Highlighting is not allowed as it does not always show in copies, therefore
rendering the diagram unusable if copied.

§ 5014. Property Owner Approval
Business and Professions Code section 19322, subsection (a)(3) requires that an applicant submit
with the application “evidence of the legal right to occupy and use the proposed location.” This
proposed section describes the specific documentation required of an applicant to demonstrate
the owner of the real property upon which the proposed premises will be located has approved
the use of the property for commercial cannabis activity.

Proposed subsection (a) requires that when an applicant is not the owner of the real property
upon which the proposed premises will be located, the applicant must obtain a document from
the owner of the real property that states the applicant has the right to occupy the property and
permission to conduct commercial cannabis activity on the property. It also requires a copy of
the rental agreement. This section is necessary to specify what documentation an applicant must
obtain from the owner of the real property in order to provide the bureau with “evidence of the
legal right to occupy and use the proposed location.”

Proposed subsection (b) requires that if the applicant owns the real property upon which the
proposed premises is located, the applicant shall submit a copy of the title or deed to the
property. This section is necessary to specify what documentation the bureau will accept as
“evidence of the legal right to occupy and use the proposed location.”

§ 5016. Bond
Business and Professions Code section 19322, subsection (a)(11) requires that all applicants
provide proof of a bond to cover the costs of destruction of medical cannabis or medical cannabis
products if necessitated by a violation of licensing requirements. Additionally, Business and
Professions Code section 19334 specifically requires that distributor licensees and transporter
licensees be bonded at a minimum level established by the licensing authority.

This proposed section is necessary to fulfill the statutory requirement that the bureau establish a
minimum level of bond. This section establishes the bond amount minimum of $5,000. The
bureau looked at other states that had required a bond and found that it was difficult if not
impossible for licensees in other states to obtain a bond. The bureau determined that $5,000 was
a high enough amount to cover destruction while still being low enough to be reasonably obtained by licensees.

§ 5017. Waiver of Sovereign Immunity
Proposed section 5017 provides that an applicant or licensee that may fall within the scope of sovereign immunity must waive any sovereign immunity defense. Subsection (a) requires tribal government applicants and licensees applying for, or renewing an existing license, to execute and include a waiver of tribal sovereign immunity when submitting their application or renewal request. The sovereign immunity defense provides exemptions from certain state laws. This subsection is necessary to ensure that all licenses who engage in commercial medical cannabis activity are required to follow MCRSA and the regulations implementing it. This proposed section will provide for fair and efficient regulation in the cannabis industry, while allowing tribal governments the opportunity to participate in the legal regulated industry. The waiver is necessary to clarify this complex intersection of state, federal, and sovereign immunity law avoiding conflict of legal jurisdiction and choice of forum for dispute resolution.

This subsection also describes the timeframe of applicability of the waiver, intervals the waiver needs to be re-executed, and in what form the waiver should be supplied to the bureau. This subsection is necessary to avoid potential conflict with federal law and standardized the waiver process for uniform applicability. By providing a uniform process for all tribal entities seeking a commercial cannabis license it will reduce bureau processing time and will increase the accuracy application determinations based on the information contained in the applications. The requirement that a new waiver accompany each license and renewal application will ensure that a valid waiver will be in place for the entire period of the license or renewal.

Proposed subsection (a)(1) requires the applicant to demonstrate the waivers signatory has the authority to enter into such an agreement, thus binding the applicant or licensee to the terms and conditions listed therein. This subsection is necessary to ensure the waiver is validly executed contract entered into by the tribal government and the bureau. Without this showing the waiver may not have the desired legal effect, not having its desired effect of clarifying this complex intersection of state, federal, and sovereign immunity law.

Proposed subsections (a)(2) –(a)(6) require the tribal sovereignty waiver to include language that clearly states all tribal entity applicants shall conduct all cannabis business activity in full compliance with all state laws and regulations. Subsections (a)(2) through (a)(5) clarify specific regulatory features such as permitting the bureau access to all licensed areas, access to all records pertaining to commercial cannabis activity, and that all licensees may only sell product to other licensees or qualified patients. These subsections are necessary to ensure the bureau has the ability to fully enforce all statutes and regulations related to the licensing of cannabis business activity and that all cannabis licensees are regulated with the same standards and expectations. Without this specific language it may be unclear which regulations would be applicable to a tribal government creating business and enforcement uncertainty. The bureau seeks to implement
regulations that make clear the statutory intent of regulating a fair and efficient cannabis industry.

Proposed subsection (7) clarifies the applicable body of substantive and procedural laws and which legal forum will be used to resolve disputes. Without this language in the waiver it is unclear which court or administrative tribunal is the appropriate forum for redress of claims, which could lead to confusion and delay. This language is necessary to clarify this complex intersection of state, federal, and sovereign immunity law and avoid conflict of legal jurisdiction and choice of forum for dispute resolution. It also clarifies the applicable law, legal claims and rights afforded the parties. This provision is necessary to ensure that all matters related to the license issued by the bureau related to commercial cannabis activity in California will be governed by California law and litigated in California.

Proposed subsection (b) requires the licensee to notify the bureau when any material changes have been made to their business entity, their premises, or any other information supplied in their application. Without requiring a licensee to update the bureau of material alterations of facts there is no assurance the changes are permitted within the statutory and regulatory framework. Without an affirmative duty placed on a licensee to notify the bureau, a noncompliant change may go a significant amount of time before discovery. Altering ownership, business structure, or premises without notification could also hinder bureau investigations and audits making site visits take longer, more disruptive to the business and potentially unsafe for the licensee, bureau staff and/or the public. Placing an affirmative duty to notify ensures the bureau is kept consistently aware of the shape, condition and legality of the licensee and licensed premises. This requirement is applicable to other licensees as well, therefore it is included here for clarity.

Proposed subsection (c) clearly states the consequences for statutory or regulatory non-compliance. This subsection is necessary to clarify non-compliance of any of these terms and conditions could lead to denial or discipline of a licensee. This subsection also clarifies that all licensees, tribal governments and non-tribal governments, are will be governed by the same standards and disciplinary guidelines.

§ 5018. Requirements for Continued Operation While Application Pending
Business and Professions Code section 19321 requires the bureau to establish a deadline by which the bureau must receive an application in order to continue operating once the bureau begins accepting applications. This section provides an application receipt deadline of July 2, 2018. This gives applicants six months to review the application and licensure requirements and obtain all the required documents. This is a reasonable and fair amount of time given that state licensure of commercial cannabis activity is new. This also ensures the bureau avoids a backlog by having a large number submitted at one time.

It is expected that applicants will need time to complete their applications and obtain all the necessary documents. The regulations will not be finalized until right before the January 1, 2018
deadline for the bureau to begin accepting applications. Six months provides applicants with sufficient time to become familiar with the application and licensure requirements, obtain all necessary documents, and complete the application. Six months also ensures that the bureau avoids a backlog of applications when it begins accepting and processing them. The bureau has had a large number of stakeholders attend pre-regulatory meetings and is aware that there are a large number of applicants currently operating that will be submitting applications by the deadline to continue operating. An earlier submission deadline would mean receiving all the applications on or around that deadline. However, with a six month time frame it is anticipated that applications will come in to the bureau throughout that time and not all at once thus preventing a backlog.

§ 5020. Priority Review
Business and Professions Code section 19321 requires that in issuing licenses the bureau “prioritize any premises or person that can demonstrate to the authority’s satisfaction that the premises or person was in operation and in good standing with the local jurisdiction by January 1, 2016.”

This proposed regulation provides clarity on which applicants can receive priority review of their application and provides the bureau with a means for determining the order in which it processes applications that it receives at or around the same time. The bureau received feedback from the public at pre-regulation meetings that supported prioritizing applicants that have been in operation and in good standing with the local jurisdiction and who will be operating at the same premises and under the same ownership structure. Businesses that are currently operating will likely be submitting their applications as soon as possible as they are eager to come in to full compliance with the MCRSA. Applications will be processed in the order received to allow for efficient processing.

§ 5022. Date Operation Began
Business and Professions Code section 19321 requires that in issuing licenses the bureau “prioritize any premises or person that can demonstrate to the authority’s satisfaction that the premises or person was in operation and in good standing with the local jurisdiction by January 1, 2016.” The MCRSA does not define what “in operation” means and does not provide a method for determining the date a business began operating. Since local jurisdictions have different ways of authorizing commercial cannabis businesses, there is no uniform document that each applicant will have to demonstrate that they were in business. Further complicating the matter is that commercial cannabis businesses have previously operated in a legal area without clear and consistent state requirements and often did not maintain business records. This regulation provides a definition for what “in operation” means and provides applicants with a number of options to demonstrate the date they began operating their commercial cannabis businesses.
Proposed subsection (a) defines the date that an applicant began operating as the date that the applicant began actively conducting commercial cannabis activity. This is necessary because the MCRSA does not define what “in operation” means. Without a definition there are multiple ways that “in operation” could be interpreted.

Proposed subsection (b) defines “actively conducting” for purposes of this section as engaging in the transportation, distribution, or sale of medical cannabis and medical cannabis products. This definition is necessary to make clear that the mere obtainment of a business license, permit, or other authorization is not sufficient to be considered for priority. The applicant must have actually been conducting business.

Proposed subsection (c) provides applicants with a variety of documents that can be used as evidence of the date operations began. This section is necessary because there is no uniformity in the authorizations to conduct commercial cannabis activities from local jurisdictions and therefore there is no uniform document that demonstrates that applicants were in operation by January 1, 2016. Further, during pre-regulatory meetings, the public favored having the option of using a variety of records to provide evidence of the date operations began.

§ 5024. Good Standing

Business and Professions Code section 19321 requires that in issuing licenses the bureau “prioritize any premises or person that can demonstrate to the authority’s satisfaction that the premises or person was in operation and in good standing with the local jurisdiction by January 1, 2016.” However, the MCRSA does not define or provide evidence of what constitutes “good standing.” Because the local jurisdictions have different rules and regulations for conducting commercial cannabis activity within each jurisdiction, the bureau determined that whether or not a premises or person was in operation and in good standing by January 1, 2016 is a determination for the local jurisdiction to make.

Proposed subsections (a) through (c) identify the applicant, premises, and license type for which the applicant is applying for. This is necessary to verify that the applicant for a license from the bureau is the same person that is operating the commercial cannabis business in the local jurisdiction.

Proposed subsections (d)-(g) provide information on the local jurisdiction and the contact person that can verify that the applicant is in good standing in the local jurisdiction. This information is necessary for the bureau to confirm the validity of the document.

Proposed subsection (h) provides a statement for the applicant or local jurisdiction to use in the document that the local jurisdiction will sign that verifies the applicant has been issued a license, permit, or other authorization to conduct commercial cannabis activity and that the applicant was operating and in good standing on or before January 1, 2016. This section is necessary because it provides the evidence the bureau needs in order to grant priority review to the applicant in a clear and concise statement.
§ 5026. Additional Information
Business and Professions Code section 19322 subsection (a)(8) states that the bureau may require additional information in the application. This section clarifies that the bureau may require additional information and provides specific information on how the deadline for submittal of the additional information will be determined by the bureau.

The bureau has listed everything it will need to process applications in the application. In some cases additional information may be needed to verify or clarify something provided in the application. This proposed section is necessary to provide the bureau with the authority and flexibility to request additional information when it needs to do so in order to fully assess the application.

§ 5028. Incomplete Applications
The proposed regulation is necessary for the bureau to implement licensing of commercial cannabis businesses under the MCRSA and specifically implement the application review process. The bureau anticipates that it will receive incomplete applications. This proposed regulation specifies how the bureau will provide notice to the applicant when it determines an application is incomplete, that the applicant has one year to correct the deficiencies and if the applicant fails to do so then the application is considered abandoned. The notice provided for shall be provided in accordance with Business and Professions Code section 124 applicable to licensing entities within the Department of Consumer Affairs so that applicants are aware of this provision. The proposed regulation also clarifies that an applicant may reapply anytime following an abandoned application and that the bureau will not refund application fees for incomplete applications.

§ 5030. Withdrawal of Application
The bureau anticipates that some applicants may decide that they do not want to go through with licensure for a number of reasons. This may include changes in ownership or changes in premises after submission of an application. This section allows a withdrawal anytime before the bureau makes a decision on the application. However, the application fee will not be refunded because the bureau will spend time on processing an application submitted even if it is later withdrawn. The regulation also contains a provision consistent with Business and Professions Code section 118, applicable to licensing entities with the Department of Consumer Affairs so that applicants are aware of this provision. This proposed section is necessary to provide applicants with the process for withdrawing their applications and the effects and consequences of withdrawing.

§ 5032. Substantially Related Offenses
Business and Professions Code section 19323, subsection (b)(4) states that the bureau may deny an application if the applicant has been convicted of an offense that is substantially related to the qualifications, functions, or duties of the business or profession for which the application is made. This section is necessary to clarify the requirements of section 19323.
Business and Professions Code section 19323 requires the bureau conduct a thorough review of the nature of convictions including evidence of rehabilitation from criminal acts that are substantially related to the qualifications, functions, or duties of conducting commercial cannabis activity.

Proposed subsection (a) specifies specific convictions that would be considered substantially related to the qualifications, functions, or duties of the business requesting licensure from the bureau. This subsection is important to inform applicants of which specific convictions may affect their application for licensure.

Proposed subsection (a)(1) identifies a conviction that is specified as a substantially related offense in Business and Professions Code section 19323, subsection (b)(4)(B). The proposed regulations repeat the business and professions code section for the convenience of the reader. By restating the requirement along with other offenses that will be considered substantially related, the proposed regulations will not require the reader to refer to both the regulations and the business and professions code to determine which offenses may be considered to be substantially related.

Proposed subsection (a)(2) identifies a conviction that is specified as a substantially related offense in Business and Professions Code section 19323, subsection (b)(4)(C). The proposed regulations repeat the business and professions code section for the convenience of the reader. By restating the requirement along with other offenses that will be considered substantially related, the proposed regulations will not require the reader to refer to both the regulations and the business and professions code to determine which offenses may be considered to be substantially related.

Proposed subsection (a)(3) identifies a conviction that is specified as a substantially related offense in Business and Professions Code section 19323, subsection (b)(4)(C). The proposed regulations repeat the business and professions code section for the convenience of the reader. By restating the requirement along with other offenses that will be considered substantially related, the proposed regulations will not require the reader to refer to both the regulations and the business and professions code to determine which offenses may be considered to be substantially related.

Proposed subsection (a)(4) identifies a type of felony conviction that will be considered substantially related for the purposes of this section. This subsection is required in order to allow potential applicants to determine which offenses may be considered to be substantially related for the purposes of this section. The section lists convictions involving employing or selling controlled substances to minors as a substantially related offense. The bureau is required to create regulations that will protect the health and welfare of the public. The bureau has determined that a history of committing crimes involving controlled substances and minors is related to licensure as the regulated market has a goal of keeping cannabis out of the hands of
children. The bureau has determined that the offenses listed in this subsection may affect the applicant’s ability to obtain a license. This is also contained in the AUMA provision, therefore, this provides consistency for applicants seeking licensure under both MCRSA and AUMA.

Proposed subsection (a)(5) identifies a type of felony conviction that will be considered substantially related for the purposes of this section. This subsection is required in order to allow potential applicants to determine which offenses may be considered to be substantially related for the purposes of this section. The section lists convictions involving the trafficking of illegal drugs as a substantially related offense. The bureau is required to create regulations that will protect the health and welfare of the public. The bureau has determined that an applicant with a history of committing crimes involving trafficking illegal drugs is relevant to licensure. The bureau has determined that the offenses listed in this subsection may affect the applicant’s ability to obtain a license. This provision is also contained within the AUMA, therefore, this provides consistency for applicants seeking licensure under both MCRSA and AUMA.

Proposed subsection (b) clarifies that a felony conviction for offenses involving controlled substances may not be considered substantially related to the duties of the business or profession the applicant is submitting an application for if certain criteria are met. This subsection is necessary to inform potential applicants how the bureau will treat prior convictions in which the sentence was effectively served, in regards to a license application. The proposed subsection also specifies that a conviction for a controlled substance felony subsequent to licensure will be grounds for revocation. This subsection is necessary to provide applicants and licensees with the necessary warning that certain actions may impact their license.

§ 5033. Criteria for Rehabilitation

The purpose of this proposed section is to clarify the factors that the bureau is to consider in determining whether an applicant who has had a past criminal conviction has been rehabilitated for the purposes of being fit to receive a license from the bureau. Determining whether an applicant is fit for licensure or not, requires the consideration of many different factors. This section is necessary to inform potential applicants of the factors being considered in this portion of the application process.

Proposed subsection (a)(1) requires the bureau to consider the nature and severity of the act or offense. This is required because the nature and severity of the offense may provide some indication of whether or not the offense will be repeated. The bureau should not provide licenses to individuals who are a high risk of repeating their past criminal acts.

Proposed subsection (a)(2) requires the bureau to consider whether the offense would still be considered a crime taking recent legislation into account. This is required because the sale of cannabis has historically been illegal. In fact, it remains illegal in federal law. However, the bureau is licensing medical cannabis businesses. It is important to consider whether the acts that
the applicant was convicted for in the past are the very same acts the bureau is currently licensing them to perform. This factor affects an applicant’s fitness for licensure.

Proposed subsection (a)(3) requires the bureau to consider the applicant’s criminal record as a whole. This is required because the applicant’s criminal record as a whole may provide some indication of whether or not the offense will be repeated. The bureau should not provide licenses to individuals who are a high risk of repeating their past criminal acts.

Proposed subsection (a)(4) requires the bureau to consider evidence of any act committed subsequent to the act or offense under consideration. This is required because an applicant’s subsequent acts may provide some indication of whether or not the offense will be repeated. The bureau should not provide licenses to individuals who are a high risk of repeating their past criminal acts.

Proposed subsection (a)(5) requires the bureau to consider the time that has elapsed since commission of the act. This is required because the nature and severity of the offense may provide some indication of whether or not the offense will be repeated. A lapse of a large amount of time since the offense was committed may be evidence that the applicant is unlikely to recommit the offense. The bureau should not provide licenses to individuals who are a high risk of repeating their past criminal acts.

Proposed subsection (a)(6) requires the bureau to consider the extent to which the applicant has complied with any terms of parole, probation, restitution, or any other sanctions lawfully imposed against the applicant. This is required because this factor may provide some indication of whether or not the offense will be repeated. The bureau should not provide licenses to individuals who are a high risk of repeating their past criminal acts.

Proposed subsection (a)(7) requires the bureau to consider evidence of dismissal of the offense. This is required because evidence of the dismissal of the offense may provide some indication of whether or not the offense will be repeated. Additionally, evidence of a dismissal indicates that a court for one reason or another has determined that the offense be dismissed. This is an important factor in determining whether an applicant is fit for licensure.

Proposed subsection (a)(8) requires the bureau to consider certificates of rehabilitation obtained by the applicant. This is required because a certificate of rehabilitation is direct evidence that a court believes that the applicant is rehabilitated. This should be considered by the bureau in determining whether or not an applicant is fit for licensure.

Proposed subsection (a)(9) requires the bureau to consider other evidence of rehabilitation submitted by the applicant. This allows the bureau and the applicant flexibility in what evidence may be provided by the applicant and considered by the bureau in determining whether or not an applicant is fit for licensure. This is important to allow the bureau to consider as much evidence as possible before making a determination of whether or not an applicant is fit for licensure.
Proposed subsection (b) specifies that an individual who is denied a license may request a hearing to determine if the applicant should be licensed. This section is necessary to inform applicants of their right to request a hearing if their application is denied. The right to have a hearing upon the denial of a license is stated in Business and Professions Code section 19324. The provision is repeated here for the ease of the reader.

§ 5036. Additional Grounds for Denial of a License

The purpose of this proposed section is to define additional grounds for which the bureau may deny a license. Business on Professions Code section 19323 states non-inclusive grounds for denial of a license.

When applying for a license from the bureau, applicants are required to submit certain documents to the bureau, including operating procedures and a diagram of their proposed premises. Subsection (a) and (b) of this proposed regulation clarify that the bureau may deny an applicant whose premises does not comply with standards set in regulation or whose premises is substantially different from the premises diagram submitted to the bureau. The applicant’s premises is substantially different from the diagram of the premises submitted by the applicant, in that the size, layout, location of a common entryways, doorways, or passage ways, means of public entry or exit, or limited-access areas within the licensed premises are not the same. This allows the bureau to take action if the applicant misrepresents the premises in the diagram, therefore, ensuring that a license is not issued if the premises does not comply with MCRSA.

Business and Professions Code section 19327(c) grants licensing authorities, including the bureau, the authority to inspect the premises of a licensee, as deemed necessary by the licensing authority to perform its duties. Subsection (c) of this proposed regulation will ensure that the bureau is able to deny a license to an applicant that denies the bureau access to their premises for the purposes of inspection.

Proposed subdivision (d) specifies that committing a material misstatement on a license application is grounds for denial of a license. The bureau relies on information in the application to determine whether an applicant is qualified for licensure. It is imperative that the information provided be accurate. The bureau has determined that this proposed subsection is necessary to deter material misstatements on applications and to clarify that the bureau may deny an application if such misstatements were to occur.

Proposed subsection (e) provides that the bureau may deny a license if the applicant failed to correct deficiencies in the application in accordance with proposed section 5028.

Proposed subsection (f) provides that the applicant may be denied a license, permit, or other authorization to engage in commercial cannabis activity by a state or local licensing authority. This is necessary because there are two other state licensing authorities and hundreds of local licensing authorities. If one of the other licensing authorities denies an applicant the bureau must be able to take that denial into consideration.
§ 5039. Notification of Change
The purpose of this section is to require existing licensees to timely notify the bureau of any changes to the information listed in the application. It also clarifies that any change to the business organizational structure or ownership requires a new application.
Proposed subsection (a) is necessary for the bureau to effectively administer its duties under the MCRSA. The bureau must have current information on each licensee, including things such as phone numbers, email addresses, mailing addresses, and web addresses (URL). Proposed subsection (c) is necessary to clarify that anytime ownership changes or the business changes its organizational structure a new application is required. This is necessary because of the need to verify ownership and conduct background checks on owners.

Business and Professions Code section 19322, subsection (a)(6) requires that a licensee who employs 20 or more employees provide a statement that the licensee will enter into or has entered into a labor peace agreement. Proposed subsection (b) clarifies that licensees who employed less than 20 employees and were not subject to this provision at the time the license was obtained, must comply with the requirements of the statute if at some point after licensure, they employ 20 or more employees and become subject to this provision.

§ 5042. Renewal of License
Proposed subsection (a) requires that the bureau receive a renewal packet from a licensee no earlier than 60 days before the expiration of the license and no later than the day before the license expires. This is required to clarify when renewal applications must be provided to the bureau. The requirement that renewal applications be submitted no earlier than 60 days prior to the expiration is required so that the bureau does not receive applications for renewal too early. Submitting renewal applications earlier than 60 days would not provide any benefit, as renewal applications are likely to be processed closer to the actual expiration date. Early submissions only increase the possibility that something may change in the application. The MCRSA only allows a license to be valid for 12 months, thus, any renewal must be done before the expiration date.

Proposed subsection (b) specifies that a licensee who’s license has expired is no longer authorized to conduct medical cannabis business. This subsection is required to clarify that there is no grace period for expired licenses. Licensees are expected to renew their licenses in a timely manner, or cease all operations of the medical cannabis operation to be in compliance with the 12 month license requirement in MCRSA.

Proposed subsection (c) specifies the information the applicant must provide to the bureau for processing. The MCRSA does not specify when a licensee needs to submit an application for renewal. This proposed section is necessary to provide licensees with directions on when to provide the renewal application and fee to the bureau and lists the information that is required in the renewal application.
§ 5045. Surrender of License
The purpose of this section is to specify when a license must be surrendered and when it may be surrendered. Proposed subsection (a) requires a licensee that surrenders, abandons, or quits the licensed premises or who closes the licensed premises for a period exceeding 30 consecutive calendar days to surrender the license to the bureau. This section is necessary to provide licensees with direction on when they must surrender their license. Proposed subsection (b) is necessary to clarify that a licensee may request that the bureau cancel the license if the licensee no longer wants to be licensed.

§ 5048. Physical Modification of Premises
The purpose of this section is to specify that a licensee shall not make a physical change, alteration, or modification of the licensed premises that materially or substantially alters the licensed premises or the use of the licensed premises without the prior written approval of the bureau.

Proposed subsection (a) requires the licensee to request in advance before making any material alterations. Without requiring a licensee to update the bureau of material alterations there is no assurance that the changes are permitted within the statutory and regulatory framework. Without the affirmative duty of a licensee to notify the bureau, a change may go a significant amount of time in noncompliance before discovery. Altering premises without notification could also hinder bureau investigations and audits, make site visits take longer, and potentially be unsafe. By requiring an affirmative duty to notify the bureau of material changes the regulations ensure that the bureau is consistently aware of the shape, condition and legality of licensed premises.

Proposed subsection (b) lists examples of material changes and is necessary to inform licensees of what premises changes will require prior approval from the bureau. The changes listed may impact whether the premises are appropriate for licensure. Proposed subsection (c) provides the requirements that a request for approval of a physical change, alteration, or modification must have and is necessary to specify what a licensee must provide to the bureau with the initial request. Proposed subsection (d) provides that a licensee shall provide additional documentation as requested by the bureau, and is necessary for situations where the bureau needs additional information in order to approve or deny the licensee’s request for premises modification.

§ 5050. Track and Trace Requirements
The purpose of this section is to allow for the effective monitoring of the movement of medical cannabis goods by requiring all licensees to comply with specific requirements of the track and trace system. Business and Professions code section 19335 requires that all licensees participate in a track and trace program. The purpose of the track and trace program is to allow the bureau and other licensing authorities to track the movement of all medical cannabis goods as the products move from licensee to licensee and eventually to the patient. Proposed subsection (a) requires licensees to create and maintain active accounts within the track and trace system prior
to engaging in commercial medical cannabis activity. In order for the track and trace system to be effective, all licensees must actively participate in the system.

Proposed subsection (b) requires that licensees designate one individual as the licensee’s designated track and trace administrator. The reason for this requirement is to provide the bureau with a singular contact from the licensee for track and trace issues. Additionally, it allows one individual to be responsible if there are any problems with a licensee’s use of the track and trace system.

The designated administrator may allow other licensees or individuals to access the track and trace system on behalf of the licensee. However, this section requires that individuals only log onto the track and trace system using log-in information that was assigned to that specific individual. Additionally, proposed subsection (c) states that the licensee is responsible for ensuring that only authorized individuals are accessing the licensee’s track and trace system. The reason for these requirements is to ensure that information uploaded to the system is accurate by only allowing authorized individuals access to the system. Also, if there is a problem with a licensee’s use of the track and track system, the bureau will be able to identify the individual who accessed the system by tracking their log-in. This section also requires licensees to maintain a list of all system administrators and provide the list to the bureau upon request. This will allow the bureau to effectively identify who is providing information to the track and trace system on behalf of each licensee and can be used in the case of an investigation.

Proposed subsections (d)(1)-(4) requires that each licensee of the bureau comply with other regulatory sections which detail which transactions must be recorded in the track and trace system, as well as what information must be recorded with those transactions. This is important because the track and trace system requires that all transactions be entered into the system properly in order to effectively track the movement of medical cannabis goods. If licensees fail to enter the proper information into track and trace, the system will not work as intended.

Proposed subsection (e) requires that licensees input all information regarding transactions into the track and trace system before the end of the day that the transaction occurred. Timely reporting of information is vital to the effectiveness of the track and trace system. Knowledge of the location of medical cannabis goods is only useful if the information regarding the products’ location is accurate. Ideally, licensees would be required to provide the track and trace system with information regarding a transaction immediately after a transaction occurs. However, in some circumstances, this may be overly burdensome or impossible. Allowing the licensee to update the track and trace information by the end of the day achieves the balance of providing the bureau with timely information as well while giving the licensees a reasonable time to upload the information.

Proposed subsection (f) also provides licensees with requirements for any instances when the track and trace system become inaccessible. The system may become inaccessible for many
reasons. If this were to occur, licensees would be allowed to continue operating. However, once the track and trace system becomes accessible, all information is required to be uploaded by the licensee. This takes into account the possibility of technical problems impeding the ability of licensees to properly update the track and trace system. This section also ensures that the bureau is provided with all the information required once the track and trace system is operational once again.

Proposed subsection (g) requires licensees to only enter accurate information into the track and trace system and to immediately correct wrong information upon discovery. Ensuring licensees follow the applicable Medical Cannabis Regulation and Safety Act tracking regulations is necessary to ensure cannabis goods are sold in a safe and secure method, preventing inversion of untested product or diversion of product into the black market. Improper or incomplete tracking of cannabis products can place the public at risk and not properly tracking product slows, hinders, or prevents the bureau from investigating inventory or manifest discrepancies. These delays could inhibiting the bureau from investigating product loss in a timely fashion and prevent the bureau from effectively locating or mitigating the impact of the product loss.

§ 5051. Licensee’s Responsibility for Acts of Employees and Agents
The purpose of this proposed section is to clarify when the actions of a person acting for or employed by a licensee shall be deemed the actions of the licensee. Business and Professions Code section 19302.1(d) gives the bureau the authority to regulate licenses for the transportation, testing, distribution, and sale of medical cannabis. For the purposes of regulating and enforcing the actions of licensees, it is necessary for the bureau to define and clarify when the actions of a person acting for or employed by a licensee will be considered the actions of the licensee. This will avoid a situation in which licensees avoid responsibility for violations of the MCRSA or regulations by having an agent or employee act for them and ensure that the public safety is protected through compliance with the regulatory scheme.

§ 5054. Additional Grounds for Disciplinary Action
Business on Professions Code section 19311 states non-exclusive grounds for disciplinary action. The purpose of this proposed section is to define additional grounds for which the bureau may take disciplinary action on a licensee.

When applying for a license from the bureau, applicants are required to submit certain documents to the bureau, including operating procedures and a diagram of their proposed premises. Subsection (a) of this proposed regulation clarifies that the bureau may take disciplinary action on a licensee whose premises is substantially different from the premises submitted to the bureau in the original premises diagram.

Business and Professions Code section 19327(c) grants licensing authorities, including the bureau, the authority to inspect the premises of a licensee, as deemed necessary by the licensing authority to perform its duties. Subsection (b) of this proposed regulation clarifies that a
licensee’s refusal to allow the bureau to inspect he licensed premises is grounds for disciplinary action. This will ensure that the bureau is able to take disciplinary action on a licensee who denies the bureau access to their licensed premises for the purposes of inspection.

Business and Professions Code section 19307 grants licensing authorities’ permission to make, or cause to be made, investigations. Subsection (c) of this proposed regulation clarifies that the bureau may take disciplinary action on a license for impeding an investigation by the bureau, law enforcement, or any other licensing authority. This will ensure that the bureau is able to properly carry out enforcement functions as required by these regulations and the Business and Professions Code.

§ 5056. Record Retention
The purpose of this proposed section is to define what must be stored and maintained as a record, to clarify how and how long records must be stored, to clarify that a licensee may contract with a third party to provide custodial or management services of the records, and to clarify that all records related to commercial cannabis activity are subject to inspection by the bureau.

For the purposes of clarity and consistency, subsections (a) and (c) of this proposed regulation are restatements of similar subsections within the Business and Professions Code. Portions of proposed subsection (a) are a restatement of Business and Professions Code section 19327(b). Proposed subsection (c) is a restatement of Business and Professions Code section 19327(c). These subsections have been restated for the purpose of clarity. The subject matter covered by this proposed regulation and the statutes cited above are close enough that restating the requirements of the statutory section in this proposed regulation would provide more clarity to the reader. The alternative would be to require the reader to simultaneously refer to the proposed regulation and the statutory sections to obtain the requirements for record retention.

Specifically, proposed subdivisions (a)(1) through (a)(6) includes financial records, personnel records, training records, contracts with other licensees, local authorizations, and security records as records which must be maintained by a licensee. This makes specific the type of documents that must be kept; therefore providing clarity to licensees. The requirement that these be maintained as records will aid the bureau in enforcing these regulations, conducting investigations, and in preventing diversion and other illegal activity.

The purpose of proposed subsection (c) is to require that records be kept in a manner that allows them to be immediately produced for the bureau at the licenses premises. This will ensure that the bureau is able to conduct timely inspections when needed.

Licensees may generate a large number of commercial cannabis activity records during daily functions. The purpose of proposed subsection (d) is to clarify that licensees may contract with a third party for the purposes of custodial or management services of the licensees records.
Business and Professions Code section 19327 requires a licensee to keep accurate records of commercial cannabis activity. However, this section does not define what types of records of commercial cannabis activity must be maintained. Proposed subsection (a) clarifies the types of records that a licensee must maintain. The purpose of this proposed subsection (a) is to define what must be stored and maintained as a record.

§ 5058. Significant Discrepancy in Inventory

It is important the bureau be aware of any inventory discrepancies to assist with preventing diversion. The statute does not define the term significant discrepancy in inventory. In order to provide licensees with a clear idea of when their notice requirements are triggered under the statute, this definition is required. In order to avoid over reporting due to loss that is experienced in the regular course of business, the bureau has decided to set the amount of a significant discrepancy at $1,000 in a 7 day period or $2,000 in a 30 day period. The bureau has determined that inventory discrepancies at this amount would be much larger than the amount of medical cannabis goods that are expected to be lost during the regular course of business.

§ 5060. Notification of Criminal Acts, Civil Judgements, and Revocation of a Local License, Permit, or Other Authorization After Licensure

This section describes the licensee’s notification requirements for specific events. Business and Professions Code section 19311 provides for discipline of a license for conviction of a crime or failure to comply with provisions of the Act or regulations adopted pursuant to the Act. Business and Professions Code section 19320 subsection (d) states that the revocation of a licensee’s local license, permit, or other authorization terminates the ability of the licensee to operate in that jurisdiction. Section 19320 subsection (d) also requires the bureau to inform other relevant licensing authorities when a licensee’s local license, permit, or other authorization is revoked.

Without this requirement, the bureau may not be aware of these events. The bureau would only potentially learn of these events at time of renewal. The enumerated events are relevant and material to the on-going qualifications of the applicant.

Proposed subsections (a) and (b) require a licensee to notify the bureau within 48 hours following a conviction of criminal activity or following the rendering of a civil penalty or judgment against a licensee. It is necessary for the bureau to be notified of a criminal conviction or a civil penalty or judgment of a licensee because the conviction, civil penalty, or judgment may impair the licensee’s ability to hold a license from the bureau. Notice of the event is the first necessary step in order for the bureau to investigate whether or not disciplinary action should be taken. Requiring a licensee to notify the bureau of a criminal conviction or the rendering of a civil penalty or judgment will ensure that the bureau is able to properly enforce the provisions of the regulations and the MCRSA.

Proposed subsection (c) requires a licensee to notify the bureau within 48 hours following the revocation of a licensee’s local license, permit, or other authorization. It is necessary for the
bureau to require a licensee to report the revocation of his or her local license, permit, or other authorization to the bureau so the bureau can inform other relevant licensing authorities as required in statute. This will ensure that the bureau and other licensing authorities are informed in a timely fashion of the status of their licensees. This will also allow the bureau and other licensing authorities to conduct their own investigations and take disciplinary action if necessary.

§ 5062. Notification of Diversion, Theft, Loss, or Criminal Activity Pertaining to Medical Cannabis or Medical Cannabis Products
Business and Professions Code sections 19334(e)(2) and 19334(e)(3) require a dispensary to notify the bureau and law enforcement authorities within 24 hours of the discovery of diversion, theft, loss, or any criminal activity pertaining to the operation of a dispensary or pertaining to actions taken by any agent or employee of a dispensary. These provisions apply only to dispensaries. Business and Professions Code section 19334(b) requires the bureau to establish minimum-security requirements for the transportation, storage, and delivery of medical cannabis goods. Requiring notice to the bureau as described in this proposed section is part of those minimum security standards.

This section is necessary to extend the requirement that dispensaries notify the bureau when they discover diversion, theft, loss, or any criminal activity pertaining to medical goods to all licensees. It is necessary for the bureau and law enforcement authorities to be informed of possible diversion, theft, loss, or any criminal activity pertaining to medical cannabis goods so proper enforcement action can be taken to prevent future occurrences and to remedy existing ones. This reporting requirement will also allow the bureau to be informed of situations that may lead the bureau to take disciplinary action on a licensee.

§ 5064. Access to Limited-Access Areas
The MCRSA does not clarify who can be present in the limited-access areas of licensed premises. The purpose of this proposed regulation is to clarify requirements for visitors to a licensed premises, who are not employed or contracted with the licensee, to be escorted at all times by an employee of the licensee. The goal of this section is to minimize security risks arising from having unaccompanied visitors on the licensed premises.

§ 5066. Licensee Employee Badge Requirement
Current law requires the safe and secure handling of medical cannabis goods but does not clearly enumerate all safety and security measures to be taken. Business and Professions Code section 19334 subsection (d)(3) requires dispensaries to establish limited-access areas that are accessible only to authorized dispensary personnel. Differentiating employees from nonemployees through the use of a badge as required by this proposed regulation will further the security of limited access areas. Business and Professions Code section 19334 subsection (b) requires the bureau to establish minimum-security requirements for the transportation, storage, and delivery of medical cannabis goods. The employee badge requirements as described in this proposed section are part of those minimum security standards.
The purpose of this section is to require licensees and their employees to display an identification badge that has specific information, including the “doing business as” name of the licensee, the license number, and the employee’s full name and photograph, while engaging in commercial cannabis activity. This section will ensure that licensees and their employees can be clearly designated from individuals who are not a licensee or not employed by the licensee. Requiring the license number on the badge will allow customers, the bureau, and law enforcement authorities to clearly identify the license under which a licensee or employee is operating. The 2x2 inch color photo requirements will expedite identification verification by providing a picture of the associated individual.

§ 5068. Video Surveillance System

Current law requires the safe and secure handling of medical cannabis goods but does not clearly enumerate all safety and security measures to be taken. Business and Professions Code section 19334(b) requires the bureau to establish minimum security requirements for the commercial transportation, storage, and delivery of medical cannabis goods.

The proposed section is necessary to reduce the risk of unlawful cannabis entering the regulated market, and to prevent diversion of product into the illegal and unregulated market. Licensed premises may have a significant risk of theft, diversion, or other criminal activity due to the high value and controlled nature of the products they handle. Requiring licensed premises to have a digital video surveillance system will reduce this risk. A video surveillance system will both deter criminal activity and will allow identification of individuals who engage in criminal activity. Subsection (a) requires a video surveillance system to use a minimum resolution of 1280 x 1024 pixels. This minimum resolution will ensure the identity of individuals recorded by the system can clearly be identified. Resolutions lower than 1280 x 1024 pixels are less capable of consistently producing clear images that allow the identification of individuals.

Subsection (b) requires that the surveillance system storage device or the cameras used be transmission control protocol/ TCP/ capable of being accessed through the internet. This will ensure that the storage system or cameras are capable of communication on a standardized protocol that can be used by the bureau to review recordings and not locked to a proprietary system.

Subsection (c) requires all areas recorded by the video surveillance system to have adequate lighting to allow the cameras to effectively record images. This requirement will ensure that the cameras are consistently able to produce clear images.

Subsection (d) outlines the requirements for camera positioning. This section requires cameras to be immobile and placed in a permanent location that allows the identification of activity occurring within 20 feet of all points of entry and exit on licensed premises. This subsection will ensure increased security at entry and exit points which will likely receive the most use by the licensee, employees of the licensee, and customers.
Subsections (e)(1) through (e)(6) require video surveillance of specific areas on a premises. Proposed areas requiring surveillance in subsection (e)(1) and (e)(2) include areas where medical cannabis goods is weighed, packed, stored, quarantined, loaded and unloaded, prepared, moved, and destroyed. Proposed subsections (e)(3) through (e)(6) require video surveillance of limited-access areas, security rooms, areas where a surveillance system storage device is kept, and entrances and exits to a premises. Proposed subsections (e)(1) through (e)(6) will ensure that high-risk areas of a licensed premises receive proper monitoring and help prevent diversion into the illegal market.

Subsection (f) specifies specific locations where dispensaries are required to place surveillance cameras. This includes any point-of-sale areas and areas where medical cannabis goods are displayed for sale. The additional camera locations are required for the bureau to be able to effectively investigate any issues that may arise from a specific sales transaction. Additionally, proposed subsection (f) requires that the placement of the cameras in these sections allow for the clear identification of any individual purchasing or selling medical cannabis goods. This is required because the purpose of the camera is to be able to identify the individuals involved in the transaction. If the footage from the camera does not provide that information, the dispensary and the bureau do not get the intended benefit of these additional camera requirements.

Subsection (g) requires that surveillance cameras record 24 hours per day at a minimum of 20 frames per second. The requirement for of 24 hour surveillance is required because it is the most effective way of ensuring that violations are not occurring while the cameras are turned off. The bureau has determined that recording at 20 frames per second is the minimum framerate that would allow the surveillance footage to effectively be used to determine what occurred by watching the footage.

Subsection (h) requires that the media used to store surveillance footage be kept secure. If surveillance footage is allowed to be tampered with or destroyed, the requirements of this section would yield no benefit to the licensee or the bureau. It is important that the footage captured by the cameras be reliable. Preventing the tampering of the footage is required to ensure reliability of the footage.

Subsection (i) requires that recording be kept for at least 30 days. The bureau has determined that 30 days is an appropriate amount of time given the potential costs of storage and the amount of time it would reasonably take the bureau or law enforcement to respond to an incident that occurred on a licensee’s premises and determine whether a review of the surveillance footage is necessary.

Proposed subsection (j) clarifies that all surveillance footage is subject to inspection by the bureau. This subsection is necessary to provide licensees with notice that they must be able to provide the footage to the bureau upon request. Access to the footage is necessary for the bureau to effectively conduct enforcement.
Proposed subsection (k) specifies that recorded images clearly display the time and date of the recording measured in accordance with the United States National Institute Standards and technology standards. This information is necessary for the effective use of surveillance footage for enforcement purposes. The subsection is necessary in order to provide notice to licensees that display of the date and time of recording based on a reliable standard is a required function of their video surveillance system.

§ 5070. Security Personnel
The MCRSA mandates the bureau to craft regulations that ensure a safe and secure operation of the medical cannabis goods market. Security personnel will assist in keeping medical cannabis goods and persons at the dispensary safe. Current law permits the use of security personnel, but does not clarify the type or quality. This section is necessary to provide clarity on the applicable definition of security personnel and ensure any security personnel are licensed for the activities to be conducted as required by the Bureau of Security and Investigative Services.

§ 5072. Locks
Current law mandates the bureau to craft regulations that ensure a safe and secure operation of the commercial cannabis market. Current law permits the use of locks, but does not clarify the type or quality. This section is necessary to clarify for licensee on the type and quality of locks permitted for use. As the licensed premises are commercial businesses, it is appropriate to require locks made for that purpose.

§ 5074. Alarm System
This proposed section requires each licensee to keep and maintain an alarm system as defined in the Business and Professions Code section 7590.1, subsection (n). The MCRSA mandates the bureau craft regulations that ensure a safe and secure operation of the commercial cannabis market. Current law permits the use of alarm systems but does not clarify the type or quality. Proposed subsection (a) clarifies the requirement that licensees maintain alarm systems and specifies that a licensee ensure a licensed alarm company installs, maintains, monitors, and responds to the licensed alarm system. Proposed subsection (b) requires a licensee to make all information related to the alarm system available to the bureau upon request.

§ 5076. Returns Between Licensees
The purpose of this section is to protect public health and safety and ensure an effective method of tracking medical cannabis goods by specifying the requirements for return transactions between licensees.

Subsection (a) clarifies the situations in which a licensee may return medical cannabis goods purchased form another licensee. The subsection indicates that a manufactured medical cannabis good purchased from a licensee by another licensee that is found to be defective may be returned. The subsection also requires that the item be exchanged for a non-defective version of the same item. Manufactured medical cannabis goods may be defective. This is especially true
for vaporizer cartridges and other medical cannabis goods which contain concentrated cannabis. The bureau intends to allow for a mechanism for a licensee who discovers that a product is defective to be able to exchange the defective product with a working product from the licensee the product was purchased from. Returns of this type may occur frequently due to the fact that the defectiveness of a product is not often discovered until after the product has been sold to a patient.

Subsection (b) indicates that aside from the situation described in subsection (a), no other returns between licensees will be permitted. The MCRSA requires that all medical cannabis goods be monitored through a state-wide track and trace system. The bureau has determined that transactions in which medical cannabis goods are transferred between licensees without a recorded sale transaction is susceptible to abuse and would make it difficult to effectively monitor the movement of product. For example, allowing licensees to return product in exchange for different products may negatively impact the tracking system and prevent accurate measurement of tax liability. In order to effectively track the movement of medical cannabis product through the track and trace system, the bureau proposes that returns between licensees will not be allowed.

§ 5080. Cannabis-Waste Management
Proposed section 5080 prescribes the way in which batches of medical cannabis goods that have failed laboratory testing are destroyed and managed. This section applies to all medical cannabis goods that require destruction, for whatever reason.

Proposed subsection (a) clarifies that cannabis waste may not be sold. This section is necessary to ensure that cannabis waste is not used for any unauthorized purposes.

Proposed subsection (b) would require that all medical-cannabis-related hazardous waste be dealt with in compliance with hazardous waste laws to protect public safety.

Proposed subsection (c) would make it unlawful for a licensee to dispose of medical cannabis goods or cannabis waste in a trashcan, dumpster, or other similar receptacle. The bureau proposes this regulation because medical cannabis goods that have failed testing or are otherwise not sellable pose a threat to human and animal health. Disposing of such goods and waste in an unsecured receptacle would create a risk of people or animals obtaining the goods, and increase the risk of such goods and waste being diverted into the illegal market.

Proposed subsection (d) would require that, prior to rendering medical cannabis goods into cannabis waste, a licensee quarantine the medical cannabis goods on the licensee’s premises for at least 72 hours. The 72-hour requirement allows the bureau a reasonable time to investigate or witness the destruction process. This is important because such a requirement helps to prevent diversion of product into the illegal, unregulated market by ensuring that the cannabis goods are actually destroyed and rendered into cannabis waste.
Proposed subsection (e) generally prescribes how medical cannabis goods are rendered into cannabis waste. A licensee who wishes to render medical cannabis goods into cannabis waste must grind up the cannabis and mix it with other ground material. The resulting mixture must be at least 50% non-cannabis material. Licensees must render goods into cannabis waste one batch at a time and track that batch through its disposal under subsection (h). The mingling of more than one batch when creating cannabis waste would be disallowed. This process protects public safety by reducing the risk of this cannabis from entering the illegal market.

Proposed subsection (f) would require that the rendering medical cannabis goods into cannabis waste be performed on the surveillance video required under section 5068. This would allow the bureau to witness the destruction remotely or after the fact to ensure diversion of product into the illegal and unregulated marketplace does not occur.

Proposed subsection (g) outlines what a licensee must mix with the medical cannabis goods to be rendered into cannabis waste when that licensee wishes to deposit the cannabis waste with a compostable materials handling operation or facility or an in-vessel digestion operation or facility. Dried flower, kief, and hashish may end up at a compostable materials handling operation or facility, whereas edibles may be more suited for an in-vessel digestion operation or facility. Licensees are advised to learn beforehand which types of operation or facilities accept which types of solid waste. This will assist with proper destruction.

Proposed subsection (h) would require that a licensee dispose of or deposit his or her cannabis waste with one of three types of operation or facilities. The first, most likely for cannabis waste made from manufactured cannabis batches, would need to be disposed of at a fully permitted solid waste landfill that has a person working there at the time of disposal who can provide a receipt required in subsection (k).

The second operation or facility where cannabis waste may be deposited is at a manned compostable materials handling operation or at a manned and fully permitted compostable materials handling facility. The operation or facility must have a person working there when the deposit is made in order for the licensee to obtain the receipt required in subsection (k).

The third type of operation or facility where cannabis waste may be deposited is a manned in-vessel digestion operation or a fully permitted and manned in-vessel digestion facility. An in-vessel digestion operation or facility is one in which certain compostable materials are broken down in a large vessel. Edibles that have been rendered into cannabis waste may be the type of cannabis waste deposited here.

Proposed subsections (i) and (j) would require licensees to track the quarantine, rendering into cannabis waste, and disposal or deposition of the cannabis waste using the track and trace database. The weights before and after the medical cannabis goods have been rendered into cannabis waste would need to be part of the information entered into the database. This is to ensure the bureau may track the batch from seed to disposal.
Proposed subsection (k) would require a licensee to obtain a receipt or record of some sort from the solid waste operation or facility where the cannabis waste was disposed of or deposited. The record would need to contain the name and address of the operation or facility, the date the cannabis waste was turned over to the operation or facility, the volume or weight of the cannabis waste, and the name and signature of the employee who is at the operation or facility. This record would then need to be kept along with all other business records of the licensee and would be part of the records the bureau could inspect. This requirement is important because the bureau need to track the cannabis from seed to the end of its lifecycle. Such a record would provide the bureau with information regarding whether the cannabis waste was truly disposed of or deposited at a solid waste operation or facility.

Proposed subsection (l) would require the licensee, after the disposal or deposition of the cannabis waste to be entered into the track and trace database. Like subsection (k), this requirement ensures the bureau may track the batch up to the point that it exits the track and trace system.

CHAPTER 2. DISTRIBUTORS

§ 5082. Distributor Taking Title Before Manufacturing
The MCRSA allows a distributor to take title before performing the duties required of the distributor under the MCRSA. The MCRSA also allows for a distributor of medical cannabis goods to enter into a service contract with the cultivator or manufacturer who holds title to the medical cannabis goods to perform the duties required of the distributor under the MCRSA. The MCRSA does not specify at which point the distributor may take title, nor does it specify when the distributor may take possession of the medical cannabis goods to which he or she holds title.

This section specifies that a distributor may take title to medical cannabis goods after harvest but before manufacturing, and it specifies that a distributor may also take possession of the medical cannabis goods to which the distributor holds title after harvest and before manufacturing. The proposed regulation is necessary because the statute does not address the points in time when title or possession may pass to the distributor.

A distributor may want to purchase medical cannabis goods wholesale before the medical cannabis goods have been further processed or after, and this proposed regulation ensures that the distributor’s right to purchase wholesale and take possession is clearly stated. Allowing distributors to purchase prior to manufacturing gives commercial cannabis businesses more flexibility to enter into business arrangements of their choosing.

§ 5084. No Consignment
This proposed regulation prohibits consignment by distributors. The proposed regulation requires that distributors who held title to medical cannabis goods that were delivered to a dispensary
relinquish title once physical transfer of possession is made to a dispensary. This requirement therefore de facto prohibits consignment sale.

A distributor selling medical cannabis goods to a dispensary on consignment would pose logistical problems and would conflict with the bureau’s proposed return regulations. The bureau proposes to prohibit returns of medical cannabis goods between licensees. If a distributor were able to sell medical cannabis goods on consignment, any unsold medical cannabis, after a certain period, would be returned to the distributor. The distributor would have to re-sell the remaining medical cannabis goods or destroy them, which would add another transfer of possession. Allowing for many transfers of possession of medical cannabis goods after the medical cannabis goods have been delivered to and sold by retail dispensaries would make it harder for the bureau to track the medical cannabis goods to ensure medical cannabis goods are not being unlawfully diverted.

§ 5086. Distributor-to-Distributor Sales
Allowing for various types of business transactions and arrangements is important to the health of the commercial cannabis economy in California. The bureau has not identified a safety concern with sales occurring between distributors as long as the final distributor to hold title performs the functions required under Business and Professions Code section 19326. Therefore, the bureau proposes to allow distributor-to-distributor sales.

§ 5088. Distributor as Destroyer
The bureau proposes to allow a licensed distributor to destroy medical cannabis goods, with or without compensation. Under the MCRSA, distributors act as a sort of quality-control agent, ensuring medical cannabis goods are tested and up to quality standards. Because other parts of the proposed regulations require distributors to destroy medical cannabis goods under certain circumstances, the bureau proposes allowing other license types (or other distributors) to pay or otherwise arrange for distributors to destroy medical cannabis goods for them. Distributors will most likely have the capacity for destruction and therefore may be the best suited in some situations to destroy medical cannabis goods.

§ 5090. Storage
All medical cannabis goods must go through a licensed commercial cannabis distributor. Therefore, all medical cannabis goods will at some point be stored on a distributor’s premises. To ensure the traceability of medical cannabis batches, it is imperative that the distinct batches be readily identifiable while in storage.

Proposed subsection (a) requires distributors store different batches in such a manner that the batches are not mixed in any way. Proposed subsection (b) specifies some ways in which this must be done. This subsection proposes that labels be attached to each container holding medical cannabis goods with information relevant to determining which batch each container of medical cannabis goods belongs to.
Proposed subsection (c) requires that a distributor’s storage area be in a building (no outside storage is allowed) that has temperature and humidity control. Temperature, light, and humidity alter the chemical composition of cannabis, and therefore a distributor’s storage facility should be such that these conditions can be controlled for.

The exact storage temperature and humidity are not articulated in this proposed regulation except for edibles and harvest batches because ideal conditions may vary depending on product. There should, however, be ways to control the temperature and humidity at the distributor’s premises, and in no case shall the distributor allow medical cannabis goods be stored in direct sunlight.

Subsection (c) also requires that the distributor store medical cannabis goods in a building in which the entry of environmental contaminants like smoke and dust may be prevented. Because all medical cannabis goods will be tested by a testing laboratory and labeled according to those test results, it is imperative that new contaminants are not introduced into the medical cannabis that is being stored at the distributor’s premises during testing. For the same reason, proposed subsection (d) requires all kitchen and eating areas, changing rooms for employees, and bathrooms be completely separate from and not open into medical cannabis goods storage areas.

Proposed subsection (e) requires that edible cannabis products requiring refrigeration and harvest batches (dried flower) be refrigerated and kept in a darkened area. There is also a requirement that harvest batches not be exposed to greater than 60% humidity. Distributors are expected to store medical cannabis goods while the samples are being tested. It is important that the medical cannabis goods held at a distributor do not deteriorate in such a manner so as to make the testing laboratory results inaccurate. In order for this to be the case, steps have to be taken to ensure that the medical cannabis goods do not degrade or change in any way from the point samples are taken for testing all the way to when the medical cannabis goods are sold to patients. The bureau has determined that maintaining a specific temperature and humidity range is an effective way to ensure that the medical cannabis goods do not degrade or change in a way that would render the testing laboratory results inaccurate. The bureau has determined that edible cannabis products should be refrigerated at 35 to 42 degrees in order to maintain the integrity of the goods. The bureau has also determined that storing medical cannabis at 60% humidity or less is necessary to prevent degradation.

§ 5092. Storage Only
This proposed section allows for a distributor to store medical cannabis goods for another licensee without performing the quality-assurance duties of Business and Professions Code section 19326. Along with proposed section 5086, this proposed regulation allows for flexibility in business arrangements.

§ 5094. Packaging and Labeling
The bureau proposes in this section allowing distributors to package and label medical cannabis goods for other licensees so that, after a batch has gone through laboratory testing, the medical...
cannabis goods need not return to the cultivator or manufacturer for packaging and labeling. Along with storage and destruction, the ability of a distributor to package and label medical cannabis goods for a licensee will allow for the easier flow of medical cannabis goods through the distribution system set up in statute and will prevent the unnecessary transfer of possession. This allowance is provided for in proposed subsection (a).

Proposed subsection (b) allows distributors to re-package or re-label dried flower when the need arises, such as the prior label did not reflect the testing-laboratory results or because the original packaging was deficient in some way. This subsection negates the necessity of the cultivator having to re-take possession simple to re-package or re-label themselves.

Proposed subsection (c) allows another person, either a medical cannabis licensee or a non-licensee, to package and label on the distributor’s premises. Again, this provision would negate the need to transfer possession back to the originating cultivator or manufacturer, allowing for easier flow of medical cannabis goods through the supply chain. Under proposed subsection (c), the distributor is the licensee responsible for the packaging and labeling performed on the distributor’s premises.

Proposed subsection (d) prohibits a distributor from accepting medical cannabis goods that have not already been packaged by the manufacturer who manufactured the products. The bureau and the State Department of Public Health agree that this provision is necessary because packaging of manufactured medical cannabis goods should take place in an environment most conducive to following good manufacturing practices for packaging. Such an environment is more likely to exist at the manufacturing site than at a distributor’s premises.

§ 5096. Non-Medical-Cannabis Distribution Activities
This proposed section prohibits the distribution or storage of non-medical-cannabis goods in the distributor’s licensed premises. The bureau has enforcement power over the licensee and licensee’s premises, and allowing other non-licensed activities to take place on the licensed premises would make enforcement less clear cut. Therefore, to ensure the bureau enforcement resources are used in the most efficient way possible, it is necessary to clearly delineate what may and may not occur on the licensed premises. Because the bureau does not license non-commercial-cannabis activities, it is proposed that such activities be prohibited.

§ 5098. Laboratory-Testing Logistics
The MCRSA at Business and Professions Code section 19326 requires distributors ensure laboratory testing of medical cannabis goods takes place. This section specifies how distributors go about ensuring laboratory testing occurs.

Proposed subsection (a) requires a distributor to contact a licensed testing laboratory and contract for testing, as required by Business and Professions Code section 19326. Once a lab has been secured, the distributor must arrange for sampling in one of two ways. Proposed subsection (a)(1) allows a distributor to arrange for a sampling agent of the testing laboratory to come to the
distributor’s premises and collect samples for testing. Proposed subsection (a)(2) provides an alternative: the distributor, under his or her transporter license, transports the entire batch to the testing laboratory, and the laboratory’s testing agent collect the sample at the laboratory.

Proposed subsection (b) requires the distributor witness the laboratory agent collect the sample and that the sample collect occur on video in compliance with section 5068. Because laboratory testing is the most integral part of quality assurance for medical cannabis, the collection of samples for testing is extremely important. Without proper sampling, laboratory test results would be meaningless, which in turn would make the entire quality-control system put in place by the MCRSA also meaningless. Therefore, the bureau proposes distributors witness sampling in person and that it be recorded on video with the batch number stated at the beginning of the video and a visible time and date indication on the video recording footage. The latter requirement would allow the bureau to examine video footage of sampling should there be a need for enforcement purposes. This requirement addresses the situations of nonexistent or improper sampling, intentional tampering with medical cannabis during sampling, and any disputes between licensees that may arise regarding procedures used to sample. Proposed subsection (b) also requires the distributor to ensure that samples are not taken from harvest batch that exceeds 10 pounds. This provision is necessary to clarify the maximum size of a harvest batch from which a sample is obtained. Placing a limit on the size of the harvest batch for testing will allow for more-manageable sample collection, transportation, storage, and testing. This will also limit the ability to hide cannabis that does not meet testing standards within a batch. The bureau has determined that setting the harvest batch size at a maximum of 10 pounds is reasonable given current industry practices, where the average batch size of dried flower is approximately 15 pounds.

Proposed subsection (c) protects the integrity of the sample collection process and the testing process by requiring that the distributor and laboratory agent document the collection of samples for testing. This requirement ensures that the individuals who participated in the sample collection process can be held accountable if any problems with the process are discovered.

§ 5100. Testing Sample
This proposed section requires the distributor be physically present to witness the laboratory agent obtain the testing sample and that the distributor not interfere in any way with the collection of the sample by the testing-laboratory sampling agent. Because laboratory testing is the most integral part of quality assurance for medical cannabis goods and because sample collection is key to being able to perform a scientifically valid analysis, the collection of samples for testing is extremely important. Without proper sampling, laboratory test results would be meaningless, which in turn would make the entire quality-assurance system put in place by the MCRSA also meaningless.
Therefore, the bureau proposes distributors witness sampling in person and not interfere with sample collection. Only a trained sampling agent may collect a sample, and no other licensee or other person should be participating in sample collection.

§ 5102. Laboratory Testing Results
This section defines when a medical cannabis batch passes or fails the official state-mandated laboratory test. Under proposed subsection (a), a batch passes a laboratory test if the testing samples analyzed by the testing laboratory do not exceed the action levels set in regulation in Chapter 5 of this division. Conversely, as stated in proposed subsection (c), the batch fails laboratory testing if the testing samples analyzed by the laboratory exceed the action levels set in Chapter 5 of this division, which is forthcoming in the bureau’s testing laboratory regulations. It is necessary to have standards for determining if cannabis goods are safe to sell to purchasers.

In proposed subsection (b), if a batch passes laboratory testing, the distributor in possession of the medical cannabis goods must transport, under his or her transporter license, the medical cannabis goods to one or more retail dispensaries. Alternatively, the distributor (or other interested licensee) may arrange for a licensed transporter to transport the medical cannabis goods to one or more retail dispensaries.

The bureau proposes in subsection (d) that, when a manufactured cannabis batch fails laboratory testing, the distributor destroy the manufactured cannabis batch, which will be stored at the distributor’s premises. The bureau proposes failed manufactured cannabis batches be destroyed because the MCRSA at Business and Professions Code section 19345(c)(3) requires harvest batches be destroyed after failing laboratory testing unless the harvest batch can be remediated. Manufactured cannabis batches, unlike harvest batches, cannot easily be remediated due to the concentrated nature of any contaminants contained in the products. Therefore, the bureau is proposing all failed manufactured cannabis batches be destroyed after failing the official, state-mandated laboratory testing. Additionally the distributor is in the best position to destroy the products because the batch will be stored at the distributor’s premises, and the distributor will have the proper set up to perform destruction.

Regarding harvest batches (i.e., dried flower), if a harvest batch fails official, state-mandated laboratory testing, it must either be destroyed by the distributor or the harvest batch may be transported to a manufacturer for processing, depending on whether the harvest batch may safely be processed into a manufactured cannabis batch. This process is laid out in proposed subsections (e) and (f) to ensure only goods meeting state standards are sold.

If the harvest batch may safely be processed into a manufactured cannabis product, a distributor may transport or arrange for transport of the failed harvest batch to a manufacturer. Which licensee transports the batch and which manufacturer receives the harvest batch for processing will be determined by contract between the relevant licensees.
When destruction of medical cannabis batches is required, the distributor must destroy the batches on video in accordance with sections 5068 and 5080. In addition, the distributor shall enter the destruction event into the track and trace database.

Proposed subsection (g) prohibits a distributor from transporting, under his or her transporter license, or arranging for the transport of medical cannabis batches that have failed laboratory testing unless allowed under this proposed section. The only time transport of a failed batch would be allowed under this section and these proposed regulations would be when the failed batch is a harvest batch that can be processed by a manufacturer into a safe manufactured cannabis batch.

§ 5104. Quality Assurance Review

This proposed section contains the process by which distributors perform quality assurance reviews as required by the MCRSA at Business and Professions Code section 19326(c)(2) after a batch passes the official, state-mandated laboratory testing.

Proposed subsection (a) would require that distributors ensure that the certificate of analysis received from the licensed testing laboratory corresponds to the batch currently being held by the distributor. This requirement is to ensure that batches are not accidentally mixed up and that a batch that may fail a laboratory test is not mistakenly transported to a retail dispensary for sale to patients and primary caregivers. Many medical cannabis batches will look alike, and a case of mistaken identity could easily happen.

Proposed subsection (b) requires that the distributor ensure that, prior to transport to one or more dispensaries, the information on the affixed label on the package of medical cannabis goods is accurate in regards to the cannabinoid content and contaminants required to be tested by law. As stated in this proposed subsection, “accurate” means the information regarding cannabinoid content and contaminants on the label is the same as the information contained in the certification of analysis. This is important because patients rely on the information contained on the labels in making purchasing decisions. The labels on medical cannabis goods must be accurate, otherwise the benefits of the testing process are diminished.

Under proposed subsection (c), the distributor shall ensure the medical cannabis packaging conforms to specifications required in law, such as “special packaging” (i.e., child-resistant) rules proposed in the California Department of Public Health’s proposed regulations for commercial cannabis manufacturers. No medical cannabis goods shall be delivered to a dispensary unless the packaging conforms to law. This subsection requires the distributor to perform the final check on the medical cannabis goods because, in the MCRSA-created supply chain, the distributor is tasked with quality assurance.

Proposed subsection (d) requires packaging be tamper evident and defines that as the use of a seal affixed to the opening of the packaging. The seal or seals must be affixed in such a way over the opening or openings of the package that the seal must be broken in order to open the
package. A broken seal would be evidence of tampering. This is an important requirement because medical cannabis goods are consumer goods that are consumed, making the assurance that the product has not been adulterated an issue of paramount import.

Proposed subsection (e) would require a distributor to verify the weight or quantity of the batch matches that entered into the track and trace database. This is to ensure the batch is complete and there has not been any diversion of product.

Proposed subsection (f) clarify that all events in this section must be recorded in the track and trace system. This is important because the track and trace system is how the bureau is going to monitor the movement of medical cannabis good through the system. In order for the system to be effective, accurate information regarding all relevant transactions must be logged.

§ 5106. Grace Period for Testing and Labeling
This proposed section sets a date by which laboratory testing and labeling as required under these proposed regulations becomes mandatory. The bureau proposes a grace period for compliance until 180 days after licensure to allow commercial cannabis businesses to liquidate their inventories, as they exist on January 1, 2018, without having to rapidly change their business practices. Having a grace period for testing and labeling compliance will allow businesses to change their business practices without stopping the supply chain.

§ 5108. Insurance Requirements
The purpose of this section is to clarify the statutory requirement for insurance for a distributor licensee. Business and Professions Code section 19334, subsection (a)(2) states that “A distributor shall be bonded and insured at a minimum level established by the licensing authority.” Subsection (a) requires that prior to receiving a license, a distributor applicant must provide the bureau with proof of insurance. This is required because distributors are required to carry insurance by the statute and the only way that the bureau can verify that the applicant is adequately insured is to require that an applicant for a distributor license provide their proof of insurance to the bureau. Failure to obtain insurance is a violation of the statutory requirements. Therefore, the bureau cannot provide a distributor license to applicants who do not have the proper insurance.

Subsection (b) further clarifies the insurance requirements for distributor licensees. The subsection requires that distributor licensees at all times carry and maintain commercial liability insurance and commercial umbrella insurance. The bureau has determined that requiring that distributor licensees carry both commercial liability insurance and commercial umbrella insurance is most likely to ensure that the licensee’s insurance policy adequately covers all of the situations in which a distributor may require insurance. The subsection also specifies the type of claims that are required to be covered by the licensee’s insurance policy. Additionally, the subsection requires that the licensee’s insurance policy cover up to $1,000,000. The bureau has determined that setting the required insurance level at $1,000,000 is likely to ensure that
distributor licensees have adequate insurance for the activities that they are expected to be engaging in.

Subsection (c) further clarifies the insurance requirements for distributor licensees. This subsection requires that licensees obtain insurance policies from insurance companies that are authorized to conduct business in the State of California. The reason for this rule is to prevent licensees from obtaining insurance policies from companies that are not authorized to conduct business in California. Such insurance policies would be illegal.

Subsection (d) requires a licensee to inform the bureau within 10 calendar days if the licensee’s insurance policy lapses. Having adequate insurance is a statutory requirement for distributors. Therefore, the bureau must verify that all distributors carry the proper insurance. In the even that a licensee’s insurance policy lapses, the most efficient way for the bureau to be informed is for the licensee to directly inform the bureau. The bureau has determined that it is very important that the bureau be informed that a distributor licensee is potentially operating without insurance as soon as reasonably possible. It is a violation of the statutory requirements for a distributor licensee to operate without proper insurance. The bureau is aware that there may be some circumstances which make it impossible for a licensee to inform the bureau of a lapse in insurance coverage on the same day the insurances lapses. That is why licensees are given a 10 day window to inform the bureau of a lapse in insurance.

§ 5110. Employee Requirements

The bureau proposes this conflict-of-interest regulation because under MCRSA distributors may not have a financial interest in other medical cannabis licenses except their own transporter licenses. Proposed subsection (a) would prohibit employees of a distributor from being employed or volunteering with another medical cannabis licensee unless the other licensee is also a distributor or transporter. Subsection (a) is proposed because if a distributor were to have employees with an interest in other medical cannabis licenses, the employees may have a reason to behave in a less neutral way, which would be contrary to the spirit of the enabling statutes.

Proposed subsection (b) would require a distributor to ensure his or her employees do not have financial interests as defined in proposed section 5006, subsection (b)(22)(K) and to maintain an attestation for each employee in which the employee attests to not having a financial interest in another medical cannabis license except as permitted under this proposed section.

§ 5112. Inventory Reconciliation

Diversion of cannabis into the illegal or unregulated market is a major concern of the state and of the federal government as evidenced by the 2013 Cole memo. Therefore, proposed subsection (a) would require a distributor to reconcile all inventories of medical cannabis on the premises at least once a week.

Proposed subsection (b) would require a distributor to keep an inventory log with complete information for each batch on the premises. Proposed subsections (b)(1) through (11) enumerate
what information must be maintained for each batch in the inventory log. These include where the batch originated and with whom; the date and time possession of the batch was transferred to the distributor; the weight or amount of the batch; where the batch is stored on the distributor’s premises; the storage conditions under which the batch is being stored; the best-by date for the batch, if any; and copies of contracts pertaining to the batch, along with any warehouse receipts. These items are necessary for the complete tracking of the batches being stored at the distributor’s premises and will work to prevent diversion or accidental loss of medical cannabis or medical cannabis products. This information will also enable licensing enforcement officials of the bureau more easily verify the existence of medical cannabis.

Proposed subsection (c) would require a distributor to conduct a full investigational audit if the distributor finds a discrepancy between the physical inventory and the inventory log. If the distributor is unable to account for the discrepancy between the inventory log and the physical inventory, the distributor must notify the bureau of a discrepancy greater than that in proposed section 5058 within 24 hours. Also, if a distributor finds signs of theft or diversion to the illegal market, the distributor shall notify the bureau immediately. This allows for prompt notification that medical cannabis goods have gone missing and for investigation to begin quickly.

§ 5114. Records
This proposed section lists the records distributors would be required to keep. These records would be available under these regulations for enforcement officials of the bureau to inspect. Proposed subsection (a)(1) requires that a licensee maintain records relating to branding and packaging and labeling. These records are important because there are specific requirements for packaging and labeling of products. The bureau is responsible for ensuring that all of those requirements are followed by all licensees. In order to effectively enforce these rules, the bureau will require information regarding each licensee’s branding, packaging, and labeling practices. A review of this documentation may provide the bureau with the information needed. Proposed subsection (a)(2), (8), and (9) requires that a licensee maintain inventory records. An accurate record of a licensee’s inventory is necessary to determine what specific medical cannabis goods are in the possession of the licensee. If there a theft or some other sort of loss, an audit of the inventory may be needed. In this instance, a record of the inventory is needed to perform the audit. Proposed subsection (a)(3) requires that a licensee maintain transportation bills of lading and shipping manifests. This ensures that the licensee received their inventory of medical cannabis goods through the proper supply chain. Maintaining these records would easily allow the licensee to prove when and from whom the licensee received medical cannabis goods that are in their inventory. Proposed subsection (a)(4) requires that licensees maintain records pertaining to the licensees quality assurance practices. One of the responsibilities of a licensed distributor is to perform quality assurance on the medical cannabis goods that flow through their distribution. In order to evaluate the licensee’s quality assurance practices, the bureau requires those quality assurance records. Proposed subsection (a)(5) requires the licensee to maintain records relating to the destruction of medical cannabis goods. The destruction of medical cannabis good is one
way medical cannabis exits the track and trace system. Therefore, it is important to truly verify that the product set for destruction was actually destroyed. Failures in the destruction process may lead to unsafe medical cannabis goods being sold in the illegal market. In order to effectively verify that the proper steps are being taken in the destruction of medical cannabis goods, a review of destruction records may be necessary. Proposed subsection (a)(6) requires that a licensee maintain laboratory records received from testing laboratories. This requirement will ensure that the testing results for any medical cannabis goods held by the distributor are available to the distributor prior to the sale of the goods. A distributor is not permitted to sell medical cannabis goods to a dispensary unless the medical cannabis goods have gone through laboratory testing and has received a positive result. Proposed section (a)(7) requires distributors to maintain laboratory records, the bureau will be able to verify that all medical cannabis goods sold by the distributor to a dispensary went through the testing process by referring to the records of the laboratory testing results.

§ 5116. Track and Trace Requirements
This proposed section specifies the transactions which are required to be entered into track and trace by a licensed distributor. The proposed section also provides the information that must be included with each entry. The track and trace system is intended to track the movement of medical cannabis goods throughout the supply chain. Each transaction, in which medical cannabis goods are physically transferred, must be entered into the system. The recording of all of the events listed below into the track and trace system are necessary for the effective functioning of the system.

Proposed subsection (a) requires that a distributor record the receipt of medical cannabis goods from a cultivator, manufacturer, or distributor into the track and trace system. Proposed subsections (a)(1)(A), (B), and (F) indicate the information that is required to be entered into the track and trace system in order to allow for the identification of the licensees and individuals involved in the transaction. Proposed subsections (a)(1)(C), (D), (E), and (H) indicate the information that is required to be entered into the track and trace system in order to allow for the identification of the specific medical cannabis goods involved in the transaction. Proposed subsection (a)(1)(G) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of when the transaction occurred. Proposed subsection (a)(1)(I) indicates that if any other information is required by some other authority, but not stated in the regulations, the licensee is still required to provide that information. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the supply chain. Additionally, in the even that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (b) requires that a distributor record the taking of a sample by a testing laboratory into the track and trace system. Proposed subsections (b)(1)(A) and (B) indicate the information that is required to be entered into the track and trace system in order to allow for the
identification of the licensees and individuals involved in the transaction. Proposed subsection (b)(1)(C) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of the specific medical cannabis goods involved in the transaction. Proposed subsection (b)(1)(D) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of when the transaction occurred. Proposed subsection (b)(1)(E) indicates that if any other information is required by some other authority, but not stated in the regulations, the licensee is still required to provide that information. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the system. Additionally, in the even that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (c) requires that a distributor record the sale of medical cannabis goods to a dispensary into the track and trace system. Proposed subsection (c)(1)(A) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of the licensees and individuals involved in the transaction. Proposed subsection (c)(1)(C) and (D) indicate the information that is required to be entered into the track and trace system in order to allow for the identification of the specific medical cannabis goods involved in the transaction. Proposed subsection (c)(1)(B) and (E) indicate the information that is required to be entered into the track and trace system in order to allow for the identification of when the transaction occurred. Proposed subsection (c)(1)(F) indicates that if any other information is required by some other authority, but not stated in the regulations, the licensee is still required to provide that information. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the supply chain. Additionally, in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (d) requires that a distributor record the transportation of medical cannabis goods to a dispensary into the track and trace system. Proposed subsections (d)(1)(A) and (B) indicate the information that is required to be entered into the track and trace system in order to allow for the identification of the licensees and individuals involved in the transaction. Proposed subsection (d)(1)(D) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of the vehicle used in the transaction. Proposed subsection (d)(1)(C) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of the specific medical cannabis goods involved in the transaction. Proposed subsection (c)(1)(E) indicates the information that is required to be entered into the track and trace system in order to allow for the identification of when the transaction occurred. Proposed subsection (c)(1)(F) indicates that if any other information is required by some other authority, but not stated in the regulations, the licensee is still required to provide that information. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the supply chain. Additionally,
in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (e) and (f) list two more events that must be entered into the track and trace system. These are destruction and the results of testing performed by a licensed testing laboratory. These events are important and the logging of their occurrence in the track and trace system is necessary for the effective monitoring and enforcement.

CHAPTER 3. TRANSPORTERS

§ 5118. Medical Cannabis Transporter
This proposed regulation describes the permitted licensed activity for transporters. This proposed section clarifies the MCRSA by specifying that only persons licensed by the bureau as a transporter may transport medical cannabis goods between licensees unless that person is exempt under Business and Professions Code section 19319. This section is necessary to clearly restate the existing Business and Professions Code’s permissive activities for transporter licensees.

§ 5122. Transporter May Not Hold Title to Medical Cannabis Goods
This proposed section clarifies that a transporter shall not hold legal title under its transporter license to medical cannabis goods; however, a licensee may hold legal title to medical cannabis goods if the licensee also holds another license, that permits the licensee to hold title under the MCRSA. Without this provision, the demarcation of allowable licensed activity is not clear and may cause confusion in the industry. Prohibiting transporters from holding title under the transporter license ensures that the licensee will not violate the cross-licensure prohibitions within the MCRSA.

§ 5124. Transporter Requirements
This section describes the permitted means and method of transport as well as required vehicle security for the transport of medical cannabis goods. Typically, the transportation industry is heavily regulated under federal law; however, federal law does not provide for cannabis goods transport. The proposed regulation provided needed clarity to identify what methods of transportation are permissible under California law. The MCRSA does not specify what methods of transport are permissive. Additionally, while the MCRSA mandates the safe and secure transport of medical cannabis goods, it does not specify what safety and security measures are required.

Proposed subsection (a) is necessary to help licensees navigate the complex entwinement of federal regulation within the transportation industry. The proposed regulation prohibits various modes of transportation in order to reduce potential conflict with federal law. Additionally, the bureau does not have the ability or equipment to enforce transportation by air, watercraft, or drones. Human-powered and unmanned vehicles are prohibited for the safety of the public and the medical cannabis goods.
Proposed subsections (b) through (f) are necessary to clearly identify the methods needed to safely and securely transport medical cannabis goods. Requiring medical cannabis goods to not be visible or identifiable during transport will reduce the probability of robbery of shipments and theft, which may place the general public in harm’s way, and will prevent diversion of product into the illegal and unregulated market. Securely locking the product in a box within the interior of the vehicle, requiring alarm systems, and not permitting the vehicle to be left unattended in a residential neighborhood is to discourage theft and protect public safety.

Proposed subsection (g) is necessary to ensure that the already tested product will arrive at the receiving licensee in the same quality and condition it was in before the transporter took possession.

Proposed subsection (h) is necessary to ensure medical cannabis goods stay within the designated supply chain and prevents diversion into the illegal and unregulated market. Limiting the transporter to only traveling between licensees shipping or receiving medical cannabis goods and its own licensed premises, ensures the transporter is not transporting mixed goods - medical cannabis goods and non-medical cannabis goods. This limitation reduces exposure to potential diversion. This proposed subsection also recognizes the need for business efficiency and flexibility in transport. By clearly allowing a licensee to transport more than one medical cannabis goods shipment at a time, this will lessen the number of transport trips and the impacts on the environment and roads.

Proposed subsection (i) is necessary to specifically allow bureau representatives to inspect commercial transport vehicles of medical cannabis goods and specifically permit access to all licensed premises to ensure regulatory compliance. This section also clarifies that commercial vehicles used to transport medical cannabis goods may be inspected by the bureau at any licensed location, or during transport, to ensure the vehicle is properly equipped, carrying the required documentation, and contains a shipment compliant with the MCRSA and regulations.

§ 5126. Additional Transport Vehicle Application Requirements
The purpose of this section is to clarify the additional application requirements that are applicable only to applicants for transporter licenses. Proposed subsection (a)(1) requires the applicant to provide proof of ownership or lease of the vehicle that is planned to be used for the transportation activities of the potential licensee. This is required because the bureau would like to ensure that all licensed transporters are using vehicles that they have a legal right to use.

Subsection (a)(2) requires that the applicant provide the bureau with information vital to the identification of the vehicle that is to be used in the transportation activities. This is important because, in order to effectively monitor and track these transportation vehicles, the bureau must first be able to identify the vehicles. This information will allow the bureau to identify the vehicles.
Subsection (a)(3) requires that the applicant provide the bureau with proof of auto insurance in the amount of $1,000,000. Business and Profession Code section 19334, subsection (a)(4) requires that a transport licensee be insured at a minimum level established by the licensing authority. The bureau has determined that an insurance policy in the amount of $1,000,000 is likely to be adequate for insuring the expected activities of a transporter licensee. Transporters may be using larger vehicles for the transportation of medical cannabis goods. It is reasonable to expect that these vehicles carry larger insurance policies than the average vehicle on the road.

Subsection (c) requires that a transporter licensee inform the bureau in writing when they plan to use a new vehicle in the transportation of medical cannabis goods. This is required in order for the bureau to continue to effectively monitor the activities of the licensee. It is imperative that the bureau be informed of what vehicles a transporter licensee is using to transport medical cannabis.

Subsection (e) requires that a transporter licensee provide the bureau with written notice within 30 days if any information required by the section changes. The bureau needs to have accurate up-to-date information regarding their licensees in order to effectively regulate. The bureau has determined that 30 days is a fair an appropriate amount of time to require the notice.

§ 5128. Transport Personnel Requirements
This proposed section specifies the required age and employment affiliations of transport drivers and the permitted passengers of commercial vehicles transporting medical cannabis goods. Under current California law, individuals 21 years of age or older are permitted to possess cannabis without a recommendation. The MCRSA was designed to keep medical cannabis goods out of the hands of children and be restricted to patients, whenever possible. When medical cannabis goods are being transported, there is a higher potential for diversion into illegal or unregulated markets.

To further clarify the statutory intent behind the MCRSA, restricting the age for drivers and passengers of licensed transport vehicles helps to ensure individuals who have dominion and control, or access to, medical cannabis goods are of the proper age. Requiring that only a licensee’s employees be permitted to be present during transport provides the bureau with the ability to take appropriate action against a licensee’s license for improper activity or malfeasance during transport, helping to discourage diversion, theft, and children having access to cannabis.

§ 5130. Transporter Storage of Medical Cannabis Goods
This proposed section permits storage of medical cannabis goods on the licensee’s premises for no longer than 72 hours. Effectuating transportation may require medical cannabis goods to be temporarily stored before transportation can be reasonably completed. Allowing medical cannabis goods to be stored without regulation could compromise the quality of the medical cannabis goods before they reach patients and allow for diversion. Under the MCRSA, the licensed entity that is intended for and best situated for medium and long term storage of medical
cannabis goods is the distributor. Not limiting the timeframe a transporter can possess the medical cannabis goods would permit them to potentially act as a de facto distributor, frustrating the statute’s purpose.

§ 5132. Storage
This proposed regulation clarifies how a transporter may store medical cannabis goods awaiting transport and imposes requirements consistent with storage by other licensees.

Proposed subsection (a) requires transporters to store different batches in such a manner that the batches are not mixed in any way. Proposed subsection (b) specifies some ways in which this must be done. This subsection proposes that labels be attached to each container holding medical cannabis goods with information relevant to determining which batch each container of medical cannabis goods belongs to.

Proposed subsection (c) requires that a transporter’s storage area be in a building (no outside storage is allowed) that has temperature and humidity control. Temperature, light, and humidity alter the chemical composition of cannabis, and therefore a transporter’s storage facility should be such that these conditions can be controlled for.

The exact storage temperature and humidity are not articulated in this proposed regulation except for edibles and harvest batches because ideal conditions may vary depending on product. There should, however, be ways to control the temperature and humidity at the transporter’s premises, and in no case shall the transporter allow medical cannabis goods be stored in direct sunlight, which may more quickly change the properties of the product.

Subsection (c) also requires that the transporter store medical cannabis goods in a building in which the entry of environmental contaminants like smoke and dust may be prevented. Because all medical cannabis goods will be tested by a testing laboratory and labeled according to those test results, it is imperative that new contaminants are not introduced into the medical cannabis that is being stored at the transporter’s premises particularly after testing has occurred.

For the same reason, proposed subsection (d) requires all kitchen and eating areas, changing rooms for employees, and bathrooms be completely separate from medical cannabis goods storage areas.

Proposed subsection (e) requires that edible cannabis products requiring refrigeration and harvest batches (dried flower) be refrigerated and kept in a darkened area. There is also a requirement that harvest batches not be exposed to greater than 60% humidity. The bureau has determined that maintaining a specific temperature and humidity range is an effective way to ensure that the medical cannabis goods do not degrade or change in a way that would render the testing laboratory results inaccurate. The bureau has determined that edible cannabis products should be refrigerated at 35 to 42 degrees in order to maintain the integrity of the goods. The bureau has
also determined that storing medical cannabis at 60% humidity or less is necessary to prevent degradation of harvest batches.

§ 5136. Notification of Shipment
This proposed regulation clarifies that before transporting any medical cannabis goods, the transporting licensee shall complete an electronic shipping manifest and transmit it to the bureau and the licensee receiving the shipment as required by the MCRSA.

The transportation of medical cannabis goods without a shipping manifest created in advance of transport provides excessive opportunity for malfeasance. This section is necessary to ensure that each and every transport of medical cannabis goods is properly accounted for and identified in advance of transport. By requiring that the manifest be both transmitted to the bureau and to the receiving licensee, the proposed regulation aids bureau enforcement officers who can examine the contents of the transport vehicle for consistency. By requiring the transporting licensee to account for each and every shipment in advance also adds documentary barriers discouraging improper entry of unauthorized cannabis into the regulated market or diversion of medical cannabis goods into the illegal market.

§ 5138. Shipping Manifest
This proposed section clarifies the information required to be contained in the statutorily mandated shipping manifest. In order to prevent entry of untested and potentially unsafe medical cannabis goods into the marketplace and diversion of medical cannabis goods into the unregulated or illegal market, MCRSA mandated a shipping manifest to accompany every transport. MCRSA does not specify what information is required to be on the manifest. If a shipping manifest is incomplete or does not have specific information about the medical cannabis goods being shipped, or the destination, the enforcement or inspection officer would have a very difficult time determining the legality and validity of the shipment. Clearly stating the information transport licensees are required to have on their shipping manifest allows for uniformity of records across transport licensees. Clearly stating the information required allows the bureau to better train enforcement and inspection officers on what to expect and how to efficiently inspect a shipment.

Proposed subsections (a), (b), and (h) will require the shipping manifest to include the name of licensee, names of the authorized drivers, along with the make, model, and license plate number of the transport vehicle. This information is necessarily included so that inspection officers can easily and quickly determine the legality and validity of the shipment.

Proposed subsection (c), (d), and (e) are necessary to ensure medical cannabis goods stay within the regulated supply chain, to prevent untested and potentially unsafe product from entering the system and to help prevent diversion into illegal or unregulated markets. By requiring the shipping manifest to include type, quantity, weight, and unique identifiers of all medical cannabis goods onboard, the requirements of proposed subsections (c), (d), and (e) provides
sufficient information for an inspection officer to adequately audit or reconcile the load while in transport, helping to prevent improper entry or diversion of products.

Proposed subsections (f) and (g) require the shipping manifest to have estimated times of departure and arrival of the shipment. These regulations are necessary to ensure the transported medical cannabis goods are not diverted into the unregulated or illegal markets.

§ 5140. Records
This proposed regulation clarifies that in addition to those records required of all licensees under proposed section 5056, a transporter shall maintain commercial vehicle maintenance and ownership records, and all shipping manifests for completed transports and for medical cannabis products in transit.

Under the MCRSA, licensed entities must keep and maintain associated commercial cannabis activity records, related to vehicle maintenance and ownership and shipping manifests. This section is necessary to clarify which records are to be kept and maintained and allows for uniformity of retained records across transport and to ensure the shipments of medical cannabis goods are accounted for. The better informed and prepared the enforcement officers are, the better positioned they are to stop unauthorized activity including unauthorized entry and diversion of medical cannabis goods.

§ 5142. Transporter Track and Trace Requirements
This proposed regulation clarifies the information a licensed transporter must upload in to the track and trace system.

This proposed section describes the specific information the licensee must upload into the track and trace database and describes actionable events that would trigger the information to be updated and re-entered into the track and trace database. In order to prevent unauthorized entry of untested and potentially unsafe medical cannabis goods into the marketplace and diversion of medical cannabis goods into the unregulated or illegal market, the MCRSA mandated a track and trace recording system. Within the transport process there are reasonable yet unanticipated events that compromise the safety or security of the medical cannabis goods. The MCRSA does not identify the specific information that licensees must upload into the recording system and does not clearly describe events that may create the need for updated information to be entered.

This section is necessary to identify the specific information and unanticipated events that would require the licensee to update the track and trace recording system. By enumerating the information needed, it allows licensees to better prepare and track the medical cannabis goods within their control, better ensuring product safety for the patient and security of the product for the community.

Proposed subsections (a) through (e) require the licensee to enter into the track and trace system the license number of the transporter, date shipment was received and delivered, amount and
weight of product, and the unique identifiers assigned to the goods. This information is necessary to effectively trace from cultivation to patient sale, preventing unauthorized entry of untested product and diversion of product into the unregulated or illegal market.

Proposed subsections (f) through (h) require the transporter licensee to enter spoilage or fouling of product or any event resulting in exposure or compromise of the medical cannabis good. Requiring this disclosure seeks to prevent compromised product from reaching a dispensary and potentially endangering patient safety. It also seeks to ensure the medical cannabis goods transported remain in a safe condition with its labeled potency.

CHAPTER 4. DISPENSARIES

§ 5145. Subletting of Premises
This proposed section states that a licensed dispensary shall not sublet any portion of the licensed premises of the dispensary.

The purpose of this section is to protect public health and safety by ensuring that the licensee is the only one in control of the licensed premises. Security is very important in operating a dispensary. Allowing a licensee to sublet any portion of the licensed premises may result in the licensee losing control over who enters the premises, which may lead to an increased risk of theft or other unauthorized activity. Additionally, an unlicensed person is not subject to the rules and regulations for operating a licensed dispensary. By not allowing licensees to sublet the premises, the risk of the licensee losing control over the premises to a subtenant is eliminated. This section ensures that the licensee will have sole control over the licensed premises. More importantly, this section ensures that only the licensee will be responsible for visitors to the premises.

§ 5148. Access to Dispensary Premises
This proposed section specifies that, with the exception of medical cannabis patients younger than 18 years old, all persons that enter a dispensary premises must be at least 18 years old and have a bona fide business reason for entering the premises. If a medical cannabis patient is under 18 years of age, that patient may enter the dispensary but must be accompanied by a parent, guardian, or primary caregiver as applicable.

The purpose of this proposed section is to protect public safety and limit the exposure of minors to medical cannabis goods by preventing individuals who are under the age of 18 and individuals who have no reason for entering the dispensary premises from entering the premises. Security of the dispensary is very important. Business and Professions Code section 19334, subsection (d), requires that a licensed dispensary implement security measures to both deter and prevent unauthorized entrance into areas containing medical cannabis goods and theft of medical cannabis goods at the dispensary. Under Business and Professions Code section 19334, subsection (d)(1), a licensed dispensary is to prevent individuals from remaining on the premises of the dispensary if they are not engaging in activity expressly related to the operations of the
dispensary. In order to comply with these statutory requirements, only certain individuals should be allowed to enter the premises

Proposed subsection (a) limits access to the dispensary premises to individuals who have a business reason for entering the premises by not allowing any other individuals to enter the premises. If the rule is followed, individuals who do not have a legitimate reason for being on the premises will not be allowed onto the premises. This will result in a reduction in the risk of theft or other crimes. Additionally, this section has the benefit of limiting the exposure of minors to medical cannabis goods.

The purpose of proposed subsection (b) is to create an exemption to proposed subsection (a) of this section. Individuals under the age of 18 may be medical cannabis patients and require access to medical cannabis goods. Additionally, this subsection requires that medical patients under the age of 18 be accompanied by his or her parent, legal guardian, or primary caregiver when entering a dispensary.

By creating an exception to proposed subsection (a), medical cannabis patients under the age of 18 are permitted to have access to medical cannabis goods. Additionally, this section requires that medical cannabis patients under the age of 18 be accompanied by an adult. Since a medical cannabis patient under the age of 18 is not legally an adult, the section requires that the medical cannabis patient be accompanied by an adult in order to ensure that there is an adult present who will be responsible for the underage medical cannabis patient. This section allows a medical cannabis patient under the age of 18 to have access to medical cannabis.

§ 5151. Limited-Access Areas
This proposed regulation specifies who may access the limited-access areas of a dispensary. The purpose of proposed subsections (a) through (c) is to preserve the safety and security of the licensed facility by preventing the access of unauthorized individuals into the limited-access areas. A limited-access area means an area in which medical cannabis goods are stored or held and is only accessible to a licensee and his or her employees and contractors. Business and Professions Code section 19334, subsection (d), requires that a licensed dispensary implement security measures to both deter and prevent the unauthorized entrance into areas containing medical cannabis goods and the theft of medical cannabis goods at the dispensary. These subsections clarify who is allowed in the limited-access area while stating that all others are not allowed to enter the limited-access area. The expected benefit of these subsections is that it will prevent unauthorized individuals from entering the limited-access area, which will decrease the risk of theft and other crimes.

The purpose of proposed subsection (d) is to preserve the safety and security of the licensed facility by ensuring that authorized individuals who enter the dispensary limited-access area are escorted by at least one dispensary employee at all times. For various reasons, individuals who are not dispensary employees may be required to enter the limited-access area. For example, a
plumber or electrician may need to enter to make repairs. This section addresses the increased risk of theft or other crime if these non-employee individuals are not supervised while in the limited-access area. By requiring that a dispensary employee supervise a non-employee who is in the limited-access area, this section reduces the risk of theft or other crime. The employee will be able to watch the non-employee while he or she is in the limited-access area to ensure that all applicable rules are followed. Additionally, this subsection ensures that the licensee is aware of what occurs in the limited-access area at all times. This will also result in a reduction of the risk of theft or other crimes.

The purpose of proposed subsection (e) is to preserve the safety and security of the licensed premises and limit the exposure of minors to medical cannabis goods by limiting access to the limited-access area to individuals who are 21 years old or older. The problem addressed by this section is the exposure of minors to medical cannabis goods. With the exception of individuals who are medical cannabis patients, individuals who are under the age of 21 are not allowed on the licensed premises. Therefore, there should be no reason for an individual who is under 21 years old to have access to the limited access area which is one of the secure locations on the licenses premises. This will result in a decrease in the exposure of under-age individuals to medical cannabis goods.

The purpose of proposed subsection (f) is to protect the safety and security of the licensed facility by requiring all dispensaries to keep a log of all of the authorized individuals who are not employees of the dispensary that enter the limited-access area. Because the limited-access area is where the dispensary’s inventory of medical cannabis goods is kept, it is important to keep a record of who enters the area. This section addresses the problem of not knowing who has entered the limited-access area. This subsection requires that a licensed dispensary keep a record of when individuals who are not the licensee’s employees enter the limited-access area. In the case of a theft or any other crime that occurred within the limited-access area, the dispensary will be able to refer to the record to determine who has been in the area. The bureau will also be able to use the record for its investigations. The expected benefit of this section is that all licensed dispensaries will keep a log of all non-dispensary employees who enter the limited access area. This log can be used during the course of an investigation by the bureau or the dispensary.

The purpose of proposed subsection (g) is to protect the safety and security of the licensed facility by preventing dispensaries from requiring that patients pay money or any other form of compensation to enter the limited-access area. Only authorized individuals should be allowed in the limited-access area while engaged in business in that area. A dispensary should not require anyone to pay compensation to enter the area if it is required for the business. Additionally, large amounts of medical cannabis goods may be kept in the limited-access area. Access to the area should be limited to those individuals who require access for the operation of the dispensary. A licensed dispensary that allows an unauthorized individual into the limited-access area for any reason is increasing the risk of theft or other crime.
§ 5154. Retail Area
The purpose of this proposed section is to protect the safety and security of the licensed premises by ensuring that licensed dispensaries only allow individuals who are legally permitted to purchase medical cannabis goods into the retail area of the dispensary. The section also requires that a licensee employee be present in the retail area when there are non-employees in the area. The problem addressed by this section is the risk of providing individuals who cannot legally obtain medical cannabis goods access to medical cannabis goods. Under current law, a medical cannabis dispensary is only allowed to provide medical cannabis goods to medical cannabis patients or the designated caregivers of medical cannabis patients. This proposed section also addresses the security risk of having customers or other individuals in the retail area unsupervised which may lead to an increase in the risk of theft or other crimes.

Only medical cannabis patients or primary caregivers are legally allowed to purchase medical cannabis goods from a licensed dispensary. Therefore, only these individuals should be allowed access to the retail area where medical cannabis goods are sold. This section requires that the licensee employees verify the identity of a medical cannabis patient or primary caregiver by requiring proper identification, a physician recommendation, and paperwork authorizing the primary caregiver be provided.

Additionally, the section requires that a licensee employee be present in the retail area any time there are non-employees in the area. This will allow the licensee employee to monitor the activities of non-employees in the area which should reduce the risk of theft or other crimes. This will help ensure that only licensee employees, medical cannabis patients, and primary caregivers will be allowed access to the dispensary retail area for the purposes of buying or selling medical cannabis goods. Controlling the number of individuals who have access will lower the risk of theft or other crime. This section will also deny access to medical cannabis goods to individuals who are not authorized to purchase these products. Additionally, this section should ensure that non-licensee employees are never in the retail area without a licensee employee.

§ 5157. Hours of Operation
This proposed regulation specifies the hours during which a dispensary may sell medical cannabis goods and provides safety and security requirements for the dispensary for the hours it is not open to the public. These requirements include requiring the premises be securely locked, equipped with an active alarm system, have all medical cannabis goods stored in a locked safe or vault on the licensed premises, and limiting access to the premises to only authorized employees and contractors.

Proposed subsection (a) requires that a licensed dispensary not sell medical cannabis goods during the hours of 9:00 p.m. to 6:00 a.m. During these hours there is a greater risk of crime because it is darker and there are fewer people in public. Therefore, requiring that dispensaries be closed during these hours, the risk of crime is reduced. During these hours, the dispensary’s inventory will be locked up securely and the dispensary employees will not be on the premises.
A potential thief would not be able to simply walk into the dispensary and find product on display in the retail area, cash in the registers, and employees on the premises. Therefore, the risk of robbery or other crime is lowered.

Proposed subsection (b) requires that certain security measures be taken while the licensed dispensary is closed. These requirements include locking the entrances to the premises, activating an alarm system, securing product in a safe or vault, and limiting who can enter the premises during these hours. All of the measures are intended to reduce the risk of theft or other harm while the dispensary is closed and the dispensary employees may not be on the premises to observe the area and contact law enforcement in an event where law enforcement is needed.

§ 5160. Dispensary Customers
This proposed section prohibits a licensed dispensary from selling medical cannabis goods to an individual unless that person has been identified as a medical cannabis patient or primary caregiver. This section requires that the licensee’s employees identify a customer as a medical cannabis patient or primary caregiver by verifying the customer’s medical recommendation, identification, and in the case of primary caregivers, the documentation establishing the individual as a primary caregiver. This requirement will ensure that dispensaries only sell medical cannabis goods to individuals who are able to legally purchase these items. Additionally, proposed section 5226 of the proposed regulations requires that the patient information of each purchaser be recorded by the dispensary for every sale of medical cannabis goods.

§ 5163. Medical Cannabis Goods Display
This proposed section limits the sales display of medical cannabis goods to the retail area of the dispensary and only during the operating hours of the dispensary. By limiting displays to the retail area, the dispensary is better able to monitor the displays to ensure that no theft occurs. By limiting the use of displays to operating hours, the dispensary will be able to ensure that medical cannabis goods are only used for display when there are actually customers in the dispensary to interact with the displays and when licensee employees are present. All medical cannabis goods, including medical cannabis goods used for display will be securely locked in a safe or vault when the dispensary is closed for business to decrease the risk of theft.

Subsection (b) requires that all medical cannabis goods used for display is limited to the retail area. Additionally, medical cannabis goods may not be displayed in a place where it is visible from outside of the licensed premises. The purpose for this subsection is to control the amount of medical cannabis goods that are used for display. Additionally, the subsection restricts the locations where products may be displayed. The intent of this subsection is to reduce the risk of theft and other crime.

Subsection (c) ensures that a dispensary customer cannot easily steal medical cannabis goods on display from the retail area. By requiring that all display medical cannabis goods are not readily accessible to customers, the dispensary can ensure that a customer must request assistance from a

Bureau of Marijuana Control, Initial Statement of Reasons
licensee employee before handling a “sample.” Since a licensee employee is required to assist the customer who intends to interact with a “sample,” the risk of theft is reduced.

Subsection (d) limits the amount of medical cannabis goods that a dispensary can have out for display to the average amount of medical cannabis goods the dispensary sells in one day. In order to decrease the risk of theft, the amount of medical cannabis goods used for display should be limited to the amount needed for display and immediate sale. There is no reason why a dispensary would require more than a day’s worth of medical cannabis goods for display. Therefore, requiring a licensed dispensary to limit the amount of medical cannabis goods displayed to the amount sold in a single day while storing the rest of the dispensary’s medical cannabis goods in a secure location would limit the amount of medical cannabis goods that may be lost due to theft or robbery.

Subsection (e) allows a dispensary to remove some medical cannabis goods from packaging and place it in a separate container for display purposes. This will allow potential customers to visually inspect the medical cannabis goods either visually, or by touch or smell.

Subsection (f) protects the health and safety of patients by preventing dispensaries from selling any products that are removed from their packaging and used for display. This subsection requires that any product removed from its packaging for display purposes is destroyed once it is no longer being used as display. This ensures that all product sold to patients is still sealed in packaging and free from potential adulteration.

§ 5166. Medical Cannabis Goods for Sale
This proposed section requires that licensed dispensaries only sell medical cannabis goods that have gone through the proper distribution and testing channels. This will help prohibit cannabis goods from the illegal and unregulated market from being sold. This section prohibits a licensed dispensary from selling any medical cannabis goods that are past their expiration or sell-by date, if there is one. The risk of a patient being harmed by spoiled medical cannabis goods is reduced if licensed dispensaries are not allowed to sell any medical cannabis goods past the recommended expiration or sell-by date set by the manufacturer.

§ 5172. Daily Limits
This proposed section mirrors the limits specified in Health and Safety Code section 11362.77. This section explicitly prohibits a licensed dispensary from selling medical cannabis goods to any individual in excess of the limits a patient is allowed to possess in a single day. The rationale for limiting the amount of medical cannabis goods that an individual may purchase in a single day is to prevent a licensed dispensary from allowing an individual to violate Health and Safety Code section 11362.77. Additionally, placing a limit on the amount an individual can purchase reduces the risk of the customer becoming a target of crime as they leave the dispensary with a large amount of medical cannabis goods. Also, limiting the amount that can be purchased in a
single day reduces the risk of a customer purchasing more medical cannabis goods than they need for themselves and then illegally selling the excess medical cannabis goods.

§ 5175. Medical Cannabis Goods Returned by Patients or Primary Caregivers
All medical cannabis goods sold at a licensed dispensary are required to be tested by a licensed testing laboratory prior to sale. If the medical cannabis goods are then returned to the dispensary, there is no way to effectively ensure that the medical cannabis goods were not contaminated or adulterated in any way.

Proposed subsection (a) defines the word “return” for purposes of this proposed section as a return of medical cannabis goods that were purchased from a dispensary back to the dispensary the medical cannabis goods were purchased from. This is done to differentiate a return from a medical cannabis patient back to a dispensary from a return from one licensee back to another licensee. For clarity, this section is limited to discussing returns from patients and primary caregivers back to dispensaries.

Proposed subsection (b) clarifies that a dispensary may choose to allow customers to return medical cannabis goods, which allows for customer service. This section does not require dispensaries to allow returns.

Proposed subsection (c) clarifies that a dispensary may not resell medical cannabis goods that have previously been returned. Since there is no way for a dispensary to be certain that the returned medical cannabis goods are not defective or have not been adulterated in any way, the dispensary cannot sell the returned medical cannabis goods to another customer.

Proposed subsection (d) requires that any medical cannabis goods abandoned on the dispensary premises be treated as a return and not be allowed to be resold, because the medical cannabis goods may have been contaminated or adulterated.

Proposed subsection (e) requires that a dispensary destroy all returned medical cannabis goods in accordance with section 5080 of this division. This requirement further ensures that medical cannabis goods that have been returned will not be resold to other patients.

§ 5178. Customer Samples
Proposed subsection (a) explicitly prohibits a licensed dispensary from providing free samples of medical cannabis goods to customers. One concern with free samples is whether or not the samples were properly tested as required by law before being provided to the customer. A licensed dispensary should not be providing customers with any medical cannabis goods that have not been properly tested. Another concern with allowing free samples is the risk of abuse of the track and trace system. A licensed dispensary is required to track all movement of medical cannabis goods through the track and trace system. If given the ability to enter medical cannabis goods as a free sample in the track and trace system, a dispensary may have the ability to hide losses of medical cannabis goods by designating the lost medical cannabis goods as medical
cannabis goods that were given away as a free sample. This would make it virtually impossible to accurately track the movement of medical cannabis goods through the track and trace system.

Proposed subsection (b) prohibits a licensed dispensary from providing samples from a third party on the dispensary premises. If free samples from third parties were permitted, a licensed dispensary may be allowing their customers to receive medical cannabis goods that have not been tested or properly entered into the track and trace system. A customer who is provided with a free sample on the premises of a licensed dispensary may mistakenly believe that the free sample is being provided by the dispensary and that the medical cannabis goods being given as free samples have undergone the testing requirements that are required for all products in the dispensary’s inventory. Additionally, only a licensed dispensary is authorized to provide medical cannabis goods directly to medical cannabis patients or primary caregivers. Licensed cultivators or manufactures may not provide medical cannabis goods directly to customers.

§ 5181. Packaging and Labeling
Under Business and Professions code section 19326, all medical cannabis goods must be tested by a licensed testing laboratory and must receive a certificate of analysis from a licensed testing laboratory before being transported to a dispensary for sale. The results of the testing must be printed on the label of the packaging of the medical cannabis goods. In order to ensure that the printed test results that appear on the label of the packaging are accurate, the packaging of the medical cannabis goods must not be opened between the time the testing occurs and the time the medical cannabis goods are sold to the final user. Packaging or repackaging at the dispensary facility may result in contamination or adulteration of the medical cannabis goods, which would render the test results on the packaging inaccurate. In order to ensure that the label that was affixed to the packaging of the medical cannabis goods at the distributor’s facility are accurate, a dispensary must not be allowed to open the packaging or repackage the product prior to selling the medical cannabis goods to a customer. The section protects the public by ensuring accurate labeling and safe products.

§ 5184. Exit Packaging
This proposed regulation requires that there be an exit package and it be opaque and difficult to open for a child under the age of five. The federal regulation regarding packaging that is cited by the proposed section requires that the design of the package be such that it is difficult to open by a child younger than five years of age. Children under five are unlikely to be able to effectively identify medical cannabis goods. Therefore, in order to reduce the risk of a young child accidentally gaining access to medical cannabis goods and accidentally consuming the medical cannabis goods, the packages that the medical cannabis goods are stored in, must be difficult for a child younger than five years of age to open. Requiring that all medical cannabis goods be sold in a package that is opaque and difficult for a child to open reduces the risk that a child will see the contents of the package and be enticed to attempt to open the package. In the event that a child does attempt to open the package, the design of the package should prevent a child from successfully opening the package and consuming the medical cannabis goods inside.
This proposed section exempts certain specific medical cannabis goods from the exit package requirements. The reason for exempting these medical cannabis goods is that the medical cannabis goods are already packaged in an opaque container that is difficult for a child to open.

§ 5187. Delivery
Under current California law, an individual must be at least 21 years old to legally possess cannabis without a recommendation.

MCRSA mandates the bureau to craft regulations that ensure a safe and secure operation of the commercial cannabis market. MCRSA also permits delivery by dispensaries; however it does not clarify safety and security measures to be implemented. Under current California law, individuals under the age of 21 years are permitted to work and potentially deliver medical cannabis goods. Proposed subsection (b) requires that all delivery employees be at least 21 years old. This is important to keep medical cannabis out of the hands of minors.

Proposed subsections (a) and (c) require that all deliveries be performed by an employee of the licensee and that no deliveries of medical cannabis goods be performed by an independent contractor or a courier service on behalf of the dispensary. The purpose for these requirements is to ensure that the licensee maintains as much control as possible over the delivery process. The licensee and its employees are responsible for following the rules pertaining to delivery. By requiring that only licensee employees be allowed to perform deliveries, this proposed section ensures that the licensee retains all responsibility.

Proposed subsection (d) requires in person deliveries. The reasoning for this requirement is so that the delivery employee can verify the identity of the medical cannabis patient or primary caregiver requesting the delivery before providing the medical cannabis goods to the customer. Additionally, the use of drones or other automated delivery vehicles may result in an increased risk of loss due to theft and other crimes. An automated delivery vehicle may present as a target for theft.

Proposed subsection (e) clarifies when a delivery begins and ends. This proposed subsection specifies that the process of delivery begins when the delivery employee leaves the licensed premises with the medical cannabis products to be delivered, and ends when the delivery employee returns to the licensed premises after completing the deliveries. This is important to specify when a delivery begins and ends so that delivery employees will be informed as to when they are required to comply with all of the requirements for actively performing a delivery.

Proposed subsection (f) requires that the delivery employee always carry a copy of the dispensary’s license, the employee’s identification card, and an employee badge while making deliveries. The requirement to maintain these documents while making deliveries is required by Business and Professions code section 19340.
Proposed subsection (g) requires that the dispensary maintain a list of their delivery employees. It is important for the dispensary to maintain a list of delivery employees. A dispensary must be able to identify all of the individuals who are actively performing deliveries on behalf of the dispensary.

Requiring that identifying information of delivery drivers be kept and maintained provides the bureau with the necessary information to properly and effectively audit the licensed dispensary. Ensuring only employees of the licensee are permitted to deliver medical cannabis goods and that the delivery be done in person provides the bureau the ability to take appropriate action against a licensee’s license for improper activity or malfeasance during delivery. This section also further clarifies the statutory intent behind the MCRSA, by limiting the age of majority for delivery drivers helping to ensure individuals who handle and have dominion and control of the medical cannabis goods are 21 years old or older.

§ 5190. Delivery to Physical Address
Under MCRSA, delivery is permitted, but the law does not provide any specific guidance or limitation on how to avoid conflicts with federal law or regulation. Clarity is needed to identify what delivery locations and methods are permissible. The bureau’s selection of acceptable delivery locations and roadways to get to the desired location, limiting the route to be entirely encompassed within the state, are to mitigate the intersection of regulation and conflict of federal law. Not specifying the actual location of the final delivery transaction would potentially permit delivery to occur at any location, including parks, near schools, and other unauthorized locations. Also, without a clear and specific recorded delivery location, bureau enforcement and compliance investigations would be significantly impeded.

Proposed subsection (a) requires that all deliveries be made to a physical address in California. By requiring the delivery of medical cannabis goods to a specific physical address, the bureau is able to effectively track that all medical cannabis goods are reaching medical cannabis patients or primary caregivers in California and are not being diverted into the illegal or unregulated market or to other states.

Proposed subsection (b) requires that a delivery employee not leave the State of California while delivering medical cannabis goods. By requiring the delivery of medical cannabis goods to locations and routes wholly within the State of California, the proposed regulations helps to mitigate the conflict with federal narcotics laws.

Proposed subsection (c) prevents a dispensary from making a delivery to an address on publicly owned or leased land or buildings. This provision also mitigate the intersection of regulation and conflict of federal law by not allowing the delivery of medical cannabis to national parks, federally owned buildings, or other government-owned properties.
§ 5193. Methods of Delivery

The MCRSA mandates the bureau to craft regulations that ensure a safe and secure operation of the commercial cannabis market. MCRSA permits dispensaries to deliver medical cannabis goods but does not provide clarification on how the delivery is to be executed.

This proposed section is necessary to mitigate potential theft, diversion into the illegal and unregulated market, and unsafe licensed activities while the medical cannabis goods are being delivered. The provisions in this proposed section are intended to reduce the risk of theft of product. Providing delivery vehicle information allows the bureau to accurately and expeditiously identify vehicles eligible for inspection.

Proposed subsection (a) describes the requirements for a vehicle used in the delivery of medical cannabis goods. The vehicle is required to be an enclosed motor vehicle in order to decrease the risk of any medical cannabis goods in the vehicle being stolen.

Proposed subsection (b) requires that the delivery employee ensure that any medical cannabis goods that are being delivered are not visible to the public. This requirement limits the risk of the delivery employee becoming a target of theft or other criminal activity.

Proposed subsection (c) requires that medical cannabis goods not be left unattended in a car that is not secured with an alarm system. This reduces the risk of medical cannabis goods being stolen from within the delivery vehicle while the delivery staff is making the delivery.

Proposed subsection (d) requires that all delivery vehicles be outfitted with a device for tracking the vehicle’s geographic location. The subsection requires that the device be permanently or temporarily affixed to the vehicle. The subsection also requires that the device be functioning the entire time the vehicle is making deliveries. It is essential that a licensed dispensary have a record of where its delivery vehicles are located at all times and that the bureau can be provided that information for enforcement purposes. The devices must be affixed to the vehicle at all times during delivery so that the device is not removed from the vehicle while the delivery employee is making a delivery. This is likely to happen if the device being used is a cellular phone. In addition, if a delivery vehicle with medical cannabis goods inside of it is stolen, it would be beneficial to have the tracking device inside of the vehicle for tracking purposes.

Proposed subsection (e) requires the licensee to provide the bureau with information pertaining to delivery vehicles, including the make, model, color, VIN, and license plate number. These requirements are important in order for the bureau to effectively monitor that licensees are properly conducting deliveries.

Subsection (f) allows the bureau to inspect any vehicle that is used for delivery. This is important for the bureau’s ability to effectively monitor licensees and ensure that the delivery vehicles meet the requirements.
§ 5196. Delivery Hours of Operation
The MCRSA mandates the bureau to craft regulations that ensure a safe and secure operation of the commercial cannabis market. The MCRSA does not provide clarity as to the delivery hours of operation for commercial cannabis businesses.

In order to mitigate potential theft, diversion, and unsafe activity, the medical cannabis goods delivery is limited to the hours proposed. During the hours of 9 p.m. and 6 a.m., there is an increased risk of crime due to the fact that it is darker and there are fewer people out in public. Data indicates that violent crime peaks at 10 p.m. and is at a low point by 6 a.m. By starting deliveries at 6 a.m. and ending deliveries at 9 p.m., the proposed regulation would permit the dispensary to deliver the product to the medical cannabis patient or primary caregiver while providing the flexibility for delivery after the end of the traditional work day at 5 p.m. while avoiding the period of time when there is an increased risk of theft or other crime.

§ 5199. Medical Cannabis Goods Carried During Delivery
The MCRSA mandates the bureau craft regulations that ensure a safe and secure operation of the commercial cannabis market. The MCRSA does not provide clarity as to the permissible amount medical cannabis goods that may be sent out of the dispensary for delivery.

This proposed section is necessary to mitigate diversion into the illegal and unregulated market, and prevent unauthorized sales. Limiting the amount of medical cannabis goods that a delivery employee may carry also limits the amount of loss that may occur in the case of theft as well as reducing the risk of consumption during delivery. The bureau has determined that $3,000 is an appropriate maximum amount for a delivery employee to carry in the vehicle, allowing for multiple deliveries but not too much of a large amount. Based on an average order of approximately $100, a delivery person would be able to make approximately 30 deliveries in one trip.

§ 5202. Medical Cannabis Consumption During Delivery
The MCRSA mandates the bureau craft regulations that ensure a safe and secure operation of the commercial cannabis market. This section is necessary to protect public safety by ensuring that drivers are not making deliveries while impaired.

§ 5205. Delivery Request Receipt
Business and Professions Code section 19340, subsection (d), mandates each delivery be accompanied by a receipt; however it fails to specifically identify what information is to be captured on the receipt. The Business and Professions Code also does not clearly state the manner and method of receipt collection and retention.

Proposed subsection (a) lists the information that is required to appear on the delivery request receipt. The name and address of the dispensary is necessary to identify the dispensary that completed the delivery. The name of the delivery employee is also important to identify the identity of the individual employee who performed the delivery. The name of the employee who
prepared the delivery is important because if the employee who delivered the medical cannabis goods was not the same employee who prepared the delivery, any problem with the preparation of the order would be attributable to the preparer and not the delivery employee. This information is required to identify the preparing employee. The identity of the medical cannabis patient who requested the delivery is important because the identity of the patient may need to be verified. Additionally, his or her status as a valid medical cannabis patient or primary caregiver may require verification as well. The date and time the delivery request was made and completed is important for the identification of the transaction. The delivery address is necessary because the bureau may need to verify that the delivery was made to a valid California address. Additionally, the bureau or law enforcement may need to get in contact with the medical cannabis patient who requested the delivery in the event of an investigation. A description of the medical cannabis goods delivered and the total amount paid for the delivery is important to identify the transaction. Additionally, information regarding the medical cannabis goods sold and the amount paid may be vital in the case of an investigation and to track the product was legally sold to a patient or primary caregiver. The signature of the customer who received the delivery is important in verifying that the customer did in fact receive the order.

Proposed subsection (b) requires that the delivery employee provide the customer with a copy of the receipt and bring a copy of the receipt back to the dispensary. This is important because it provides the customer with an opportunity to verify the transaction before signing the receipt. Also, by having to maintain copies of all transactions, in the case of an investigation, a dispensary will be able to provide any information on every delivery it performed.

Proposed subsection (c) requires that all laws regarding patient privacy be followed in the preparation of the delivery receipt. This is a restatement of a requirement in Business and Professions Code section 19340.

This section is necessary to effectively track medical cannabis goods deliveries. Ensuring that every transaction is associated with a legitimate sale to a medical cannabis patient or primary caregiver is vital to preventing the entry of untested medical cannabis goods into the market and diversion of medical cannabis goods into the illegal unregulated market. By clearly identifying what information is required, this section provides the bureau unique and specific information which can be utilized during dispensary audits. Requiring the receipt be prepared in advance of the delivery helps to prevent diversion of medical cannabis goods and ensures that all medical cannabis goods leaving the dispensary are accounted for.

§ 5208. Delivery Route

By not clearly defining an approved delivery route, a dispensary has unfettered freedom of movement. This freedom could potentially increase the opacity of the activity, making diversion and illegal activity more likely to occur. Without a clearly defined delivery plan, enforcement of proper and improper activity is more difficult.
This section is necessary to ensure medical cannabis goods stay within the designed supply chain and prevent diversion and other illegal activity. This section requires that delivery employees travel between the licensed dispensary to the delivery address, from one delivery address to another delivery address, or from a delivery address back to the licensed dispensary. This requirement lowers the duration that product is on route, which lowers the risk of loss due to theft or other crime. This section also recognizes the need for flexibility in delivery of medical cannabis goods and provides reasonable exceptions for justifiable delivery path deviations.

§ 5211. Producing Dispensary License
Business and Professions Code section 19334, subsection (a)(3), indicates that the holder of a Type-10A may hold up to three Type-10 dispensary licenses as well as a cultivation or manufacturing license, or both. Additionally, section 19334, subsection (a)(3), indicates that each dispensary owned by the holder of a Type-10A license must be individually licensed. This proposed regulation clarifies that the holder of a Type-10A license must also hold at least one Type-10 dispensary license and must assign the Type-10A license to a Type-10 dispensary facility held by the same person. This section provides clarity regarding the rules for Type-10A licensure.

§ 5214. Storage of Inventory
The purpose of this section is to preserve the safety and security of the licensed premises and the medical cannabis goods stored on site by providing licensees with rules for the storage of inventory of medical cannabis goods. It is important for licensed dispensaries to secure their inventory in order to decrease the risk of theft or other crimes and to maintain the quality of the medical cannabis goods.

Proposed subsection (a) requires that a dispensary’s storage area be in a building (no outside storage is allowed) that has temperature and humidity control. Temperature, light, and humidity alter the chemical composition of cannabis, and therefore a dispensary’s storage facility should be such that these conditions can be controlled for.

The exact storage temperature and humidity are not articulated in this proposed regulation except for edibles and harvest batches because ideal conditions may vary depending on product. There should, however, be ways to control the temperature and humidity at the dispensary premises, and in no case shall the dispensary allow medical cannabis goods be stored in direct sunlight.

Subsection (a) also requires that the dispensary store medical cannabis goods in a building in which the entry of environmental contaminants like smoke and dust may be prevented. Because all medical cannabis goods will be tested by a testing laboratory and labeled according to those test results, it is imperative that new contaminants are not introduced into the medical cannabis that is being stored at the dispensary’s premises during testing.
For the same reason, proposed subsection (b) requires all kitchen and eating areas, changing rooms for employees, and bathrooms be completely separate from medical cannabis goods storage areas.

Proposed subsection (c) requires that edible cannabis products requiring refrigeration and harvest batches (dried flower) be refrigerated and kept in a darkened area. There is also a requirement that harvest batches not be exposed to greater than 60% humidity. The bureau has determined that maintaining a specific temperature and humidity range is an effective way to ensure that the medical cannabis goods do not degrade or change in a way that would render the testing laboratory results inaccurate. The bureau has determined that edible cannabis products should be refrigerated at 35 to 42 degrees in order to maintain the integrity of the goods. The bureau has also determined that storing medical cannabis at 60% humidity or less is necessary to prevent degradation.

§ 5217. Receiving Shipments of Inventory
This section clarifies that all shipments of inventory be delivered by a licensed transporter as required under Business and Professions Code section 19326. This proposed regulation limits the time a licensed dispensary may accept shipments of inventory to between 6:00 a.m. and 9:00 p.m. Dispensaries face an increased risk of theft or other crime while receiving shipments between the hours of 9:00 p.m. and 6:00 a.m. This is due to the fact that it is typically darker at this time and there are fewer people out in public. By requiring dispensaries to avoid receiving shipments of inventory during these times, the dispensaries are able to reduce the risk of theft or other crime that may occur while a dispensary is receiving a shipment of inventory. This section requires that dispensaries receive shipments of inventory through an entryway that is not used by the public to enter or exit the premises. This reduces the risk of an individual who is not an employee of the licensee gaining access to the products that are being received by the dispensary. Requiring the use of an entryway that is free of customers and other non-employee individuals reduces the risk of theft or other crime that may occur while a dispensary is receiving a shipment of inventory. This section requires that dispensaries receive shipments of inventory immediately be placed in a secure location. The longer medical cannabis goods are held outside of a secure location, the greater the risk of theft or other crime. Requiring that inventory be immediately placed in a secure location after being received reduces the risk of theft or other crime that may occur while a dispensary is receiving a shipment of inventory.

§ 5220. Inventory Documentation
This proposed section requires that a dispensary keep records of specific information for all medical cannabis goods in the dispensary’s inventory. The information requested in subsections (a) and (b) is necessary for inventory documentation. By documenting the description of each item in the inventory and the amount of each item, a dispensary will know what items it should find in its inventory. Additionally, the bureau may use this information to cross-reference with the track and trace system to verify that all of the dispensary’s transactions and inventory levels were properly reported in the track and trace system.
The information requested in subsection (c) is required to ensure that the dispensary’s records are consistent with the information in the track and trace system. Subsection (d) is necessary to verify that the dispensary is not carrying any items for sale that are past their sell-by or expiration date if one is provided. The information requested in subsections (e), (f), and (g) are necessary for verifying that the information entered into the track and trace system corresponds with the dispensary’s inventory records.

All of the information required by this section is information that will allow of the identification of all medical cannabis goods in the dispensary’s inventory as well as information for tracking the movement of all products. In order for the bureau to effectively regulate its licensees, the bureau requires accurate information regarding the movement of medical cannabis goods. Requiring that all dispensaries keep records of this inventory information and make it available to the bureau will assist the bureau in effectively regulating its licensees.

§ 5223. Inventory Reconciliation

Inventory reconciliation is necessary in order to verify that the dispensary’s inventory record is accurate. Inventory reconciliation is an effective method for identifying diversion. If, through inventory reconciliation, a dispensary discovers that some amount of inventory is unaccounted for, an investigation of the possible diversion of the missing medical cannabis goods can begin with the goal of returning the missing medical cannabis goods and preventing that type of loss from occurring in the future. This section requires that inventory reconciliation occur at least every seven days. The reason for this requirement is that the inventory of a dispensary is constantly changing because the dispensary receives shipments of new medical cannabis goods and sells medical cannabis goods from its current inventory to customers. Regular inventory reconciliations ensure that the dispensary’s inventory is up-to-date and that any indications of diversion, theft, or loss are identified early. The bureau has determined that requiring inventory reconciliations every seven days will allow for the early identification of evidence of diversion, theft, or loss.

Business and Professions Code section 19334, subsection (e), requires that a licensed dispensary notify law enforcement and the licensing authority if a significant discrepancy in inventory is identified or if diversion, theft, or loss occurs. This section reinforces the dispensary’s responsibility to notify the licensing authority and law enforcement if the inventory reconciliation results in a significant inventory discrepancy or there is evidence of diversion, theft, or loss. The diversion, theft, or loss of any amount of medical cannabis goods is an important concern and should be taken seriously. However, in order to avoid over reporting due to loss that is experienced in the regular course of business, the bureau has decided to set the amount of a significant discrepancy at $1,000 in a seven day period or $2,000 in a 30 day period. The bureau has determined that inventory discrepancies at this amount would be much larger than the amount of medical cannabis goods that is expected to be lost during the regular course of business. The section requires that the value of any missing medical cannabis goods be measured at the price the dispensary paid to acquire the medical cannabis goods. That value is
used because the value is clearly recorded in the dispensary’s records and accurately represents
the value of the medical cannabis goods because it was the price the dispensary paid.

§ 5226. Record of Sales
The information required to be kept by these subsections is required for the bureau to effectively
enforce regulations regarding medical cannabis goods sales. The name of the licensed dispensary
employee is necessary for who completed the sale. The name of qualified patient or caregiver is
also necessary for identifying the other party to the sale transaction. The date and time of the
transaction is necessary for identifying when the transaction took place. The list of all medical
cannabis goods purchased is necessary to effectively audit the transaction if necessary. The total
price paid for the sale is also necessary to effectively audit the transaction.

These elements are needed because the record of each sale can be used by the bureau to monitor
dispensary activity and ensure that the dispensary is following the rules regarding sales. If it
becomes necessary for the bureau to investigate a specific sales transaction for enforcement
purposes, the information required by these subsections will aid the bureau in obtaining needed
information regarding the sale.

§ 5229. Grace Period for Compliance
Under the MCRSA, all medical cannabis goods that are sold by a dispensary are required to
undergo testing by a licensed testing laboratory. However, the transition to a regulated market
will take time. This section would allow a dispensary to continue to sell its existing inventory of
medical cannabis goods during the transition for 180 days after licensure or until December 31,
2018. The section also requires that any medical cannabis goods that are sold but have not been
tested must be properly labeled to inform the purchaser that the product has not been tested.

Additionally, dispensaries may package and sell medical cannabis not already packaged. This
will allow medical cannabis to be available as licensing of dispensaries and other commercial
cannabis businesses begins.

§ 5232. Dispensary Track and Trace Requirements
This proposed section specifies the transactions which are required to be entered into the track
and trace database by a licensed dispensary. The proposed section also provides as the
information that must be included with each entry. The track and trace system is intended to
track the movement of medical cannabis goods through the system. In order to effectively track,
each transaction in which medical cannabis goods are physically transferred, must be recorded.
All of the event listed below as events that must be entered into the track and trace system are
necessary for the effective functioning of the regulatory system.

Proposed subsection (a) requires that a dispensary record the receipt of medical cannabis goods
from a distributor or transporter into the track and trace system. Proposed subsection (a)(1)(A)
through (H) indicate the information that would be required to be entered into the track and trace
system. The information that is required by these proposed subsections is necessary to identify
the specific licensees and individuals who were involved in the transaction, the specific products that were involved in the transaction, and information regarding when the transaction occurred. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the system. Additionally, in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (b) requires that a dispensary record the sale of medical cannabis goods to a patient or primary caregiver into the track and trace system. Proposed subsections (a)(1)(A) through (F) indicate the information that is required to be entered into the track and trace system. The information that would be required by these proposed subsections are necessary to identify the specific licensees and individuals who were involved in the transaction, the specific products that were involved in the transaction, and information regarding when the transaction occurred. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the system. Additionally, in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (c) requires that a dispensary record the return of medical cannabis goods from a patient or primary caregiver into the track and trace system. Proposed subsection (a)(1)(A) through (F) list the information that is required to be entered into the track and trace system. The information that would be required by these proposed subsections is necessary to identify the specific licensees and individuals who were involved in the transaction, the specific products that were involved in the transaction, and information regarding when the transaction occurred. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the system. Additionally, in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (d) requires that a dispensary record the return of medical cannabis goods back to a distributor into the track and trace system. Proposed subsection (a)(1)(A) through (H) indicate the information that is required to be entered into the track and trace system. The information that would be required by these proposed subsections is necessary to identify the specific licensees and individuals who were involved in the transaction, the specific products that were involved in the transaction, and information regarding when the transaction occurred. All of this information is necessary for the effective monitoring of the movement of medical cannabis goods through the system. Additionally, in the event that an investigation is necessary, all of the basic information regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (e) requires that a dispensary record the destruction of any medical cannabis goods into the track and trace system. Proposed subsection (a)(1)(A) through (E) indicate the
information that is required to be entered into the track and trace system. The information that
would be required by these proposed subsections are necessary to identify the specific licensees
and individuals who were involved in the transaction, the specific products that were involved in
the transaction, and information regarding when the transaction occurred. All of this information
is necessary for the effective monitoring of the movement of medical cannabis goods through the
system. Additionally, in the event that an investigation is necessary, all of the basic information
regarding the transaction in question will be readily available in the track and trace system.

Proposed subsection (f) requires that a dispensary record the transfer of medical cannabis goods
to a distributor for destruction into the track and trace system. Proposed subsection (a)(1)(A)
through (G) indicate the information that is required to be entered into the track and trace system.
The information that would be required by these proposed subsections are necessary to identify
the specific licensees and individuals who were involved in the transaction, the specific products
that were involved in the transaction, and information regarding when the transaction occurred.
All of this information is necessary for the effective monitoring of the movement of medical
cannabis goods through the system. Additionally, in the event that an investigation is necessary,
all of the basic information regarding the transaction in question will be readily available in the
track and trace system.

§ 5235. Law Enforcement Notification
Business and Professions code section 19334, subsection (e), requires that the licensee notify law
enforcement and the bureau if any of the situations listed in this section occur.

This section clarifies the standard for notice that is required when a licensee becomes aware of or
has reason to suspect various things listed in Business and Professions code section 19334,
subsection (e). This restatement is necessary in order to reaffirm the licensee’s responsibilities
regarding contacting the bureau and law enforcement if evidence of crime or loss is found.
Additionally, the term “significant discrepancy” was used in Business and Professions code
section 13334, subsection (e), but the term was not defined in the MCRSA. The term “significant
discrepancy” was defined in these proposed regulations, and in order to clarify that the
definition in the proposed regulations is the definition to be applied to the licensee under
Business and Professions code section 19334, subsection (e), the code section was restated in the
proposed regulations.


16. Pre-Regulatory meeting notes from the following:
   a. September 19, 2016 – Redding
   b. September 20, 2016 – Sacramento
   c. September 22, 2016 – Santa Rosa
   d. September 26, 2016 – Oakland
   e. September 27, 2016 – Fresno
   f. October 4, 2016 – Los Angeles
   g. October 5, 2016 – San Diego
   h. October 18, 2016 – Santa Ana


21. United States Attorney General Memorandum of Guidance


INTERNATIONAL COMPARISONS

International cannabis control regimes vary greatly, with some countries allowing the use of cannabis for medicinal purposes, while others ban the use of cannabis entirely. The proposed regulations are intended to align California’s cannabis regulations with international best practices and to ensure that California’s cannabis industry is competitive with other jurisdictions.

The proposed regulations are expected to increase the total compliance cost by $524 per pound. The proposed regulations are expected to result in an increase in the medical cannabis industry’s revenue by $113 million with a decrease in quantity sold by 5,000 pounds when compared to the non-regulated baseline. The lower-cost alternative is expected to increase compliance costs by $225 per pound, or $299 per pound less than the proposed regulations. The lower-cost alternative is expected to result in an increase in the medical cannabis industry’s revenue by $71 million with an increase in quantity sold by 8,000 pounds when compared to the non-regulated baseline. The higher-security alternative is expected to increase compliance costs by $873 per pound or $349 per pound more than the proposed regulations. The higher-security alternative is expected


ALTERNATIVES CONSIDERED

In considering the proposed regulations, the bureau considered a lower-cost alternative and a higher-security alternative. The proposed regulations impose a 10 pound maximum batch size for testing. The proposed regulations also require the use of an enclosed vehicle for deliveries of medical cannabis and allow for one dispensary employee to make deliveries on their own. Additionally, the proposed regulations require that licensees maintain security cameras in specific locations with at least a 1280 x 1024 resolution at a minimum of 20 frames per second. The proposed regulations also require that video footage be stored for at least 30 days.

The lower cost alternative would remove the maximum batch size for testing. The lower cost alternative would also allow for delivery using a bicycle, motorcycle, or scooter in addition to enclosed vehicles. Like the proposed regulations, the lower cost alternative would allow for one employee to make deliveries by themselves. The lower cost alternative does not have any security-video requirements.

The higher-security alternative would lower the maximum batch testing size to five pounds. The higher-security alternative would also require the use of enclosed vehicles for delivery, but would require that at least two employees make deliveries together. Additionally, the higher security alternative would require security cameras to be placed at specific locations. Under the higher-security alternative would require that the cameras record at least at a resolution of 1280 x 2024 at a minimum of 20 frames per second and that the footage be stored for at least 90 days.

The proposed regulations are expected to increase the total compliance cost by $524 per pound. The proposed regulations are expected to result in an increase in the medical cannabis industry’s revenue by $113 million with a decrease in quantity sold by 5,000 pounds when compared to the non-regulated baseline. The lower-cost alternative is expected to increase compliance costs by $225 per pound, or $299 per pound less than the proposed regulations. The lower-cost alternative is expected to result in an increase in the medical cannabis industry’s revenue by $71 million with an increase in quantity sold by 8,000 pounds when compared to the non-regulated baseline. The higher-security alternative is expected to increase compliance costs by $873 per pound or $349 per pound more than the proposed regulations. The higher-security alternative is expected
to result in an increase in the medical cannabis industry’s revenue by $105 million with a
decrease in quantity sold by 30,000 pounds when compared to the non-regulated baseline.

The lower-cost alternative was not chosen because the additional safety and security obtained
from the proposed regulations are important enough to warrant the additional cost. Adequately
monitoring the premises of licensees, preventing theft during deliveries, and ensuring adequate
and accurate testing are all very important in maintaining the safety and security of the public.
Additionally, the lower-cost alternative is expected to result in smaller industry revenue than the
proposed regulations. Therefore, the bureau elected to proceed with the proposed regulations
over the lower-cost alternative.

The higher-security alternative was not chosen because the higher costs of this alternative are not
warranted by the marginal increase in safety and security. Having at least two delivery
employees make deliveries does decrease the risk of theft while making deliveries. However, this
decrease in theft can be achieved through other methods without having to employ an additional
employee. For example, if a delivery employee ensures that the vehicle they use for deliveries
has all of the required security features, and the employee does not leave medical cannabis goods
in the vehicle unattended, the risk of theft can be decreased without the need for an additional
employee. The smaller maximum batch limit of 5 pounds as compared to the 10 pound limit in
the proposed regulations is expected to greatly increase cost, but provide very little benefit in
terms of more accurate testing. Also, the higher-security alternative is expected to have a smaller
increase in industry revenue when compared to the proposed regulation. Therefore, the bureau
has elected to proceed with the proposed regulations over the higher-security alternative.
Economic Costs and Benefits
of Proposed Regulations for
the Implementation of the
Medical Cannabis Regulation
and Safety Act (MCRSA)

Standardized Regulatory Impact Analysis

Prepared for the Bureau of Marijuana Control
by the University of California Agricultural Issues Center
April 7, 2017
Table of contents

1. Statutory authority ........................................................................................................... 87
2. Nature and scope of regulatory impacts considered ................................................... 88
3. Approach to economic modeling .................................................................................. 89
4. Overview of data collection and initial market conditions .......... 91
5. Baseline market conditions after adult-use ................................................................. 92
6. Overall market impact of the proposed regulations ................................................... 96

Table 1. Impact of proposed regulations on prices, quantities, revenues, and taxes for medical cannabis in California ................................................................. 98

7. Assessment of whether the proposed regulations meet the “major regulation” standard in Government Code § 11342.548 ................................................................. 101

8. Determination of the impact of the regulatory proposal on the state economy, businesses, and the public welfare, as described in Government Code § 11346.3(c) ... 102

9. Benefits of the proposed regulations, expressed in monetary terms to the extent feasible and appropriate ..................................................................................... 109

10. Types of costs considered for implementation of the proposed regulations ............ 110

11. Effects on the General Fund, special state funds, and affected local government agencies attributable to the proposed regulations .................................................. 110

12. Evaluation of two reasonable alternatives to the proposed regulation .................. 112

Table 2. Proposed regulations and two alternative regulatory packages: key axes of regulatory variation .................................................................................................. 113

Table 3. Estimated compliance costs per pound of proposed regulations and two alternative regulatory packages ........................................................................... 116

13. Final remarks ............................................................................................................ 117
Medical Cannabis Regulation and Safety Act (MCRSA)

Economic Costs and Benefits of Proposed Regulations
Standardized Regulatory Impact Analysis (SRIA)

The Bureau of Marijuana Control (bureau), formerly named the Bureau of Medical Cannabis Regulation and the Bureau of Medical Marijuana Regulation, will be proposing regulations to implement the Medical Cannabis Regulation and Safety Act (MCRSA), which establishes the bureau as the state’s licensing and enforcement authority for the distribution, transportation, testing, and dispensing of medical cannabis in California.

This Standardized Regulatory Impact Analysis is submitted for the purpose of evaluating the benefits and costs of the regulations proposed by the bureau, which will go into effect on January 1, 2018. The University of California Agricultural Issues Center (AIC) assessed the costs and benefits of the bureau’s proposed regulations and two alternative sets of regulations.

For some issues, the MCRSA provided detailed regulatory specifications that the proposed regulations implement precisely. For other issues, the MCRSA provided broader guidance about the regulations. This SRIA considers the full package of proposed regulations, including those that implement precise statutory requirements. AIC gathered detailed cost, price, quantity, and other information to assess the impact of the proposed regulations on the industry and on the state. The results of this analysis are presented in this SRIA with background information and details provided in the Appendix.

AIC’s analysis of the medical segment of the cannabis industry in California was conducted in the context of other cannabis segments in the state. Adult use of cannabis was legalized by Proposition 64 in the California general election of November 8, 2016, and is scheduled to be regulated alongside the medical segment beginning on January 1, 2018. In this document, we use the term “adult use” to refer to the segment of non-medical cannabis sales that will become legal and regulated starting in 2018. We use the term “illegal” to refer to the segment of unlicensed non-medical cannabis sales in California that is currently unlawful and will remain so in 2018.

After outlining statutory authority, this SRIA summarizes the scope of analysis and outlines AIC’s approach to the calculations of economic impacts. A key feature of the approach is defining a baseline against which to measure the economic impacts of the proposed
regulations. These direct economic impacts are characterized in terms of effects on prices, quantities, revenues and taxes.

After measuring the economic effects within the medical cannabis segment, AIC used a standard economy-wide model (IMPLAN) to project ripple effects on the California economy more broadly. The SRIA outlines findings in terms of employment, impacts on businesses, potential influence on broad indicators of benefits and costs, and government revenues. Finally, in addition to the benefits, costs and related impacts of the proposed regulations, AIC evaluated the benefits and costs of two alternatives: an alternative to represent a lower-cost package of regulations and an alternative to represent a higher-security package of regulations.

1. Statutory authority

The Medical Cannabis Safety and Regulation Act (MCSRA), which became effective in 2016, established the bureau within the California Department of Consumer Affairs and assigned to the bureau the responsibility of creating and administering a licensing and enforcement structure for the distribution, transportation, testing, and retail sale of medical cannabis in California.

Under Government Code section 11346.3, a California state agency proposing a “major regulation,” which Government Code section 11342.548 defines as “any proposed adoption, amendment, or repeal of a regulation subject to review by the Office of Administrative Law . . . that will have an economic impact on California business enterprises and individuals in an amount exceeding fifty million dollars ($50,000,000), as estimated by the agency,” is required to prepare a Standardized Regulatory Impact Analysis (SRIA) to be submitted to the state Department of Finance for review and comment before the regulations are noticed to the public.

The first requirement of a SRIA is that it must verify that the regulation under review meets the definition of “major regulation” under Government Code § 11342.548. The regulations adopted by the Department of Finance further define the threshold as $50 million in either costs or benefits occurring within one year of full implementation of the proposed regulations. The proposed regulations are scheduled to go into effect on January 1, 2018; therefore, the scope of consideration for the “major regulation” standard would be impact that occurs during the 2018 calendar year.
AIC calculations showed that these proposed regulations met the definition of “major regulation” in Section 7 below. In our approach to this and other determinations to be made in the SRIA, AIC relied on guidance from the 2015 joint report from the Office of Administrative Law and Department of Finance, which clarifies the interpretation of Government Code section 11346.3 with respect to SRIA content, purpose, and the “major regulation” determination.¹

2. Nature and scope of regulatory impacts considered

In order to isolate the effect of the proposed regulations from intervening factors that may also have major effects on the California medical cannabis industry, the analysis must recognize that other factors operating over the same time period may also affect the California cannabis industry. The most important expected change to the cannabis industry in California is the legalization of non-medical use of cannabis by adults 21 and over, as per Proposition 64. The relevant statutes, collectively known as the Control, Tax and Regulate Adult Use of Marijuana Act (AUMA), added adult-use as a legal segment of the total cannabis market, establish a new tax structure for medical and adult-use cannabis, and assign the bureau responsibility for regulating both California’s adult-use cannabis industry and medical cannabis industry.

The economic calculations and simulations reported below proceeded in three steps. First, we empirically assessed the November 2016 situation for medical cannabis in California. Second, in order to establish a relevant base for the regulatory analysis, we projected the impacts of legal sales of adult-use cannabis and taxation of all legal cannabis on the medical cannabis market segment. This step, which we call the “Taxation and Adult-Use Legalization,” provides the baseline against which the proposed medical cannabis regulations may be measured. Evaluating this baseline before evaluating the impact of regulations allows analysts to consider each of these two sets of effects independently. The third step, and central focus of the SRIA, is to calculate and simulate the impact of the proposed regulations on the medical cannabis segment separately from the effects of taxation and adult-use legalization. We call this final market scenario “Proposed Regulation.”

More precise definitions of each of these segments and simulated changes are set out in Appendix Chapter 5.

¹ November 1, 2015, report by the Directors of the Office of Administrative Law and Department of Finance to the Chair of the Senate Committee on Governmental Organization and the Chair of the Assembly Committee on Governmental Organization, SB 617 and Finance Regulations appended.
3. Approach to economic modeling

Measuring the economic impact of a regulation is contingent on estimating relevant baseline market prices, quantities, revenues, taxes, and related aggregates that would occur in the absence of the regulation. The creation of such a baseline is often not as simple as assuming current conditions continue to apply in the absence of the regulations, even when data about market conditions are readily available.

The economic data and modeling underlying this SRIA are unusually complex for two reasons: (1) the unavailability of much relevant government or other public data and unavailability of much relevant banking, accounting, or other private data; and (2) the necessity of developing a counter-factual projected baseline that enabled the analysis to estimate the separate effects of taxation and adult-use legalization from the impacts of the proposed regulations.

First, there are no official government data sources on output, prices, jobs, or other economic aggregates for the industry to which the proposed regulations on medical cannabis apply, and official tax collections reflect a minority of operating businesses. Because much of the industry to which the proposed regulations apply has long been prohibited by Federal law, normal industry data have not been reported in standard authoritative Federal sources.

Moreover, businesses have not reported their financial results in standard ways. In many cases, businesses have been operating with cash, outside of the normal banking system, in a quasi-legal, quasi-regulated manner. Furthermore, the closely related adult-use segment has been illegal even under state law.

The lack of reliable authoritative public or private data required AIC to develop estimates of data that would have been readily available for most other industries. For instance, we collected data from more than 500 dispensaries in California. Estimates of economic aggregates and relationships provided below are approximations based on the best available information as of November 2016.

Second, as noted in Section 2, the bureau’s MCRSA regulations are anticipated to take effect at the same time that AUMA legalizes adult-use cannabis, regulates sales of adult-use cannabis, and imposes taxes on both legal medical and legal adult-use cannabis. The joint launch of these two regulatory systems, which is expected to take place on January 1, 2018, creates legal sales in two cannabis segments—medical cannabis and adult-use cannabis. When in place, such a
system will enable many buyers who had previously been buying in the medical segment to shift purchases to the adult-use segment without any significant foreseeable switching costs. In addition, regulations related to the cultivation of cannabis, taxation of cannabis leaving the cultivation site, and regulation of the manufacturing of cannabis products will commence at the same time.

In order to isolate the impact of the proposed regulations in the relevant economic situation and context, AIC modeled and simulated the implications and effects of the emergence of a legal adult-use cannabis segment that is scheduled to exist side-by-side with the legal medical cannabis segment. This first simulation step also included the taxation of both legal cannabis segments (medical and adult-use) that are scheduled to accompany adult-use legalization.

These effects, created the baseline against which we simulated the impacts of regulations. We then analyzed the impacts of the proposed regulations on the medical cannabis segment in the context of the (hypothetical) cannabis industry with the baseline of taxation and adult-use legalization in place.

Let us illustrate the magnitude of the issue more concretely and foreshadow the estimates presented below. Based on our best assessment, the California medical cannabis segment, as of fall 2016, had aggregate revenue on an annualized basis of about $2 billion. After legalization of the cultivation and sale of adult-use cannabis and taxation of legal cannabis, but without yet considering the implications of the proposed regulations, economic calculations suggest that revenue in the medical cannabis segment will fall to about $600 million. Thus, the medical cannabis proposed regulations are likely to apply to a medical cannabis segment that is approximately 30% the size of the current medical cannabis segment.

Projecting the effects of market changes requires the specification of supply and demand response parameters. These are often expressed as elasticities. In this case, key estimates and assumptions include how responsive demand for cannabis overall is to prices and how responsive demand for cannabis in each segment is to relative prices in those segments. Simulation also requires evidence and assumptions about shifts in demand affecting each segment. On the supply side, we used assumptions about how responsive supply in each segment was to relative prices across segments. Evidence and assumptions about shifts in costs were required as well.
In summary, in order to isolate the impact of the proposed regulations, our procedure was to incorporate the changes to the marketplace step by step. Based on initial conditions for the November 2016 cannabis market, we first simulated the economic effects of taxation and adult-use legalization. Next, we incorporated the impact of the proposed regulations into the model and solved for economic aggregates. Finally, we assessed the impact of the proposed regulations by comparing the baseline taxation-and-adult-use-legalization scenario with a scenario that adds the effects of regulations on top of that baseline.

Finally, we assumed that the proposed regulations regarding the newly created legal adult-use cannabis segment (which are scheduled to be implemented at the same time as are the proposed regulations for medical cannabis) were expected to be similar to the proposed regulations for medical cannabis. Therefore, our analysis of regulatory impact assumes that both segments will become regulated with relatively small differences between the two.

4. Overview of data collection and initial market conditions

In constructing initial estimates of prices and quantities in the California cannabis market that applied in November 2016, AIC drew upon a variety of sources, including our own AIC retail cannabis price survey, which was conducted by several AIC researchers throughout the months of October and November, 2016 (details and results are in Appendix Chapter 4); third-party longitudinal retail and wholesale price surveys (Appendix Chapters 3 and 5); an AIC meta-analysis of published scientific journal articles, white papers, and government reports; and confidential AIC interviews with market experts and industry participants (Appendix Chapters 3 and 5). The appendix includes a complete list of references to documents cited and reviewed.

AIC started from estimates of the revenue of California medical cannabis dispensaries as of November 2016. There are no official or widely accepted industry estimates of the size of the medical cannabis industry in either revenue or quantity terms. AIC estimated that there is about $2 billion of total annual sales revenue (not including sales taxes collected) in the medical cannabis segment.

We developed that $2 billion revenue estimate as follows: The California Board of Equalization has estimated sales tax revenue from medical cannabis dispensaries was almost $60 million in 2015. No full year data were available for 2016. The statewide average tax rate is about 8.8% and that the rate of tax compliance was estimated at about one third. Using an effective tax rate of about 0.03 (0.088 times 0.34), $60 million in sales tax receipts implies industry revenue
of about $2 billion. Although an approximation, this estimate is in the range of other published estimates. (For more detail, see discussion and tables in Appendix Chapter 5).

Using data from the AIC survey, we observed the November 2016 market price of retail medical cannabis in California to be $3,453 per flower-equivalent pound. By flower-equivalent pound, we simply mean a unit of cannabis sold at retail that is equivalent to one pound of dried flowers for medical dispensary sales. More specifically, the data from the AIC survey (Appendix Chapter 4) provided information on a variety of prices from a sample of more than 500 dispensaries from many regions of the state. AIC collected data on prices of two package sizes for dried flowers and on prices of non-flower products. Unfortunately, no product quantities were available. AIC therefore used auxiliary information from interviews with industry participants and industry publications to develop weighted averages of product prices. AIC focused on the cannabis dried flower prices to create a flower-equivalent average price.

With the price of $3,453 per pound, the California medical dispensary sales revenue of about $2 billion implied a retail quantity of flower-equivalent units of approximately 583,000 pounds of medical cannabis sales on an annual basis.

AIC estimated that in November 2016, about 25% of total cannabis by volume (i.e. flower-equivalent pounds) that was sold in California was sold in the legal medical segment, and the remaining 75% was sold in the illegal segment. This estimate is based on the literature reviewed in Appendix Chapter 5 and interviews with industry participants. We estimate that as of November 2016, aggregate annual sales in the medical segment were $2 billion per year, sales in the illegal segment were $5.7 billion, and total cannabis industry sales were $7.7 billion.

5. Baseline market conditions after taxation and adult-use legalization

For about two decades, the only cannabis legally available for sale in California has been medical cannabis, which, according to the Brown Guidelines, can be sold only to California state residents over the age of 18 with doctors’ recommendations and for the use of those between ages 12 and 18 with parental guidance. In 2016, a doctor’s recommendation has been relatively easy to acquire, and receiving a recommendation has not required an in-person medical examination. Under the requirements of MCRSA, an in-person examination will be required. The general consensus of industry observers is that most consumers over the age of 21 in the medical cannabis segment could readily shift to the adult-use segment which would not require the added costly step of obtaining a doctor’s recommendation.
In some other states, the recent institution of the adult-use system has altered the trajectory of the previously existing market for medical cannabis. Revenues for medical cannabis in Washington State, for instance, fell by one-third in the first year after the legal adult-use cannabis system took effect, and by more subsequently. See Appendix Chapter 10 for details and references to comparative literature.

In California, buying in the medical segment will have no clear advantage over buying in the adult-use segment, with a few exceptions. Remaining buyers in the medical segment include buyers who are under 21, buyers for whom a medical dispensary is more convenient, and buyers for whom a medical recommendation is important to their personal acceptance of cannabis use (say, for personal values, family relationships, or job rules). Some high-volume buyers may find the legislated sales-tax exemption to be cost effective; however, eligibility requires obtaining a state-authorized identification card, which we estimate will cost about $100 per year.2 Current state records indicate that relatively few medical cannabis buyers (less than 7,000 annually for the past few years) have obtained a state-authorized identification card.3 The AIC analysis suggested that consumers who do not fit into one of the above exceptions could realize cost savings by switching from the medical segment to the adult-use segment, and we identified no economic constraints that might limit most consumers from switching.

There are also no apparent supply-chain advantages for the medical cannabis segment that might translate to lower consumer prices for medical cannabis relative to adult-use cannabis. Based on these and other reasons that are explained in greater detail in Appendix Chapters 5, 6, and 7, the AIC review of the evidence concluded that in the environment of 2018, California’s medical cannabis segment will be much smaller than it was at the end of 2016.

AIC analysis indicated that the opening of the market for adult-use cannabis and associated taxation will cause demand and supply in the existing cannabis market to change in several important ways that are relevant to the impact of medical cannabis regulations. First we specify three demand-side effects, and then we explain major supply-side effects.

5.1 Demand-side effects resulting from taxation and adult-use legalization

---

2 https://www.boe.ca.gov/pdf/1481.pdf
Demand effect (A): We estimated that 60% of current demand in the legal medical cannabis segment (the initial medical cannabis is 25% of total quantity in pounds, by assumption) will shift to the newly legal adult-use segment due to the lower annual transaction costs. Adult-use cannabis purchase does not require an annual doctor’s recommendation, which is costly for buyers of medical cannabis. Costs are likely to be $50 to $100 or more per year plus the cost of time and inconvenience. Relevant costs include an in-person doctor visit, which is mandated by MCRSA. In our models, demand effect A is represented as a reduction in the demand in the legal medical segment and an increase of the same magnitude in the legal adult-use segment. This demand effect is described in more depth in Appendix Chapters 5 and 7.

Demand effect (B): We projected that when legally allowed, slightly more than half of the demand currently in the illegal adult-use segment will quickly move to the legal adult-use segment to avoid the inconvenience, stigma, and legal risks of buying from an unlicensed seller. Of course, legal sales in the adult-use segment are not allowed until 2018. In our models, the demand effect B is represented as a reduction in demand of the current illegal segment counteracted by an increase in the newly-legal adult-use segment by the same magnitude. This demand effect is described in more depth in Appendix Chapters 5 and 7.

Demand effect (C): The third demand-side effect of taxation and adult-use legalization is a growth in the aggregate consumer demand for legal cannabis among consumers who were not previously in the California cannabis market at all. AIC modeled this as an increase in the demand for legal adult-use cannabis by about 9.4% of total cannabis sold in the period before taxation and adult-use legalization. This percentage was calculated by assuming an increase of 25% in the adult-use segment due to the demand of new buyers (i.e., 0.09375=0.75 x 0.5 x 0.25). (Recall that the initial illegal quantity was assumed to be 75% of total cannabis sales, by flower-equivalent pounds, before taxation and adult-use legalization. We estimated that about half of this illegal share would now shift to the newly legal adult-use segment.)

We expect this demand increase for two reasons. The first is new demand created by the opening of the cannabis market to consumers in the state who have interest in the product but have avoided it until now. Some of these potential consumers did not want to get a medical cannabis recommendation when they had no medical condition that warranted use. Moreover, many potential consumers may have avoided the illegal market because of inconvenience, legal risk, or unwillingness to participate in illegal drug activity because of moral concerns or social stigma.
The second component of the outward demand shift resulting from adult-use legalization is new demand created by the opening of the cannabis market to California’s out-of-state leisure and business visitors. There are more than 260 million visits to California from residents of other places per year. These visitors spend more than $122 billion in California.\(^4\) A significant portion of this spending is on leisure goods and services. For instance, tourists have been estimated to spend $7.2 billion per year on wine in California.\(^5\) Demand for new forms of leisure spending by tourists and other visitors to California is potentially large. Given that adult-use cannabis remains illegal in most other states, California’s legalized adult-use industry may attract some new visitors whose primary reason for visiting the state is cannabis tourism, as has been observed in Colorado. This effect is discussed in the context of tourism survey data from Colorado in Appendix Chapter 10 and modeled in Appendix Chapter 7.

### 5.2 Cost reduction effects resulting from taxation and adult-use legalization

As cannabis is moved more into the mainstream of the economy through legalization of adult-use cannabis, suppliers have better access to capital, technology and management. With legalization of adult-use cannabis, sellers have a lower chance of loss from forfeiture and lower probabilities of criminal prosecution. Recent data have shown that the cannabis industry has unusually high costs compared production and marketing other agricultural products, and that many of these costs, including risk premiums, can be attributed to the illegality of adult-use cannabis sales prior to November 2016. This is reflected in the large differences (large compared with non-cannabis industry norms) that AIC and other industry observers have documented between costs per unit reported by businesses and receipts per unit at each stage in production, processing, distribution, and retailing of both medical and illegal cannabis.

AIC anticipates that adult-use legalization will result in a 35% reduction in the costs of supplying formerly illegal cannabis, which in this scenario now becomes legal adult-use cannabis without state regulation. We assume a smaller 20% reduction in the costs of the medical cannabis when adult-use legalization occurs. The costs in the medical cannabis segment fall as the cannabis industry as a whole becomes more mainstream and more investment, better management and improved practices are adopted throughout the supply chain. More information on these assumptions is found in Appendix Chapters 3 and 6, and are modeled in Chapter 7.

---


Finally, a new system of taxes accompanies adult-use legalization. The excise tax of 15% on retail revenue was added to the existing sales tax. The sales tax is about 8.8% for cannabis sales (7.5% state sales tax and a 1.3% average of local sales taxes that vary across the state). We assumed that the new $9.25 per ounce tax on cultivation in the legal segments was incorporated into the cost of raw materials. We assumed full compliance after taxation and adult-use legalization.

The changes in demand, costs, and taxes, as included in our simulation of the California cannabis market, can be summarized as follows. Once these market changes are incorporated, the legal, adult-use segment will have about 61.5% of the overall market as measured in pounds. The unregulated illegal segment will have about 29.5% of the overall market, and the legal medical cannabis segment will have about 9% of the overall market.

Our regulatory impact analysis used this hypothetical taxation-and-adult-use-legalization scenario of prices, quantities, and taxes as the baseline. We evaluated the impact of regulations relative to this baseline.

6. Overall market impact of the proposed regulations

AIC simulated the impacts of taxation and adult-use legalization in order to identify the expected economic effects of the proposed medical cannabis regulations. Controlling for taxation and adult-use legalization before inputting the regulatory impact factors into our simulations was necessary to isolate the economic impact of the proposed regulations from the impact of taxation and legalization of adult-use cannabis.

6.1 Drivers of economic impacts of proposed regulations

The economic effects of the proposed regulations on market aggregates derive from two sources: (1) the costs imposed on the industry by the regulations compared with the situation without regulations but with taxation and adult-use legalization, and (2) an increase in consumer willingness to pay for the regulated product compared with the situation without regulations but with taxation and adult-use legalization.

First, the regulations impose costs on the cannabis industry. Details about components of the industry costs of complying with the proposed regulations are described below in Section 12. In that section, compliance costs of the proposed regulations are compared with compliance costs
of two alternatives: an alternative package of lower-cost options and an alternative package of higher-security and higher-cost options. Recall that the proposed package of regulations includes those that were specified in detail in the MCSRA. The costs of compliance, and the data and calculations underlying them, are discussed in more detail in Appendix Chapter 6.

Overall, we found that the proposed regulations (compared to no regulations) add approximately $520 per pound of marketable dried-flower equivalent in direct operating costs. Most of the addition to costs, about $400 per pound, is due to the added costs of cannabis testing. In addition to regulations that have direct quantifiable costs, we model proposed regulations, which are based directly on the MCRSA, to restrict vertical integration of dispensaries into distribution or transport, which is required under MCRSA. AIC approximated the costs of restrictions on vertical integration as an added cost equivalent to a 1% increase in costs relative to the situation without regulation but with taxation and adult-use legalization.

In the simulation models, AIC specified that the cost increase in the medical segment caused by the proposed regulations was approximately 16% of the initial value of $3,453 per flower-equivalent pound. This was calculated as $520/$3,453 plus the 1% for the vertical integration restrictions.

The adult-use regulations are expected to be similar to the regulations regarding medical cannabis, thus AIC expected regulatory costs to be similar for the adult-use segment. Price in the adult-use segment is estimated to be about 5% lower than the price in the medical segment. Therefore, the direct cost of regulations as percentage of the base was calculated as: $520/$3,280 = 16%. This percentage was applied in the AIC simulations because the limits on vertical integration are less restrictive in the adult-use cannabis segment (a 20% vs. 5% limit on ownership across multiple tiers).

The second source of economic effects of the proposed regulations is an increase in consumer willingness to pay for legal cannabis that has more security, traceability, labeling information, and intensive product testing. In the AIC simulation the increase in willingness to pay modeled as equivalent to an increase of 6% in demand compared with the situation without regulation but with taxation and adult-use legalization. We discuss increased willingness to pay for government regulations on product traceability, testing and labeling with reference to some of the relevant literature in Appendix Chapters 5, 7, and 8.

6.2 Economic impacts on price, quantity, revenue and tax
Summary results for the medical cannabis segment are reported in Table 1. (Detailed estimates of market prices, quantities, revenues and taxes are reported in Appendix Chapter 8.) Column 1 lists variables of interest: cannabis price per pound, tax rate per pound, quantity in pounds, segment revenue and segment sales and excise taxes paid to governments. Column 2 presents simulated values for estimates of prices, quantities, revenues, and taxes for medical cannabis with adult-use legalization but without regulations. Note that the industry revenue (without including sales and excise taxes) is about $601 million and tax revenue is $143 million. Column 3 reports prices, quantities, revenues, and taxes with the proposed regulations imposed. In this column the market price is higher (because costs per unit rise with regulations) and the quantity is slightly lower than the corresponding estimates in column 2. In column 3, the revenue of the medical cannabis segment is $714 million and tax revenue is $170 million.

Column 4 reports the effects of the regulations on the medical cannabis segment by subtracting column 2 from column 3. In column 3, price is higher by $551 per pound, quantity is lower by about 5,000 pounds, revenue is higher by $113 million and tax receipts are higher by $27 million than the baseline figures in column 2 which depict the scenario of taxation and adult-use legalization with no regulation.

Table 1. Impact of proposed regulations on prices, quantities, revenues, and taxes per pound for medical cannabis in California

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline with taxation and adult-use legalization</th>
<th>After regulation imposed on the baseline</th>
<th>Difference: after regulation from the baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price per pound without tax</td>
<td>$2,556</td>
<td>$3,107</td>
<td>$551</td>
</tr>
<tr>
<td>Tax rate per pound</td>
<td>$608</td>
<td>$739</td>
<td>$131</td>
</tr>
<tr>
<td>Quantity, pounds</td>
<td>235,000</td>
<td>230,000</td>
<td>-5,000</td>
</tr>
<tr>
<td>Revenue without tax</td>
<td>$601 million</td>
<td>$714 million</td>
<td>$113 million</td>
</tr>
<tr>
<td>Tax revenue</td>
<td>$143 million</td>
<td>$170 million</td>
<td>$27 million</td>
</tr>
</tbody>
</table>

Source: Results derived from simulations of effects of taxation and adult-use legalization in the first step and then regulations imposed on that baseline. Pounds are dried-flower equivalent.
6.3 Summary of economy wide impacts of proposed regulations on the medical cannabis segment

The medical cannabis-specific effects summarized in Table 1 were introduced into a modified IMPLAN model in order to determine AIC estimates of economy-wide impacts. These economy-wide impacts are summarized in this section, with more discussion and comparisons provided in Appendix Chapter 9.

The IMPLAN database, which uses U.S. industry classifications, does not have cannabis industry categories. Therefore, to approximate the economy-wide impacts, AIC first specified industries that were as close a match as possible to the medical cannabis sectors required for the analysis. Then the economic ratios in these matching industries were modified based on available data for the corresponding cannabis sectors. For medical dispensaries, AIC modified some of the ratios in the retail drug store industry (IMPLAN industry 401) to better reflect shares of costs of goods sold. The allocation of industry revenue minus costs of goods sold to taxes and other costs was modified using data that were available from the AIC review of medical cannabis dispensary accounting costs, a process that is detailed in Appendix Chapter 3.

For medical cannabis distribution businesses, the IMPLAN wholesale trade industry was the closest match (industry 395). The main adjustment was for the ratio of price to distributors minus costs of goods sold to better fit AIC data on medical cannabis costs. Note that the dollar value of output for retail and wholesale industries in IMPLAN is based on the difference of price minus cost of goods sold times quantity in the sector. That is, these companies are assumed to provide output in terms of wholesale or retail services added to the cost of goods that pass through the industry.

The information on the IMPLAN courier services industry was the closest match to the medical cannabis transport sector. No data were available to modify the IMPLAN ratios for this sector. The closest IMPLAN match for laboratory testing of medical cannabis was medical and diagnostic laboratories. No data were available to adjust the economic ratios for that sector.

As noted, AIC calculations in the IMPLAN analysis were based on the simulation model results for market prices and quantities (presented in Table 1). The model input included detailed data on costs of regulations, which were especially important for the testing sector. The IMPLAN results are presented at the change in the value of output, value added, and jobs compared to
the baseline situation with adult-use cannabis legalization but without the proposed regulations.

Based on the IMPLAN simulations, in the dispensary sector, the output in the sector (measured by revenue above costs of goods sold) rises compared to the no-regulations baseline by $43 million, value added rises by $34 million, labor income rises by $18.5 million, and direct jobs rises by 456 jobs. After considering multiplier impacts, the California economy-wide value added rises by $54 million, and 655 added jobs may be attributed to the increase in dispensary value of output. In the distribution sector, margin rises by $12.5 million and number of direct jobs rises by 60. The total number of jobs in California attributable to distribution rise by 136. Transport revenue changes very little, because quantity shipped falls slightly, but value of shipments rises. Jobs change very little in the transport sector.

Under the regulations, the expanded laboratory testing sector is subject to significant new economic activity. Revenue rises by $90 million; direct value added rises by $61 million; and the number of jobs in the sector rises by 713. Economy-wide value added attributable to the testing expansion rises by $119 million, and the number of jobs economy-wide rises by 1,290. Overall, the economy adds 1,223 jobs in the medical cannabis sectors. Overall, jobs in California rises by 2,071 jobs.

These impacts are expected to be distributed geographically across California roughly in proportion with populations. Some evidence (discussed in Appendix Section 5.4) suggests that cannabis use is particularly prevalent among young adults. Thus there may be some concentration of dispensaries and resulting multiplier effects in locations with more young people, including urban centers.

**6.4 Comparison of regulated scenario with 2016 scenario**

Based on our comprehensive review of industry information and especially data and assessments from California tax authorities that we detailed in the appendix to the SRIA, we estimated that medical cannabis sales were about $2 billion (retail value) in the fall of 2016 (on an annual basis). The AIC survey of medical cannabis dispensaries across a wide range of locations in California found a representative retail price of about $3,450 per pound. Hence, the implied quantity of medical cannabis is about 580,000 pounds on an annual basis before taxation and legalization.
The regulation scenario presented in Table 1 of this SRIA indicates 230,000 pounds at a price without tax of about $3107 per pound and tax of about $739 per pound.

When regulations are placed on top of taxation and legalization of adult-use, the quantity of medical cannabis is projected to be about 60% smaller than the quantity in the fall of 2016. The price including state taxes is projected to be about 11.4% higher than the price in the fall of 2016 and the price excluding taxes is projected to be about 10% lower than the price in the fall of 2016.

The economy-wide impacts of the proposed regulations summarized in this SRIA are largely based on the increased revenues from higher prices under the regulated scenario compared to the baseline that included taxation and legalization of adult use cannabis. However, annual revenue under the proposed regulation is projected to be about $883 million or about 56% lower than the annual revenue of $2 billion in the 2016 situation. We expect the economy-wide contributions of medical cannabis to be commensurately lower compared to the earlier economic situation of the industry. As noted in this SRIA, we expect most of the shift of consumption away from medical cannabis to be associated with a shift into adult use cannabis as sales in that segment become legal and regulated.

7. Assessment of whether the proposed regulations meet the “major regulation” standard in Government Code § 11342.548

After performing the analyses described above, we have determined that the total economic impact of the proposed regulations exceeds the one-year $50 million minimum economic impact threshold, as measured by costs or benefits, that is required for the proposed regulations to meet the standard for a “major regulation” for the purposes of Government Code § 11342.548.

As noted, this SRIA calculated the impact of a package of regulations by comparing the economic outcome in the market situation without regulations in place against the economic outcome in the situation with the proposed regulations in place, all other things being equal (here, including, especially, the assumption that taxation and adult-use legalization applies either way). Using this definition of impact, we calculated the effect on medical cannabis segment revenue as $113 million per year. We calculated that consumer expenditure rose by
$140 million (because of the tax component); see Table 1 above for details.\textsuperscript{6} We also note that the impact applies to the market after some initial short-term dislocations in the market are settled. The short period just after implementation of taxation and adult-use legalization and the proposed regulations may have even more economic impact on the industry if the cannabis market is in a state of flux temporarily.

Measured benefits of the proposed regulations to buyers are reflected in their higher willingness to pay per pound of medical cannabis with the proposed regulations in place. Note that quantity falls very little with substantially higher prices, and therefore consumer expenditures (dispensary revenue) rise significantly when industry per-unit costs rise.

The direct economic impacts on the medical cannabis segment do not include multiplier impacts, as changes in the medical cannabis segment ripple through the rest of the economy. Once the ripple effects are taken into account, the economy-wide economic impact would be even greater. Either way, the estimates of costs or benefits are sufficient to meet the “major regulation” standard in Government Code § 11342.548.

8. Determination of the impact of the regulatory proposal on the state economy, businesses, and the public welfare (Government Code § 11346.3(c))

In Government Code § 11346.3(c), the markers to be used in assessing the economic impact of the proposed regulations in a SRIA are the following:

(1) The creation or elimination of jobs in the state;
(2) The creation of new businesses or the elimination of existing businesses in the state;
(3) The competitive advantages or disadvantages for businesses currently doing business in the state;
(4) The increase or decrease of investment in the state;
(5) The incentives for innovation in products, materials, or processes; and

\textsuperscript{6} An alternative, narrower method of calculating the impact of the proposed regulations in isolation would be to compare the economic outcome in the situation with a set of minimum statutory requirements against the economic outcome in the situation with the proposed regulations. That would require determining precisely the statutory minimum package of regulations and conducting a simulation of costs and benefits under a counterfactual baseline assuming those regulations applied.
(6) The benefits of the proposed regulations, including, but not limited to, benefits to the health, safety, and welfare of California residents, worker safety, environment and quality of life, and any other benefits identified by the agency.

Quantitative estimates in this section were based where possible on the IMPLAN projections of economy-wide impacts presented in Section 6.

**Assessment 8.1. The creation or elimination of jobs in the state**

As noted in Section 6, the proposed regulations will increase jobs by an estimated 456 jobs in California’s medical cannabis dispensaries. The total effect on jobs in the dispensary sector, including ripple effects, is an increase of 655 jobs.

The other major increase in jobs is in the medical cannabis laboratory testing sector. The IMPLAN results based on the AIC simulations project that the proposed regulations will create 713 new jobs directly and 1,290 new jobs when multiplier impacts are included. In the distribution sector of the medical cannabis segment, the IMPLAN results based on the AIC simulations project that the proposed regulations will create 60 new jobs directly and 136 new jobs in total when multiplier impacts are included. In the transport sector of the medical cannabis segment, the IMPLAN results based on the AIC simulations project that the proposed regulations will cause a loss of 6 jobs directly and a loss of 10 jobs when multiplier impacts are included.

Overall, we found 1,223 more jobs in the medical cannabis segment due to the proposed regulations, and 2,071 jobs added in California after including multiplier effects.

We expect these jobs to move, likely to urban areas, especially for laboratory testing, and in places where cannabis consumption is more prevalent.

**Assessment 8.2. The creation of new businesses or the elimination of existing businesses in the state**

AIC analysis of available data indicates that, on average, medical dispensaries sell about 600 pounds of cannabis each. If the total number of pounds sold declines by about 5,000 pounds as indicated in Table 1, this would imply about eight fewer medical dispensaries state-wide due to the proposed regulations if average size of dispensaries did not change. Of course, with significant new regulations there may be existing businesses that find their operations less
suited to the regulatory environment and other businesses that may enter to replace some existing businesses that exit.

Both creation and elimination of businesses is a natural occurrence for any significant change to the business conditions. Regulations related to license holder characteristics may cause some business to leave the segment because the current business owners find it difficult to meet requirements. Exits from the industry will generally be accompanied by other business entering or current businesses expanding.

Table 1 and the discussion in Section 6 indicate a large increase in the size of the medical cannabis laboratory testing sector. Table 1 reported that about 230,000 pounds per year were projected to be sold in the medical segment after taxation and adult-use legalization, and testing costs (and associated revenue for testing businesses) in the medical segment alone were projected to be about $92 million. Assuming that each laboratory tests almost 12,000 pounds annually, and thus has revenue of almost $5 million, these figures imply about 20 laboratory testing businesses in the medical segment.

Information from industry sources indicates that as of November 2016, there are two to four medical cannabis testing laboratories currently operating in California that are equipped with the type of wet-lab facilities that would be necessary to conduct the required pesticide tests. Therefore, most testing businesses will be new businesses generated by the proposed regulations. These businesses are expected to be located near distribution centers and spread across the state in major centers of medical dispensary sales.

MCRSA requires that the distribution function be separated from the cultivation and dispensary functions, and the proposed regulations reflect this requirement. There is a large geographic spread of urban centers and rural areas with significant numbers of dispensaries around the state. We assumed that distribution businesses could realize cost advantages by locating near clusters of dispensaries. We therefore estimated that the proposed regulations will create about 40 medical cannabis distribution businesses across the state, assuming about 5,800 pounds distributed per distribution business per year. No data were available to estimate the number of distribution businesses that would be created with adult-use legalization, but without a regulatory requirement for separate distribution businesses. We therefore assume that most of the new distribution businesses will be generated by the proposed regulations, and not by adult-use legalization.

We anticipate that most transporter license holders will be affiliated with other licensed
businesses. These may be cultivators, manufacturers or distributors for transport to distributors and may be distributors for transport to dispensaries. With an economically efficient system, we assumed that the full cost of distribution through the system would be no higher and might be lower under the new regulations relative to the pre-regulation system. There will be efficiencies from using a hub and spoke system that goes through the required distribution businesses in a market with many small cultivators and many small retailers. There will be an additional step in the system with the addition of the distributor level. However, if the distributor is also the transporter, the distributor should experience lower transportation costs because of the distributor’s increased volume, the ability to transport numerous products from different cultivators to the same dispensary, and the ability to transport to many dispensaries on the same delivery route.

Based on the reasoning and evidence, we project few, if any, separate transport businesses. The distributor license holders can easily subsume the transportation function. However, a few specialized transport businesses, separate from the distribution businesses could develop. This would result in the creation of new businesses. These businesses would coordinate with, but be distinct businesses from the distributor business. Such transportation companies could specialize, for example, in moving cannabis from cultivators to manufacturers or distributors, or moving samples to the testing laboratories. Additionally, a few small, local, or specialized transport businesses could be created in local areas or for specific products not well served by transporters who also hold distribution licenses. These smaller businesses may not transport high volumes or handle a large share of total value, there may be the creation of new transport businesses.

**Assessment 8.3. The competitive advantages or disadvantages for businesses currently doing business in the state**

AIC analysis indicates some advantages for businesses currently doing business in California. Recall that this SRIA shows estimates of the impacts of medical cannabis regulations imposed upon the cannabis industry relative to the baseline with taxation and adult-use legalization in effect. To be relevant, this sub-section therefore discusses competitive advantages and disadvantages relative to the counter-factual baseline, not relative to the current situation. Here, as elsewhere, we considered only the impact of the proposed regulations, with the baseline assumption that taxation and adult-use legalization are already in place.

The MCRSA limits vertical integration, and the proposed regulations of the medical cannabis segment provide more detailed direction to implement those restrictions. Since many existing
medical cannabis dispensaries are vertically integrated with upstream operations, this part of the proposed regulations will impose adjustments on the organizational structure of existing businesses. Such adjustments may affect the competitive advantage of some current dispensaries.

AIC simulations did not include any results about the characteristics of businesses that may benefit or not from restrictions on vertical integration, and specifically, we have no quantitative information on how such restrictions may affect businesses currently in the industry relative to new entrants. Vertical restrictions will weaken the competitiveness of businesses that now rely on integration upstream or downstream. For example, dispensaries with business linkages with cultivators that would have to change under the proposed regulations may lose that competitive advantage. In general, the requirement that medical cannabis be transported to a distribution business before it is sent to a dispensary changes current practices and may adversely impact the competitive advantages of some current businesses.

The MCRSA requires that current companies that own or operate both dispensaries and testing labs either divest of one of the operations or set up new legal structures. This reduces the competitive advantages to some businesses currently doing business in the state.

We expect that some businesses will adjust to the proposed regulations relatively easily, and that others will find adjustment too costly and will leave the industry. (Recall that during the time of the initial implementation of these rules, volume in the medical cannabis segment is likely to fall substantially, so significant exit from the industry is likely in any case.) Given the nature of the adjustment costs, we expect larger businesses with strong management personnel and access to the capital and legal services necessary to meet the new regulatory standards, to adjust more readily, and thus to have a competitive advantage over new entrants. We expect that the existing businesses without these qualities, however, will be placed at a competitive disadvantage.

Sections 6 and 8 documented a large increase in economic activity including revenue and jobs in medical cannabis laboratory testing. Subsection 8.2 projected several new laboratory testing businesses. AIC discussions with industry sources indicated that medical cannabis testing laboratories as they currently operate in California would not be fully compliant with the proposed regulations. The existing business would need to make adjustments to comply.

Current medical cannabis laboratory testing businesses have two competitive advantages. First, they already operate in what is likely to be an expanding sector. Second, their applications for
licenses have priority under the statutory requirements of MCRSA. Existing labs’ main disadvantage is that their services will require upgrading to meet proposed regulations, which is costly and time-consuming. (See Appendix Chapter 6 for details, and see Appendix Chapter 10 for a discussion of laboratory testing concerns and dislocations experienced in other states.)

Most medical cannabis distribution and transportation operations are currently integrated with upstream or downstream businesses. Thus, there are few current distinct businesses in these sectors that are advantaged or disadvantaged.

**Assessment 8.4. The increase or decrease of investment in the state**

We estimated that the regulations will increase investment in California medical cannabis businesses relative to the baseline. As noted, medical cannabis revenue will rise by about $113 million from the adult-use-legalization base, and this added revenue would be accompanied by investment. Some additional investment (for example in security equipment) in the distribution business sector would likely follow from proposed regulations. Most dispensaries would make additional investments to comply with the proposed regulations in that industry sector as well. Additional transport investment will likely be made mostly by business in the other business sectors that we anticipate would conduct most of the transporting.

As documented in Sections 6 and 8, many of the added costs of the proposed regulations are associated with laboratory testing. In order to generate about $92 million in annual revenue, the laboratory testing sector will require a substantial increase in investment in equipment.

**Assessment 8.5. The incentives for innovation in products, materials, or processes**

MCRSA mandates that the proposed regulations include substantial new medical cannabis testing requirements. Information provided by government laboratory testing specialists and industry sources indicated that proposed regulations are likely to create incentives for innovations in testing procedures. For example, the proposed regulations create incentives for innovation to reduce costs for wet-lab testing machinery, perhaps including mobile testing laboratories. (More information on the testing requirements, incentives and potential innovations are provided in Appendix Chapter 6.) The proposed regulations create few direct incentives for innovations in the other business sectors, transport, distribution and dispensaries in the medical cannabis segment.
Assessment 8.6. The benefits of the proposed regulations, including, but not limited to, benefits to the health, safety, and welfare of California residents, worker safety, environment and quality of life, and any other benefits identified by the agency

8.6.1 Public safety benefits. The proposed regulations include a number of specific items related to public safety. These are discussed more fully in Section 12 and described in more detail in Appendix Chapters 6 and 12. In summary, video surveillance and archival requirements benefit public safety by improving the ability of licensing agencies to investigate bad actors, and by improving the ability of the bureau and other agencies to document violations, collect penalties, and enforce sanctions on unlawful operations. They may also benefit public safety insofar as they are able to help law enforcement apprehend criminals who are outside the jurisdiction of the bureau. These security measures apply to transport, testing, distribution, and dispensary sectors of the medical cannabis segment.

The proposed track-and-trace and other regulations that guard the integrity of the product as it makes its way through the supply chain benefit public safety by preventing the diversion of cannabis into the illegal market and becoming a source of income for criminal enterprises. We expect general safety benefits from careful regulation of an enterprise that has historically been linked with violent and harmful activity. In addition, we expect some deterrence of criminal activity due to the enhanced security measures from the proposed regulations. These benefits apply to security measures in the proposed regulations in all four industry sectors of the medical cannabis segment, including transport, distribution, testing and dispensing. AIC has not quantified these benefits.

8.6.2 Public health benefits. As noted, the MCRSA and the proposed regulations include requirements for laboratory testing of medical cannabis. The proposed regulations may benefit the public by protecting consumers against the possibility of purchasing contaminated cannabis that many consumers wish to avoid. As noted above, our simulation model assumed an increased willingness to pay for cannabis that has been regulated and tested. The assumption was that this willingness to pay for testing offsets the cost of the proposed regulations such that quantity sold in the medical market is little affected by regulatory costs.

By comparison, relevant examples are abundant in agriculture. USDA’s regulation of meat and poultry production and FDA’s regulation of American food manufacturers have been shown to increase willingness to pay in food markets. However, we do not anticipate a major shift of consumers from adult-use cannabis toward medical cannabis to result from consumers’ higher valuation of cannabis that meets health and safety standards, because we anticipate that adult-
use cannabis will be similarly regulated in ways that are relevant to consumer safety and the protection of public health.

In addition to testing, proposed regulation concerning the track-and-trace system may provide additional security against contamination and therefore public health benefits. These proposed regulations apply to transporters, distribution businesses and dispensaries.

Appendix Chapter 6 provide more information on proposed regulations in this area. Appendix Chapter 8 contains discussion and references on demand effects of food safety and traceability regulations. Cannabis-specific scientific evidence on safe levels of potential contaminants is, however, incomplete.

8.6.3 Worker safety. The proposed regulations include measures that reduce the risk of crime, thereby enhancing worker safety while improving public safety.

8.6.4 Environmental and other quality-of-life benefits. AIC analysis did not quantify specific environmental or other quality of life benefits of the proposed regulations for the medical cannabis segment. Recall that the proposed regulations under consideration have very small impacts on the total quantity of cannabis produced or consumed in California. General quality of life benefits may occur in locations near to the regulated dispensaries because these licensed businesses will have more incentives to operate in ways conducive to good neighbor practices. With respect to environmental issues, some small additions to transport fuel use may follow from required transport to and from distribution businesses and to testing facilities. There may also be environmental or quality of life benefits in neighborhoods where licensed dispensaries are located as they comply with security and related regulations and have an incentive to minimize environmental impacts that might be attributable to them. We expect that any such environmental impacts are likely to be relatively small. More significant environmental impacts may follow from regulations of the cultivation industry, which have been investigated in the context of those proposed regulations.

9. Benefits of the proposed regulations, expressed in monetary terms to the extent feasible and appropriate

Section 6 above described the overall economic impact of the regulations and highlighted perceived benefits of regulations to consumers in terms of higher willingness to pay per flower-equivalent pound of cannabis. As shown in Table 1 in Section 6, with only a 2% reduction in aggregate quantity, medical cannabis consumers are willing to pay approximately $113 million
per year ($551 per pound) for benefits derived from the proposed regulations. This monetary value indicates that consumers draw quantifiable benefits from the regulations.

These figures state the impacts within a single year after the proposed regulations take effect. For a longer time horizon—for example for the lifetime of the regulation—the impact would be far larger. Using a discount rate of 5% and assuming these benefits continue indefinitely, the present value of the sum of discounted benefits accrued into future years is given by: $113 million/0.05 = $2.23 billion.

10. Types of costs considered for implementation of the proposed regulations

The costs to the industry necessary to comply with the proposed regulations comprise the most immediate, first-order costs. These costs are provided in detail below where we discuss regulatory alternatives in Section 12. Added costs include additional product testing, safety, and security measures that are discussed in Sections 6, 8 and 12. Fees to support the regulatory program compose a relatively small share of the whole.

AIC projected that the proposed regulations would have very small effects on the quantity of medical cannabis consumed (Table 1). Therefore, any social costs associated with the changes in the use of cannabis from proposed regulations would be small.

11. Effects on the General Fund, special state funds, and affected local government agencies attributable to the proposed regulations

As shown in Section 6, the proposed regulations increase sales revenue of dispensaries. Since tax receipts are calculated as about 23.8% of dispensary sales revenue, the proposed regulations indirectly cause tax receipts to rise. AIC simulations project that the proposed regulations will increase sales tax and excise tax receipts by about $27 million. Most of the projected additional tax receipts ($17 million) was derived from the 15% excise tax that is scheduled to apply to medical cannabis starting in 2018. The existing 7.5% state sales tax would generate an additional $8.5 million in tax receipts for the state. The final $1.5 million in sales tax receipts is attributable to local sales taxes.

Local jurisdictions may also levy taxes or fees on medical cannabis. No data were available on local taxes and fees for medical cannabis, or on whether tax or fee rates are expected to change in response to state regulations. If these fees are based on cannabis quantities transacted or on
the number of dispensaries, the additional receipts would be expected to decline slightly because AIC simulation projected a slight 2% decline in quantities of medical cannabis sold. If local taxes or fees are based on medical cannabis revenue, then local tax receipts would be expected to rise in proportion to medical cannabis revenue, which AIC simulations projected to rise by about 19% due to the proposed medical cannabis regulations.

To estimate economic and fiscal impacts of proposed regulations requires estimates of costs licenses caused by proposed regulations. We develop an estimated licensing cost per pound was calculated because the economic modeling was developed on a per pound basis. The licensing fees discussed in this paragraph are calculated as an average of full license fees on a per pound basis. These total costs do not represent the actual licensing fees per business operation that will be required by the bureau. Fees for licenses were calculated to match the bureau’s expected total operating costs including costs associated with the medical cannabis segment and the adult-use cannabis segment. These cost estimates also include the cost to the licensee of operating the track and trace system. The license fees (including all license types) were calculated to be about $20 per pound. Applying this rate of fees per pound to the quantity of 230,000 pounds of medical cannabis (estimated as the market size in the situation with regulations applied) yields the total fee receipts of $4.6 million.

Many cities and counties in California are in various stages of developing and implementing regulations, taxes and fees for medical cannabis and adult use cannabis sold in their jurisdictions. The taxes and fees will generate local revenue and expenditures. We note that developing local regulations and fees are quite different around the state, not available in summarized form and have yet to be determined for 2018. These range from a straightforward 15% tax on both medical and adult use cannabis sales (Hayward and Alameda Counties) to licenses fees and taxes that are higher for adult use cannabis that for medical cannabis. For example, we have seen proposed retail taxes that range from zero to 15% for medical cannabis. For the purposes of this SRIA, there is an assumption that local regulatory costs will be low enough that companies will choose to comply.

An average local tax rate of 5% would generate $44 million in local revenue based on our estimated total industry size of $884 million (inclusive of state taxes). License fees for dispensaries would add additional revenues as they do under some current local laws. Local revenues and expenses may be affected by the proposed state medical cannabis regulations. Relative to taxation and legalization baseline without the effects of the proposed regulations,
the regulations are expected to increase local tax revenue by $7 million statewide, using an assumed 5% average local tax rate.

Local regulations, taxes and fees may also affect the balance between medical, adult use and illegal sales of cannabis and thus interact with the proposed state regulations. Some jurisdictions are considering permitting local sales of medical cannabis, but not adult use. If large local impediments or costs are imposed on legal cannabis, there may be a reduction in the overall legal sales relative to illegal sales. Similarly, if medical cannabis sales receive favorable local treatment relative to adult use cannabis, medical sales could remain larger than our model anticipates. An important caveat to the importance of local impediments for statewide aggregate impacts is that consumers could as they do now; avoid purchasing in unfavorable local areas. For example, areas of the state that do not allow local medical cannabis dispensaries are served by delivery dispensaries located nearby. Thus, statewide impacts are likely to be significantly smaller than without such adjustments. Overall, for medical cannabis sales, we see relatively little impact on aggregate measures from local impediments some of which may increase (from what they would otherwise be) the size of medical sales relative to adult use sales.

12. Evaluation of two reasonable alternatives to the proposed regulations

This section introduces and provides analysis of two alternative regulations: a lower-cost package and a higher-security package of regulations. This section compares these alternatives relative to the proposed regulations. Summary description is provided in Table 2. Next, we assess the costs for each alternative and provide the summary costs in Table 3 for each of these alternatives and the proposed regulations. (Detailed calculations of the costs of the package of proposed regulations and the two alternative packages of regulations can be found in the Appendix Chapter 6.) Finally, simulations of economic impacts with the two alternative packages of regulations are compared to the proposed regulations.

12.1 Alternatives summarized

The two alternative sets of regulations can be compared to the proposed regulations in terms of three features of the packages, which are summarized in Table 2.
Table 2. Proposed regulations and two alternative regulatory packages

<table>
<thead>
<tr>
<th>Category</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Testing regulations</td>
<td>• No maximum batch size</td>
<td>• 10-lb maximum batch size</td>
<td>• 5-lb maximum batch size</td>
</tr>
<tr>
<td>2. Delivery methods</td>
<td>• E-bikes allowed</td>
<td>• Cars only</td>
<td>• Cars only</td>
</tr>
<tr>
<td></td>
<td>• one employee can make deliveries alone</td>
<td>• one employee can make deliveries alone</td>
<td>• Deliveries must be made by two or more</td>
</tr>
<tr>
<td>3. Security-video archival requirements</td>
<td>• No requirements</td>
<td>• 1280 x 1024, 20 fps*, 30 days archive</td>
<td>• 1280 x 1024, 20 fps, 90 days archive</td>
</tr>
</tbody>
</table>

* The term “1280x1024” indicates pixel resolution; the term “20 fps” indicates frames per second of recorded video; term “30 days archive” indicates length of time the business is required to store video, as calculated according to Seagate.com surveillance video storage guidelines and Amazon.com cloud storage rates; see Appendix Chapter 6 for detailed cost calculations.

12.1.1 Testing. The lower-cost alternative assumes an array of contaminant, pesticide, and other tests that together is estimated to cost $1,000 per test, according to California Department of Public Health (CDPH) estimates. The proposed regulations impose contamination and pesticide tests that raise the cost to approximately $1,200 to $1,500 per test, according to CDPH. We used $1,350 per test, the midpoint in this range.

Maximum testing batch size also affects the cost of testing per pound of medical cannabis sold, especially for businesses capable of producing large batches for testing. There is no requirement in MCRSA regarding batch size. Therefore, the batch size for the lower-cost alternative is no maximum batch size. We estimate that the cost impact of the lower-cost regulations would be approximately $177 per pound.
The proposed testing regulations institute a more stringent set of pesticide tests than those in the lower-cost alternative and establish a 10-pound maximum batch size for testing. These requirements raise the cost of medical cannabis by $407 per pound, or $230 more per pound than the lower-cost alternative.

The higher-security alternative, which keeps the same set of tests in place but lowers the maximum batch size to five pounds, raises the estimated testing cost per pound of medical cannabis to $624. This is approximately $217 per pound more than the proposed regulations (10-lb maximum batch size). A smaller batch size may allow for more accurate testing. (More on testing and background on cost estimates is included in the Appendix Chapter 6.)

12.1.2 Delivery methods. Retail medical cannabis deliveries are typically done by car. However, some urban dispensaries make deliveries on foot, bicycle, electronic bicycle (e-bike), or scooter at a significant cost savings. The proposed regulations prohibit on-foot, bicycle, e-bike, or scooter deliveries.

The lower-cost alternative places no regulatory restrictions on delivery methods. Delivery costs currently add approximately $150 per pound to the average cost of medical cannabis. This estimate relies on the AIC price survey data that 40% of medical cannabis is transferred to consumers via delivery services. (See Appendix Chapter 4 for details on that estimation.) Allowing the lower-cost delivery methods lowers the average cost of medical cannabis in the state by approximately $25 per pound compared with the proposed regulations.

Unenclosed vehicles do not allow as much security as enclosed vehicles. Attaching a lock-box to a person would be impossible, and attaching a lock-box to a bicycle, e-bike, or scooter would likely be impractical. With these delivery vehicles allowed, the security objectives of the proposed lock-box regulatory provisions would be ineffective at the delivery stage, increasing the potential for criminal activity in neighborhoods surrounding dispensaries.

A higher-security alternative is to require two employees to be in each delivery vehicle (one driver and one delivery representative), which would enable one employee to be with the medical cannabis inventory at all times. This would provide an additional level of security. The additional labor costs that would result from the higher-security alternative would increase the cost of medical cannabis by approximately $105 per pound relative to the proposed regulations. (Appendix Chapter 6 provides details on the calculations of delivery costs with lower-cost and higher-security alternatives.)
12.1.3 Security video archival requirements. The MCRSA does not contain specific security video or archival requirements. The proposed regulation includes the requirement that licensees other than transporters maintain security cameras with high enough quality for facial recognition (proposed to be 1280 x 1024 pixels at 20 frames per second) covering many areas of the inside of and entrances to the building, and to maintain 30-day video archive of footage from these cameras. The 30-day video archival requirement achieves the bureau’s enforcement objectives as well as law enforcement objectives not directly related to the bureau’s activities, but which have benefits to the public safety as discussed above.

We estimated that the average dispensary will require either five or six cameras to achieve coverage. We estimated the cost per pound of retail medical cannabis to rise by approximately $40 per pound compared with the lower-cost alternative, which requires no surveillance archive storage. A higher-security alternative would be to require footage to be maintained for 90 days. This would raise costs by $25 per pound above the proposed regulations. (Appendix Chapter 6 provides our interpretation of the video requirements.)

12.2 Simulation results for alternatives

We introduced the two alternative regulation packages into the simulation model that we used to analyze impacts of the proposed regulations. Recall that the proposed regulations were assumed to shift out demand by 6% compared to the baseline with taxation and adult-use legalization but without regulation. Likewise, each of the alternative regulations were also assumed to raise demand relative to the baseline. The lower-cost alternative was assumed to shift out demand by 4% relative to the baseline. The higher-security alternative was assumed to shift out demand by 6% relative to the baseline.

Next, we introduce the increase in costs. Recall that the proposed regulations raised costs by 16% relative to the baseline. The lower-cost alternative was calculated to raise costs by 6% compared with the baseline with taxation and adult-use legalization but without regulation. The high cost alternative was assumed to raise costs by 26% compared with the baseline with taxation and adult-use legalization but without regulation.
### Table 3. Estimated compliance costs per pound of alternative regulatory packages

<table>
<thead>
<tr>
<th>Cost per pound dried-flower equivalent</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>License fees¹</td>
<td>$20</td>
<td>$20</td>
<td>$20</td>
</tr>
<tr>
<td>Distribution &amp; transport compliance²</td>
<td>$3</td>
<td>$7</td>
<td>$9</td>
</tr>
<tr>
<td>Retail-delivery-method restrictions³</td>
<td>None</td>
<td>$25</td>
<td>$130</td>
</tr>
<tr>
<td>Dispensary compliance²</td>
<td>$25</td>
<td>$65</td>
<td>$90</td>
</tr>
<tr>
<td>Testing compliance⁴</td>
<td>$177</td>
<td>$407</td>
<td>$624</td>
</tr>
<tr>
<td><strong>Total compliance costs per pound</strong></td>
<td><strong>$225</strong></td>
<td><strong>$524</strong></td>
<td><strong>$873</strong></td>
</tr>
</tbody>
</table>

Notes: Numbers below $20 were rounded to the nearest $1. See Appendix Chapter 6 for details. Cost components do not add up exactly to total costs, because of rounding.

1. License fees per pound are calculated to cover the bureau’s annual operating budget, which includes license fees for and costs of regulation of adult-use cannabis.

2. Not including dispensary delivery, which is covered in the row above, “retail-delivery-method restrictions.” Proposed regulations require a 30-day surveillance video archive, quarantine, and laminated badges for employees. Higher-security alternative extends video archive requirement to 90 days.

3. Proposed regulations prohibit on-foot, bicycle, e-bike, or scooter deliveries. Higher-security alternative requires two employees to make a delivery.

4. The lower-cost testing regime is estimated to cost $1,000 per test, with no maximum batch size; we assume 10% failure rate and 15-pound average batch (equivalent to current market average). Testing in proposed regulations is estimated to cost $1,350 per test (to which we add $25 in additional handling costs), with a 10-pound maximum batch size; we assume 20% failure rate and 8-pound average batch. Higher-security alternative sets a 5-pound maximum batch size and assumes a 4-pound average batch.
The key results of simulations in the two alternative regulation packages are as follows. With the lower-cost alternative regulations, industry revenue is higher than the baseline by $71 million, and quantity sold is higher than the baseline by about 8,000 pounds.

With the higher-security alternative regulations, industry revenue is higher than the baseline by $105 million, but quantity is lower than the baseline by 30,000 pounds, or about 10%. The higher security option provides relatively little benefit as assessed by businesses and their customers, but imposes substantial extra costs. The implication is substantially smaller sales of medical cannabis (and more sales in the illegal markets) because the price is substantially higher. These results can be compared with AIC simulation results for the proposed regulations that were presented in Table 1. Industry revenue is higher than the baseline by $113 million, and quantity sold is lower than the baseline by 5,000 pounds. Note that under both alternative sets of regulations, the increase in industry revenue relative to the baseline is less than the increase in revenue under the proposed regulations. Detailed calculations underlying these conclusions are reported in Appendix Chapter 8.

13. Final remarks

This SRIA summarized the AIC economic analysis of proposed regulation of the medical cannabis segment in California. Specifically, the SRIA considered proposed regulations of transport, distribution, testing and dispensing in the medical cannabis segment. The proposed regulations were projected to impact economic costs or benefits to industry participants by more than $50 million within the first year after taking effect, compared with the baseline relevant to proposed implementation in January 2018. As discussed in some detail, the relevant baseline assumes taxation and adult-use legalization, but not the proposed regulations.

Among the most costly aspects of the proposed regulations is laboratory testing. However, the assessment presented in this SRIA was that such testing also is likely to raise willingness to pay for medical cannabis, and that benefits thus offset costs. The proposed regulations increase economic activity and jobs in the medical cannabis segment—especially in the laboratory testing part of that segment. The analysis also used a standard approach to assess economywide “multiplier” effects, and found that the added economic activity in the medical cannabis segment raises economic activity broadly in the state.
Economic Costs and Benefits of Proposed Regulations for the Implementation of the Medical Cannabis Regulation and Safety Act (MCRSA)

_Report prepared as an appendix to a Standardized Regulatory Impact Analysis_

Prepared for the Bureau of Marijuana Control in the California Department of Consumer Affairs by the University of California Agricultural Issues Center
February 23, 2017
Table of Contents

Introduction ............................................................................................................................... 120

1. Context and authority ................................................................................................. 122

2. Statutory and regulatory background ......................................................................... 124

3. Background on operating costs for medical cannabis dispensaries .................... 127

4. Retail cannabis prices and price patterns in California ...................................... 137

5. The California cannabis market ................................................................................. 154

6. Compliance costs of proposed regulations and alternatives .................................... 176

7. Modeling the effects of shifts in cannabis demand and supply on prices and quantities .......................................................... 192

8. Numerical simulation of changes in cannabis prices, quantities, revenues and taxes in response to changes in proposed regulations ............... 207

9. Economy-wide impacts of proposed medical cannabis regulations ................ 216

10. Legal cannabis policy and markets: A comparative review of West Coast states .......................................................................................... 226

11. Brief historical review of alcohol control in the United States, with potential lessons for the impact of cannabis regulation ......................... 241

12. Health, safety, community, and environmental benefits ........................................ 249

13. A primer on IMPLAN methodology ........................................................................ 252

Cited references and other consulted materials ................................................................ 259
Introduction

This report provides background research and documentation for a Standardized Regulatory Impact Analysis (SRIA) of proposed regulations related to medical cannabis. This report functions as an appendix to the SRIA, which provides an executive summary of methodology and results.

We begin by laying out the legal background related to the regulations under consideration and the requirements for a SRIA. This provides the specific context for the economic analysis to follow. Chapter 1 presents the context and authority, and Chapter 2 presents the statutory and regulatory history and situation.

Because cannabis is illegal under federal law, official data are scarce and incomplete. In Chapters 3 through 5, we provide data that provide a snapshot of the industry as it stood in November 2016. We provide background on costs (Chapter 3), prices (Chapter 4), quantities (Chapter 5), and demand characteristics (Chapter 5) from a variety of sources, including a survey of medical dispensaries. In Chapter 6, we provide data and analysis on the compliance costs of the proposed regulations and of two alternative packages of regulations: a lower-cost alternative and a higher-security alternative.

Chapter 7 is more technical and mathematical than the previous chapters. It lays out in detail the economics underlying the model we developed to simulate the impact of proposed regulations on the medical cannabis segment of the overall cannabis industry in California. The model proceeds in steps. We did not directly compare the impacts of the regulations with the November 2016 situation, because the legalization, regulation, and taxation of non-medical adult-use cannabis will be implemented alongside the regulation and taxation of medical cannabis in January 2018. Simply comparing the November 2016 situation with the January 2018 situation would yield impact calculations that included the effects of taxation and adult-use legalization, which are outside the scope of this SRIA. We thus used a taxation and adult-use legalization scenario as the baseline against which we analyzed the impacts of the proposed regulation. The construction of the baseline is explained in the SRIA itself, and Appendix Chapter 7 lists assumptions and parameters in detail.

Chapter 8 provides the detailed background assumptions for our simulation model and reports our simulation model results for the proposed regulations and the two alternatives. The impact
is measured as the difference between the results with regulations in place and the results with only taxation and adult-use legalization in place. Those results are presented in Table 8.2. Chapter 9 uses the results of Table 8.2 to derive economy-wide impacts of the proposed medical cannabis regulations. Again, the impacts on value added, labor income, and jobs are measured as differences from a taxation and adult-use legalization baseline.

The final sections of the report provide useful background information that helps document our modeling and parameter choices and data used in the analysis.

In sum, this report serves as a background appendix to the main SRIA. It contains material useful in understanding and interpreting the regulatory impact analysis provided in the SRIA.
1. Context and authority

1.1 Background legal setting

For the two decades since the 1996 passage of the Compassionate Use Act (Proposition 215), the ballot initiative that made California the first state in the United States to decriminalize the use of medical cannabis, California’s medical cannabis industry has been operating under an inconsistently enforced patchwork of local ordinances, with little state-level oversight.

The Medical Cannabis Regulation and Safety Act (MCRSA), passed in 2015 as Assembly Bill 266, Assembly Bill 243, and Senate Bill 643, establishes a Bureau of Medical Cannabis Regulation, (Bureau), now known as the Bureau of Marijuana Control, within the California Department of Consumer Affairs (DCA). The Bureau is tasked with setting up and administering a licensing and enforcement system governing the distribution, transportation, testing, and retail sale of medical cannabis in California.

This Specialized Regulatory Impact Analysis (SRIA) was commissioned by the Bureau for the purpose of calculating the costs and benefits of the MCRSA-implementing regulations proposed by the Bureau, which are aimed at going into effect on January 1, 2018. This SRIA was prepared by the University of California Agricultural Issues Center (AIC).

In the California general election of November 8, 2016, California voters passed the ballot initiative known as Proposition 64, the Control, Tax and Regulate Adult Use of Marijuana Act (AUMA), which legalized adult-use cannabis in California. AUMA immediately eliminated criminal penalties for personal use, re-named the Bureau the Bureau of Marijuana Control, established a new tax structure for medical and adult-use cannabis, and assigned the Bureau responsibility for also regulating California’s adult-use cannabis industry.

The task of calculating the economic impact of the Bureau’s proposed implementation of the medical cannabis regulations required by MCRSA now requires us to account for the economic implications of the legalization, regulation, and taxation of adult-use cannabis that will begin on January 1, 2018, the same date as the new regulations governing medical cannabis take effect.
This SRIA thus incorporates the expected impact of AUMA on the economic costs and benefits of the regulations proposed by the Bureau to implement MCRSA, but it does not include any specific analysis of the proposed regulations pertaining to AUMA.

1.2 Nature and scope of regulatory impacts considered

We analyze the medical segment of the cannabis industry in California in the context of the adult-use cannabis segment. The medical segment is so closely related to the adult-use segment that impacts of regulations must be considered in the broader context of all cannabis sold in California. After estimating economic effects within the medical cannabis segment, we use a standard economy-wide model to project ripple effects on the California economy more broadly.

At the heart of our analysis is an evaluation of the costs and benefits to (1) California businesses, (2) California consumers, and (3) the California state government of three possible sets of medical cannabis regulations, which we call “regulatory packages”: (A) the regulations currently proposed by the Bureau; (B) an alternative package of regulations that would be less costly than the proposed regulations while still fulfilling the minimum statutory requirements of MCRSA; (C) an alternative package of regulations that would impose higher security standards than the proposed regulations.

To isolate the effects of the proposed regulations and alternatives from intervening factors that may also have major effects, we took into account other factors operating over the same time period that are also affecting the California market for cannabis. In this case, the major change to the California medical cannabis segment is the passage of the adult-use legalization ballot question (Proposition 64) in the California general election of November 8, 2016. That set of statutes, known as the Control, Tax and Regulate Adult Use of Marijuana Act (AUMA), established a new tax structure for medical and adult-use cannabis and assigned the Bureau responsibility for regulating California’s adult-use cannabis industry, as well as its medical cannabis industry.

To arrive at the economic calculations and simulations reported below, we proceeded in three steps. First, we assessed the current (fall 2016) situation for medical cannabis in California. Second, to establish a relevant baseline for the regulatory analysis, we assessed the impacts of legal sales of adult-use cannabis and taxation of all cannabis on the medical cannabis segment.
This step provided us with the baseline upon which medical cannabis regulations were analyzed, and it allowed us to separately observe the effects of the two major changes to the medical cannabis segment that will occur. The third step was to calculate and simulate the impact of the proposed regulations and alternatives on the medical cannabis segment separately from the effects of taxation and adult-use legalization.

2. Statutory and regulatory background

2.1 Compassionate Use Act (1996)

The ballot initiative known as Proposition 215 made California the first state to decriminalize medical cannabis. In the 20 years since then, the state has played an extremely limited role in regulating medical cannabis. Legal guidelines coming from the state that has exerted influence on the behavior of medical cannabis businesses and patients have been largely limited to Senate Bill 420 (see Section 2.2) and the non-binding Brown Guidelines (see Section 2.3).

2.2 Senate Bill 420 (2003)

In 2003, the California Legislature passed Senate Bill 420, which added (section 11362.7 et seq. to the California Health and Safety Code relating to controlled substances. SB 420 established a basic framework for the legal operation of medical cannabis entities.


In 2008, the laws regarding medical cannabis were clarified for operators of medical cannabis entities in an opinion issued by then-Attorney General Jerry Brown, an opinion many of the industry operators we spoke with cite as their canonical reference document on how to comply with California state law in the pre-regulation environment. Municipal and county ordinances generally concur with the Brown Guidelines but otherwise vary widely in their local regulation and licensing approach, ranging from a total prohibition on the medical cannabis industry in some areas to robust ordinances in others (Mendocino, San Francisco, and Oakland, for instance) to a total lack of regulation in some rural areas.
2.4 Compliance with SB 420 and Brown Guidelines to date

Operators’ degrees of compliance to SB 420 and the Brown Guidelines have been widely divergent. In the absence of an agency to supervise the state’s medical cannabis businesses, these documents have generally served more as loose behavioral guidelines than as functioning rules.

Nonetheless, operators seem to have been consistent in their observance of the Brown Guidelines standards. Most currently operating dispensary storefronts require patients to submit the original hard copy of their physician’s recommendation (which is checked against a database maintained by the prescribing physician’s office), an original document verifying California residency, and a completed medical intake form before they can purchase medical cannabis or even enter the area of the store in which products are displayed.

In many cases, dispensary operators have cited local (rather than state) enforcement as their primary incentive to follow the Brown Guidelines. In other segments within the medical cannabis industry, on the other hand, the Brown Guidelines appear to have been less consistently observed amongst delivery services without fixed retail locations, and private, low-profile medical collectives who do not advertise their services to their public. Such businesses may not observe the medical recommendation or California state residency requirements, for instance, in spite of their participation in the legal medical cannabis segment.

2.5 Medical Cannabis Regulation and Safety Act (2015)

The MCRSA, which added Business and Professions Code sections 19300 through 19355 and Labor Code section 147.5, and Health and Safety Code sections 11357 through 11362, introduced a new state-wide structure for the governance of the California medical cannabis industry as well as a system by which the state may collect licensing and enforcement fees and penalties from cannabis businesses.

The Bureau shares responsibility for promulgating and enforcing regulations implementing MCRSA with the California Department of Public Health (CDPH), and the California Department of Food and Agriculture (CDFA) The responsibilities assigned to the Bureau include the issuance

---

7 This is not intended to be a comprehensive list of all MCRSA provisions.
of licenses to and the collection of license and penalty fees from medical cannabis distributors, retail and delivery dispensaries, testing laboratories, and transporters.

The Bureau was initially funded with a $10,000,000 startup loan from the state General Fund, which is to be paid back with proceeds from licensing fees collected by the Bureau.

2.6 Adult Use of Marijuana Act (2016)

Although the scope of this SRIA is limited to evaluating the economic impact of the proposed regulations governing medical cannabis, the legalization of adult-use cannabis in California in November 2016 by Proposition 64 is likely to have a considerable material impact on the state’s medical cannabis market.

This impact is likely to arise due to consumer substitution. In this SRIA, we rely on the working assumption that medical cannabis and adult-use cannabis\(^8\) are to a large extent substitutable. This implies that businesses in these two parallel systems will thus compete for customer demand, and that the systems themselves will compete with each other for new entrants in the sense that entrants will weigh the pros and cons of each. That is, in the short run, prices in the adult-use cannabis segment will be likely to affect quantities transacted in the medical cannabis segment. If the price of adult-use cannabis is significantly lower than the price of medical cannabis, then consumers will be likely to demand less medical cannabis and more adult-use cannabis; if the price of medical cannabis is significantly lower, then consumers will be likely to do the opposite.

We must now make assumptions about economic behavior that are informed by the knowledge that regulations implementing AUMA and MCRSA will take effect simultaneously on January 1, 2018, and that the issuance of new licenses under both systems are also set to begin simultaneously.

The MCRSA framework imposes certain costs not found in the AUMA framework. For example, under MCRSA, a testing laboratory must contract with a third-party transport licensee to move product samples between licensees’ premises and their own testing labs. This requirement is not in AUMA.

\(^8\) In much of the literature, medical cannabis is referred to as “medical marijuana” and adult-use cannabis is referred to as “recreational marijuana.”
3. Background on operating costs for medical cannabis dispensaries

In fall 2016, through a series of confidential informal interviews and information requests guaranteeing respondents’ anonymity, AIC assembled a set of hypothetical income statements from California medical cannabis dispensaries in four broad size categories constructed for the purpose of roughly representing the distribution of dispensaries of various sizes across the state.

We developed idealized estimates of itemized dispensary cost and revenue line-item averages for four different idealized representative dispensary sizes. Dispensaries were sorted into these four idealized categories based on their annual revenues. The model dispensary in the first category, which we call “micro,” received approximately $1,000,000 in annual revenue from selling 290 flower-equivalent pounds (defined in Section 5.3.1), at the assumed retail price of $3,453 per pound (derived from AIC calculations from the AIC dispensary survey, whose details are found in Section 4).

The second idealized dispensary category, “small,” averages $2.4 million in annual revenue and 695 flower-equivalent pounds sold per location. The third idealized category, “medium,” averages $6 million in annual revenue and 1,738 flower-equivalent pounds sold per location. The fourth and largest idealized category, “large,” averages $24 million in annual revenue and 6,950 flower-equivalent pounds sold per location.

Separating dispensaries into four categories was necessary to account for the considerable economies of scale in larger operations and arrive at a reasonable approximation of the business landscape in order to calculate the effects of regulations on costs per flower-equivalent pound of dispensing cannabis. In the interest of simplicity, we did not account for any possible retail price differences between dispensaries of different sizes.

3.1 Raw material costs

The single largest component of dispensary costs is the cost of raw materials (in this case, dried cannabis flower). Raw material costs are not the subject of our analysis but are important for understanding the industry cost structure. As of November 2016, US wholesale prices for dried
cannabis flower hovered with relative stability around 35% to 40% of retail price, based on the Cannabis Benchmarks data described and cited in Tables 3.1 and 3.2 and Figure 3.1. As of the end of November 2016, Cannabis Benchmarks set the weekly US spot wholesale price at $1,465 per pound of dried flower. This Cannabis Benchmarks index was down 28% for the year (in January 2016, it had stood at $2,032).\(^9\)

At the end of November 2016, the Cannabis Benchmarks spot price for California dried flower was $1,332 per pound, or 38.6% of AIC’s estimated retail price (calculated based on the results of our survey, as described in Section 4). Data-collection methodology employed by Cannabis Benchmarks favors more highly compliant and therefore slightly-more-expensive-than-average suppliers of raw material.

We also note that wholesale prices were falling throughout 2016, and that such surveys may be slightly delayed in tracking these changes. We assume that the true wholesale price per pound is $1,199, 10% lower than Cannabis Benchmarks’ estimate of $1,332. Rounding this result, we used $1,200 as the raw material input price for our economic models. This wholesale price is 34.7% of our estimated retail price of $3,453, which is consistent with the observed national range of wholesale-to-retail price ratios.

Table 3.1. California wholesale price snapshot, November 2016

<table>
<thead>
<tr>
<th>Cultivation method</th>
<th>Low price</th>
<th>High price</th>
<th>Weighted average</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outdoor</td>
<td>$1,150</td>
<td>$1,750</td>
<td>$1,423</td>
</tr>
<tr>
<td>Greenhouse</td>
<td>$1,275</td>
<td>$1,900</td>
<td>$1,437</td>
</tr>
<tr>
<td>Indoor</td>
<td>$949</td>
<td>$2,200</td>
<td>$1,447</td>
</tr>
<tr>
<td><strong>Weighted average</strong></td>
<td><strong>$1,439</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Source: Cannabis Benchmarks archive. December 16, 2016 data used to observe end-of-November prices, assuming two-week lag between market prices and Cannabis Benchmarks price data.

Table 3.2. Avg wholesale cost as percentage of retail price, first 8 months of 2016

<table>
<thead>
<tr>
<th></th>
<th>Jan-16</th>
<th>Feb-16</th>
<th>Mar-16</th>
<th>Apr-16</th>
<th>May-16</th>
<th>Jun-16</th>
<th>Jul-16</th>
<th>Aug-16</th>
</tr>
</thead>
</table>

\(^9\) Throughout this SRIA, we assume a two-week lag between market prices and Cannabis Benchmarks price data. End-of-November prices are thus taken from the Cannabis Benchmarks reports of December 16, 2016.
Wholesale costs  42%  42%  39%  39%  39%  40%  43%  33%

Source: Cannabis Benchmarks (2016); PerfectPrice.

Figure 3.1. Avg US retail and wholesale prices, one ounce dried flower, first 8 months of 2016

Source: Cannabis Benchmarks (2016); PerfectPrice.

Fluctuations of prices after November 2016 seem to have been affected by the legalization of personal adult-use possession and reductions in penalties for non-medical sale.

3.2 Dispensary margins and risk-premium (illegal-operation) effects

The sale and possession of cannabis remains illegal under Federal law. Therefore, all owners and operators of cannabis businesses in California risk violating Federal law.

An economic situation in which industry participants are operating legally or partially legally with respect to state law and still fully illegal on a federal level presents many cost-related concerns. Atypical business risks (e.g., arrest, seizure of property) as well as atypical business challenges (e.g., the vagaries of local municipal law, denial of access to the banking system) face
cannabis cultivators, intermediaries, and retailers compared with the farmers, intermediaries, and retailers of other agricultural products. Such risks drive up business costs across the board, especially labor costs. For example, workers willing to risk arrest expect to be rewarded with premium wages. According to Krissman (2016), cannabis trimmers in California command a 200% wage premium over the market for agricultural labor.

Such extra business costs have a direct effect on consumer prices. The extra price paid by consumers for the products of industries with significant probability of losses is sometimes known in economics as the “risk premium.” Sifaneck et al. (2007), for example, observed a street price of $50 to $80 for a one-eighth ounce of cannabis from a New York City delivery service in the mid-2000s in New York, where criminal restrictions for cannabis sale and possession were tightly enforced. Before adjusting for inflation, this is approximately double the median price for generic delivery-service medical cannabis in California.

Comparing the price of non-medical adult-use cannabis between countries demonstrates the workings of risk premiums more clearly. For instance, in Uruguay, where adult-use cannabis is decriminalized, the street price an ounce for medium-quality dried flower is about US$172. (Marijuana Travels, 2016). In Germany, where adult-use cannabis is illegal but possession laws are generally not enforced, and where medical cannabis is legal, the street price for medium-quality dried flower is about US$239 per ounce (Williams, 2016; Marijuana Travels, 2016). In China, where personal possession can land a first offender in prison for six months, the illegal-market price for one ounce of medium-quality dried flower is about $696 per ounce (Hill, 2015; Marijuana Travels, 2016). (We recognize that there are other legal and economic differences influencing relative prices in these locations.)

A more controlled way of observing risk premium effects is by comparing current prices between US states. When cannabis prices in US states are compared, the five states with the highest average prices are the states with some of the harshest state-level penalties in the United States for cannabis offenses, as is illustrated in Table 3.3.
Table 3.3 Cannabis prices and penalties: most expensive and least expensive states, 2015

Five most expensive US states for retail cannabis, avg market price of 1 lb dried flower

<table>
<thead>
<tr>
<th>State</th>
<th>Street price (source: Forbes)</th>
<th>Adult use cannabis</th>
<th>Medical cannabis</th>
<th>Min penalty for possession of 1 oz cannabis</th>
</tr>
</thead>
<tbody>
<tr>
<td>North Dakota</td>
<td>$6,192¹</td>
<td>Illegal</td>
<td>Illegal</td>
<td>30 days incarceration¹</td>
</tr>
<tr>
<td>Virginia</td>
<td>$5,808¹</td>
<td>Illegal</td>
<td>Illegal</td>
<td>1 yr incarceration² (mandatory minimum)</td>
</tr>
<tr>
<td>South Dakota</td>
<td>$5,760¹</td>
<td>Illegal</td>
<td>Illegal</td>
<td>1 yr incarceration³</td>
</tr>
<tr>
<td>Maryland</td>
<td>$5,760¹</td>
<td>Illegal</td>
<td>Illegal</td>
<td>1 yr incarceration³</td>
</tr>
<tr>
<td>Louisiana</td>
<td>$5,744¹</td>
<td>Illegal</td>
<td>Illegal</td>
<td>6 mo incarceration³</td>
</tr>
</tbody>
</table>

Five least expensive US states for retail cannabis, avg market price of 1 lb dried flower

<table>
<thead>
<tr>
<th>State</th>
<th>Street price (source: Forbes)</th>
<th>Adult use cannabis</th>
<th>Medical cannabis</th>
<th>Current penalty for possession of 1 oz cannabis³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oregon</td>
<td>$3,264¹ ²</td>
<td>Legal</td>
<td>Legal</td>
<td>None⁴</td>
</tr>
<tr>
<td>California</td>
<td>$3,453⁴</td>
<td>Legal, not yet regulated</td>
<td>Legal, not yet regulated</td>
<td>$100 fine⁴</td>
</tr>
<tr>
<td>Washington</td>
<td>$3,712¹</td>
<td>Legal</td>
<td>Legal</td>
<td>None⁴</td>
</tr>
<tr>
<td>Colorado</td>
<td>$3,888¹</td>
<td>Legal</td>
<td>Legal</td>
<td>None⁴</td>
</tr>
<tr>
<td>Nevada</td>
<td>$4,240¹</td>
<td>Legal, not yet regulated</td>
<td>Legal</td>
<td>$600 fine⁴</td>
</tr>
</tbody>
</table>

¹ Source: Bi (2015), collecting and analyzing May 2015 data set from priceofweed.com for Forbes. Prices reported for 1 oz purchase; we multiplied by 16 to arrive at price per pound.

² Does not account for fall 2016 retail price increases observed in the Whitney report caused by the testing-laboratory supply shortage.

³ Source: SRIA estimate of $3,453/lb based on AIC retail price survey. Priceofweed.com’s California estimate as quoted by Forbes is $3,872/lb, which would move it below Washington on the rank list of states with the lowest retail prices.

⁴ Source: NORML website.

Taking the national and international comparative data into account, we conclude that the differences between retail prices are not fully explained by differences in production costs, but must also integrate risk premiums, which translate into higher retail margins over the cost of
production as a reward for operators who are willing to assume a certain set of business and legal risks that arise out of regulatory uncertainty, conflicts of law, and social stigma.

When illegal-market prices are observed, the price differences between heavy-penalty states and light-penalty states become even more exaggerated. A survey of 6,000 dispensaries (PerfectPrice, 2016) found that the states with the cheapest medical cannabis had illegal-market street prices that were cheaper, proportionally, than the illegal-market street prices in more expensive (high-security) states.

3.3 Summary of costs

The data used to construct Tables 3.4 through 3.6 come from an aggregation of the informal AIC survey, fall 2016. To use these data to model baseline industry costs and regulatory variation, we then convert these business costs into per-pound units. These per-pound cost estimates inform our other modeling efforts necessary to assess the impacts of regulations.

For our calculations of California dispensary costs, we assume a risk premium of $420.00, as shown in Table 3.4, which accounts for the discrepancy between our retail price estimate ($3,453) and the sum total of direct costs ($2,569.68) and net income ($464.00) reported by dispensaries.

These data are averages of the more detailed costs estimates that are provided by size category in Table 3.5. Note that labor is the largest direct cost after raw materials.
Table 3.4 Average dispensary operating costs per pound, AIC estimates, November 2016

**Average dispensary operating costs per lb**

<table>
<thead>
<tr>
<th>Category</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raw material supply cost</td>
<td>$1,200.00</td>
</tr>
<tr>
<td>Sales, general, and admin costs</td>
<td></td>
</tr>
<tr>
<td>Labor costs (including benefits &amp; HR)</td>
<td>$777.00</td>
</tr>
<tr>
<td>Rent, supplies, and overhead</td>
<td>$265.00</td>
</tr>
<tr>
<td>Community giving, education programs</td>
<td>$40.00</td>
</tr>
<tr>
<td>Legal, accounting, and local compliance costs</td>
<td>$57.00</td>
</tr>
<tr>
<td>Local permit fees, and application preparation</td>
<td>$22.00</td>
</tr>
<tr>
<td>Public relations</td>
<td>$57.00</td>
</tr>
<tr>
<td>Delivery costs</td>
<td>$152.00</td>
</tr>
<tr>
<td><strong>Total dispensary operating costs per lb</strong></td>
<td><strong>$2,570.00</strong></td>
</tr>
</tbody>
</table>

**Average dispensary margins**

<table>
<thead>
<tr>
<th>Category</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk &amp; non-mainstream premium (16%)</td>
<td>$420.00</td>
</tr>
<tr>
<td>Net income (18%)</td>
<td>$464.00</td>
</tr>
<tr>
<td><strong>Total dispensary revenue per lb</strong></td>
<td><strong>$3,453.00</strong></td>
</tr>
</tbody>
</table>

*Note: All data averaged across a group of anonymous businesses from which AIC collected approximate current accounting information. See Table 3.5 for more detailed calculations of averages. Numbers rounded to the nearest dollar and may not add up exactly due to rounding error.*

1 Source: AIC estimate. See Section 3.1 for details.

2 Source: Anonymized dispensary internal accounting data collected by AIC.

3 Source: AIC vehicle delivery cost analysis. Dispensaries to customers only; does not include transportation between other licensees.

4 Source: AIC economic analysis.
Table 3.5. Detailed operating costs per pound for four different representative dispensary sizes

*November 2016 estimates, current snapshot without regulations in place.*

*Averages across a group of anonymous businesses.*

<table>
<thead>
<tr>
<th>Dispensary size categories: aggregates</th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>All locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of locations in category¹</td>
<td>471</td>
<td>378</td>
<td>47</td>
<td>15</td>
<td>911</td>
</tr>
<tr>
<td>Category’s share of total locations²</td>
<td>51.7%</td>
<td>41.5%</td>
<td>5.2%</td>
<td>1.6%</td>
<td>100%</td>
</tr>
<tr>
<td>Aggregate volume in category (lb)</td>
<td>137,000</td>
<td>260,000</td>
<td>82,000</td>
<td>104,000</td>
<td>583,000</td>
</tr>
</tbody>
</table>

| Aggregate revenue in category         | $471 million | $898 million | $282 million | $360 million | $2.01 billion |

<table>
<thead>
<tr>
<th>Raw material margin per location</th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>All locations</th>
<th>Averages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume per location (flower-equivalent pounds)³</td>
<td>290 lb</td>
<td>695 lb</td>
<td>1,738 lb</td>
<td>6,950 lb</td>
<td>583,000 lb</td>
<td>640 lb</td>
</tr>
<tr>
<td>Revenue per location²</td>
<td>$1,000,000</td>
<td>$2,400,000</td>
<td>$6 million</td>
<td>$24 million</td>
<td>$2.01 billion</td>
<td>$3,453/lb</td>
</tr>
<tr>
<td>Raw material costs per location³</td>
<td>$345,000</td>
<td>$800,000</td>
<td>$2,100,000</td>
<td>$8.3 million</td>
<td>$700 million</td>
<td>$1,200/lb</td>
</tr>
</tbody>
</table>

| Total raw material margin per location | $655,000 | $1,600,000 | $3,900,000 | $15.7 million | $1.31 billion | $2,253/lb |

<table>
<thead>
<tr>
<th>Fixed, labor, and administrative costs per location²</th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>All locations</th>
<th>Averages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labor costs (including benefits and human resources)</td>
<td>$296,000</td>
<td>$540,000</td>
<td>$1,260,000</td>
<td>$5,550,000</td>
<td>$453 million</td>
<td>$834/lb</td>
</tr>
<tr>
<td>Rent, supplies and other ops expenses</td>
<td>$58,000</td>
<td>$139,000</td>
<td>$619,000</td>
<td>$3,053,000</td>
<td>$155 million</td>
<td>$265/lb</td>
</tr>
</tbody>
</table>

Source: AIC anonymized dispensary accounting cost survey.
Community giving, education programs

<table>
<thead>
<tr>
<th></th>
<th>$15,000</th>
<th>$35,000</th>
<th>$52,000</th>
<th>$71,000</th>
<th>$23.6 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$40/lb</td>
</tr>
</tbody>
</table>

Legal, tax, and regulatory compliance

<table>
<thead>
<tr>
<th></th>
<th>$16,000</th>
<th>$38,000</th>
<th>$110,000</th>
<th>$398,000</th>
<th>$33 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$57/lb</td>
</tr>
</tbody>
</table>

Permit fees and application preparation

<table>
<thead>
<tr>
<th></th>
<th>$8,000</th>
<th>$18,000</th>
<th>$35,000</th>
<th>$63,000</th>
<th>$12.9 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$22/lb</td>
</tr>
</tbody>
</table>

Public relations

<table>
<thead>
<tr>
<th></th>
<th>$18,000</th>
<th>$45,000</th>
<th>$84,000</th>
<th>$225,000</th>
<th>$33.2 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$57/lb</td>
</tr>
</tbody>
</table>

**Total fixed, labor, and administrative costs per location**

<table>
<thead>
<tr>
<th></th>
<th>$411,000</th>
<th>$815,000</th>
<th>$2,160,000</th>
<th>$9,360,000</th>
<th>$710 million</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>$1,275/lb</td>
</tr>
</tbody>
</table>

*Estimates between $500,000 and $5 million rounded to nearest $10,000. Estimates between $5 million and $100 million rounded to nearest $100,000. Estimates above $100 million rounded to nearest $1,000,000.*

1 Represents number of discrete retail business premises. A single firm may operate several locations.

2 Source: Anonymized dispensary internal accounting data collected via AIC interviews and surveys. Does not include delivery costs or delivery employees.

3 Source: AIC estimates based on fall 2016 Cannabis Benchmarks wholesale price data and estimates from Era Economics.

**Labor costs.** Table 3.6 uses aggregate AIC accounting cost survey information to break down labor costs into categories. Wages average approximately $18 per hour for non-manager employees and $75 per hour for managers. Costs of labor are integrated into the dispensary accounting costs used in our simulation model in Chapter 7, the results of Chapter 8 and the IMPLAN analysis reported in Chapter 9.
Table 3.6 Detailed dispensary labor cost breakdowns for four different representative dispensary sizes, November 2016, without regulations in place

Dispensary size categories:

<table>
<thead>
<tr>
<th>aggregates</th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>All locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of locations in category</td>
<td>471</td>
<td>378</td>
<td>47</td>
<td>15</td>
<td>911</td>
</tr>
<tr>
<td>Category's share of total locations</td>
<td>51.7%</td>
<td>41.5%</td>
<td>5.2%</td>
<td>1.6%</td>
<td>100%</td>
</tr>
<tr>
<td>Aggregate volume in category (lb)</td>
<td>137,000</td>
<td>260,000</td>
<td>82,000</td>
<td>104,000</td>
<td>583,000</td>
</tr>
<tr>
<td>Aggregate revenue in category</td>
<td>$471 million</td>
<td>$898 million</td>
<td>$282 million</td>
<td>$360 million</td>
<td>$2.01 billion</td>
</tr>
</tbody>
</table>

Labor costs per location

<table>
<thead>
<tr>
<th></th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>Avg location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avg employees per dispensary(^1)</td>
<td>6</td>
<td>10</td>
<td>20</td>
<td>60</td>
<td>9.22</td>
</tr>
<tr>
<td>Revenue per location(^1)</td>
<td>$1,000,000</td>
<td>$2,400,000</td>
<td>$6 million</td>
<td>$24 million</td>
<td>$2.01 billion</td>
</tr>
<tr>
<td>Avg employees per $1M revenues(^1)</td>
<td>6.00</td>
<td>4.17</td>
<td>3.33</td>
<td>2.50</td>
<td>4.20</td>
</tr>
<tr>
<td>(incl managers + non-managers)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Avg revenue per employee(^1)</td>
<td>$166,667</td>
<td>$240,000</td>
<td>$300,000</td>
<td>$400,000</td>
<td>$238,202</td>
</tr>
<tr>
<td>Managers per dispensary(^1)</td>
<td>1</td>
<td>2</td>
<td>4</td>
<td>10</td>
<td>1.71</td>
</tr>
<tr>
<td>Annual salary per manager(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(incl benefits &amp; HR costs)</td>
<td>$116,000</td>
<td>$126,500</td>
<td>$171,000</td>
<td>$355,000</td>
<td>$149,485</td>
</tr>
<tr>
<td>Avg hourly wage per manager(^3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(assuming 2000 hrs per yr)</td>
<td>$58</td>
<td>$63</td>
<td>$86</td>
<td>$178</td>
<td>$74.74</td>
</tr>
<tr>
<td>Non-manager employees per dispenser(^1)</td>
<td>5</td>
<td>8</td>
<td>16</td>
<td>50</td>
<td>7.51</td>
</tr>
<tr>
<td>Non-manager annual salary(^1)</td>
<td>$36,000</td>
<td>$36,000</td>
<td>$36,000</td>
<td>$40,000</td>
<td>$36,414</td>
</tr>
</tbody>
</table>

Bureau of Marijuana Control, Initial Statement of Reasons
## Avg Hourly Wage per Non-Mgr

<table>
<thead>
<tr>
<th></th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>Avg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avg hourly wage per non-mgr</td>
<td>$18</td>
<td>$18</td>
<td>$18</td>
<td>$20</td>
<td>$18.21</td>
</tr>
</tbody>
</table>

## Total Labor Costs

<table>
<thead>
<tr>
<th></th>
<th>Micro</th>
<th>Small</th>
<th>Medium</th>
<th>Large</th>
<th>Avg location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avg total annual labor costs</td>
<td>$296,000</td>
<td>$541,000</td>
<td>$1,260,000</td>
<td>$5,550,000</td>
<td>$533,901</td>
</tr>
<tr>
<td>Avg annual salary per employee</td>
<td>$49,333</td>
<td>$54,100</td>
<td>$63,000</td>
<td>$92,500</td>
<td>$57,889</td>
</tr>
</tbody>
</table>

*Note: All numbers averaged across a group of anonymous businesses from which AIC collected approximate current accounting information. Estimates between $500,000 and $5M rounded to nearest $10,000. Estimates between $5M and $100M rounded to nearest $100,000. Estimates above $100 million rounded to nearest $1M.*

1. Source: Anonymized dispensary internal accounting data collected via AIC surveys and interviews.
2. Does not include delivery employees, who are accounted for under “delivery costs.”

### 4. Retail Cannabis Prices and Price Patterns in California

Public information on cannabis is scarce. Official data sources on current and historical prices, such as those published Federally by the Bureau of Labor Statistics for most other common agricultural products, are unavailable. Estimates of prices are complicated because there are many different types of cannabis products sold in dispensaries. Furthermore, as with other consumer products, prices vary geographically and depend on the unit of quantity sold (for example, one-eighth-ounce sized packages versus one-ounce-sized packages). These complications mean that price data need to be handled carefully.

This section reports on a variety of information used to develop the representative price that is used in modeling and estimation. As an important component of this effort, AIC surveyed dispensaries in California from September through November 2016. The AIC survey collected price ranges (as highs and lows) by cannabis product, location, and by unit of quantity. We recorded whether the dispensary was delivery only and its customer rating. The majority of this section is devoted to discussing data-collection methods, data descriptions, and patterns. We also compare our survey information with price data available from other sources.
4.1 Product overview

Dried flower from the cannabis plant, which is generally inhaled through joints or pipes, is the dominant cannabis product at retail. Dried flower is sold in one-gram, eighth-ounce, quarter-ounce, half-ounce, and one-ounce packages and generally labeled by strain (e.g., “Sour Diesel,” “Blue Dream,” “Jack Herer”). Other information sometimes included on labels includes species (sativa, indica, or “hybrid,” indicating a sativa-indica cross-breed), outdoor-grown (“OG”), strength (in active-ingredient concentration as measured by THC and CBD percentages), and occasionally branded quality or origin certifications.

According to informal industry sources and industry press reports, the fastest-growing portion of the California retail cannabis market is concentrated cannabis oil cartridges, which is vaporized and inhaled using battery-powered “vape pens” (hand-held devices similar to e-cigarettes). Cartridges contain oil concentrate (also known as “extract”) that is generally extracted to THC levels between 50% and 75% and packaged in 500-milligram cartridges. Other popular forms of concentrate include wax and shatter. Concentrates can also be consumed by “dabbing” or can be used in making edible cannabis products. Some concentrates at the top end of the market are now advertised in terms of aromatic compounds known as “terpenes,” whose clinical effects are unclear.

Concentrates have been claiming increasing share in the cannabis market, especially for those willing to pay high prices. If the prices of the various products mentioned above are converted into prices per gram of THC in the package, edible cannabis products are the most expensive way of purchasing cannabis, followed by concentrates, and dried flower is the cheapest (Orens et al. 2015).

The AIC retail price survey, which is presented below, does not measure edible prices, but it confirms the Orens et al. finding that THC in cartridge form sells for more than twice the price of THC in dried flower form. This reflects the additional costs of manufacturing and packaging, and in some cases it also reflects the margins of an additional business in the supply chain (the manufacturer who buys dried flower or oil and produces packaged cartridges or edibles).

See Section 5.3.1 for an explanation of the “flower equivalent” methodology we used to combine various forms of cannabis and estimate aggregate market prices and quantities.
4.2 Survey methods

AIC conducted a survey of medical cannabis dispensaries in California during the fall of 2016. The main purpose of the survey was to learn about current distributions and other patterns of prices for medical cannabis.

Dispensaries are collectively representative of the varied demographics of California. We selected counties and cities to approximate the distribution of the medical cannabis retail outlets in the state and arrived at approximations of state-wide retail prices.

By using internet sources including WeedMaps, Leafly, Yelp!, Google Local, and dispensaries’ own websites, we collected prices and other related information from each dispensary. We called dispensaries when web information was unclear or insufficient. Data were collected during the 60-day span between September 25 and November 23, 2016. Our data set consists of information collected from 565 dispensaries, including both physical storefronts and delivery-only, in eight counties across California.

4.3 Information collected

Our data set consists of several types of information for each retailer, including the retail location, characteristic (shop and/or delivery), cannabis retail prices, and the online ratings of the retailer. Retail location was categorized by county and city, and for storefront shops, we recorded the address. We also recorded website and phone number for most dispensaries.

**Retailer characteristic:** Some retailers operate their businesses without having a physical storefront with a physical address. In these cases, transactions are conducted online or via phone and the product is delivered to the consumer’s home. For each retailer, we recorded whether the business is based out of a storefront dispensary, whether the retailer delivers the products to consumers, or both.

**Retail medical cannabis prices:** Among the differentiated cannabis-based products sold, we chose three leading products that we judged to be most representative and comparable across different retail environments. In an initial pre-survey, we determined that one gram, one-eighth ounce, and one ounce are the three most common dried flower packages for sale at California dispensaries, and that the 500-milligram cartridge was the most common concentrate or
extract package. We chose not to collect one-gram package prices due to their higher degree of variability within and between locations. We thus collected prices for one-eighth-ounce and one-ounce dried flower and 500-milligram cartridges. As expected, we observed substantial quantity discounts per ounce for buying dried flower in one-ounce portions vs. one-eighth-ounce portions.

We collected maximum and minimum prices in each of these three product categories at each dispensary. We chose this approach in part because many dispensaries have a price schedule with just two levels for eighth-ounce and one-ounce packages: low (which we call “generic”), and high (“top-shelf,” which we call “premium”) prices. Some dispensaries had three to four price levels, but we rarely observed more than five. In the interest of simplicity, we collected two prices from each dispensary: one “generic” price, representing the lowest product in the price range for the given product, and one “premium” price, representing the highest. Thus, the low and high prices for each of the three products generate six different prices in our data set.

As observed by Sifaneck et al. (2007) and discussed above, prices vary by characteristics and the quality level as perceived by consumers. It is important to note that perceived quality does not necessarily correspond to objective quality in terms of hedonic preferences. In the US wine market, a wide price spread between generic and premium prices appears to be stable even though the difference between generic-priced and premium-priced products are not readily distinguishable by wine consumers in blind taste tests (Goldstein et al. 2008), and beer consumers pay price spreads for premium brands whose physical properties they cannot readily differentiate (other than the label and branding; Almenberg et al. 2014). For the cannabis marketplace, we collected data on both generic and premium prices to better understand the retail market, and we are thus able to observe consumer willingness to pay in two different perceived-quality categories.

### 4.4 Data overview

Table 4.1 reports the summary statistics of our survey data. Out of 565 retailers, 57% conduct business from a storefront (with a physical address of the dispensary), and 47% conduct business using a delivery service. Only 4% of surveyed retailers sell through both storefront retail and a delivery service. We believe that this 4% is likely to be an underestimate due to reporting bias (some delivery services are not fully compliant with the Brown Guidelines or local municipal ordinances, and would prefer not to disclose their existence to non-customers).
Even though not all retailers report all six prices considered here, almost all retailers (561 out of 565) list the price of one-eighth ounce dried flower, which interviews consistently cite as the most frequently purchased item at dispensaries (we do not yet have reliable data on the distribution of package sizes within dried flower purchases, however). Comparing the high and low prices of dried flower for one-eighth ounce and one ounce, two observations emerge. First, the high price is, on average, almost twice the low price. The price differential between high and low for cartridges is much smaller than dried flower, perhaps because (1) quality difference in raw material after distillation may be less critical than in manufactured products, and (2) the product is already premium-positioned, so the low price is not for a truly “generic” product.

Second, there are considerable discounts for larger quantity. Our data indicate that the quantity discounts are as much as 25% for both high and low categories. The low and high prices for one-eighth ounce dried flower are $28.28 ($226 per ounce) and $54.58 ($436 per ounce), respectively. These prices are 25% and 27% higher for low and high than the equivalent prices for dried flower sold in one-ounce packages.

Our data on ratings indicate that most retailers were rated highly. The reported rating means in Table 4.1 come from individual rating averages specific to review site. For each retailer, we used a considerable number of reviews to construct individual rating averages.

The distributions of dried flower and cartridge prices are presented in the panels of Figure 4.1. Comparing the distributions of low and high prices for dried flower indicates that low prices tend to be more clearly multi-modal than high prices for both 1/8 ounce and one ounce dried flower. We may infer some market structure information from these price distributions. The multi-modality of generic markets may indicate more variability in the quality of products even within the generic category, or may suggest the influence of other key factors relative to the single-modal premium market products. Unlike dried flower, the distribution of low prices of cartridges has a single mode and resembles a normal distribution.
Table 4.1. Summary statistics of AIC survey of cannabis dispensaries in California

<table>
<thead>
<tr>
<th>Variable</th>
<th>Obs.</th>
<th>Mean</th>
<th>Std Dev</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retail and/or delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retail (yes=1)</td>
<td>565</td>
<td>57%</td>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Delivery (yes=1)</td>
<td>265</td>
<td>47%</td>
<td></td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Retail price</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low price</td>
<td>561</td>
<td>$28.20</td>
<td>$9.70</td>
<td>$8.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>High price</td>
<td>561</td>
<td>$54.50</td>
<td>$16.40</td>
<td>$13.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>1 oz dried flower</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low price</td>
<td>503</td>
<td>$181.30</td>
<td>$68.00</td>
<td>$20.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>High price</td>
<td>503</td>
<td>$341.70</td>
<td>$111.5</td>
<td>$70.00</td>
<td>$1,000.00</td>
</tr>
<tr>
<td>0.5g Cartridge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low price</td>
<td>327</td>
<td>$30.30</td>
<td>$7.80</td>
<td>$10.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>High price</td>
<td>328</td>
<td>$41.50</td>
<td>$13.10</td>
<td>$15.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Rating</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Google Local</td>
<td>89</td>
<td>4.4</td>
<td>0.6</td>
<td>0.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Yelp</td>
<td>127</td>
<td>4.2</td>
<td>0.9</td>
<td>0.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Weedmaps</td>
<td>556</td>
<td>4.7</td>
<td>0.4</td>
<td>0.0</td>
<td>5.0</td>
</tr>
<tr>
<td>Leafly</td>
<td>105</td>
<td>4.6</td>
<td>0.6</td>
<td>0.0</td>
<td>5.0</td>
</tr>
</tbody>
</table>

Source: AIC cannabis price survey conducted in fall 2016.

Figure 4.1. Distribution of low and high prices for dried flower and cartridges

![Distribution of Low Prices for 1/8 oz dried flowers](image1)

![Distribution of High Prices for 1/8 oz Dried Flowers](image2)
4.5 Complexities in price distributions

Here we examine complexity in price distributions using one-ounce dried flower prices. The analysis below begins by censoring the data into price categories with a range of $25 each, which yields a multi-modal frequency distribution of prices that is not easily described by conventional distribution forms.

*Source: AIC cannabis price survey conducted in fall 2016.*
Figure 4.2. Distribution of one ounce retail dried flower prices, California

Source: AIC cannabis price survey conducted in fall 2016.

For the low-priced category, we see two modes, local modes of $175 to $200 per ounce and $100 to $125. What we are likely seeing at the $100 and $200 levels is quality differentiation: normal-potency dried flower at the higher primary mode versus lower-potency “shake” or “schwag” at the lower secondary mode. The mean price per ounce across dispensaries for the low prices is $181, and the mass of the distribution is skewed to the left of center.

For the high-price observations, the frequency distribution has a modal price of $276 to $300. The mean of the high prices per ounce is $342, and the mass of the distribution is skewed to the left of center with a long, stretched tail on the right side of the distribution. One interpretation of the price distributions is that neither consumers nor sellers know quality. Another is that there are many quality classes of cannabis products, which have not been standardized.

4.6 County- and region-specific analyses

Table 4.2 presents the summary statistics of various prices by county, where the mean is the average of the midpoints between the high and low prices. The table includes the coefficient of
variation (CV) for each price (the standard deviation divided by the mean) to represent the dispersion of prices around the mean. The higher CV represents the greater dispersion of prices.

Cannabis prices, especially of dried flower, tend to be lowest in the counties of Fresno, Kern, and Butte. Price differences across counties tend to be smaller for cartridges than for dried flower. High prices of dried flower tend to be considerably higher in Santa Clara and San Diego counties. It is plausible that consumers have a general higher willingness to pay in coastal areas, where quality is higher or costs are higher for dispensaries.

Table 4.2. Summary Statistics of Prices, by County

<table>
<thead>
<tr>
<th>County</th>
<th>Obs.</th>
<th>Mean</th>
<th>Std Dev</th>
<th>CV</th>
<th>Minimum</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alameda County</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower, low price</td>
<td>15</td>
<td>$31.3</td>
<td>$10.0</td>
<td>0.32</td>
<td>$15.0</td>
<td>$50.0</td>
</tr>
<tr>
<td>high price</td>
<td>15</td>
<td>$55.0</td>
<td>$10.0</td>
<td>0.18</td>
<td>$35.0</td>
<td>$75.0</td>
</tr>
<tr>
<td>1 oz dried flower, low price</td>
<td>13</td>
<td>$215.1</td>
<td>$72.4</td>
<td>0.34</td>
<td>$100.0</td>
<td>$325.0</td>
</tr>
<tr>
<td>high price</td>
<td>13</td>
<td>$355.8</td>
<td>$52.2</td>
<td>0.15</td>
<td>$280.0</td>
<td>$440.0</td>
</tr>
<tr>
<td>500-mg cartridge, low price</td>
<td>14</td>
<td>$29.0</td>
<td>$8.7</td>
<td>0.30</td>
<td>$10.0</td>
<td>$40.0</td>
</tr>
<tr>
<td>high price</td>
<td>14</td>
<td>$52.1</td>
<td>$25.2</td>
<td>0.48</td>
<td>$15.0</td>
<td>$120.0</td>
</tr>
<tr>
<td><strong>Butte County</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower, low price</td>
<td>22</td>
<td>$29.3</td>
<td>$8.5</td>
<td>0.29</td>
<td>$20.0</td>
<td>$45.0</td>
</tr>
<tr>
<td>high price</td>
<td>22</td>
<td>$47.3</td>
<td>$11.6</td>
<td>0.25</td>
<td>$30.0</td>
<td>$90.0</td>
</tr>
<tr>
<td>1 oz dried flower, low price</td>
<td>17</td>
<td>$162.1</td>
<td>$53.0</td>
<td>0.33</td>
<td>$100.0</td>
<td>$275.0</td>
</tr>
<tr>
<td>high price</td>
<td>17</td>
<td>$291.8</td>
<td>$58.5</td>
<td>0.20</td>
<td>$190.0</td>
<td>$390.0</td>
</tr>
<tr>
<td>500-mg cartridge, low price</td>
<td>11</td>
<td>$35.9</td>
<td>$6.6</td>
<td>0.18</td>
<td>$20.0</td>
<td>$45.0</td>
</tr>
<tr>
<td>high price</td>
<td>11</td>
<td>$47.3</td>
<td>$10.6</td>
<td>0.22</td>
<td>$30.0</td>
<td>$60.0</td>
</tr>
<tr>
<td><strong>Fresno County</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower, low price</td>
<td>46</td>
<td>$33.1</td>
<td>$8.5</td>
<td>0.26</td>
<td>$15.0</td>
<td>$50.0</td>
</tr>
<tr>
<td>high price</td>
<td>46</td>
<td>$53.4</td>
<td>$17.5</td>
<td>0.33</td>
<td>$30.0</td>
<td>$100.0</td>
</tr>
<tr>
<td>1 oz dried flower, low price</td>
<td>39</td>
<td>$189.1</td>
<td>$67.8</td>
<td>0.36</td>
<td>$100.0</td>
<td>$375.0</td>
</tr>
<tr>
<td>high price</td>
<td>39</td>
<td>$302.2</td>
<td>$91.4</td>
<td>0.30</td>
<td>$180.0</td>
<td>$650.0</td>
</tr>
<tr>
<td>500-mg cartridge, low price</td>
<td>22</td>
<td>$31.8</td>
<td>$6.5</td>
<td>0.20</td>
<td>$20.0</td>
<td>$45.0</td>
</tr>
<tr>
<td>high price</td>
<td>22</td>
<td>$38.6</td>
<td>$9.8</td>
<td>0.25</td>
<td>$25.0</td>
<td>$60.0</td>
</tr>
<tr>
<td><strong>Kern County</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower, low price</td>
<td>43</td>
<td>$21.1</td>
<td>$8.1</td>
<td>0.39</td>
<td>$10.0</td>
<td>$40.0</td>
</tr>
<tr>
<td>high price</td>
<td>43</td>
<td>$52.1</td>
<td>$17.5</td>
<td>0.34</td>
<td>$25.0</td>
<td>$100.0</td>
</tr>
<tr>
<td>1 oz dried flower, low price</td>
<td>32</td>
<td>$160.1</td>
<td>$61.6</td>
<td>0.38</td>
<td>$80.0</td>
<td>$285.0</td>
</tr>
<tr>
<td>high price</td>
<td>32</td>
<td>$340.3</td>
<td>$143.0</td>
<td>0.42</td>
<td>$180.0</td>
<td>$840.0</td>
</tr>
<tr>
<td>500-mg cartridge, low price</td>
<td>23</td>
<td>$29.6</td>
<td>$5.8</td>
<td>0.20</td>
<td>$20.0</td>
<td>$45.0</td>
</tr>
<tr>
<td>high price</td>
<td>23</td>
<td>$35.4</td>
<td>$7.2</td>
<td>0.20</td>
<td>$30.0</td>
<td>$60.0</td>
</tr>
<tr>
<td><strong>Los Angeles County</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1/8 oz dried flower, low price</td>
<td>243</td>
<td>$25.9</td>
<td>$9.2</td>
<td>0.36</td>
<td>$8.0</td>
<td>$55.0</td>
</tr>
</tbody>
</table>
Table 4.3 presents the statistics aggregated by region, where “Northern California” includes Alameda, Sacramento, Butte, and Santa Clara counties; “San Joaquin Valley” includes Fresno and Kern counties; and “Southern California” includes Los Angeles and San Diego counties. Our regional statistics suggest that Southern California prices are highest. The relatively high overall prices in Southern California (versus the rest of California) are driven more by high prices for premium dried flower than by high prices for generic dried flower.

Table 4.3. Summary Statistics of Prices, by Region

<table>
<thead>
<tr>
<th>Variable</th>
<th>Northern California</th>
<th>Central California</th>
<th>Southern California</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Obs.</td>
<td>Mean</td>
<td>Std Dev</td>
</tr>
<tr>
<td>1/8oz, low</td>
<td>120</td>
<td>$28.5</td>
<td>$8.5</td>
</tr>
<tr>
<td>1/8oz, high</td>
<td>120</td>
<td>$51.4</td>
<td>$10.5</td>
</tr>
<tr>
<td>1oz, low</td>
<td>108</td>
<td>$180.0</td>
<td>$64.1</td>
</tr>
<tr>
<td>1oz, high</td>
<td>108</td>
<td>$332.7</td>
<td>$75.4</td>
</tr>
<tr>
<td>500mg cart, low</td>
<td>78</td>
<td>$29.2</td>
<td>$9.5</td>
</tr>
</tbody>
</table>

Source: AIC cannabis price survey conducted in fall 2016.
Table 4.4 reports the share of physical storefront retailers and delivery-service retailers, by county. These shares differ considerably across counties. For example, none of the retailers in Butte County has a storefront location. Also, while few of the retailers in our survey report both a physical storefront and deliveries, Alameda County is an exception. Our data indicate that over half of retailers we surveyed (53%) in Alameda County report a physical storefront and delivery service.

Table 4.4. Dispensary characteristics, by county, storefront vs. delivery

<table>
<thead>
<tr>
<th>County</th>
<th>Obs.</th>
<th>Retail %</th>
<th>Delivery %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alameda</td>
<td>15</td>
<td>73</td>
<td>80</td>
</tr>
<tr>
<td>Butte</td>
<td>22</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Fresno</td>
<td>47</td>
<td>17</td>
<td>89</td>
</tr>
<tr>
<td>Kern</td>
<td>43</td>
<td>81</td>
<td>21</td>
</tr>
<tr>
<td>Los Angeles</td>
<td>245</td>
<td>75</td>
<td>26</td>
</tr>
<tr>
<td>Sacramento</td>
<td>67</td>
<td>42</td>
<td>58</td>
</tr>
<tr>
<td>San Diego</td>
<td>109</td>
<td>39</td>
<td>67</td>
</tr>
<tr>
<td>Santa Clara</td>
<td>17</td>
<td>94</td>
<td>12</td>
</tr>
<tr>
<td><strong>California</strong></td>
<td><strong>565</strong></td>
<td><strong>57</strong></td>
<td><strong>47</strong></td>
</tr>
</tbody>
</table>

Source: AIC cannabis price survey conducted in fall 2016.

4.7 Relationships Between High and Low Prices and Product Characteristics

4.7.1 Scatter diagrams of the price relationships. In Figure 4.3, we plot the high (premium) price against respective low (generic) price for the sample. For all three categories of products, we found a positive correlation between low and high prices. Among the three categories of products, the positive price relationship seems stronger for one-ounce dried flower.
Figure 4.3. Scatter diagrams for 1/8-ounce and one ounce dried flower and 500 mg cartridges

Source: AIC cannabis price survey conducted in fall 2016.

4.7.2 Concentration premium effects in the California retail cannabis market. To get a broad picture of the relationship between prices and product THC levels, we solicited a separate sample of 106 price-THC pairs from a stratified sub-sample of 8 dispensaries scattered across the state. We then partitioned the data into nine price categories and created an ordinal “price category” variable. We then calculated the mean THC measurements of products falling into
each of these nine categories, which allowed us to observe a smoothed version of the price-THC relation in the sub-sample for which THC was reported. We note a tendency for price to rise with THC.

### Table 4.6. Summary statistics, sub-sample

<table>
<thead>
<tr>
<th>Price range</th>
<th>Products</th>
<th>Mean THC level</th>
</tr>
</thead>
<tbody>
<tr>
<td>$100 to $150</td>
<td>2</td>
<td>20.80%</td>
</tr>
<tr>
<td>$151 to $200</td>
<td>7</td>
<td>21.87%</td>
</tr>
<tr>
<td>$201 to $250</td>
<td>14</td>
<td>22.24%</td>
</tr>
<tr>
<td>$251 to $300</td>
<td>38</td>
<td>23.10%</td>
</tr>
<tr>
<td>$301 to $350</td>
<td>27</td>
<td>23.81%</td>
</tr>
<tr>
<td>$351 to $400</td>
<td>10</td>
<td>22.16%</td>
</tr>
<tr>
<td>$401 to $450</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>$451 to $500</td>
<td>5</td>
<td>25.80%</td>
</tr>
<tr>
<td>$501 to $550</td>
<td>1</td>
<td>48.30%</td>
</tr>
</tbody>
</table>

*Source: AIC cannabis price survey conducted in fall 2016.*

Next, we considered a price-category linear regression that turns each of these nine price categories into an ordinal variable from 1 to 9 (i.e., we predicted average THC level given a price category, coding price category as an ordinal variable from 1 to 9). This regression yields a coefficient. In this model, the price-category coefficient (0.0055) means that moving up 1 unit on the 1-to-9 price-category scale, which corresponds to an increase in price of $50 per ounce of dried flower, the expected average THC level of all products in the price category rose by approximately 0.5%. We have not weighted this regression by sample size in each category, and we ignore one outlying category with only one observation of a single product that had almost double the THC of any other product in the sample.
Figure 4.7. Price category-THC relationship, sub-sample

Regression equation:

\[ THC\% = 0.0055 \times \text{PriceCategory} + 0.2051 \]

\[ R^2 = 0.75 \]

Source: Sub-sample from AIC cannabis price survey conducted in fall 2016.

Table 4.7 displays the low and high prices for each of the 8 sub-sample dispensaries.

Table 4.7. Low and high prices and THC levels

<table>
<thead>
<tr>
<th>Dispensary</th>
<th>Low Price</th>
<th>THC Level</th>
<th>High Price</th>
<th>THC %</th>
<th>Price spread</th>
<th>THC spread</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>$360</td>
<td>19.00%</td>
<td>$480</td>
<td>25.80%</td>
<td>$120</td>
<td>6.80%</td>
</tr>
<tr>
<td>#2</td>
<td>$250</td>
<td>21.10%</td>
<td>$380</td>
<td>30.50%</td>
<td>$130</td>
<td>9.40%</td>
</tr>
<tr>
<td>#3</td>
<td>$199</td>
<td>22.80%</td>
<td>$350</td>
<td>28.46%</td>
<td>$151</td>
<td>5.66%</td>
</tr>
<tr>
<td>#4</td>
<td>$240</td>
<td>21.40%</td>
<td>$330</td>
<td>23.72%</td>
<td>$90</td>
<td>2.32%</td>
</tr>
<tr>
<td>#5</td>
<td>$120</td>
<td>21.50%</td>
<td>$400</td>
<td>22.67%</td>
<td>$280</td>
<td>1.17%</td>
</tr>
<tr>
<td>#6</td>
<td>$285</td>
<td>15.65%</td>
<td>$360</td>
<td>17.70%</td>
<td>$75</td>
<td>2.05%</td>
</tr>
<tr>
<td>#7</td>
<td>$200</td>
<td>15.90%</td>
<td>$340</td>
<td>23.70%</td>
<td>$140</td>
<td>7.80%</td>
</tr>
<tr>
<td>#8</td>
<td>$140</td>
<td>20.10%</td>
<td>$280</td>
<td>26.48%</td>
<td>$140</td>
<td>6.38%</td>
</tr>
<tr>
<td><strong>Means</strong></td>
<td><strong>$224</strong></td>
<td><strong>19.70%</strong></td>
<td><strong>$365</strong></td>
<td><strong>24.90%</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Source: Sub-sample from AIC cannabis price survey conducted in fall 2016.

4.8 Determination of a representative California retail price

The representative price of $3,453 per pound dried flower that we used as an initial situation in our simulation analysis was derived with the following procedure. Our initial data consist of high and low prices in each sampled dispensary for 1/8-ounce packages and full one-ounce packages. We did not include the manufactured products in this calculation because those products contain additional processing and packaging costs that add to the complexity of deriving the cannabis equivalent prices.

To calculate a representative high and low price per pound of flower-equivalent product, we used the statewide averages for each. The first step was to assign a volume share for the low prices and high prices. We noted that for most consumer products, the highest-priced product has a much lower market share (by volume) than the low-priced product, meaning that the volume-weighted average market price falls below the mid-point between the generic and premium prices (See Section 4.9 for an example from the beer market).

In many dispensaries, there are other packages available at prices between the two extremes. As a broad simplifying assumption, relying on other industries for guidance, we assumed that about the low price represents 90% of the volume transacted and the high price (which tends to be extreme) represents 10% of the volume.

We used the statewide average by package size for high prices and low prices that we present in Table 4.1 to generate flower-equivalent-pound volume averages. The state average low price for 1/8-ounce packages is $3,584 per pound. The state average high price for 1/8-ounce packages is $6,912 per pound. The volume-weighted average is $3,917. For one-ounce packages, the flower-equivalent pound (as defined in Section 5.3.1) averages for the low and high prices are $2,896 and $5,472 per pound, respectively, for a volume-weighted average of $3,154 per pound. Finally, guided by evidence from the beer industry as explained in Section 4.9, we used the weighted average of these prices using the aggregate quantity shares of about 61% for 1/8-ounce products and 39% for one-ounce products.

Using these shares, the weighted average price, which will be used as an aggregate representative retail price in our analysis, is calculated as $3,453.
4.9 Quantity-weighted average prices tend to be well below midpoints and medians

We examined the price distribution of beer and wine to help confirm that market volumes tend to be higher for products that sell in the lower price categories, such that average market prices tend to below midpoint or median prices.

Most product categories are composed of goods with varying attributes that sell for different prices and in different volumes. To determine the weighted average price of a good in a particular category, we must know both the volume and price of the good. Beer and wine sales in the United States are examples of price diversity within a broad category.

Below is a chart of retail beer sales in the United States by volume and total dollar for the first 11 months of 2016. These data are from based on the market surveys conducted by IRI (a firm specialized in retail surveys including scanner data). The unpublished summary in Table 4.8 was supplied to us courtesy of the National Brewers Association. Volume units are in cases (24 cans of 12 ounces per container, or 288 ounces per case).

Table 4.8 Distribution of beer prices and volumes by price category

<table>
<thead>
<tr>
<th>Beer segment</th>
<th>Retail sales ($ millions)</th>
<th>Share of Category</th>
<th>Volume Sales (millions of cases, 24 x 12 oz)</th>
<th>Volume Share of Category</th>
<th>Retail Price ($/case)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Domestic sub-premium</td>
<td>$4,788</td>
<td>16%</td>
<td>299</td>
<td>24%</td>
<td>$16</td>
</tr>
<tr>
<td>Domestic premium</td>
<td>$11,699</td>
<td>40%</td>
<td>567</td>
<td>45%</td>
<td>$21</td>
</tr>
<tr>
<td>Import</td>
<td>$5,192</td>
<td>18%</td>
<td>173</td>
<td>14%</td>
<td>$30</td>
</tr>
<tr>
<td>Craft</td>
<td>$3,224</td>
<td>11%</td>
<td>89</td>
<td>7%</td>
<td>$36</td>
</tr>
<tr>
<td>All and Average</td>
<td>$29,248</td>
<td>100%</td>
<td>1,272</td>
<td>100%</td>
<td>$23</td>
</tr>
</tbody>
</table>

The average of the lowest price per case ($16.00) and the highest price per case ($36.08) is $26.04. However, the actual weighted average case price is $22.99, approximately 13% below the average of the high and low prices.

Table 4.9 is from the 2013 Gomberg-Fredrikson Report of wholesale wine shipments from California wineries to wholesalers in the United States. Retail wine prices differ by category more than do beer prices. Some wines retail under $3 per bottle, while others retail at well over $100 per bottle. This price diversity is reflected in the Gomberg-Fredrikson data, which show an average wholesale case price of $51 but a range of $20 to $128 per case.

### Table 4.9 Distribution of wine prices and volumes by price category, 2013

<table>
<thead>
<tr>
<th>Wine segment (750-mL bottle price)</th>
<th>Wholesale Dollar Sales ($ millions)</th>
<th>Share of Category</th>
<th>Volume Sales (millions of cases, 12 x 750 ml)</th>
<th>Volume Share of Category</th>
<th>Wholesale Price ($/case)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;= $3</td>
<td>$958</td>
<td>9%</td>
<td>47</td>
<td>22%</td>
<td>$20</td>
</tr>
<tr>
<td>&gt;$3-$7</td>
<td>$2,309</td>
<td>21%</td>
<td>71</td>
<td>34%</td>
<td>$33</td>
</tr>
<tr>
<td>&gt;$7-$14</td>
<td>$3,961</td>
<td>37%</td>
<td>64</td>
<td>31%</td>
<td>$62</td>
</tr>
<tr>
<td>&gt;$14</td>
<td>$3,573</td>
<td>33%</td>
<td>28</td>
<td>13%</td>
<td>$128</td>
</tr>
<tr>
<td>Totals/averages</td>
<td>$10,801</td>
<td>100%</td>
<td>210</td>
<td>100%</td>
<td>$51</td>
</tr>
</tbody>
</table>


### 5. The California cannabis market

In this chapter we evaluate the California retail cannabis market. We first clarify our framework for constructing and modeling the cannabis market and its segments. We then draw on data and market research, which is presented in Sections 5.3 and 5.4 below, to construct estimates of prices and quantities in the November 2016 California cannabis market as it stood before Proposition 64 was passed, and before any state cannabis regulations went into effect.
5.1 Market segments

Until November 2016, the sale of medical cannabis was legal under state law, but the sale of non-medical cannabis was not. We look at a snapshot of the early November 2016 market prior to any form of adult-use legalization. This early November 2016 cannabis market was divided into two parts, which we call “segments”: the legal medical cannabis segment, which in November 2016 was regulated only at the county and municipal level and not at the state level (hereafter denoted as “medical,” or “m” in the notation used in Appendix Chapter 7); and the illegal non-medical cannabis segment, which, by construction, was unregulated (hereafter denoted as “illegal,” or “i” in the notation used in Appendix Chapter 7).

The terms “legal” and “illegal” can be confusing, especially in the context of cannabis, which is illegal under Federal law is likely to remain so in 2018 and beyond. In the present discussion, by “legal,” we mean to refer only to the status of sales in the segment under California state law at the specific time to which the discussion applies. Even this determination can be unclear, as for example some cannabis sellers in November 2016 were operating in observance of some parts of SB 420 and the Brown Guidelines and others were not.

We handle such confusion simply by constructing our “medical” cannabis segment broadly to include all cannabis that is sold upon the presentation and verification of a medical recommendation, including but not limited to sales at storefront dispensaries, delivery services, and patients’ collectives. We use the term “illegal” segment to refer to the rest of cannabis sales at that time. This segment includes all cannabis that was sold during that period to any consumers (whether medical patients or non-patients) via non-medical channels, including street dealers, non-medical delivery services, and direct grower-to-consumer sales.

In Section 5.3, we survey a range of available data describing the market through November 2016. We state our assumptions and make estimates of prices and quantities in the legal medical cannabis segment, the illegal non-medical cannabis segment, and the total California cannabis market in the November 2016 situation, which we assume to be a snapshot of the market as measured prior to the California election of November 8, 2016. Because many of our data sources are monthly indicators, and assuming that market prices will take more than three weeks to reflect the effects of partial adult-use decriminalization due to Proposition 64, we
collected measurements (including our AIC retail price survey) through the end of November 2016.

As is detailed in Section 5.3, we agree with other industry analysts in estimating that the majority of cannabis sold in the marketplace as of November 2016 went through illegal channels. Specifically, we estimate that the illegal segment comprises 75% by weight (in flower equivalent; see Section 5.3.1 for explanation of units and conversion methodology) of the November 2016 cannabis market, and that the medical segment comprises 25% by weight.

5.2 Effects of changes to market segments

Before proceeding to describe some data of the situation in November 2016, we briefly explain how these estimates will be used in the simulation model that is detailed Chapter 7. The situation in 2018 will be different from the November 2016 situation in three major ways: sale of all legal cannabis will be taxed, the sale of adult-use cannabis will be legalized, and the sale of all legal cannabis will be regulated. In order to separate out the respective economic impacts of taxation and legalization of adult use cannabis (taken together) from the economic impacts of proposed regulations, we apply the changes to our model in two separate steps, estimating at each step the new prices and quantities generated by the model.

We also must make a number of additional assumptions to simulate impacts, including estimates of price elasticities of demand for each segment, supply elasticities and the expected cost (supply) and demand shifts that are assumed to be caused by the two major changes. With these assumptions we are then able to make projections effects of each of the major changes on prices and quantities in the medical (“m”) segment, in the illegal (“i”) segment, and in a new legal adult-use segment (“a”), which is created by adult-use legalization and thereby competes with the other two segments.

The two major changes and their resulting cost (supply) and demand shifts are described next. The magnitudes of the estimated shifts, along with elasticities and other assumptions, are reported in Chapter 7 and Chapter 8.

5.2.1 Change 1: Taxation and adult-use legalization. The first major change, which we call “taxation and adult-use legalization,” results in a new hypothetical scenario (understood to be after November 2016, but not pegged to any specific date, as it is a counter-factual scenario) in
which the sale of adult-use cannabis becomes legal and the cultivation and excise taxes on cannabis are imposed, but the California cannabis industry remains otherwise unregulated by the state. Note that this is a purely counter-factual scenario, constructed for the purposes of separately isolating the impacts of proposed regulations. It does not correspond to the passage or implementation of AUMA or to any other real-life market environment that is expected to arise now or in the future. So as to cleanly separate our starting market snapshot from the changes whose effects we estimate, the market data in this chapter are meant to describe the California cannabis market up to the point in November 2016, when Proposition 64 passed.

In the actual California cannabis situation, we recognize that the AUMA framework is taking effect in two temporal stages. First, in November 2016, immediately upon the passage of Proposition 64, several cannabis activities were decriminalized for all adults 21 and over, including adult possession of up to one ounce, the cultivation of up to six plants for personal consumption, and the distribution of free cannabis. Also in November 2016, the sale of cannabis and possession of larger quantities of cannabis was reclassified from a felony to a misdemeanor under state law. Second, in January 2018, the state will implement regulations that legalize adult-use sales and begin collecting new taxes for legal sales of cannabis.

We continued to survey data for our November 2016 market snapshot through the end of the month of November, under the assumption that it would take at least several weeks, if not months, for the effects of the decriminalization of personal adult-use possession (but not sale) due to Proposition 64 to begin to have significant effect on market prices or quantities. Data we collected in December 2016 and January 2017, however, were not used to construct the November 2016 market snapshot.

The unregulated “taxation and adult-use legalization” scenario which we use for the counter-factual baseline to assess impacts of regulations does not correspond to the real-life partially decriminalized 2017 situation (which does not include taxation or legal adult use dispensary sales) or to the real-life 2018 marketplace (in which state regulations will be in effect as well as adult-use sales). Rather, the “adult-use legalization and taxation” hypothetical is understood to be a situation in which adult-use cannabis is legally sold at retail and all legal cannabis sales are fully taxed, but in which the regulations are not implemented.

The supply and demand shifts we project from adult-use legalization may first begin to partially manifest during 2017, as the information that adult-use cannabis has been legalized may
already begin to lower risk premiums, open capital markets, attract new consumers, and so on. However, since a retail adult-use storefront industry is not likely to exist before 2018, so the shifts in supply in demand attributable to taxation and adult-use legalization will not manifest fully until after that.

Thus the “taxation and adult-use legalization without regulation” scenario will remain a counter-factual hypothetical and never materialize in the actual California marketplace.

Supply effects of Change 1: First, adult-use legalization legitimizes the industry in the eyes of trading partners and the potential labor market, and it opens up new mainstream sources of risk-averse capital, enabling investment in more efficient technology and expansion to enable scale economies. The removal of taboos and social stigma may also expand the labor market to include a new pool of potential managers and other employees.

Second, adult-use legalization lowers the “risk premium” for supplying cannabis, which, as explained in Appendix Section 3.2, is a significant cost of doing business in the November 2018 pre-legalization market. This reduction of risk premium costs is greatest in the newly legal adult-use segment, as formerly illegal sellers whose business activities that had formerly been punishable by lengthy imprisonment terms open legal adult-use operations with little fear of state criminal prosecution. This lowers the premium wages that illegal cannabis businesses would previously have had to pay employees in exchange for assuming such risks, as well as lowering security costs, costs of concealment, and other costs of doing illegal business. This results in a shift downward of costs for supplying adult-use cannabis (shift right in the supply curve).

Risk premium costs are also lowered in the medical segment. Although their prior risk premium costs had not been as high as they were in the illegal market, the opening of mainstream capital labor markets that results from de-stigmatization also lowers the costs of doing business for medical cannabis businesses. These effects combine to lower the total cost of supplying cannabis in the adult-use and medical segments, with shifts downward (right) in their respective supply curves.

Finally, cultivation and excise taxes are applied to legal cannabis at two different points along the supply chain, resulting in an additional percentage cost increase for supplying all legal
cannabis and an additional shift upward (left) of the supply curves in the medical and adult-use segments.

**Demand effects of Change 1:** Adult-use legalization is expected to have four main effects on demand for cannabis. The first demand effect is the migration of consumers from the illegal market to the adult-use market due to the lower perceived risks of punishment, unsatisfactory product quality, or fraudulent seller activity. This results in a shift outward (right) of the demand curve for adult-use cannabis and a shift inward (left) of the demand curve for illegal cannabis. Note that consumers under 21 must stay in the medical market if they wish to purchase legally; for more on the under-21 portion of the market, see Section 5.4.

The second demand effect is the migration of consumers from the medical market to the adult-use market due to adult-use dispensaries’ competitive advantage of not requiring a medical recommendation, which we currently estimate at $50 per year per consumer plus the inconvenience of obtaining the recommendation. This results in a shift inward (left) of demand for medical cannabis and a shift outward (right) of demand for adult-use cannabis.

The third demand effect is the emergence of new cannabis demand from risk-averse non-medical consumers who had previously been unwilling to buy cannabis illegally due to the risks of punishment, social stigma, or moral disutility. This results in a shift outward (right) of demand for adult-use cannabis.

The fourth demand effect is the expansion of the cannabis market to include tourists and other out-of-state visitors, who are prohibited from buying in the medical segment but can participate in a legalized adult-use market (see Section 5.2.2 for details on this effect). This results in a shift outward (right) of demand for adult-use cannabis.

5.2.2 Expected demand shift from out-of-state consumers. There are more than 260 million visits to California from residents of other places per year. These visitors spend more than $122 billion in California.¹⁰ A significant portion of this spending is on leisure goods and services. For instance, tourists

---

¹⁰ [http://industry.visitcalifornia.com/Find-Research/California-Statistics-Trends/]
have been estimated to spend $7.2 billion per year on wine in California.\textsuperscript{11} Demand for new forms of leisure spending by tourists and other visitors to California potentially large.

Given that adult-use cannabis remains illegal in most other states, California’s legalized adult-use industry may attract some new visitors whose primary reason for visiting the state is cannabis tourism, as has been observed in Colorado (Miller, 2015), where adult-use cannabis was legalized in 2014. Colorado, whose tourism industry, like California’s, is a significant contributor to GDP, may be the most relevant available comparison with respect to the potential impact of an adult-use cannabis industry on tourism.

A survey by Strategic Marketing and Research Insights (Miller, 2015), commissioned by the Colorado Tourism Office and reported in the Denver Post (Blevins, 2015), conducted 33-question surveys of approximately 3,250 tourists from Chicago, Dallas, Houston, San Diego, and several other cities, of which about 10% had vacationed in Colorado between April and September, 2015, the year after adult-use legalization first took effect in Colorado.

8% of the Miller (2015) respondents reported visiting an adult-use cannabis dispensary, of which 85% said cannabis was a “primary motivator” of their visit to Colorado.

5.2.3 Change 2: Regulation. The second major change, which we call “regulation,” is then applied to the “taxation and adult-use legalization” scenario, resulting in a scenario that corresponds to the actual situation expected in California in 2018, with state regulation established under the proposed regulations governing medical cannabis plus a set of hypothetical regulations governing adult-use cannabis that are assumed to be substantially similar to the medical regulations.

\textit{Supply effects of Change 2:} The costs of licensing and compliance with testing, surveillance, transportation, and other new regulations, which are calculated and explained in Chapter 6, add an increase to the cost of supplying all legal cannabis, but not to the illegal segment. This results in a shift upward (left) of the supply curve in the medical and adult-use segments.

\textsuperscript{11} Estimates of California wine tourism at http://www.discovercaliforniawines.com/media-trade/statistics/.
Demand effects of Change 2: The contaminant and pesticide testing, labeling, and track-and-trace requirements established by the regulations communicate higher quality, consistency, and product safety to consumers, adding value to the product sold in the two regulated cannabis segments. This results in a shift outward (right) of the demand curve in the medical and adult-use segments.

A summary of the scenarios and supply and demand effects described above is presented in Table 5.1. Following this, we proceed to our estimates of the magnitude cannabis quantity sold to consumers in California, a summary of published market size estimates, and finally a discussion of the under-21 and under-18 portions of the market.
Table 5.1. Summary of baseline market scenarios, changes, and supply and demand effects

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Supply effects</th>
<th>Demand effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 2016</td>
<td>Starting situation</td>
<td>Starting situation</td>
</tr>
<tr>
<td>Medical legal Adult use illegal No cannabis taxes No state regulations</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change 1</td>
<td>1. Sale, cultivation, and possession decriminalized for 21+; threat of criminal prosecution eliminated: greater efficiency and reduced operating costs translate to cost savings for legal cannabis sellers</td>
<td></td>
</tr>
<tr>
<td>Medical legal Adult-use legal</td>
<td>2. Risk premium costs decrease amongst the portion of formerly illegal sellers who switch to running legal adult-use operations</td>
<td></td>
</tr>
<tr>
<td>+New taxes applied</td>
<td>3. Risk premium costs also decrease for medical sellers</td>
<td></td>
</tr>
<tr>
<td>No state regulations</td>
<td>4. Cultivation and excise taxes increase costs for medical and adult-use sellers</td>
<td></td>
</tr>
<tr>
<td>Change 2</td>
<td>1. Costs of compliance increase medical cannabis supply costs</td>
<td>1. Higher perceived safety and quality increases demand for both medical and adult-use</td>
</tr>
<tr>
<td>Medical legal Adult-use legal</td>
<td>2. Costs of compliance increase adult-use cannabis supply costs</td>
<td></td>
</tr>
<tr>
<td>New taxes applied +New state regulations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5.3 Quantity estimation methodology

Due to the high level of measurement error inherent to the analysis of markets that have historically been largely illegal, current estimates of the size of the California and US medical and adult-use cannabis markets vary widely.
The market size estimates that would be imputed by taking tax collection information or voluntary patient registration information at face value are not reliable. They vary dramatically compared with the market projections of industry analysts, informal estimates by industry insiders, and our own estimates.

We begin by explaining the methodology with which we size the market in flower equivalent pound units, and then we report our own AIC market size estimates in Table 5.2. We follow this by reporting and annotating the estimates of other researchers and industry analysts in Tables 5.3a through 5.8.

For cultivation and manufacturing estimates, we rely on projections and calculations made by the economic teams carrying out research for CDPH and DFA.

As indicated in Table 5.2, we estimate the size of the California medical cannabis market in November 2016 at approximately $2 billion of total annual sales revenue (not including sales taxes collected) in the medical cannabis segment. Tax revenue is estimated by the California Board of Equalization leadership to be about $60 million.12

Based on Board of Equalization estimates and our calculations, we estimate tax revenue to be about 33% of taxes that would be owed if dispensaries were reporting full revenues.13 That is we used data from the AIC survey to create an index for the price of medical cannabis, stated as a flower-equivalent price, of $3,453 per pound, which implies a retail quantity of flower-equivalent units of 583,333 pounds on an annual basis.

5.3.1 Flower equivalent units and THC content. An additional challenge in estimating market quantities and prices was accounting for quantities transacted within the various sub-divisions of the existing market, which, as described above, is characterized by a mix of different forms of cannabis as well as different routes from producer to end consumer. The way we confront this challenge is by stating our quantity estimates in terms of “dried flower equivalent,” which we derive as follows, benchmarking according to THC levels.

---

12 These data are from https://www.boe.ca.gov/news/marijuana.htm
13 The calculation is based on estimates of how much cannabis sales revenue is generated and how much sales tax receipts are collected. http://www.latimes.com/politics/la-pol-sac-pot-taxes-20160830-snap-story.html
At dispensaries, THC content is the dominant measurement used to test and communicate the strength of a portion of dried cannabis flowers or cannabis oil. THC is also the dominant means of measuring the number of portions of cannabis contained within an edible product. Converting grams of cannabis products into grams of THC is thus the only straightforward conversion between different categories of cannabis products using information currently provided on product labels. Measuring the grams of THC in a given end-consumer product also corresponds approximately to the amount of raw cannabis that was harvested and processed in order to generate such product.

In a sub-sample of 106 price-THC level pairs for dried flower that we solicited as part of the AIC retail price survey, we observed a mean THC level in dried flower of 23.29%, with a standard deviation of 5.46%. Median THC level was 23.30%, almost identical to the mean, suggesting that the distribution is not significantly skewed. (A more sophisticated analysis of this sub-sample is presented in Appendix Section 4.7.2.)

In our sub-sample, we observe average high prices of $28.00 per 1/8 oz of generic dried flower with an average THC level of 19.7%, or 0.698 g THC, which is equivalent to $40.11 per gram pure THC. For premium dried flowers the price is $45.63 per 1/8 oz of premium dried flower with an average THC level of 24.9%, or 0.882 g THC, which is equivalent to $51.73/g pure THC. The price increase per unit THC for premium vs. generic dried flower is $11.62 or 29%.

By comparison, a report on cannabis portion equivalency by Orens et al. (2015) for the Colorado Department of Revenue observes an average THC level of 17.1% THC for dried flower, and THC equivalent prices of $55.50/g pure THC equivalent for “discounted” dried flower and $69.40/g for “most common” dried flower, representing a price premium per unit THC of 25.0% for premium vs. generic dried flower.

Although we rely on our own sub-sample for the THC-price regression analysis presented in Section 4.7.2, we rely on the Orens et al. (2015) averages, rather than the averages from our own retail price survey, in obtaining the ratios necessary to convert between different products and estimate total volume, as the AIC survey does not include THC levels of concentrate cartridges or edibles at dispensaries. Due to the large variety of edible products available and the lack of standardization of such products across the marketplace, the AIC survey does not include data on retail prices of edibles.
One-eighth ounce of dried cannabis flower with 17.1% THC (the Orens et al. average) contains 0.61 grams of pure THC equivalent, whereas a 0.5 g cartridge with 62.1% THC (the Orens et al. average) contains 0.31 grams of pure THC equivalent. Using the Colorado retail prices observed in Orens et al. for conversion, THC purchased in vape-cartridge form sells for an average of 2.28 times the price of THC purchased in 1/8-oz dried flower form, and that THC in edible form sells for an average of 3.00 times the price of THC purchased in 1/8-oz dried flower form.

In the AIC survey, cartridge prices averaged $30.30 and $41.50 for high-end. Assuming that the THC concentration ratio for premium vs. generic cartridges is the same (24.9% / 19.7% =) 1.264 as it is for premium vs. generic dried flowers, and taking the Orens et al. (2015) estimate of 62.1% to represent the generic market, we arrive at a generic cartridge THC price of $97.74/g pure THC equivalent, and a premium price of $105.91/g pure THC equivalent. This represents a generic-cartridge-to-generic-dried-flower THC-equivalent price ratio of ($97.74 / $40.15) = 2.43, and a premium-cartridge-to-premium-dried-flower THC-equivalent price ratio of ($105.91 / $51.70) = 2.05. The midpoint between these two ratios is 2.24, which is close to the Orens et al. (2015) observed ratio of 2.28, which gives us confidence in the applicability of Orens et al. (2015) to the California market.

We further assume that the additional markups on THC when sold in the “high-end” forms of concentrates, cartridges, or edibles reflect the additional costs of processing cannabis into other forms, such as concentrates (which require the use of solvents or other processing agents, as well as processing machinery) or edibles (which require even more processing, starting with concentrates and then adding other food ingredients to the mix).

On the low end, meanwhile, some consumers are currently buying dried cannabis flower at prices barely above wholesale. According to anonymized AIC interviews with industry participants at the BMCR pre-regulatory meetings, some non-profit cooperatives with few operating expenses (none, in some cases) are operating in compliance with the Brown Guidelines (at least to an equivalent extent as currently operating dispensaries), and thus form part of the legal medical market while also displaying systematic price heterogeneity unobserved by our retail price survey. If cannabis purchased by consumers through these co-operators were incorporated into our retail price averages, it would exert a downward pressure on the low end of the price distribution.
As these price anomalies at the high end and the low end are difficult to measure and affect only their respective tails of the price distribution, we assume that the integrity of mean and median prices estimated by our retail price survey are reasonable approximations of the market mean and median prices.

We convert the physical quantity of cannabis transacted in a given market into “flower-equivalent” pounds, wherein one flower-equivalent pound equals the THC-content equivalent of one pound marketable dried cannabis flower containing our retail price survey average of 23.30% THC. The estimates of average prices and quantities that are found throughout the SRIA and Appendix are thus stated in flower-equivalent units.

### 5.4 AIC quantity estimates

We estimate that 25% of total cannabis by weight, in flower-equivalent units, is currently sold in the medical (legal) segment and 75% is in the illegal segment, which translates to an overall cannabis industry of approximately $7.7 billion in November 2016. These estimates are within the range of other estimates in the industry press.

#### Table 5.2. AIC estimates of current California cannabis market segments, November 2016

<table>
<thead>
<tr>
<th>Segment</th>
<th>Share</th>
<th>Lbs flower equivalent</th>
<th>Retail price</th>
<th>Total value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legal medical cannabis</td>
<td>25%</td>
<td>583,333</td>
<td>$3,453/lb = $216/oz</td>
<td>$2.0 billion</td>
</tr>
<tr>
<td>Illegal cannabis</td>
<td>75%</td>
<td>1,750,000</td>
<td>$3,194/lb = $200/oz</td>
<td>$5.7 billion</td>
</tr>
<tr>
<td>Total cannabis market</td>
<td>100%</td>
<td>2,333,333</td>
<td>$3,259/lb = $204/oz</td>
<td>$7.7 billion</td>
</tr>
</tbody>
</table>

*Sources: AIC retail price survey; Board of Equalization tax data; AIC market size meta-study, taking into account credible industry, and analyst estimates as detailed in Tables 5.3a–5.8.*

### 5.5 Other quantity estimates

ArcView estimates are presented in Table 5.3a, and Table 5.3b summarizes a large variety of estimates that provide context to the size of the California market.
Table 5.3a. California cannabis market size, 2014–2016, ArcView estimates

<table>
<thead>
<tr>
<th>Segment</th>
<th>Legal medical cannabis</th>
<th>Illegal cannabis</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014 market size</td>
<td>$2.69B</td>
<td>$4.2B</td>
<td>$6.9 billion</td>
</tr>
<tr>
<td>2015 market size</td>
<td>$2.76B (61% of US medical market, 48% of total US legal market)</td>
<td>$4.5B</td>
<td>$7.3 billion</td>
</tr>
<tr>
<td>2016 market size Projected to end of year from 6-month data</td>
<td>$2.81B (56% of US medical market, 40% of total US legal market)</td>
<td>$5.0B</td>
<td>$7.8 billion</td>
</tr>
</tbody>
</table>


Table 5.3b. Industry, and analyst estimates of current California legal cannabis market size

<table>
<thead>
<tr>
<th>Market size</th>
<th>Relevant market</th>
<th>Specific market projection</th>
<th>Publication reference</th>
<th>Source of value data</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>$2.0 billion</td>
<td>California legal, medical</td>
<td>2016 revenue from CA medical market</td>
<td>“Five More States Could Legalize Adult-use Cannabis On Election Day.” Debra Borchardt, Forbes</td>
<td>David Dinenberg, CEO, KIND (cannabis software firm)</td>
<td>10/10/2016</td>
</tr>
<tr>
<td>$2.7 billion</td>
<td>California legal, medical</td>
<td>2016 revenue from CA medical market</td>
<td>“In California, Cannabis is Smelling Like Big Business.” Ian Lovett, New York Times</td>
<td>ArcView Group; New Frontier (industry analysts)</td>
<td>4/11/2016</td>
</tr>
</tbody>
</table>

Table 5.4 summarizes a variety of estimates about the likely size of the California market in 2018 after implementation of adult-use cannabis statutes (AUMA), including an October 2016 report prepared for Truth Enterprises (University of the Pacific, 2016), which estimates total 2018 legal market quantities at 1.4 million to 1.7 million pounds.
Table 5.4. Media, industry, and analyst estimates of future size of California legal cannabis market with regulation

<table>
<thead>
<tr>
<th>Market size</th>
<th>Relevant market</th>
<th>Specific market projection</th>
<th>Publication reference</th>
<th>Source of value data</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4.3 billion</td>
<td>California legal, all segments, 2018</td>
<td>2018 total revenue from CA legal market</td>
<td>“How Will Cannabis Legalization Affect California’s Black-Market Exports?” Madison Margolin, LA Weekly</td>
<td>New Frontier analysis (Cannabist website)</td>
<td>12/05/2016</td>
</tr>
<tr>
<td>$5 billion</td>
<td>California legal, all segments</td>
<td>“Future” revenue from CA medical and adult-use markets</td>
<td>“Five More States Could Legalize Adult-use Cannabis On Election Day.” Debra Borchardt, Forbes</td>
<td>David Dinenberg, CEO, KIND (cannabis software firm)</td>
<td>10/10/2016</td>
</tr>
<tr>
<td>$8.38 billion</td>
<td>California legal, all segments</td>
<td>“Prop 64 could add $8.38 billion in annual sales to an already robust medical market worth an estimated $2.83 billion.”</td>
<td>“How California’s Cannabis Legalization Vote Could Impact The Entire Country.” Debra Borchardt, Forbes</td>
<td>Adam Bierman, CEO, MedMen (cannabis investment firm)</td>
<td>11/07/2016</td>
</tr>
</tbody>
</table>
Table 5.5 provides a summary of the size of the US market, and Table 5.6 looks toward adult-use legalization in more states.

### Table 5.5. Media, industry, and analysts estimates of size of current US legal cannabis market

<table>
<thead>
<tr>
<th>Market size</th>
<th>Relevant market</th>
<th>Specific estimate</th>
<th>Publication reference</th>
<th>Source of value data</th>
<th>Publication date</th>
</tr>
</thead>
</table>
### Table 5.6. Media, industry, and analyst estimates of future size of US legal cannabis market

<table>
<thead>
<tr>
<th>Market size</th>
<th>Relevant market</th>
<th>Specific estimate</th>
<th>Publication reference</th>
<th>Source of value data</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>$22 billion</td>
<td>USA legal, all segments, 2020</td>
<td>“The market for both adult-use and medicinal cannabis is projected to grow to $22 billion in 4 years.”</td>
<td>“Election May Be a Turning Point for Legal Cannabis”. Thomas Fuller, <em>New York Times</em></td>
<td>ArcView Group (industry analyst)</td>
<td>10/24/2016</td>
</tr>
<tr>
<td>$23 billion</td>
<td>USA legal, all segments, 2020</td>
<td>2020 revenue from US legal market</td>
<td>“The nation’s legal cannabis industry is expected to climb to $23 billion in 2020, up from $5.7 billion in 2015.”</td>
<td>New Frontier (industry analyst)</td>
<td>8/23/2016</td>
</tr>
<tr>
<td>$50 billion</td>
<td>USA legal, all segments, 2026</td>
<td>“Investment firm Cowen &amp; Co. believes legal cannabis sales could soar...to $50 billion by 2026.”</td>
<td>“The Number of Cannabis Jobs Could Triple in the Years to Come.” Sean Williams, <em>The Motley Fool</em></td>
<td>Cowen &amp; Co. (investment firm)</td>
<td>12/11/2016</td>
</tr>
</tbody>
</table>

Table 5.7 provides summary statistics on these estimates from a variety of sources.

### Table 5.7. Summary statistics from Tables 5.2 – 5.3 compared with AIC estimates

*Note: The calculation of means and medians for future projections group together market-size projections for different years, as well as undated market size projections, into a single statistic. Such estimates vary widely and do not appear to correlate with time scale, but in any case the summary statistics should not be interpreted as externally valid meta-statistics. We do not rely on any of the above estimates or projections for our AIC estimates or projections, but we include them in this report by way of comparison and context for our findings.*

#### Current (Fall 2016) California legal cannabis market

- Range: $2.0 billion—$2.83 billion
- Mean: $2.51 billion / Median: $2.7 billion
- Standard deviation: $0.45 billion
AIC estimate: $2.0 billion

**Future California legal cannabis market with adult-use legalization and regulation**

Number of estimates: 6

Range: $4.3 billion—$11 billion

Mean: $7.03 billion / Median: $6.75 billion

Standard deviation: $2.43 billion

**Current US legal cannabis market**

Number of estimates: 3

Range: $5.6 billion—$7 billion

Mean: $6.2 billion / Median: $6.0 billion

Standard deviation: $0.72 billion

**Future US legal cannabis market**

Number of estimates: 3

Range: $22 billion—$50 billion

Mean: $31.7 billion / Median: $23 billion

Standard deviation: $15.9 billion

Table 5.8 summarizes a number of estimates of current and potential tax revenues from cannabis in California.

**Table 5.8. Estimates of current and future California tax collections by mainstream, business, and industry media and analysts**

<table>
<thead>
<tr>
<th>Tax Receipts</th>
<th>Relevant market</th>
<th>Specific estimate</th>
<th>Source of media citation</th>
<th>Source of value data</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>$40 million</td>
<td>California current annual sales tax revenue</td>
<td>Current annual California state sales tax revenue collected from medical segment</td>
<td>“California regulators will be swamped by $1 billion in pot taxes.” David Downs, San Francisco Chronicle</td>
<td>Fiona Ma, Chairwoman, California BOE</td>
<td>11/4/2016</td>
</tr>
<tr>
<td>$1 billion</td>
<td>California future annual tax revenue</td>
<td>“Future” annual tax revenue from legal cannabis production</td>
<td>“Former California Mayor Connects Cities With Cannabis Companies.” Julie Weed, Forbes</td>
<td>No specific source of data given</td>
<td>10/1/2016</td>
</tr>
</tbody>
</table>

### 5.6 Younger consumers in the market

Under AUMA, adult-use cannabis can be sold only to adults 21 or older, whereas under MCRSA, adults between 18 and 20 are permitted to obtain a physician’s recommendation for medical cannabis and to enter a medical cannabis dispensary unaccompanied by a guardian. Therefore, consumers between 18 and 20 will not legally be able to substitute adult-use cannabis for...
medical cannabis (although they can illegally obtain adult-use cannabis from friends who are 21 or older, as under-21 alcohol consumers do). In terms of economic impact, this disparity in age is the single most substantive distinction between the adult-use and medical regulatory systems.

Cannabis sales to the 18- to 20-year-old consumer group make up a significant portion of the overall consumer cannabis market. According to Johnston et al. (2016), nearly 40% of 19- and 20-year-old Americans consume cannabis at least once per year, and this percentage grew from 2010 to 2015 (Johnston et al. 2016). In 2010, 5.1% of 19- to 20-year-old consumers surveyed reported having consumed cannabis during the prior day, 18.0% had consumed during the prior 30 days, and 30.6% had consumed during the prior year.

By 2014, those numbers had all risen sharply: 7.9% of 19-to-20-year-old consumers surveyed had consumed during the previous day (a 55% increase over the five-year period), 24.3% had consumed during the previous 30 days (a 35% increase), and 38.0% had consumed during the previous year (a 24% increase). Whether measured by frequent or infrequent consumption, Americans between the ages of 19 and 20 are more likely to be cannabis consumers than people of any other age (Johnston et al. 2016).

A 2012 California Behavioral Risk Factor Surveillance System (BRFSS) survey of 7,525 Californians observes that 9.3% of 18-to-24-year-olds—the youngest age group surveyed in the study—report being medical cannabis patients, the highest prevalence of any age group; 25-to-34-year-olds are in a distant second place, with a prevalence of just 5.5% (Ryan-Ibarra 2012).

Our own analysis of data from the National Survey on Drug Use and Health (NSDUH), adding in several simplifying assumptions, suggests that as of 2013, 14.4% of all cannabis consumed in the United States was consumed by people between 18 and 20, and an additional 8.1% was consumed by the 12-17 age group; in total, thus, 22.5% of total cannabis consumed in 2013 was consumed by people under 21 (NSDUH 2013).

Taking all of the above evidence into consideration, we estimate that users between 18 and 20 currently make up approximately 15% of the $2 billion medical retail cannabis market, or $350 million, and 15% of the $6 billion illegal cannabis market, or $800 million. Whereas consumers over 21 will likely shift away from medical cannabis when legal adult-use cannabis becomes
more convenient, some and perhaps many consumers under 21 will remain in the legal medical market and pay for its additional barriers to consumer entry.

A SAMHSA study of 2013 to 2014 data found a 30-day use prevalence of 8.74% amongst youths aged 12 to 17 (Hughes et al. 2015), and data from NSDUH suggested that approximately 5% of all cannabis is consumed by 12-to-17-year-olds (NSDUH 2013). Under the expected MCRSA and AUMA regulations, medical cannabis patients under 18 will only be able to obtain medical cannabis at a dispensary if accompanied by primary caregivers 18-years-old or older.

Data on the whole California consumer market are summarized in Tables 5.9 and 5.10. Overall, about 14% of California residents 12 and over report cannabis use in the past year and 9% report use within the past month. The age decomposition of use is summarized in Table 5.11, which shows the peak use is in the age 18 to 24, with about 21% consuming within the prior month. Use in the age group 12 to 17 is almost 10% higher than those 25 and over.

Table 5.9. Percentage\(^1\) of individuals aged 12 or older in California that report cannabis use in the past year, by county

<table>
<thead>
<tr>
<th>Region</th>
<th>Small Area Estimate(^2)</th>
<th>95% CI (Lower)(^3)</th>
<th>95% CI (Upper)(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sacramento County</td>
<td>15.70%</td>
<td>12.99%</td>
<td>18.86%</td>
</tr>
<tr>
<td>San Francisco County</td>
<td>22.56%</td>
<td>17.94%</td>
<td>27.96%</td>
</tr>
<tr>
<td>Santa Clara County</td>
<td>12.31%</td>
<td>10.08%</td>
<td>14.96%</td>
</tr>
<tr>
<td>Contra Costa County</td>
<td>14.90%</td>
<td>12.12%</td>
<td>18.19%</td>
</tr>
<tr>
<td>Alameda County</td>
<td>14.77%</td>
<td>12.19%</td>
<td>17.79%</td>
</tr>
<tr>
<td>San Mateo County</td>
<td>13.61%</td>
<td>10.69%</td>
<td>17.17%</td>
</tr>
<tr>
<td>Los Angeles County</td>
<td>13.55%</td>
<td>12.40%</td>
<td>14.78%</td>
</tr>
<tr>
<td>Orange County</td>
<td>12.76%</td>
<td>10.83%</td>
<td>14.97%</td>
</tr>
<tr>
<td>Fresno County</td>
<td>13.20%</td>
<td>10.69%</td>
<td>16.20%</td>
</tr>
<tr>
<td>San Diego County</td>
<td>15.81%</td>
<td>13.65%</td>
<td>18.24%</td>
</tr>
<tr>
<td>San Bernardino County</td>
<td>12.45%</td>
<td>10.42%</td>
<td>14.82%</td>
</tr>
<tr>
<td><strong>California Statewide</strong></td>
<td><strong>14.32%</strong></td>
<td><strong>13.51%</strong></td>
<td><strong>15.18%</strong></td>
</tr>
</tbody>
</table>

\(^1\) Source: percentages are annual averages based on SAMHSA, Center for Behavioral Health Statistics and Quality, and National Survey on Drug Use and Health (NSDUH) 2012, 2013, and 2014.

\(^2\) Source: estimates are based on a small area estimation (SAE) methodology in which sub-state-level NSDUH data are combined with county and census block group and tract-level data from California.
The 95% confidence (credible) intervals are based on a survey-weighted hierarchical Bayes estimation approach and are generated by Markov Chain Monte Carlo techniques.

Table 5.10. Percentage\(^1\) of individuals aged 12 or older in California that report cannabis use in the prior month, by county

<table>
<thead>
<tr>
<th>Region</th>
<th>Small Area Estimate(^2)</th>
<th>95% CI (Lower)(^3)</th>
<th>95% CI (Upper)(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sacramento County</td>
<td>10.19%</td>
<td>8.04%</td>
<td>12.83%</td>
</tr>
<tr>
<td>San Francisco County</td>
<td>15.46%</td>
<td>11.52%</td>
<td>20.44%</td>
</tr>
<tr>
<td>Santa Clara County</td>
<td>7.78%</td>
<td>6.10%</td>
<td>9.89%</td>
</tr>
<tr>
<td>Contra Costa County</td>
<td>9.55%</td>
<td>7.32%</td>
<td>12.36%</td>
</tr>
<tr>
<td>Alameda County</td>
<td>10.67%</td>
<td>8.41%</td>
<td>13.44%</td>
</tr>
<tr>
<td>San Mateo County</td>
<td>9.07%</td>
<td>6.72%</td>
<td>12.13%</td>
</tr>
<tr>
<td>Los Angeles County</td>
<td>8.44%</td>
<td>7.55%</td>
<td>9.43%</td>
</tr>
<tr>
<td>Orange County</td>
<td>8.09%</td>
<td>6.58%</td>
<td>9.89%</td>
</tr>
<tr>
<td>Fresno County</td>
<td>8.10%</td>
<td>6.17%</td>
<td>10.58%</td>
</tr>
<tr>
<td>San Diego County</td>
<td>9.42%</td>
<td>7.70%</td>
<td>11.47%</td>
</tr>
<tr>
<td>San Bernardino County</td>
<td>7.62%</td>
<td>6.03%</td>
<td>9.59%</td>
</tr>
<tr>
<td>California Statewide</td>
<td>14.32%</td>
<td>13.51%</td>
<td>15.18%</td>
</tr>
</tbody>
</table>

\(^1\) Source: percentages are annual averages based on SAMHSA, Center for Behavioral Health Statistics and Quality, and National Survey on Drug Use and Health (NSDUH) 2012, 2013, and 2014.

\(^2\) Source: estimates are based on a small area estimation (SAE) methodology in which sub-state-level NSDUH data are combined with county and census block group and tract-level data from California.

\(^3\) The 95% confidence (credible) intervals are based on a survey-weighted hierarchical Bayes estimation approach and are generated by Markov Chain Monte Carlo techniques.

Table 5.11 Measures of Cannabis Use in California\(^1\), by Age Group: Estimated Numbers and Share of Age Group Population, Annual Averages Based on 2013-2014 NSDUHs

<table>
<thead>
<tr>
<th>Measure</th>
<th>12 and over</th>
<th>12-17</th>
<th>18-25</th>
<th>26 and over</th>
<th>18 and over</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cannabis users (in thousands)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past Year Use</td>
<td>4,633</td>
<td>463</td>
<td>1,506</td>
<td>2,664</td>
<td>4,170</td>
</tr>
<tr>
<td>Past Month Use</td>
<td>2,942</td>
<td>269</td>
<td>941</td>
<td>1,733</td>
<td>2,673</td>
</tr>
<tr>
<td>Share of age group population</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Past Year Use</td>
<td>14.49%</td>
<td>15.03%</td>
<td>33.69%</td>
<td>10.91%</td>
<td>14.44%</td>
</tr>
<tr>
<td>Past Month Use</td>
<td>9.20%</td>
<td>8.74%</td>
<td>21.05%</td>
<td>7.09%</td>
<td>9.25%</td>
</tr>
</tbody>
</table>

Sources: SAMHSA, Center for Behavioral Health Statistics and Quality; National Survey on Drug Use and Health, 2013 and 2014.
1 Measures are estimated using a survey-weighted hierarchical Bayes estimation approach.

6. Compliance costs of proposed regulations and alternatives

Regulations generally add to costs. The proposed regulations for medical cannabis add new compliance costs for medical cannabis businesses that are not part of their current costs of doing business without regulation (as reported in Chapter 3) nor part of the costs that are generated by the hypothetical taxation and adult-use legalization baseline scenario (as explained in Chapter 5). Potential benefits of proposed regulations are discussed in Chapter 5 and Chapters 7 and 8 in terms of increased willingness to pay by consumers for additional security and safety.

This chapter will estimate three different sets of compliance costs: costs generated by the proposed regulations; costs generated by an alternative regulatory package that are less costly than the proposed regulations; and costs generated by a second alternative package that imposes higher security than the proposed regulations, but at higher costs. We present and discuss these alternative packages in Section 6.1 and Table 6.1, and the remainder of Chapter 6 estimates and compares their respective compliance costs.

In all three cases, compliance costs are applied and analyzed in the context of a business environment with taxation and adult-use legalization already in place. Compliance costs are thus calculated as costs generated by each new scenario (with taxation, adult-use legalization, and the given regulation package in place) minus costs generated by the hypothetical baseline scenario (taxation and adult-use legalization in place but no regulations).

6.1 Evaluation of compliance costs and selection of regulatory alternatives

In the following sections, we describe and estimate compliance costs under the package of proposed regulations and compare them with compliance costs under two other hypothetical packages of regulations: a lower-cost alternative package and a higher-security alternative package. From the universe of all possible alternative regulatory packages that would meet the statutory requirements of MCRSA, we selected the lower-cost and higher-security alternative packages by varying particularly significant elements of the proposed regulations in terms of direct costs of compliance for cannabis businesses. We set out the chosen regulatory alternatives and axes of variation in Table 6.1.
Table 6.1 Major differences between the proposed regulatory package and two alternative regulatory packages with implications for direct costs of compliance

<table>
<thead>
<tr>
<th>Impact Variable</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security Alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Maximum batch size for mandatory testing</td>
<td>• No maximum batch size</td>
<td>• 10 lb maximum batch size</td>
<td>• 5 lb maximum batch size</td>
</tr>
<tr>
<td>2. Dispensary-to-consumer delivery restrictions</td>
<td>• No restrictions on vehicle type</td>
<td>• Cars only</td>
<td>• Cars only</td>
</tr>
<tr>
<td></td>
<td>• No lockboxes required</td>
<td>• Lockboxes required</td>
<td>• Lockboxes required</td>
</tr>
<tr>
<td></td>
<td>• No restrictions on number of employees</td>
<td>• No restrictions on number of employees</td>
<td>• Deliveries must be made by 2 or more employees</td>
</tr>
<tr>
<td>3. Security video archival requirements</td>
<td>• No requirements</td>
<td>• 1280x1024, 20fps</td>
<td>• 1280x1024, 20fps</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 30 days archive</td>
<td>• 90 days archive</td>
</tr>
<tr>
<td>4. Cannabis waste disposal and quarantine requirements</td>
<td>• No requirements</td>
<td>• Before disposal, all cannabis waste must be:</td>
<td>• None chosen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1. Disguised by blending with solid waste or soil</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2. Weighed and labeled with bill of lading with product info</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3. Quarantined in a dedicated area on camera for 72 hrs</td>
<td></td>
</tr>
</tbody>
</table>

Source: AIC analysis of proposed regulations, MCRSA statutes, and AIC interviews with Bureau and CDPH.

In Sections 6.2 through 6.4, we itemize and break down the compliance costs for each of the business activities that is regulated by the Bureau. We sort costs into three groups by business function along the vertical supply chain: distribution and transportation (Section 6.2 and Table 6.2), testing (Section 6.3 and Table 6.3), and dispensing (Section 6.4 and Tables 6.4–6.6). For each of these functions, we list the compliance costs under the proposed regulations and under the hypothetical lower-cost and higher-security alternatives and compare them with the baseline without regulation. In Table 6.5, we provide a
more detailed breakdown of video surveillance and archival costs, which is component of compliance costs for all functions except transport. Finally, in Section 6.5 and Table 6.7, we summarize all of the above costs and derive total compliance costs for the proposed regulations and alternatives.

6.2 Compliance costs for distribution and transportation

Table 6.2 shows our cost estimates for the distribution and transportation functions. The proposed regulations add about $6.51 per pound, whereas the lower-cost alternative adds $2.51 per pound and the higher-security alternative adds $8.92 per pound.

Table 6.2. Itemized compliance cost estimates for distribution and transportation

All costs stated per pound flower equivalent

<table>
<thead>
<tr>
<th>Compliance costs</th>
<th>Unregulated Baseline</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Video surveillance and archival¹</td>
<td>-</td>
<td>-</td>
<td>$1.45</td>
<td>$3.86</td>
</tr>
<tr>
<td>Disposal and quarantine¹</td>
<td>-</td>
<td>-</td>
<td>$2.48</td>
<td>$2.48</td>
</tr>
<tr>
<td>Laminated employee badges¹</td>
<td>-</td>
<td>-</td>
<td>$0.08</td>
<td>$0.08</td>
</tr>
<tr>
<td>Other compliance²</td>
<td>-</td>
<td>$2.51</td>
<td>$2.51</td>
<td>$2.51</td>
</tr>
<tr>
<td>Total compliance costs</td>
<td>-</td>
<td>$2.51</td>
<td>$6.51</td>
<td>$8.92</td>
</tr>
</tbody>
</table>

Difference vs. unregulated baseline $2.51 $6.51 $8.92

Source: AIC estimates based on industry data.

¹ Video, disposal, and badge costs calculated based on dispensary estimates. See Sections 6.4.1–6.4.3 for details.

² Includes track-and-trace.

³ Taxation and adult-use legalization baseline without regulations applied.

6.3 Compliance costs for testing
AIC estimates that testing is the category of regulations causing the largest compliance costs, with the proposed regulations adding approximately $407 per pound to the cost of cannabis. Table 6.3 presents our estimates of testing costs with the proposed or alternative regulations in effect vs. testing costs in the unregulated taxation-and-adult-use legalization baseline.

### Table 6.3. Itemized compliance cost estimates for testing

*All costs stated per pound flower equivalent*

<table>
<thead>
<tr>
<th>Compliance variables and costs</th>
<th>Unregulated baseline</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assumed average batch size¹</td>
<td>-</td>
<td>15 lbs</td>
<td>10 lbs</td>
<td>5 lbs</td>
</tr>
<tr>
<td>Basic lab cost per test¹</td>
<td>$200.00</td>
<td>$1,000.00</td>
<td>$1,350.00</td>
<td>$1,350.00</td>
</tr>
<tr>
<td>Handling restrictions per test¹</td>
<td>-</td>
<td>-</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Percent of total cannabis tested¹</td>
<td>10%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Testing costs per pound¹</td>
<td>$2.67</td>
<td>$66.67</td>
<td>$171.88</td>
<td>$343.75</td>
</tr>
<tr>
<td>Video surveillance and archival²</td>
<td>-</td>
<td>-</td>
<td>$0.72</td>
<td>$1.93</td>
</tr>
<tr>
<td>Disposal and quarantine²</td>
<td>-</td>
<td>-</td>
<td>$1.24</td>
<td>$1.24</td>
</tr>
<tr>
<td>Laminated employee badges²</td>
<td>-</td>
<td>-</td>
<td>$0.04</td>
<td>$0.04</td>
</tr>
<tr>
<td>Other compliance³</td>
<td>-</td>
<td>$1.25</td>
<td>$1.25</td>
<td>$1.25</td>
</tr>
<tr>
<td>Testing laboratory margin⁴</td>
<td>$0.67</td>
<td>$16.98</td>
<td>$43.78</td>
<td>$87.05</td>
</tr>
<tr>
<td>Inventory loss due to failed tests³</td>
<td>-</td>
<td>$95.80</td>
<td>$191.60</td>
<td>$191.60</td>
</tr>
<tr>
<td>Total testing compliance costs</td>
<td>$3.33</td>
<td>$180.70</td>
<td>$410.51</td>
<td>$626.87</td>
</tr>
</tbody>
</table>

**Difference vs. unregulated baseline**

- $177.37
- $407.18
- $623.53

*Source: AIC calculations based on industry data.*

¹ Baseline testing cost of $250 (assumed to be 25% margin) from informal AIC survey of two testing labs. Regulation scenario testing costs are based on CDPH and DPR estimates, assuming $1,000 per test in lower-cost alternative, $1,350 per test + $25 per test handling cost in the proposed regulations and higher-security.
alternative. Higher-security alternative varies only batch size, not lab or handling cost. Higher-security alternative assumes same cost per test as proposed regulations, and varies only maximum batch size.

2 Video, disposal, and badge costs calculated based on dispensary estimates. See Sections 6.4.1–6.4.3 for details.

3 Includes track & trace compliance.

4 Assumes 25% margin; calculated against pre-inventory-loss testing costs.

5 Assumes 10% loss in lower-cost alternative, 20% loss in proposer regulations and higher-security alternative. Assumes $150/lb resale value of failed inventory for distillation (source: interview with Era Economics).

6 Taxation and adult-use legalization baseline without regulations applied.

6.3.1 Testing costs without regulation. We do not expect that the addition of taxation and adult-use legalization would add any extra testing costs to the pre-legalization November 2016 scenario that we observed empirically, so we construct our estimate for testing costs in the taxation and adult-use legalization baseline by analyzing data from AIC’s fall 2016 survey (see Chapter 4 for details). In that survey, we observed that 6% of retail product is tested, and that virtually all businesses who test are only testing and labeling for THC and CBD content, and not testing for pesticide residues or other contaminants that require wet-lab technology.

We adjust the percentage of product tested from 6% to 10% based on our estimate that only 60% of dispensaries who test for THC report the results in their online product descriptions. As testing is currently voluntary, there is obviously no maximum batch size, so we use the industry average batch size of 7.5 pounds per batch (Cannabis Benchmarks 2016; we also use this average in our calculations of distribution and transportation costs).

Based on estimates from two leading testing laboratories in the state, SB Labs in Santa Barbara and Steep Hill Labs in Oakland, we estimate that the types of tests currently being obtained voluntarily by cannabis business are priced between $150 and $350, with $250 as a rough average. We thus obtain a net testing cost per pound of ($250 / 7.5) x 10% = $3.33 per pound, of which $2.67 is testing cost and $0.67 is testing lab margin.\footnote{We assume all testing costs to include a 25% testing lab margin (in this case, $160 costs + $40 margin), which is chosen based on AIC interviews with two anonymous lab operators. Note that we do not assume margins for the distribution or transportation functions: unlike testing labs, those functions are not currently set up as independent businesses with observable margins.}

6.3.2 Testing costs under the proposed regulations. Testing for only THC and CBD concentration, as is currently done in the industry, is relatively quick and inexpensive, and can
be done with portable technology because it uses light-based techniques. (However, there are reports of widely variable and inaccurate testing results.) Testing for pesticides and other compounds requires wet-lab procedures that are relatively immobile and require the use of costly chemical reagents and the employment of skilled lab technicians with master’s-degree-level educations.

The proposed testing regulations include DPR’s current proposed set of pesticide tests as of December 2016, which are more stringent than those specifically required by the MCRSA statute. These proposed pesticide tests are the largest source of added costs per pound in the proposed regulations. The information provided by DPR and CDPH suggests that the lab costs of the tests in the proposed regulations, will cost between $1,200 and $1,500 per test. We assume the midpoint of $1,350 per test for the proposed regulations.

The proposed regulations also add certain restrictions on the collection, storage, labeling, and disposal of samples that are relatively minor compared with the cost of pesticide testing. We estimate that these costs will add approximately $0.27 per five-gram sample, or $25 per pound tested, which we call “handling costs.” These handling costs are separate from the compliance costs for the track-and-trace requirements mandated by the MCRSA statutes, which are included as costs in all three regulatory scenarios as part of “other compliance costs.” We thus use $1,375 as our total cost per test for the proposed regulations.

The proposed regulations also establish a 10-pound maximum batch size for testing. Batch-size regulations may allow for more-precise testing and are tied to homogeneity of a batch to assure that the sample reflects the characteristics of the batch. A lower batch size allows for a more-representative sample and therefore more-accurate testing, which in turn allows for cleaner cannabis. It also dissuades people from mixing clean harvest batches with tainted batches and assuming that there is a low probability that the tainted product will be sampled for testing.

Maximum-batch-size regulations add costs to testing, as they require distributors to divide up larger cannabis lots into multiple batches for testing, thus increasing the average cost per pound of testing. For example, while a 10-pound maximum batch size rule would not affect the price per pound of testing a five-pound lot, it would double the price per pound of testing a 20-pound lot, which would have to be tested in two 10-pound batches. According to Cannabis Benchmarks (2016), the average lot size in the California wholesale market is currently about 15
pounds. We estimate that imposing a 10-pound maximum would lower the average tested batch size from 15 pounds (if each batch represented a full lot) to eight pounds, which almost doubles the number of cannabis tests that must be performed in the state. Assuming $1,375 per test and eight pounds per batch, we estimate that the proposed regulations will raise the cost of medical cannabis by approximately $407 per pound from the taxation and adult-use legalization baseline described in Section 6.3.1.

6.3.3 Testing costs under the lower-cost alternative regulations. An earlier October 2016 analysis by CDPH chemists and estimates from laboratories, conducted before the latest more costly set of pesticide testing standards were proposed by DPR, estimated the lab cost per test at $1,000. In the absence of more complete information from CDPH and DPR, we use $1,000 per test in our lower-cost alternative package. In the lower-cost alternative, we also leave out the restrictions regarding collection, storage, labeling, and disposal of samples that are not part of the MCRSA statutory requirements, so we do not add the $25 per pound in additional sample handling costs.

There is no statutory guidance from the MCRSA on maximum batch sizes, so a less costly alternative would be to specify no maximum batch size for testing. We thus assume no maximum batch size in the lower-cost alternative package of regulations. We estimate that the lower-cost alternative will raise the cost of medical cannabis by approximately $177 per pound compared with the taxation and adult-use legalization baseline described in Section 6.3.1. This is $230 per pound less than the cost of the proposed regulations described in Section 6.3.2.

6.3.4 Testing costs under the higher-security alternative regulations. The higher-security alternative varies batch size, imposing a five-pound maximum batch (as in Washington State), but otherwise assumes the same set of pesticide residue minimums, handling requirements, etc. The cost per test in the higher-security package is thus held constant at $1,375.

With a maximum batch size of five pounds, we assume an average tested batch size of four pounds (following the same logic as in Section 6.3.2 footnote 4). This raises the testing cost per pound of medical cannabis by $624 above the taxation-and-adult-use-legalization baseline. This is $217 per pound more than the proposed regulations.

---

15 This figure is lower than 10 pounds due to the fact that as long as many small lots exist, as we expect they will in the foreseeable future, the average batch size will always be lower than the maximum batch size.)
6.4 Compliance costs for dispensing

The proposed regulations have a multi-faceted impact on the cost of selling cannabis at retail. Table 6.4 reports summary compliance costs for dispensing, not including dispensary delivery.

Table 6.4 Itemized compliance cost estimates for dispensing, not including delivery

All costs stated per pound flower equivalent

<table>
<thead>
<tr>
<th>Compliance costs</th>
<th>Unregulated baseline</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Video surveillance and archival(^1)</td>
<td>-</td>
<td>-</td>
<td>$14.47</td>
<td>$38.63</td>
</tr>
<tr>
<td>Disposal and quarantine(^2)</td>
<td>-</td>
<td>-</td>
<td>$24.81</td>
<td>$24.81</td>
</tr>
<tr>
<td>Laminated employee badges(^3)</td>
<td>-</td>
<td>-</td>
<td>$0.75</td>
<td>$0.75</td>
</tr>
<tr>
<td>Other compliance(^4)</td>
<td>-</td>
<td>$25.05</td>
<td>$25.05</td>
<td>$25.05</td>
</tr>
<tr>
<td>Total dispensing compliance costs per lb, not including delivery</td>
<td>-</td>
<td>$25.05</td>
<td>$65.08</td>
<td>$89.24</td>
</tr>
</tbody>
</table>

**Difference vs. unregulated baseline**

|                      | $25.05 | $65.08 | $89.24 |

Source: AIC calculations based on industry data.

\(^1\) For assumptions, explanations, and cost detail for video surveillance, see Table 6.5.

\(^2\) Assumes 60 sq ft, $265/sq ft/yr costs, $15,880/yr/dispensary, 640 lbs/yr/dispensary.

\(^3\) Assumes $53/employee/year, 9.1 employees/dispensary, 640 lbs/yr/dispensary.

\(^4\) Includes track-and-trace compliance. Assumes $1,060/yr/employee, 9.1 employees/dispensary, 640 lbs/yr/dispensary, plus AIC estimate of $10 per pound for track-and-trace compliance.

\(^5\) Taxation and adult-use legalization baseline without regulations applied.

6.4.1 Surveillance and video archival compliance costs. The proposed regulations require license holders to maintain security cameras with 1280 x 1024 resolution at 20 frames per second, and to maintain a 30-day video archive of footage from these cameras. We estimate
that the average dispensary will require five or six cameras to achieve compliant coverage. Detailed calculations are shown in Table 6.5.

Table 6.5. Itemized compliance cost estimates for dispensary video surveillance and archive

<table>
<thead>
<tr>
<th>Compliance variables and costs</th>
<th>Unregulated Baseline&lt;sup&gt;4&lt;/sup&gt;</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cameras</td>
<td>-</td>
<td>-</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Resolution</td>
<td>-</td>
<td>-</td>
<td>1280x1024</td>
<td>1280x1024</td>
</tr>
<tr>
<td>Frames per second</td>
<td>-</td>
<td>-</td>
<td>20 fps</td>
<td>20 fps</td>
</tr>
<tr>
<td>Days of storage</td>
<td>-</td>
<td>-</td>
<td>30</td>
<td>90</td>
</tr>
<tr>
<td>Amount of storage required&lt;sup&gt;1&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>18 TB</td>
<td>54 TB</td>
</tr>
<tr>
<td>Storage cost per month&lt;sup&gt;2&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>$608.00</td>
<td>$1,825.00</td>
</tr>
<tr>
<td>Equip, maintenance &amp; power</td>
<td>-</td>
<td>-</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Cost per month&lt;sup&gt;3&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>$728.00</td>
<td>$1,945.00</td>
</tr>
<tr>
<td>Total cost per month</td>
<td>-</td>
<td>-</td>
<td>$8,736.00</td>
<td>$23,340.00</td>
</tr>
<tr>
<td>Total cost per lb</td>
<td>-</td>
<td>-</td>
<td>$728.00</td>
<td>$1,945.00</td>
</tr>
</tbody>
</table>

Difference per lb vs. unregulated baseline

- $14.47
- $38.63

Source: AIC estimates based on industry data.

<sup>1</sup> TB = terabytes. Surveillance video storage requirement estimates from Seagate.com.

<sup>2</sup> Based on Amazon Cloud storage price quote of $0.033/GB.

<sup>3</sup> Assumes $20/camera/month equipment, software, maintenance, and power costs.

<sup>4</sup> Taxation and adult-use legalization baseline without regulations applied.
Because MCRSA does not state any security video or archival rules and there is no current mandatory cost of video surveillance archival in the unregulated state, the taxation and adult-use legalization baseline and the lower-cost alternative for mandatory security video costs are both set to zero. Under the proposed regulations, we estimate the cost per pound of retail medical cannabis to rise by about $14 per pound compared with the lower-cost alternative.

A higher-security alternative would be to require footage to be maintained for 90 days. This would raise costs to $39 per pound above the lower-cost alternative, which is $27 per pound above the cost of the proposed regulations. The 30-day video archival requirement achieves Bureau regulatory enforcement and non-Bureau-related law enforcement objectives which have benefits to the public safety discussed above.

Other additions to dispensary costs are labeling and track-and-trace requirements, for which the proposed regulations are not substantially more costly than what would be required by the lower-cost alternative, as MCRSA requires a track-and-trace system. For all functions, these costs are included in the “other compliance” category in all scenarios with regulations, including the lower-cost alternative, and thus do not impact the differences between the costs of proposed regulations and the costs of lower-cost or higher-cost alternatives.

6.4.2 Disposal, quarantine, and badge compliance costs. The proposed regulations specify that licensees must follow certain procedures in order to dispose of cannabis waste. Licensees must maintain a dedicated quarantine area, take precautions to secure the area, and make cannabis waste “unusable and unrecognizable” before removing it from the premises. This must be done by “grinding and incorporating the cannabis waste with non-consumable solid waste such that the resulting mixture is at least 50% non-cannabis waste.” Permitted types of non-consumable solid waste for these purposes include paper, plastic, cardboard, food waste, grease or other compostable oil waste, a compost activator, or soil.

Cannabis waste must then be labeled with a bill of lading or shipping manifest that indicates product information and weight. Finally, it must be held in the quarantine location for at least 72 hours before being removed from the premises. All of this must be done on camera, and a separate surveillance camera with 30-day archive is required for the quarantine area. As quarantining is not currently practiced by dispensing, distribution, transport, or testing businesses in the state, it is difficult to estimate the costs of the new quarantine requirements with any degree of confidence.
We estimate that these quarantine requirements will add approximately $25 to total cost per pound for dispensaries. We base this on the assumption that the average quarantine area will be 60 square feet (assuming a 6-foot-by-10-foot space) and cost $265 per square foot per year to rent, maintain, and operate, including security, surveillance video maintenance, labor and training costs. This is a total of $15,900 per year per location.

Assuming that the average dispensary will sell 640 pounds flower equivalent per year (an estimation developed in based on data collected from currently operating cannabis businesses, as detailed in Chapter 3), we arrive at an added cost of disposal and quarantine approximately $25 per pound cannabis for dispensaries. We do not vary this standard in the higher-security alternative, as the proposed disposal and quarantine standards appear to be comprehensive.

Finally, we estimate the cost of producing compliant badges for all employees at dispensaries at $53 per employee per year, based on equipment and materials costs. Assuming 9.1 employees per dispensary and 640 pounds produced per dispensary, this converts to an overall cost of $0.75 per pound.

6.4.3 Estimation of video surveillance and archive, disposal and quarantine, and badge compliance costs for the distribution and testing functions. The video surveillance and archive, cannabis waste disposal and quarantine, and laminated badge cost calculations described in Sections 6.4.1 and 6.4.2 apply not just to dispensaries, but also to the distribution and testing functions described in Sections 6.2 and 6.3. (We do not consider transporters separately because we anticipate that almost all licensed transporters will also hold other licenses and thus already need to comply.)

In order to obtain estimates for these compliance cost inputs for the distribution and testing functions, as shown in Tables 6.2 and 6.3, we note that the costs of compliance in these categories are substantially (though not strictly) fixed per location. For instance, the construction and maintenance of a quarantine area is unlikely to vary much between an average dispensary and an average distributor, even if the distributor has a larger facility and handles 10 times the amount of cannabis as the dispensary.

To estimate video surveillance costs, disposal costs, quarantine costs, and laminated badge costs for the distribution and testing functions, we thus made the broad assumption that these per-location costs were the same per location as for dispensaries.
We thus calculate costs per pound of compliance with disposal, quarantine, and badge regulations for distribution and testing as follows: we assume that 640 pounds per year are handled by the average dispensary and that there is one distributor for every 10 dispensaries, with the average distributor thus handling 6,400 pounds per year. Video, disposal, quarantine, and badge compliance costs per pound for distributors are therefore estimated at 10% of those costs for dispensaries. We assume that there is one testing lab for every 2 distributors, or 12,800 pounds per year handled by the average testing lab. Thus, video, disposal, quarantine, and badge compliance costs per pound for testing labs are estimated at 5% of those costs for dispensaries.

6.4.4 Dispensary delivery compliance costs. Medical cannabis deliveries are now typically done by car. However, some urban dispensaries make deliveries on foot, bicycle, electronic bicycle (e-bike), or scooter at a significant cost savings to the firm.

Delivery costs currently add approximately $150 per pound to the retail cost of medical cannabis. This calculation relies on an AIC estimate that 40% of product is delivered. We derived this estimate as follows: the AIC retail price survey, as detailed in Appendix Chapter 4 and summarized in Table 4.1, found that 53% of dispensaries offered in-store sales only, 43% of dispensaries offered delivery sales only, and 4% of dispensaries offered both in-store and delivery sales. Accounting for the fact that retail dispensaries tend to have larger annual sales volume than delivery services, we estimated that approximately 40% of cannabis in California is sold via delivery, and 60% is sold via in-store sales.

MCRSA statutes do not specify any delivery-method restrictions, and there are none currently in place, so neither taxation and adult-use legalization baseline nor our lower-cost alternative generate any additional costs above the basic $150 per pound delivery cost.

The proposed regulations do not allow any of the lower-cost alternative delivery methods, which, due to their energy efficiency, we would otherwise expect to become more common business practices as the industry moves into the mainstream. As shown in Table 6.6, this restriction would raise the average cost of delivering medical cannabis in the state to $160 per pound, and would raise the cost of cannabis delivery by approximately $10 per pound compared with the unregulated baseline delivery cost. However, unenclosed vehicles do not allow as much security as enclosed vehicles. Attaching a lock-box to a person would be impossible, and attaching one to a bicycle or e-bike, or scooter would likely be impractical.
these delivery vehicles allowed, the security objectives of the proposed lock-box regulatory provisions would be ineffective at the delivery stage increasing potential for criminal activity in neighborhoods surrounding dispensaries.

A higher-security alternative is to require two employees to be in each delivery vehicle (one driver and one delivery representative), which would enable one employee to be with the medical cannabis inventory at all times. This would provide an additional level of security. The additional labor costs that would result from the higher-security alternative would increase the cost of medical cannabis by an additional $148 per pound compared with the proposed regulations.

Table 6.6 breaks down the calculations and assumptions we use to estimate dispensaries’ delivery compliance costs. Note that these compliance costs apply only to the dispensing function and not to other functions.
Table 6.6 Itemized compliance cost estimates for dispensary delivery

<table>
<thead>
<tr>
<th>Compliance cost variables</th>
<th>Unregulated baseline (^4)</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total lbs sold</td>
<td>230,000</td>
<td>230,000</td>
<td>230,000</td>
<td>230,000</td>
</tr>
<tr>
<td>Total lbs delivered (assuming 1/2 oz)(^1)</td>
<td>92,000</td>
<td>92,000</td>
<td>92,000</td>
<td>92,000</td>
</tr>
<tr>
<td>Avg lbs per delivery(^2)</td>
<td>0.03125</td>
<td>0.03125</td>
<td>0.03125</td>
<td>0.03125</td>
</tr>
<tr>
<td>Avg distance per on-foot delivery, miles</td>
<td>1</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Avg time per on-foot delivery, hours</td>
<td>0.5</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total cost per on-foot delivery, including equip &amp; labor(^3)</td>
<td>$10.80</td>
<td>$10.80</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Avg distance per e-bike delivery, miles</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Avg time per e-bike delivery, hrs</td>
<td>0.5</td>
<td>0.5</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total cost per e-bike delivery, including equip &amp; labor(^3)</td>
<td>$10.83</td>
<td>$10.83</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Avg distance per car delivery, miles</td>
<td>5</td>
<td>5</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Avg time per e-bike delivery, hrs</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Total cost per car delivery, including equip &amp; labor(^3)</td>
<td>$13.63</td>
<td>$13.63</td>
<td>$12.50</td>
<td>$23.30</td>
</tr>
<tr>
<td>Overall avg cost per delivery</td>
<td>$11.75</td>
<td>$11.75</td>
<td>$12.50</td>
<td>$23.30</td>
</tr>
<tr>
<td>Avg cost of delivery per lb delivered</td>
<td>$376.00</td>
<td>$379.18</td>
<td>$400.00</td>
<td>$745.60</td>
</tr>
<tr>
<td>Total cost of delivery per lb sold</td>
<td>$150.40</td>
<td>$150.40</td>
<td>$160.00</td>
<td>$298.24</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Difference vs. unregulated baseline</td>
<td>-</td>
<td>$9.60</td>
<td>$147.84</td>
<td></td>
</tr>
</tbody>
</table>

Source: AIC calculations based on industry data.

1 Assumes 40% of product delivered based on AIC fall 2016 survey and analysis; see Section 6.4.4 for methodology.

2 Assumes average delivery of 1/2 oz = 0.03125 lbs per trip.

3 Assumes $18/hour labor (see Chapter 3) plus 20% administrative time. We assume $0.01/mile e-bike operating costs and $0.565/mile car operating costs (the Federal reimbursement rate). Assumes that one-third of deliveries average 1 mile and could be made on foot, one-third of deliveries average 3 miles and could be made by e-bike, and one-third of deliveries average 5 miles and would be made by car.

4 Taxation and adult-use legalization baseline without regulations applied.
6.5 License fees and summary compliance costs

A summary of the costs of the package of proposed regulations and the two alternative packages of regulations are provided in Table 6.7. Testing is by far the most costly component of the proposed regulations, accounting for 80% of added costs. Surveillance video archive, cannabis waste disposal, and quarantine expenses also add significantly to compliance costs. License fees are a small share of additional costs, and would account for about 4% of added costs of compliance and well below 1% of likely consumer prices, which include substantial sales and excise taxes.

Table 6.7 Summary of license fees and compliance costs

All costs stated per pound flower equivalent

<table>
<thead>
<tr>
<th>Additional compliance costs</th>
<th>Lower-cost alternative</th>
<th>Proposed regulations</th>
<th>Higher-security alternative</th>
<th>Assumptions &amp; references</th>
</tr>
</thead>
<tbody>
<tr>
<td>License fees¹</td>
<td>None</td>
<td>$20.00</td>
<td>$20.00</td>
<td>Fees set to cover Bureau budget</td>
</tr>
<tr>
<td>Distribution &amp; transport²</td>
<td>$2.51</td>
<td>$6.51</td>
<td>$8.92</td>
<td>See Tables 6.2, 6.5</td>
</tr>
<tr>
<td>Testing⁴</td>
<td>$177.37</td>
<td>$407.18</td>
<td>$623.53</td>
<td>See Tables 6.3, 6.5</td>
</tr>
<tr>
<td>Dispensing²</td>
<td>$25.05</td>
<td>$65.08</td>
<td>$89.24</td>
<td>See Tables 6.4, 6.5</td>
</tr>
<tr>
<td>Dispensary delivery³</td>
<td>None</td>
<td>$9.60</td>
<td>$147.84</td>
<td>See Table 6.6</td>
</tr>
<tr>
<td><strong>Total compliance costs per lb</strong></td>
<td><strong>$204.93</strong></td>
<td><strong>$508.37</strong></td>
<td><strong>$889.53</strong></td>
<td></td>
</tr>
</tbody>
</table>

Source: AIC calculation based on industry data. Cost components do not add exactly to total costs due to rounding.

¹ License fees calculated to cover the Bureau’s approximate operating budget.

² The proposed regulations add 30-day surveillance video archive, quarantine, and laminated badge requirements. Higher-security alternative extends video archive requirement to 90 days.

³ The proposed regulations prohibit on-foot, bicycle, e-bike, or scooter deliveries. Higher-security alternative requires two employees to make a delivery.
7. Modeling the Effects of Shifts in Cannabis Demand and Supply on Prices and Quantities

The model outlined below first characterizes demand for cannabis in a form amenable to simulation. Next, we explain a simplified supply side of cannabis sales to consumers. We then discuss the solution for effects of changes in statutes and regulations. This chapter is necessarily more technical and contains more mathematical notation than other chapters.

7.1 Demand

The model of consumer demand for cannabis is based on a two-stage budgeting process developed in Deaton and Muellbauer (1980a, 1980b). The first stage generates a system of individual demand functions for the allocation of total expenditure among commodity categories. The second stage of the two-stage allocation generates a system of individual segment-specific demand functions within the cannabis commodity group. A comprehensive review of the literature on two-stage budgeting can be found in Deaton (1986). The first stage models of demand for cannabis as a whole. In the second stage, demand for segment-specific cannabis is modeled conditional on the total cannabis expenditure across all segments determined in the first stage.

The two-stage budgeting approach is widely used in demand simulations. Since the number of own-price and cross-price elasticities of demand increases with the square of the number of commodities, the complexity of the simulation and requirement for estimated or assumed parameters expands similarly. Under the two-stage budgeting and accompanying assumptions, the number of products can be kept relatively small. This approach offers considerable empirical convenience. The key assumption here is that cannabis (the group of the individual cannabis segments) has demand relationships with other goods as an aggregate. Theoretical consistency of the model requires developing an aggregate cannabis group price index and some conditions on consumer demand behavior between cannabis and all other goods.

Following the suggestion in Deaton and Muellbauer (1980b), we developed the aggregate cannabis price index using the Stone (1954) price index method. To derive segment-specific elasticities, we specify demand substitution parameter values. These values are developed based on data, previous studies and researcher judgments described below.
To focus on the application at hand we first note that the medical cannabis segment is distinct in access from what has been the illegal cannabis segment. The prices and quantities in this segment are designated with subscript “m.” Second, we note that the non-medical part of the market will soon separate into two segments. The prices and quantities in the newly legal adult-use segment will be designated with the subscript “a”. Finally, in the segment that remains illegal, prices and quantities will be designated with the subscript “i.”

Let us begin with the utility function expressed as (1), with notation shown in Table 11.1 for easy reference:

Total utility function: \( u = U(Q^c, Q^o) \) \hspace{1cm} (1)

Equation (2) defines the price of aggregate cannabis in terms of three cannabis segments’ prices, \( lnP_j \), and market shares, \( w_j \):

Stone's price index: \( \lnP^* = \sum_{j=1}^{[i,a,m]} w_j \lnP_j \) \hspace{1cm} (2)

Equation (3) defines the aggregate quantity in terms of the quantity of each segment (illegal, legal adult-use and legal medical):

Aggregate quantity demanded for cannabis: \( Q_c = Q_i + Q_a + Q_m \) \hspace{1cm} (3)

The following assumptions are used:

a) Demand for cannabis is weakly separable from other goods in the demand system. The weak separability assumption can be represented by \( U(Q^c, Q^o) = F(u_c(Q^c), u_o(Q^o)) \), where \( U \) is the utility function of consuming all goods, \( Q^c \) is the quantity vector for cannabis group, \( u_c(Q^c) \) is the sub-utility function associated with cannabis consumption, and \( Q^o \) is the quantity vector for any other products, \( u_o(Q^o) \) is the sub-utility function associated with consumption of products other than cannabis, and \( F \) is an increasing function in all its arguments.

b) The total cost of living (TCOL) is independent to sub-utility level (Edgerton 1997; Carpentier and Guyomard 2001), i.e. that the empirical variation of \( P^l(p^l, \overline{p}, u_l) \equiv P^l(p^l, \overline{p}^l) \), \( \forall l = c, o \).
where I is the product group index, $P^I$ is the index for total cost of living, $p^I$ is the price vector for group I, $\bar{p}^I$ is the base period prices for group I, $u_I$ is the sub-utility of consumption for group I. The product group indices include cannabis (c) and non-cannabis products (o). This capital I is not related to lower case I which represents the illegal cannabis segment within c.

Given the weak separability assumption, the group allocation problem can be defined as

$$\text{Max}_{(u_c,u_o)} F(u_c, u_o)$$

$$\text{s.t. } M = \sum_{I=I}^{c,o} c_I(p_I, u_I),$$

where $u_I$ is the value of the sub-utility function for group I, M is the total expenditure, $p^I$ is the price vector for group I, $c_I(p^I, u_I)$ is the cost function associated to the sub-utility function $u_I(q^I)$.

The cost of consuming group I at price $p^I$ can be rewritten as

$$c_I(p^I, u_I) = c_I(\bar{p}^I, u_I) \frac{c_I(p^I, u_I)}{c_I(\bar{p}^I, u_I)} = c_I(\bar{p}^I, u_I) P^I(p^I, \bar{p}^I, u_I), \forall I = c, o,$$

where $P^I(p^I, \bar{p}^I, u^I)$ is the true cost of living price index (TCOL price index) and $c^I(\bar{p}^I, u^I)$ can be thought of as a quantity index (Carpentier and Guyomard, 2001). By assuming the TCOL price index is approximately independent with subutility $u^c$ and $u^o$, i.e. $P^I(p^I, \bar{p}^I, u_I) \equiv P^I(p^I, \bar{p}^I)$, we can rewrite the utility maximization problem as

$$\text{Max}_{(c_c,c_o)} \Phi(c_c(\bar{p}^c, u_c), c_o(\bar{p}^o, u_o))$$

$$\text{s.t. } M = \sum_{I=I}^{c,o} c_I(p_I, u_I) P^I(p^I, \bar{p}^I),$$

where the $\Phi$ is the modified utility function in terms of quantity indices for cannabis and other goods, $c_I(\bar{p}^I, u_I)$ is the quantity index for group I, and $P^I(p^I, \bar{p}^I)$ is the total cost of living.
For example, based on Carpentier and Guyomard’s (2001) result, the unconditional elasticity of demand for medical cannabis and the cross-price demand elasticity between medical and illegal cannabis, using an approximation to the Slutsky substitution term, could be approximated in general forms as follows, where we illustrate the expressions with the own elasticities for medical cannabis and the cross effects between medical and illegal cannabis.

The unconditional expenditure elasticity for medical use cannabis is: \( \eta_{mY} = \eta_{cM} \).

The unconditional Hicksian demand elasticity for medical use cannabis is:

\[
\eta_{mm} = \eta_{mm}^c + w_m \eta_{mY}^c \eta_{mY}^c.
\]

The unconditional cross-price Hicksian demand elasticity between medical and illegal use cannabis is: \( \eta_{mi} = \eta_{mi}^c + w_i \eta_{iY}^c \eta_{mY}^c \).

The unconditional Marshallian demand elasticity for medical use cannabis is:

\[
\eta_{mm} = \eta_{mm}^c + w_m \left( \frac{1}{\eta_{mY}^c} + \epsilon^* \right) \eta_{mY}^c \eta_{mY}^c + w_m s_c \eta_{cM} \eta_{mY}^c (\eta_{mY}^c - 1).
\]

And, the unconditional cross-price Hicksian demand elasticity between medical and illegal use is:

\[
\eta_{mi} = \eta_{mi}^c + w_i \left( \frac{1}{\eta_{iY}^c} + \epsilon^* \right) \eta_{iY}^c \eta_{mY}^c + w_i s_c \eta_{cM} \eta_{mY}^c (\eta_{iY}^c - 1),
\]

where the subscripts m, i, and a represent cannabis segments, medical, illegal and adult-use. \( \eta_{jk} \) with \( j, k = m, i, a \), represents the cross-price Marshallian demand elasticity between group j and k. \( \eta_{jk}^* \) with \( j, k = m, i, a \), represents the cross-price Hicksian demand elasticity between group j and k. The subscript Y represents the cannabis group expenditure. \( \eta_{jY} \) with \( j = m, i, a \), represents the expenditure elasticity for group j. The subscript c represents the whole cannabis group. Elasticity \( \eta_{c}^* \) represents the Hicksian demand elasticity for cannabis group. The elasticity \( \epsilon^* \) represents the Marshallian demand elasticity for cannabis group. The superscript c means the parameter is conditional on the group expenditure and \( s_c \) is the expenditure share of cannabis of the total income.

If we assume homothetic preferences and a unit conditional expenditure elasticity (Edgerton, 1997), we could rewrite the above equation as follows.

The unconditional expenditure elasticity for medical cannabis:

\( \eta_{mY} = \eta_{cM} \).

The unconditional Hicksian demand elasticity for medicinal use cannabis:

\( \eta_{mm}^* = \eta_{mm}^{c*} + w_m \eta_{c}^* \).
The unconditional cross-price Hicksian demand elasticity between medicinal and illegal use cannabis: 
\( \eta_{mi}^* = \eta_{mi}^c + w_i \eta_i^c \).

The unconditional Marshallian demand elasticity for medical use cannabis: 
\( \eta_{mm} = \eta_{mm}^c + w_m (1 + \epsilon^*) \). (4)

The unconditional cross-price Marshallian demand elasticity between medical and illegal use cannabis: 
\( \eta_{mi} = \eta_{mi}^c + w_i (1 + \epsilon^*) \). (5)

We can rewrite equations (4) and (5), using conditional Slutsky equation under unit conditional expenditure elasticity, \( \eta_{mm}^c = \eta_{mm}^c - w_m \), and \( \eta_{mi}^c = \eta_{mi}^c - w_i \), and the conditional Hicksian cross-elasticity of demand, \( \eta_{kj}^c = w_j \sigma_{kj}^c \), where \( \sigma_{kj}^c \) is the conditional elasticity of substitution of group j and k, with the homogeneity condition, which implies in the three factor case, 
\( \eta_{mm}^c = -\eta_{mi}^c - \eta_{ma}^c \), and the symmetry condition, \( \sigma_{im} = \sigma_{mi} \), as:
\( \eta_{mm} = -w_i \sigma_{mi}^c - w_a \sigma_{ma}^c + w_m \epsilon^* \) and \( \eta_{mi} = w_i \sigma_{mi}^c + w_i \epsilon^* \). (6)

7.2 The supply side and simulation model of the changes in quantities and prices in the market

We begin with a set of assumed prices and quantities in the three segments to which proportional changes to the demand function and parameters and the supply function and parameters applied. The medical segment initial prices and quantities were developed from recent data as described in detail in later sections of this report. As an initial starting point for the prices and quantities of the newly legal adult-use cannabis segment, we assume that the current illegal market is separated into two equal sized segments: segment a, which includes that quantity demanded and supplied that is most readily transferred to the legal adult-use segment, and segment i, which includes that quantity that is less readily shifted to legal sales.

We assume initially that these two segments have equal quantities. We set the initial price in the newly legal adult-use segment as 5% below the medical dispensary price and the price in the continuing illegal segment as 10% below the medical dispensary price. These initial
situation choices are not crucial to the results and could be adjusted with appropriate adjustment to other parameters.

For the initial situation we explore proportional changes from the demand side and supply side on each segment. On the demand side, the quantity demanded for segment-specific cannabis changes \( \alpha \) which is a vector of quantity changes in percentage terms, when holding the prices and total expenditure constant.

Based on the unconditional own-price and cross-price elasticity, we can approximate the changes in quantity and total revenue for segment-specific cannabis, as

\[
\begin{align*}
\ln Q_m^d &= \eta_{mm} \ln P_m^d + \eta_{ma} \ln P_a^d + \eta_{mi} \ln P_i^d + \alpha_m \\
\ln Q_a^d &= \eta_{am} \ln P_m^d + \eta_{aa} \ln P_a^d + \eta_{ai} \ln P_i^d + \alpha_a \\
\ln Q_i^d &= \eta_{im} \ln P_m^d + \eta_{ia} \ln P_a^d + \eta_{ii} \ln P_i^d + \alpha_i
\end{align*}
\]

(8)

(9)

(10)

where the superscript \( d \) represents the variables on the demand side. For example, \( d\ln Q_m^d \) represents the change of quantity demanded for medicinal cannabis.

As with the demand side of the market, the supply side of the model focuses on the retail prices and quantities. This application of the model for the impact analysis includes shifts in costs that apply to wholesale and retail functions, including product transportation and testing. Thus we take any changes at the farm and processing level of the production process as exogenous, and we do not explore those changes in any detail.

On the supply side, the cost of production changes by \( \beta \), which is a vector of cost shifts for segment-specific cannabis. Ad valorem taxes \( t \) apply to retail revenue in two segments. Among parameters required are the supply elasticities for the three segment-specific cannabis marginal cost functions.
We then approximate the change in prices facing suppliers with tax included, as

\[
dln P^s_m = \frac{dln Q^s_m}{\xi_m} + \beta_m + t_m
\]  

(11)

\[
dln P^s_a = \frac{dln Q^s_a}{\xi_a} + \beta_a + t_r
\]  

(12)

\[
dln P^s_i = \frac{dln Q^s_i}{\xi_i} + \beta_i + t_i
\]  

(13)

where the superscript \( s \) represents the variables on the supply side. For example, \( dln P^s_m \) represents the price change of medicinal cannabis for suppliers. \( \xi_j \) with \( j = m, a, i \) represents the supply elasticity for group \( j \).

Notice that these marginal cost specifications already incorporate the price equals marginal cost equilibrium condition and are specified as vertical shifts in the supply function reflecting per unit costs. Equations (8) to (13) and the market equilibrium conditions are used in simulations to investigate how shifts in costs and demand affect prices and quantities of cannabis and prices and quantities of medical, legal adult-use and illegal cannabis. Parameters include shares, own-price and cross-price demand elasticities and supply elasticities.

### 7.3 Illustration of demand shifts in the cannabis market due to adult-use legalization

This section illustrates the shifts in Cannabis demand discussed above. The top left panel of Figure 7.1 shows a shift back in the demand from \( D \) to \( D' \) in the medical segment that accompanies the taxation and legalization of adult-use cannabis. This occurs because previous medical cannabis buyers can avoid the added costs of acquiring a medical recommendation by now buying in the adult-use segment. The top right panel of Figure 7.1 shows a shift back from \( D \) to \( D' \) in the quantity of cannabis sold in the illegal segment as some buyers leave the illegal segment for the newly legal non-medical adult-use segment.
The bottom panel of Figure 7.1 shows the initial position of demand for adult use cannabis that accompanies taxation and adult-use legalization represented by demand D and quantity Qₐ. This initial situation represents a portion of the previous demand for cannabis in the illegal segment that readily shifted to the adult-use segment. The reduction in demand shown in the top left panel is represented in the bottom panel by the shift out in demand for adult-use cannabis from D to D’. The further reduction in illegal cannabis illustrated in the upper right panel of Figure 7.1 is shown in the bottom panel as a further increase in demand for adult-use cannabis from D’ to D”. Finally, an increase in demand from buyers who previously avoided the medical or illegal segments for personal reasons and are now entering the adult-use market due to an increase of exposure of cannabis to mainstream consumers and visitors to California who now have access to legal cannabis is shown in the shift from D” to D’’’.
Figure 7.1. Demand shifts in medical, illegal, and adult-use cannabis markets that accompany adult-use legalization
7.4 Solving for implied tax rate for the simulation model

The law that set out legalization of adult-use cannabis included a percentage tax rate \( t_e \) on the retail revenue of medical and adult-use cannabis. In order to solve for the impact of that percentage tax rate on prices, quantities and implied revenue, we solve for the equivalent initial (pre-change) tax rate as a percentage of prices that would occur without adult-use legalization. The tax rate equivalent is used in equations (11) to (13) to simulate impacts.

Let us begin with the total revenue for medical cannabis after the legalization of adult-use cannabis as shown in equation (14). The medical cannabis faces a tax rate \( t_b \) before adult-use legalization. Adult-use legalization imposes \( t_m \) tax rate on top of the initial price, \( P_0 \) as follows:

Total tax revenue: \[ R_t = Q_1 P_0 \cdot (t_m + t_b). \] (14)

The revenue excluding tax and target tax rate can be written as a function of the new price \( P_1 \):

Revenue without tax: \[ R_{-t} = Q_1 P_1 - Q_1 P_0 \cdot (t_m + t_b). \] (15)

Target tax rate: \[ t_t = \frac{Q_1 P_0 (t_m + t_b)}{Q_1 P_0 (1 + dlnP - t_m - t_b)^{-1}}. \] (16)

By rearranging equation (16), we obtain equation (17) indicating the relationship of the target adult-use legalization tax rate, \( t_t \), and the imposed tax rate, \( t_m \), in terms of initial price.

\[ (1 + t_t) t_m - t_t dlnP = t_t (1 - t_b) - t_b \] (17)

We could extend the approach for adult-use cannabis. Because of adult-use legalization, adult-use cannabis faces an increase in tax rate from zero to \( t_e \) at the outcome. In terms of the initial prices before adult-use legalization, the tax rate is \( t_a \). Equation (18) represents the relationship between the target tax rate and the tax rate in terms of initial price.

\[ (1 + t_e) t_a - t_e dlnP = t_e \] (18)

The illegal cannabis faces no tax. Together with (17) and (18), we have the following equations:
\[(1 + t_t) t_m - t_t d\ln P_m = t_t (1 - t_b) - t_b \quad (19)\]

\[(1 + t_t) t_a - t_t d\ln P_a = t_t \quad (20)\]

\[t_i = 0 \quad (21)\]

### 7.5 Solution matrix

We now have a system of equations including equations (8) to (13), equations (19) to (21), and market equilibrium conditions. We will use this system of equations to solve for the price and quantity changes for each specific cannabis segment. A simplified matrix is shown below and the solution could be solved as the product of the inverse of matrix \(M\) and vector \(b\), where matrix \(M\) is the coefficient matrix on the left hand side and \(b\) is the dependent matrix on the right hand side. The solution is in terms of supply and demand elasticities, the target tax rate, and the demand function and parameter changes and supply function and parameter changes.

\[
\begin{bmatrix}
\eta_{mm} - \xi_m & \eta_{ma} & \eta_{mi} & \xi_m & 0 & 0 \\
\eta_{am} & \eta_{aa} - \xi_a & \eta_{ai} & 0 & \xi_a & 0 \\
\eta_{im} & \eta_{ia} & \eta_{ii} - \xi_i & 0 & 0 & \xi_i \\
-\xi_t & 0 & 0 & 1 + t_t & 0 & 0 \\
0 & -t_t & 0 & 0 & 1 + t_t & 0 \\
0 & 0 & 0 & 0 & 0 & 1
\end{bmatrix}
\begin{bmatrix}
dln P_m^d \\
dln P_a^d \\
dln P_i^d \\
t_m \\
t_a \\
t_i
\end{bmatrix}
= \begin{bmatrix}
-\alpha_m - \xi_m \beta_m \\
-\alpha_a - \xi_a \beta_a \\
-\alpha_i - \xi_i \beta_i \\
t_t (1 - t_b) - t_b \\
t_t \\
0
\end{bmatrix}
\begin{bmatrix}
x
\end{bmatrix}
\]

Solution: \(x = M^{-1} b\)

The quantity change \(d\ln Q_{j=m,a,i}\) for segment-specific cannabis could be obtained from equations (8) to (10). The aggregate quantity change \(d\ln Q_c\) is the weighted sum of the three segment-specific cannabis quantity changes. As an alternative, we could also derive the aggregate quantity change, \(d\ln Q_c = e^x d\ln P^* + \alpha^*\), where \(d\ln P^* = \sum_{j=i}^{i,m,a} w_j d\ln P_j\), and \(\alpha^* = \sum_{j=i}^{i,m,a} w_j \alpha_j\).
7.6 Individual segments and the change in revenue in the medical market

We consider supply-side shifts (the change in marginal cost) and demand-side shifts (the change in the quantity purchased at a given price the medical, legal adult-use and illegal cannabis). We must also include the cross effects between the different segments. Shifts affect the relative prices in cannabis segments, and this impact shifts each segment’s demand because of substitution effect over cannabis segments.

Based on the quantity and price changes of cannabis, we can approximate the total revenue change. Here we will illustrate the total revenue change and consumer surplus change in the medical segment as an example. The change of the total revenue for the medical segment is the sum of the proportional changes in medical price and the quantity and their product, based on \( d\ln R_m = d\ln (P_m \cdot Q_m) \), as, \( d\ln R_m = d\ln P_m + d\ln Q_m + d\ln P_m \cdot d\ln Q_m \).

7.7 Change in the aggregate total revenue

Based on the aggregate quantity of demand effects and the price-index change for cannabis, we can write the change of total revenue in cannabis segment as the sum of the change in total quantity and price index:

\[
d\ln TR_c = (1 + \epsilon^*)d\ln P^* + \alpha^*, \text{ where } d\ln P^* = \sum_{j=i}^{i,m,a} w_j d\ln P_j, \text{ and } \alpha^* = \sum_{j=i}^{i,m,a} w_j \alpha_j.
\]

As an alternative, the aggregated revenue change is just the weighted sum of the individual weighted sum, as \( d\ln TR_c = \sum_{j=i}^{i,m,a} w_j d\ln TR_j \).
Table 7.1. Notation used in derivation and discussion of simulation

<table>
<thead>
<tr>
<th>Notion</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$Q^l (l = c, o)$</td>
<td>The quantity vector for cannabis group and other goods.</td>
</tr>
<tr>
<td>$u_i (l = c, o)$</td>
<td>The sub-utility function of consuming cannabis and other goods.</td>
</tr>
<tr>
<td>$p^l (l = c, o)$</td>
<td>The price vector for cannabis and other goods.</td>
</tr>
<tr>
<td>$\bar{p}^l (l = c, o)$</td>
<td>The base-period price vector for cannabis and other goods.</td>
</tr>
<tr>
<td>$c_l (l = c, o)$</td>
<td>The cost function for cannabis and other goods.</td>
</tr>
<tr>
<td>$Q_c$</td>
<td>Quantity of cannabis.</td>
</tr>
<tr>
<td>$P^*$</td>
<td>The Stones’ price index of cannabis group.</td>
</tr>
<tr>
<td>$P^o$</td>
<td>The price of composite goods which includes all other products in the demand system.</td>
</tr>
<tr>
<td>$M$</td>
<td>Total income.</td>
</tr>
<tr>
<td>$P_j (j = i, a, m)$</td>
<td>The prices of illegal (i), adult-use legal adult-use (a), and medical (m) cannabis.</td>
</tr>
<tr>
<td>$w_{j} (j = i, a, m)$</td>
<td>The within-group expenditure share of illegal, adult-use, and medical cannabis. They sum to 1.</td>
</tr>
<tr>
<td>$Q_j (j = i, a, m)$</td>
<td>The quantities of illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$Y^c$</td>
<td>Total expenditure on cannabis.</td>
</tr>
<tr>
<td>$\epsilon^*$</td>
<td>The total own-price elasticity of demand for cannabis.</td>
</tr>
<tr>
<td>$\xi_j (j = i, a, m)$</td>
<td>The supply elasticity for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$\eta_{ij}$</td>
<td>The unconditional own-price Marshallian elasticity of demand for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$(ii = ii, aa, mm)$</td>
<td>The conditional own-price Marshallian elasticity of demand for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$\eta_{ij}^c$</td>
<td>The unconditional own-price Hicksian elasticity of demand for illegal, adult-use, and medical cannabis.</td>
</tr>
</tbody>
</table>

Bureau of Marijuana Control, Initial Statement of Reasons
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\eta_{ij}$</td>
<td>The conditional own-price Hicksian elasticity of demand for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$\eta_{jk}$</td>
<td>The unconditional cross-price Marshallian elasticity of demand within the group of medical, adult-use, and illegal cannabis.</td>
</tr>
<tr>
<td>$\eta^c_{jk}$</td>
<td>The conditional cross-price Marshallian elasticity of demand within the group of medical, adult-use, and illegal cannabis.</td>
</tr>
<tr>
<td>$\eta^*_{jk}$</td>
<td>The unconditional cross-price Hicksian elasticity of demand within the group of medical, adult-use, and illegal cannabis.</td>
</tr>
<tr>
<td>$\eta^c*_{jk}$</td>
<td>The conditional cross-price Hicksian elasticity of demand within the group of medical, adult-use, and illegal cannabis.</td>
</tr>
<tr>
<td>$\eta^c_{jy}$ ($j = i, a, m$)</td>
<td>The conditional expenditure elasticity of demand for illegal, adult-use and medical cannabis.</td>
</tr>
<tr>
<td>$\sigma^c_{jk}$</td>
<td>The conditional elasticity of substitution within the group of medical, adult-use, and illegal cannabis.</td>
</tr>
<tr>
<td>$\eta_{cM}$</td>
<td>The unconditional income elasticity of demand for cannabis.</td>
</tr>
<tr>
<td>$\eta_c$</td>
<td>The Marshallian demand elasticity for cannabis group</td>
</tr>
<tr>
<td>$\eta^*$</td>
<td>The Hicksian demand elasticity for cannabis group</td>
</tr>
<tr>
<td>$\alpha_j$ ($j = i, a, m$)</td>
<td>The demand shift for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$\beta_j$ ($j = i, a, m$)</td>
<td>The marginal cost shift for illegal, adult-use, and medical cannabis.</td>
</tr>
<tr>
<td>$t_t$</td>
<td>The target tax rate after adult-use legalization.</td>
</tr>
<tr>
<td>$t_j$ ($j = i, a, m$)</td>
<td>The imposed tax rate in terms of the pre-adult-use-legalization price.</td>
</tr>
</tbody>
</table>
7.8 Further demand considerations: additive behavior and the Becker approach to drug demand

We refer here to the addictive behavior approach introduced by Becker and Murphy (1988) regarding drug consumption, which is also discussed in Grossman and Chaloupka (1998) and Becker et al. (2006). This approach assumes that addicts behave rationally and emphasizes the interdependency of past, current, and future consumption of an addictive good. This indicates that consumers incorporate the effects of current consumption on future utility. This approach is generally consistent with our modeling, but we make no particular assumption about addition of habits.

For any illegal activity, a component in determining substitution between the uses is the level of enforcement for the remaining illegal production, sale and use. Becker et al. (2006) modeled the linkage between the elasticity of demand for an illegal good and the effects of enforcement against illegal goods, and thus the overall size of the illegal market. We recognize this relationship. However, although changes in enforcement of the remaining illegal market may shift marginal cost, we do not model them as changing elasticities of supply or demand in this study.

7.9 Literature on empirical estimates of the own-price elasticity of demand for cannabis

The empirical literature on the effects of price on the use of additive drugs such as cocaine, cannabis, and heroin is sparse. Nisbet and Vakil (1972) estimated a price elasticity of demand for cannabis ranging from −0.36 to −1.51 using an anonymous mail survey of students at the University of California at Los Angeles. Lkhdar et al. (2016) also estimated a cannabis price elasticity for demand using 250 French users in 2005. Their elasticity estimates were between -1.7 and -2.1, which were relatively high compared to those found in other studies.

The price elasticity estimates by Pacula et al. (2001) using high school seniors ranged between -0.002 to -0.69. Van Ours and Williams (2007) examined cannabis use by young Australians, and their elasticity estimates ranged between -0.31 and -0.70. Most recently, Jacobi and Sovinski (2016) conducted an empirical cannabis study using the Australian National Drug Household...
Survey, which was published in American Economic Review. Their estimate for price elasticity was -0.2, and we adopt this value in our study to derive cross-price elasticities.

Unlike other studies, Jacobi and Sovinski (2016) used data from the broad population of cannabis users, which is one reason we adopt this value.

7.10 Assumptions about the elasticities of demand for cannabis and categories of cannabis

To project the changes in consumer demand for the three uses of cannabis, it is critical to assess consumer substitution between these uses. To evaluate the substitution possibility and ultimately the quantity changes, we rely on previous studies, empirical data, and economic theory. To consistently derive the cross-price elasticities (which measure the extent of product substitution), we first developed an economic model that describes consumers’ consumption behavior under reasonable assumptions, and applied empirical data and some behavioral parameters from previous studies to our demand model. These elasticities play a critical role in projecting demand and in evaluating aggregate economic impact.

8. Numerical Simulation of Changes in Cannabis Prices, Quantities, Revenues, and Taxes in Response to Changes in Proposed Regulations

8.1 Simulation parameters

The simulation model described above is characterized numerically by specifying values for the parameters listed. We begin by characterizing the baseline without regulation. The price and quantity for all cannabis and shares in each category are based on the medical revenue of about $2.0 billion, a medical share of 25% and an initial retail price of $3,453 per pound of flowers. The prices for adult-use cannabis and illegal-use cannabis are assumed to be 5% and 10% cheaper, respectively, than the medical price for a standard dried follower equivalent product.

Parameters are shown in Table 8.1. Some key parameter values assumed are the aggregate cannabis price elasticity equal to -0.2, as explained in Section 7.9. The budget share of
aggregate cannabis consumption is calculated to be 0.03 based on annual expenditure of about $200 per capita. The income elasticity for cannabis is assumed to be 1.0.

The substitution elasticity between medical use and adult-use cannabis is 4.0; the substitution elasticity between medical and illegal cannabis use is 0.5; and the substitution elasticity between adult-use and illegal cannabis use is 7.0. The substitution matrix is symmetric. The conditional expenditure elasticities of each category are 1.0.

We initialize the model with equal share between the segment of suppliers who initially find it most cost effective to remain in the illegal segment and the segment of suppliers who are more prone to shift to the legal adult-use segment. The underlying parameters and initial shares lead to the matrix of own- and cross-price elasticities of demand as shown, with large elasticities within the group. Own-price elasticities are -1.74, -3.64 and -2.85 at the initial expenditure shares.

On the supply side, we assume a very elastic supply elasticity for medical cannabis (20), as the conditions between that segment and the adult-use segment are very similar and suppliers would find it easy to move between the two. We consider a high supply elasticity of 10.0 for adult-use cannabis because these suppliers can expand or contract with little effect on input costs. These elasticities apply after any bottlenecks caused by regulations (for example testing capacity) are removed. These high supply elasticities also imply that there is very small producer surplus after producers pay for the services of managers and the returns to capital, which already reflect remaining risk premiums.

The supply elasticity of illegal cannabis is 1.0, which assumes that these suppliers face some restrictions in contracting supply. In particular, these suppliers may have difficulty moving into legal supply because of operator human capital. They may also be well suited to the illegal market and earn producer surplus relative to other occupations open to them.

8.2 Shifts in demand and costs associated with adult-use legalization

With this baseline set of parameters, including shares of the three segments, we considered some demand shifts associated with adult-use legalization to establish the adult-use
legalization baseline quantities and prices. We then consider some supply side cost shifts also associated with adult-use legalization.

First, we introduce a 60% percent shift from medical to adult-use cannabis to reflect the lower costs of accessing the adult-use segment, given that to be in the adult-use segment does not require an annual cost of acquiring a medical recommendation.

Second, we introduce a further 10% shift from illegal to adult-use cannabis to reflect drawing more demand from buyers who find the adult-use segment easy to access relative to the illegal segment. This shift is in addition to the initial split of the previously illegal portion of cannabis sales into equal sized segments (by quantity). Finally, we assume a 25% additional demand increase into the adult-use segment, where each of these shifts are percentages based on the initial quantity shares.

The shifts on the supply side include cost reductions from taxation and adult-use legalization as described in Chapter 5. These cost reductions relate to reduced risk premiums from conducting illegal activities or dealing with suppliers and others engaged in illegal activities. For the newly legal adult-use cannabis segment, the marginal cost decline is 35%. For the medical segment the cost reduction is 20%—lower because dispensary businesses have been decriminalized under state law for many years, unlike the adult-use segment. There is still some marginal cost reduction because many retailers have dealt with illegal cultivation supply and distribution of raw materials even under the decriminalized environment for medical dispensaries. We assume the continuing illegal segment will face higher costs because of increased enforcement and isolation from the legal segments because of enforced track-and-trace measures. We have relatively little data to document these cost shifts, but they are consistent with the broad magnitudes of current risk premiums estimated by the differences between market prices and measured accounting costs at both wholesale and retail.

The second component on the supply side is increased enforcement of the current sales tax and new introduced cannabis specific taxes. The sales tax is about 8.8% on cannabis. The state tax rate is 7.5% and the average of county tax rates, which we assume is 1.3%, depends on how cannabis sales are distributed among local tax jurisdictions. Compliance in 2016 suggests about
an effective 3% tax rate for medical cannabis. The tax at the cultivator stage is a $148 per pound on a flower equivalent product affect raw material costs and are assumed to be subsumed in the marginal cost shifts on a per pound basis. The new ad valorem excise tax is 15% on retail sales.

In the previous section, we derived the impact of such taxes on shifts on the cost side of the model. The net effect is a lower cost curve for adult-use cannabis (inclusive of tax), a slightly higher cost curve for medical cannabis, and a higher cost for illegal cannabis. The equilibrium prices depend on the interactions of supply and demand in each segment and the solution for a new equilibrium.
Table 8.1 Baseline prices and quantities and model parameters for simulations of the impacts of regulations

Cannabis group as a whole

<table>
<thead>
<tr>
<th>Share of income spent on cannabis</th>
<th>Total quantity (1000s of lb)</th>
<th>Price/lb</th>
<th>Own demand elasticity</th>
<th>Income elasticity</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.3%</td>
<td>2,333</td>
<td>3,262</td>
<td>-0.2</td>
<td>1.0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Elasticity of substitution</th>
<th>Conditional expenditure elasticity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>share: 25% price: $3,453</td>
<td>elasticity: 4.0</td>
</tr>
<tr>
<td>Adult-use</td>
<td>share: 37.5% price: $3,280</td>
<td>elasticity: 0.5</td>
</tr>
<tr>
<td>Illegal</td>
<td>share: 37.5% price: $3,108</td>
<td>elasticity: 7.0</td>
</tr>
</tbody>
</table>

Implied demand elasticities matrix derived from basic parameters

<table>
<thead>
<tr>
<th>Demand elasticities matrix derived from baseline parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
</tr>
<tr>
<td>Medical</td>
</tr>
<tr>
<td>Adult-use</td>
</tr>
<tr>
<td>Illegal</td>
</tr>
</tbody>
</table>

Supply elasticities of medical cannabis regulations

<table>
<thead>
<tr>
<th>Supply elasticities of medical cannabis regulations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
</tr>
<tr>
<td>20.0</td>
</tr>
</tbody>
</table>
8.3 Simulated results for the adult-use legalization baseline

Results provided in Table 8.2, 8.3, and 8.4 include in the first column the baseline for prices, quantities, revenues, and taxes for the adult-use legalization baseline for medical cannabis. The top row shows the new market price facing consumers ($3,164), which includes taxes of $608 per pound (23.8%). Adult-use legalization results in a market of 235,000 pounds. Revenue with taxes (that paid by consumers) is $743 million, but the revenue of retailers is $601 million. These values are the baseline to which the situation with regulation is compared.

8.4 Simulated regulation impacts on prices, quantities, and related variables

In Section 6, we provide estimates of the costs of regulation per pound that apply for the four license types under consideration. Overall, we find that the proposed regulations add approximately $520 per pound of marketable dried flower equivalent in direct operating costs. Most of the addition to costs, about $400 per pound, is due to the added costs of required testing. In addition to these direct costs, we assume that regulations in the medical cannabis segment that restrict vertical integration of retail firms into wholesale distribution or transport have costs on the industry. We approximate those costs as about 1% of retail revenue.

We therefore assume that the cost increase due to regulations is approximately 16% of the initial value of $3,453 per pound. Since newly legal adult-use cannabis regulations are expected to be similar to the regulations on medical cannabis, we also expect regulatory costs to be similar for the adult-use market. The adult-use segment does not face limits on vertical integration and has a lower base price by 5%. We assume that the costs in that segment also rise by 16%.

The second source of economic effects is an increase in consumer willingness to pay for legal cannabis that has more wholesale security, retail security, and transport security, full traceability, and intensive product testing. We assume the increase in willingness to pay is equivalent to a 6% increase in demand (as represented by a shift out in the demand curve). Such a willingness to pay increase is consistent with USDA certification in food markets such as eggs and meats and with increased government-mandated testing, for example as introduced
in pistachios (Gray et al. 2005). It is also consistent with improved traceability as modeled in Pouliot and Sumner (2008 and 2011) and the literature they cite.

The prices, quantities, revenues, and taxes change in expected ways upon introducing the proposed regulations. Column 2 of Table 8.2 reports prices, quantities, revenues, and taxes with regulations imposed. In this column, the market prices (both with and without taxes) rise (because costs rise with regulations and the ad valorem tax is applied to the price with regulations imposed) and quantity falls slightly. The revenue of the medical cannabis segment (without taxes) is $714 million. Tax revenue itself with regulations is $170 million. Column 3 of Table 8.2 reports the effects of the regulations on the medical cannabis segment by subtracting column 1 from column 2. Price rises by $551 per pound, quantity falls by about 5,000 pounds, revenue rises by $113 million and tax receipts rise by $27 million. The share of the medical cannabis segment is down slightly in quantity terms relative to the entire cannabis industry. However, the share of the medical cannabis segment is slightly higher in revenue terms because regulations raise prices of medical cannabis relative to other segments, especially the illegal segment.

Under these parameters, Tables 8.3 and 8.4 show effects of the lower-cost regulations and higher-security regulations. They are structured like Table 8.2. The results are as expected: less-costly regulations raise price by less than more-costly (higher-security) regulations. The lower-cost regulations are estimated to shift up costs by 6% and shift out demand by 4%.

The higher-security regulations are estimated to shift up costs by 26% and shift out demand by the same 6% as the proposed regulations. Because higher costs affect the supply and demand balance, the higher-security regulations reduce quantity by 30,000 pounds or about 13% from the baseline. Price rises because of higher costs, but total revenue generated by the medical cannabis segment is lower because quantity falls by more in percentage terms than price rises. Much of the reduction in quantity shifts to the illegal market, because the higher-security regulations would apply as well to the adult-use segment.
Table 8.2 Impact of proposed regulations on the medical cannabis segment, given the baseline with taxation and adult-use legalization

<table>
<thead>
<tr>
<th>Variables</th>
<th>Baseline with taxation and adult-use legalization</th>
<th>After regulations imposed on baseline</th>
<th>Difference: After regulations imposed on baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price per lb, with tax</td>
<td>$3,164</td>
<td>$3,846</td>
<td>$682</td>
</tr>
<tr>
<td>Price per lb, without tax</td>
<td>$2,556</td>
<td>$3,107</td>
<td>$551</td>
</tr>
<tr>
<td>Tax rate per lb</td>
<td>$608</td>
<td>$739</td>
<td>$131</td>
</tr>
<tr>
<td>Quantity (lbs)</td>
<td>235,000</td>
<td>230,000</td>
<td>-5,000</td>
</tr>
<tr>
<td>Share of total cannabis quantity</td>
<td>9.1%</td>
<td>8.97%</td>
<td>-0.13%</td>
</tr>
<tr>
<td>Revenue, with tax</td>
<td>$743 million</td>
<td>$883 million</td>
<td>$140 million</td>
</tr>
<tr>
<td>Revenue, without tax</td>
<td>$601 million</td>
<td>$714 million</td>
<td>$113 million</td>
</tr>
<tr>
<td>Tax revenue</td>
<td>$143 million</td>
<td>$170 million</td>
<td>$27 million</td>
</tr>
<tr>
<td>Share of total cannabis revenue, with tax</td>
<td>9.7%</td>
<td>9.8%</td>
<td>0.1%</td>
</tr>
<tr>
<td>Share of total cannabis revenue, without tax</td>
<td>9.1%</td>
<td>9.2%</td>
<td>0.1%</td>
</tr>
</tbody>
</table>

Source: Simulation model results based on parameters discussed in the text and in Table 8.1.

For details on the proposed package of regulations, see section 6.1.
Table 8.3 Impact of lower cost regulations on the medical cannabis segment, given the baseline with taxation and adult-use legalization

<table>
<thead>
<tr>
<th>Variables</th>
<th>Baseline with taxation and adult-use legalization</th>
<th>After regulations imposed on baseline</th>
<th>Difference: After regulations imposed on baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Values of variables for medical cannabis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price per lb, with tax</td>
<td>$3,164</td>
<td>$3,423</td>
<td>$259</td>
</tr>
<tr>
<td>Price per lb, without tax</td>
<td>$2,556</td>
<td>$2,765</td>
<td>$209</td>
</tr>
<tr>
<td>Tax rate per lb</td>
<td>$608</td>
<td>$658</td>
<td>$50</td>
</tr>
<tr>
<td>Quantity (lbs)</td>
<td>235,000</td>
<td>243,000</td>
<td>8,000</td>
</tr>
<tr>
<td>Share of total cannabis quantity</td>
<td>9.1%</td>
<td>9.38%</td>
<td>0.28%</td>
</tr>
<tr>
<td>Revenue, with tax</td>
<td>$743 million</td>
<td>$832 million</td>
<td>$89 million</td>
</tr>
<tr>
<td>Revenue, without tax</td>
<td>$601 million</td>
<td>$672 million</td>
<td>$71 million</td>
</tr>
<tr>
<td>Tax revenue</td>
<td>$143 million</td>
<td>$160 million</td>
<td>$17 million</td>
</tr>
<tr>
<td>Share of total cannabis revenue, with tax</td>
<td>9.7%</td>
<td>10.1%</td>
<td>0.4%</td>
</tr>
<tr>
<td>Share of total cannabis revenue, without tax</td>
<td>9.1%</td>
<td>9.5%</td>
<td>0.4%</td>
</tr>
</tbody>
</table>

Source: Simulation model results based on parameters discussed in the text and in Table 8.1.

For details on the lower-cost package of regulations, see section 6.1.

Table 8.4 Impact of higher-security regulations on the medical cannabis segment, given the baseline with taxation and adult-use legalization
### Values of variables for medical cannabis

<table>
<thead>
<tr>
<th></th>
<th>Baseline with taxation and adult-use legalization</th>
<th>After regulations imposed baseline</th>
<th>Difference: After regulations imposed on baseline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price per lb, with tax</td>
<td>$3,164</td>
<td>$4,264</td>
<td>$1,100</td>
</tr>
<tr>
<td>Price per lb, without tax</td>
<td>$2,556</td>
<td>$3,445</td>
<td>$889</td>
</tr>
<tr>
<td>Tax rate per lb</td>
<td>$608</td>
<td>$819</td>
<td>$211</td>
</tr>
<tr>
<td>Quantity</td>
<td>235,000</td>
<td>205,000</td>
<td>-30,000</td>
</tr>
<tr>
<td>Share of total cannabis quantity</td>
<td>9.1%</td>
<td>8.15%</td>
<td>-0.95%</td>
</tr>
<tr>
<td>Revenue, with tax</td>
<td>$743 million</td>
<td>$874 million</td>
<td>$131 million</td>
</tr>
<tr>
<td>Revenue, without tax</td>
<td>$601 million</td>
<td>$706 million</td>
<td>$105 million</td>
</tr>
<tr>
<td>Tax revenue</td>
<td>$143 million</td>
<td>$168 million</td>
<td>$25 million</td>
</tr>
<tr>
<td>Share of total cannabis revenue, with tax</td>
<td>9.7%</td>
<td>9.1%</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Share of total cannabis revenue, without tax</td>
<td>9.1%</td>
<td>8.4%</td>
<td>-0.7%</td>
</tr>
</tbody>
</table>

*Source: Simulation model results based on parameters discussed in the text and in Table 8.1. For details on the higher-security package of regulations, see Section 6.1.*

### 9. Economy-wide impacts of proposed medical cannabis regulations

This chapter reports on the impacts of the proposed regulations on the broader economy outside of the cannabis industry. The impact estimates build directly on the results presented in Table 8.2 and focus on how changes in medical cannabis costs and revenues ripple through the economy. We use a modified version of the IMPLAN input/output model and data set to develop the economy-wide impacts. For readers...
unfamiliar with this approach a brief discussion of IMPLAN and similar models is provided as background in Chapter 13.

The IMPLAN version 2014 data set was adjusted to incorporate information about medical cannabis, which is not a separate covered industry in the IMPLAN data set. In particular, we adjusted the ratio of value added to intermediate purchases and the shares within value added to reflect tax payments among other modifications. The IMPLAN analysis was conducted using four sectors in medical cannabis. These are treated as “industries” in the IMPLAN nomenclature.

The four sectors correspond to the four sets of services and licenses that are the subject of proposed regulations. These are distribution, testing, transporting, and dispensing. Farm cultivation and manufacturing of medical cannabis are not a part of this analysis. We note that for wholesale and retail industries the IMPLAN framework treats “output” (in dollar value terms) as the difference between gross sales revenues collected by the wholesale or retail business sector minus the dollar value of the costs of goods sold by the wholesale or retail business sector. Therefore, IMPLAN analysis of wholesale and retail businesses does not include backward linkages from the wholesale (distribution) industry back to the raw and manufactured materials that represent costs of goods sold for distributors. Similarly, the IMPLAN linkages analyzed for the retail (dispensing) industry do not include the cost of goods that are acquired from the distributors. This means there is no double counting when we include both distribution businesses and dispensaries in the IMPLAN modeling.

For dispensing, we considered IMPLAN industry number 401 (drug stores and related retailers) as the best match from which to make adjustments. For distribution, we considered IMPLAN industry number 395 (wholesalers) as the best match from which to make adjustments. For testing, we considered IMPLAN industry number 479 (medical and diagnostic laboratories) as the best match from which to make adjustments. For transporting, we considered IMPLAN industry number 415 (couriers and messengers) as the best match from which to make adjustments.

We do not describe implications of regulations of medical cannabis for the illegal and adult-use segments of the cannabis market. Such analysis would require using simulations of the segments for illegal cannabis and adult-use cannabis. While these segments are affected by the proposed regulations, it is beyond the scope of this
report to analyze those implications. A more complete analysis would consider how proposed regulations that will apply to the whole cannabis market will impact consumers and suppliers in the cannabis market as a whole.

9.1 Multipliers

Table 9.1 provides the detailed multipliers for the four “industries” that compose the portions of the medical cannabis industry that are licensed and overseen by the Bureau, from its wholesale transfer from cultivator to distributor or dispensary to its retail transfer to the consumer. These multipliers are used to calculate impacts of the “value of output” of the industry changes. In each case, multipliers are presented as dollars per dollar of output. Recall that for distribution and dispensing, “value of output” is defined as sales revenue minus costs of goods sold. Thus, for example, the value of the output of dispensaries is their revenue minus the cost they paid for the products that they sell. Dispensary output is valued by their provision of retail services, not by their gross sales revenue. For testing and transporting, output is the value of the services provided, which is the revenue of the sector.

Value added is defined as the contribution to gross state product of the sector (output minus the value of indirect inputs purchased from other sectors). For example, for a dispensary, these indirect input purchases include normal retail-level purchases by the dispensary such as display labels, electricity services, cleaning supplies, costs of equipment such as fans or added lights, and cash registers. Labor income associated with the business is a part of value added and includes proprietor income as well as hired employee wages and salaries. Value added includes business taxes and other returns to the operation.

The final panel of Table 9.1 includes jobs per million dollars of output. This is calculated as the number of employees and managers employed in the industry divided by total value of output as defined above for each industry sector. For each industry sector, the multipliers are provided for indirect effects. These multipliers represent the ripple effects of purchases by the medical cannabis industry from other industries outside the medical cannabis segment. First-level purchases and subsequent ripples are both considered. This effect is described more fully in Section 13. The induced effects are the ripples associated with purchases made by those that earn the value added of the industry. So, for example, employee wages are spent on goods and services from other
industries ripple through the economy creating additional value added, labor income and employment. The total effect adds the direct effect to indirect and induced effects.

9.2 Economy-wide contributions under the adult-use legalization baseline

Table 9.2 builds off the results presented in column 1 of Table 8.2. The top row of Table 9.2 lists the direct value of output expected under taxation and adult-use legalization, but without proposed regulations. In this case, IMPLAN shows output of $78 million for distribution, minimal output of $1.8 million for testing, about $30 million for transport of medical cannabis, and output of about $375 million for dispensing.

We note that these outputs include taxes. Recall that taxes are about 24% of revenue for the dispensaries. Labor income is more than half of the value of output for dispensaries. Recall that this includes returns to proprietors. The reason it is not a higher share is because taxes are such a large share of value added.

Table 9.1. Statewide Impact Multipliers for the Medical Cannabis Industry Sectors of Distribution, Testing, Transporting and Dispensing

<table>
<thead>
<tr>
<th>Multiplier</th>
<th>Distribution</th>
<th>Testing</th>
<th>Transporting</th>
<th>Dispensing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Value of Output</strong></td>
<td><strong>Output for economy per $1.00 output by cannabis sector (US $)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Effect</td>
<td>1.000</td>
<td>1.000</td>
<td>1.000</td>
<td>1.000</td>
</tr>
<tr>
<td>Indirect Effect</td>
<td>0.402</td>
<td>0.349</td>
<td>0.509</td>
<td>0.285</td>
</tr>
<tr>
<td>Induced Effect</td>
<td>0.569</td>
<td>0.711</td>
<td>0.486</td>
<td>0.470</td>
</tr>
<tr>
<td>Total Effect</td>
<td>1.971</td>
<td>2.060</td>
<td>1.994</td>
<td>1.756</td>
</tr>
<tr>
<td><strong>Value Added</strong></td>
<td><strong>GDP per $1.00 of output (US $)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Effect</td>
<td>0.681</td>
<td>0.674</td>
<td>0.559</td>
<td>0.778</td>
</tr>
<tr>
<td>Indirect Effect</td>
<td>0.249</td>
<td>0.218</td>
<td>0.294</td>
<td>0.179</td>
</tr>
<tr>
<td>Induced Effect</td>
<td>0.340</td>
<td>0.425</td>
<td>0.290</td>
<td>0.281</td>
</tr>
<tr>
<td>Total Effect</td>
<td>1.269</td>
<td>1.317</td>
<td>1.143</td>
<td>1.238</td>
</tr>
<tr>
<td><strong>Labor Income</strong></td>
<td><strong>Labor income per $1.00 output by sector (US $)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bureau of Marijuana Control, Initial Statement of Reasons
<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Effect</td>
<td>0.475</td>
<td>0.661</td>
<td>0.352</td>
<td>0.426</td>
</tr>
<tr>
<td>Indirect Effect</td>
<td>0.164</td>
<td>0.140</td>
<td>0.195</td>
<td>0.104</td>
</tr>
<tr>
<td>Induced Effect</td>
<td>0.197</td>
<td>0.247</td>
<td>0.169</td>
<td>0.163</td>
</tr>
<tr>
<td>Total Effect</td>
<td>0.837</td>
<td>1.048</td>
<td>0.716</td>
<td>0.693</td>
</tr>
</tbody>
</table>

**Employment**  
*Jobs per $1 million of output*

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Direct Effect</td>
<td>4.8</td>
<td>7.9</td>
<td>9.1</td>
<td>10.5</td>
</tr>
<tr>
<td>Indirect Effect</td>
<td>2.4</td>
<td>2.0</td>
<td>2.9</td>
<td>1.6</td>
</tr>
<tr>
<td>Induced Effect</td>
<td>3.6</td>
<td>4.5</td>
<td>3.1</td>
<td>3.0</td>
</tr>
<tr>
<td>Total Effect</td>
<td>10.8</td>
<td>14.3</td>
<td>15.0</td>
<td>15.1</td>
</tr>
</tbody>
</table>

*Source: Multipliers were generated in IMPLAN using revenue and costs data provided by industry respondents to project questionnaire.*

*Note: Labor income includes employees and proprietor income.*
Table 9.2. Economic impacts of the California medical cannabis industry by sector, with taxation and adult-use legalization baseline, without regulation

<table>
<thead>
<tr>
<th>Impact Measure</th>
<th>Distribution</th>
<th>Testing</th>
<th>Transporting</th>
<th>Dispensing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Value of Sector Output</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Output</td>
<td>78.0</td>
<td>1.8</td>
<td>30.2</td>
<td>374.5</td>
</tr>
<tr>
<td>Indirect Output</td>
<td>31.4</td>
<td>0.6</td>
<td>15.4</td>
<td>106.9</td>
</tr>
<tr>
<td>Induced Output</td>
<td>44.4</td>
<td>1.3</td>
<td>14.7</td>
<td>176.1</td>
</tr>
<tr>
<td>Total Output</td>
<td>153.7</td>
<td>3.7</td>
<td>60.3</td>
<td>657.5</td>
</tr>
<tr>
<td><strong>Value Added</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Value Added</td>
<td>53.1</td>
<td>1.2</td>
<td>16.9</td>
<td>291.3</td>
</tr>
<tr>
<td>Indirect Value Added</td>
<td>19.4</td>
<td>0.4</td>
<td>8.9</td>
<td>67.1</td>
</tr>
<tr>
<td>Induced Value Added</td>
<td>26.5</td>
<td>0.8</td>
<td>8.8</td>
<td>105.1</td>
</tr>
<tr>
<td>Total Value Added</td>
<td>99.0</td>
<td>2.4</td>
<td>34.6</td>
<td>463.5</td>
</tr>
<tr>
<td><strong>Labor Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Labor Income</td>
<td>37.1</td>
<td>1.2</td>
<td>10.6</td>
<td>159.6</td>
</tr>
<tr>
<td>Indirect Labor Income</td>
<td>12.8</td>
<td>0.3</td>
<td>5.9</td>
<td>38.9</td>
</tr>
<tr>
<td>Induced Labor Income</td>
<td>15.4</td>
<td>0.4</td>
<td>5.1</td>
<td>61.0</td>
</tr>
<tr>
<td>Total Labor Income</td>
<td>65.2</td>
<td>1.9</td>
<td>21.7</td>
<td>259.4</td>
</tr>
</tbody>
</table>

**Impact Measure**

<table>
<thead>
<tr>
<th>Impact Measure</th>
<th>Distribution</th>
<th>Testing</th>
<th>Transporting</th>
<th>Dispensing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Employment</td>
<td>374</td>
<td>14</td>
<td>275</td>
<td>3,932</td>
</tr>
<tr>
<td>Indirect Employment</td>
<td>187</td>
<td>4</td>
<td>88</td>
<td>599</td>
</tr>
<tr>
<td>Induced Employment</td>
<td>281</td>
<td>8</td>
<td>94</td>
<td>1,123</td>
</tr>
<tr>
<td>Total Employment</td>
<td>842</td>
<td>26</td>
<td>453</td>
<td>5,654</td>
</tr>
</tbody>
</table>
9.3 Economy-wide contributions under the proposed regulations

Table 9.3 builds on the results presented in column 2 of Table 8.2. The top row of Table 9.3 is the direct value of output expected under adult-use legalization but before regulations are applied. In this case we expect output of $90.5 million for distribution and output of $92 million for testing. Recall that testing costs rise to about $400 per pound with the proposed regulations. The transport industry continues to have about $30 million of output for medical cannabis. Finally the output is about $417.9 million for dispensing. Much of the increase of the value of output is due to costs of regulations that add to costs at the dispensary.

Recall that taxes are about 24% of revenue for the dispensaries, and that these taxes apply to the higher market prices caused by regulations. Further, recall that because consumer willingness to pay rises with more security and product safety, the quantity sold falls little. Also recall that we assume that similar regulations, including testing, apply to adult-use cannabis.

With regulation, 4,388 direct jobs are in the dispensing sector, and these contribute 6,310 jobs to the economy overall. The testing sector is next with 727 direct jobs and 1,316 jobs to the economy overall. Distribution and transporting have few direct and total employment impacts consistent with their smaller outputs.

9.4 Economy-wide impacts of proposed regulations

Table 9.4 builds economy-wide impacts of the proposed regulations by subtracting the results in Table 9.2 from those in Table 9.3. These differences in value of output effects, value added effects, labor income effects, and jobs comprise the results presented in Table 9.4. The total dollar values in Table 9.4 are reported in millions and are relatively small for distribution and transporting where regulations add little to costs. The regulatory impacts are much more significant in testing and dispensing.

Source: Values were estimated by UC AIC staff by applying input-output multipliers generated in IMPLAN and using revenue and costs data provided by industry respondents to project questionnaire.

Note: Labor income includes employees and proprietor income.
Table 9.3. Economic impacts of the California medical cannabis industry by sector, with taxation and adult-use legalization, with proposed regulations

<table>
<thead>
<tr>
<th>Impact Measure</th>
<th>Distribution</th>
<th>Testing</th>
<th>Transporting</th>
<th>Dispensing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Value of Sector Output</strong></td>
<td><strong>Millions of US $</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Output</td>
<td>90.5</td>
<td>92.0</td>
<td>29.6</td>
<td>417.9</td>
</tr>
<tr>
<td>Indirect Output</td>
<td>36.4</td>
<td>32.1</td>
<td>15.0</td>
<td>119.3</td>
</tr>
<tr>
<td>Induced Output</td>
<td>51.5</td>
<td>65.4</td>
<td>14.4</td>
<td>196.6</td>
</tr>
<tr>
<td>Total Output</td>
<td>178.5</td>
<td>189.6</td>
<td>59.0</td>
<td>733.7</td>
</tr>
<tr>
<td><strong>Value Added</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Value Added</td>
<td>61.7</td>
<td>62.0</td>
<td>16.5</td>
<td>325.1</td>
</tr>
<tr>
<td>Indirect Value Added</td>
<td>22.5</td>
<td>20.0</td>
<td>8.7</td>
<td>74.9</td>
</tr>
<tr>
<td>Induced Value Added</td>
<td>30.7</td>
<td>39.1</td>
<td>8.6</td>
<td>117.3</td>
</tr>
<tr>
<td>Total Value Added</td>
<td>114.9</td>
<td>121.1</td>
<td>33.8</td>
<td>517.3</td>
</tr>
<tr>
<td><strong>Labor Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Labor Income</td>
<td>43.0</td>
<td>60.8</td>
<td>10.4</td>
<td>178.1</td>
</tr>
<tr>
<td>Indirect Labor Income</td>
<td>14.9</td>
<td>12.9</td>
<td>5.8</td>
<td>43.4</td>
</tr>
<tr>
<td>Induced Labor Income</td>
<td>17.8</td>
<td>22.8</td>
<td>5.0</td>
<td>68.0</td>
</tr>
<tr>
<td>Total Labor Income</td>
<td>75.7</td>
<td>96.4</td>
<td>21.2</td>
<td>289.5</td>
</tr>
<tr>
<td><strong>Employment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Employment</td>
<td>435</td>
<td>727</td>
<td>269</td>
<td>4,388</td>
</tr>
<tr>
<td>Indirect Employment</td>
<td>217</td>
<td>184</td>
<td>86</td>
<td>669</td>
</tr>
<tr>
<td>Induced Employment</td>
<td>326</td>
<td>414</td>
<td>92</td>
<td>1,254</td>
</tr>
<tr>
<td>Total Employment</td>
<td>978</td>
<td>1,316</td>
<td>444</td>
<td>6,310</td>
</tr>
</tbody>
</table>

Source: Values were estimated by UC AIC staff by applying input-output multipliers generated in IMPLAN and using revenue and costs data provided by industry respondents to project questionnaire.

Note: Labor income includes employees and proprietor income.
In the dispensary sector, the output measured by margin rises by $43.4 million, value added rises by $33.8 million, direct labor income rises by $18.5 million and direct employment rises by 456 jobs. For the dispensary sector, the California economy-wide impacts of the proposed regulations are as follows: value added rises by $53.7 million, and the increase in number of jobs attributable to the increase in dispensary output is 655 jobs. In the distribution sector, output rises by $12.5 million and direct jobs rise by 60. For the distribution sector, the California economy-wide impacts of the proposed regulations are as follows: value added rises by $15.9 million, and the increase in number of jobs attributable to the increase in distribution output is 136 jobs.

Transport revenue falls by only $0.6 million because quantity shipped falls slightly and number of shipments may increase slightly direct employment falls by 6 jobs. For the transport sector, the California economy-wide impacts of the proposed regulations are as follows: value added falls by $0.7 million, and the fall in number of jobs attributable to the fall in transport is 10 jobs.

The expanded testing sector is subject to significant new economic activity. Output measured by revenue rises by $90.2 million, direct value added by $60.8 million and direct jobs rise by 713. Economy-wide value added attributable to testing rises by $118.8 million, $94.5 million more in total economy-wide labor income, and economy wide jobs rise by 1,290 jobs.

These impacts are additive in the economy-wide calculations because the retail and wholesale sectors within IMPLAN are measured on a margin basis. Adding the sector specific impacts, the economy-wide impacts of the proposed regulations are substantial. Within the sector the increase in due to the proposed regulations of direct value added is $102.7 million. Economywide the value added rises by $187.7 million and economywide labor income (including proprietor income) rises by $134.6 million. Overall, the economy adds 1,223 jobs within the medical cannabis sector and overall California employment rises by 2,071 jobs.

These economy-wide implications are derived from and consistent with the results in Table 8.3, which shows the direct impacts of regulations in the medical cannabis segment in terms of prices, outputs, revenues, and taxes.
Table 9.4. Differences between economic impacts of the California medical cannabis industry by sector, adult-use legalization baseline from the proposed regulations

<table>
<thead>
<tr>
<th>Impact Measure</th>
<th>Distribution</th>
<th>Testing</th>
<th>Transporting</th>
<th>Dispensing</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Value of Sector Output</strong></td>
<td><strong>Millions of US $</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Output</td>
<td>12.5</td>
<td>90.2</td>
<td>-0.6</td>
<td>43.4</td>
</tr>
<tr>
<td>Indirect Output</td>
<td>5.0</td>
<td>31.5</td>
<td>-0.3</td>
<td>12.4</td>
</tr>
<tr>
<td>Induced Output</td>
<td>7.1</td>
<td>64.2</td>
<td>-0.3</td>
<td>20.4</td>
</tr>
<tr>
<td>Total Output</td>
<td>24.7</td>
<td>185.8</td>
<td>-1.3</td>
<td>76.2</td>
</tr>
<tr>
<td><strong>Value Added</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Value Added</td>
<td>8.5</td>
<td>60.8</td>
<td>-0.4</td>
<td>33.8</td>
</tr>
<tr>
<td>Indirect Value Added</td>
<td>3.1</td>
<td>19.6</td>
<td>-0.2</td>
<td>7.8</td>
</tr>
<tr>
<td>Induced Value Added</td>
<td>4.3</td>
<td>38.4</td>
<td>-0.2</td>
<td>12.2</td>
</tr>
<tr>
<td>Total Value Added</td>
<td>15.9</td>
<td>118.8</td>
<td>-0.7</td>
<td>53.7</td>
</tr>
<tr>
<td><strong>Labor Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Labor Income</td>
<td>6.0</td>
<td>59.6</td>
<td>-0.2</td>
<td>18.5</td>
</tr>
<tr>
<td>Indirect Labor Income</td>
<td>2.1</td>
<td>12.6</td>
<td>-0.1</td>
<td>4.5</td>
</tr>
<tr>
<td>Induced Labor Income</td>
<td>2.5</td>
<td>22.3</td>
<td>-0.1</td>
<td>7.1</td>
</tr>
<tr>
<td>Total Labor Income</td>
<td>10.5</td>
<td>94.5</td>
<td>-0.5</td>
<td>30.1</td>
</tr>
<tr>
<td><strong>Employment</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct Employment</td>
<td>60</td>
<td>713</td>
<td>-6</td>
<td>456</td>
</tr>
<tr>
<td>Indirect Employment</td>
<td>30</td>
<td>180</td>
<td>-2</td>
<td>69</td>
</tr>
<tr>
<td>Induced Employment</td>
<td>45</td>
<td>406</td>
<td>-2</td>
<td>130</td>
</tr>
<tr>
<td>Total Employment</td>
<td>136</td>
<td>1,290</td>
<td>-10</td>
<td>655</td>
</tr>
</tbody>
</table>

*Source: Values were estimated by UC AIC staff by applying input-output multipliers generated in IMPLAN and using revenue and costs data provided by industry respondents to project questionnaire.*

*Note: Labor income includes employees and proprietor income.*
10. Legal cannabis policy and markets: A comparative review of west coast states

The western states have long formed the core of the US cannabis market. All three states on the west coast of the continental US (Washington, Oregon, and California), as well as Colorado and (as of 2016) Alaska and Nevada, have now legalized both medical and adult-use cannabis.

Although California was the first state to decriminalize medical cannabis (in 1996), it will be the last of the three west-coast states to regulate cannabis on a state level when taxation and adult-use legalization and the proposed regulations for adult-use and medical cannabis take effect in 2018. California can therefore look to the other western markets for comparative evidence on the different forms of regulation that have come into effect in its neighboring states.

First, we summarize the comparative situation in Table 10.1, which lists the key similarities and differences in regulatory systems and timelines between California, Oregon, and Washington. We provide relevant details on the regulatory environments, economic indicators, and data sources used for each state.

This is followed by Table 10.2, which summarizes wholesale price differences and trends in six western states.

10.1 California and Colorado

Until now, the medical cannabis market has been the only legal cannabis market in California. Its retail sales have been taxed at a rate of approximately 3%, accounting for widespread non-compliance. In 2018, the legalization of adult-use cannabis and implementation of the proposed regulations will result in a new tax rate (not including cultivation taxes) of approximately 23.8% and a package of testing regulations and other regulations that will add a total cost of approximately $500 per pound.

The statutory and regulatory history, our economic calculations, and expected economic effects with respect to California are detailed in other portions of this report. In this section, we focus on the comparative analysis with Washington and Oregon. Colorado’s situation is not readily comparable to California’s because in Colorado, the adult-use cannabis regulations are significantly more costly than the ones imposed on
medical cannabis, resulting in higher relative prices of adult-use cannabis. (In section 5.2.2, however, we do consider Colorado data in the context of estimating the outward demand shift that we expect to result in the California adult-use market from tourists and other visitors to the state.)

Among California’s neighboring states, Washington and Oregon are the focus of this comparative analysis because of the unique regulatory similarities between the proposed regulations in California and the ones currently in place in Washington and Oregon, particularly with respect to testing regulations, track-and-trace, labeling, security regulations, and the relationship between medical and adult-use regulations.
Table 10.1 Comparison of major regulatory changes and subsequent economic effects in regulated U.S. states

<table>
<thead>
<tr>
<th></th>
<th><strong>Washington</strong></th>
<th><strong>Oregon</strong></th>
<th><strong>California</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Changes</td>
<td>2013: Dispensaries legalized.</td>
<td>2015: MCRSA establishes Bureau to regulate medical use.</td>
</tr>
<tr>
<td>period</td>
<td></td>
<td></td>
<td>Total市场 size grows to $7.7 billion ($2 billion medical cannabis, $5.7 billion illegal cannabis).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>changes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent economic</td>
<td>Unregulated medical market, with cost advantages over adult-use market, continues to grow modestly. Adult-use market grows much faster, surpassing medical in late 2014 and doubling size of medical market by mid-2015.</td>
<td>After adult-use legalization, adult use segment claims 50% of legal cannabis market. Market size estimated as $750M in fall 2016 ($375M = 50% legal; $375M = 50% illegal). As of Sept 2016, there were 1,300 applicants but only 200 businesses licensed.</td>
<td>Reliable data are not yet available for changes to the marketplace between Nov 2016 and Jan 2017.</td>
</tr>
<tr>
<td>effects observed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Latest regulatory changes</td>
<td>Jul 2015: regulations of medical and adult-use segments roughly equalized. Similar compliance costs imposed in both segments. Effective tax rate of 37% imposed on all medical and adult-use cannabis. Registered medical patients will be exempt only from state sales tax, a small component of overall tax rate.</td>
<td>Oct 2016: stringent new testing standards imposed on entire legal market.</td>
<td>Jan 2018: regulations of medical and adult-use segments will be roughly equivalent. Similar compliance costs are imposed in both segments. Effective tax rate of 15% imposed on all medical and adult-use cannabis (excise). Registered medical patients will be exempt only from state sales tax, a small component of overall tax rate.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subsequent</td>
<td>With compliance costs</td>
<td>Legal cannabis prices rise by</td>
<td>With compliance costs</td>
</tr>
<tr>
<td>With compliance costs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bureau of Marijuana Control, Initial Statement of Reasons
equalized, medical segment loses price and other advantages, and consumers rapidly migrate from medical segment to adult-use segment. By June 2016, 1 year after the removal of tax and regulatory incentives for consumers to remain in the medical market, adult use revenues have grown to 89% of the $630 million legal cannabis market and medical revenues have fallen to 11% of the legal market. If current trends continue, the Washington medical cannabis segment appears unlikely to survive in the long run.

27%–39% in the two-month span after testing rules take effect. Revenue falls by $23,500 per dispensary due to supply constraints. The illegal market grows from 50% to 75% while the legal market falls from 50% to 25%. equalized, medical segment has no price or other advantages, and consumers rapidly migrate from medical segment to adult-use segment. Our simulation model projects that the CA medical market will hold about 10% of the overall cannabis market, which agrees with the rates of consumer migration observed in WA under similar conditions.

Short-term supply shortages may cause temporary flight to CA’s illegal market and spike prices; but SRIA analysis’s scope of prediction is one year after implementation, by which point we project that testing will impose an additional cost of approximately 12% on cannabis in the post-regulation equilibrium.

1 Source: NORML legal history, norml.com; Washington, Oregon, and California state laws.
2 Source: Washington Department of Revenue data. Full data set shown in Tables 10.3 through 10.6. For market sizing, revenues are calculated simply as 12 times June 2016 reported revenues. Sales are growing so rapidly in this market that to construct the annualized estimate on a more sophisticated seasonal spreading basis would fail to observe the dominance of this growth in the pattern.
4 Source: AIC estimates. For detailed analysis of AIC market size calculations, see Chapter 5, with supporting empirical background material in Chapters 3 and 4.
5 Source: the 27% two-month price increase estimate comes from an AIC re-analysis of the distribution of the “price increases due to the lack of available supply” responses in Whitney Economics November 30, 2016 survey data (69 responses of 683 businesses surveyed).
6 Source: the 39% two-month price increase estimate comes from Cannabis Benchmarks’ Oregon spot prices of $1,500 on 10/28/2016 and $2,082 on 12/23/2016. The Oregon spot price peaked at $2,300 on 12/9/2016 (a 53% increase in the first six weeks after the testing regulations took effect).
7 Source: Whitney Economics, November 30, 2016 white paper and AIC re-analysis of the distribution of “lost revenue per month as a result of supply constraint” responses in Whitney survey data (72 responses of 683 businesses surveyed).
### Table 10.2. Retail and wholesale spot prices for cannabis in six western states

<table>
<thead>
<tr>
<th>State</th>
<th>Retail price per lb&lt;sup&gt;1&lt;/sup&gt;</th>
<th>Wholesale spot price per lb&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Marketing multiple&lt;sup&gt;3&lt;/sup&gt;</th>
<th>Average deal size&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oregon</td>
<td>$2,921 &lt;sup&gt;n=2,735&lt;sup&gt;5&lt;/sup&gt;&lt;/sup&gt;</td>
<td>$2,082</td>
<td>1.40</td>
<td>2.5 lbs</td>
</tr>
<tr>
<td>Washington</td>
<td>$3,024 &lt;sup&gt;n=4,496&lt;/sup&gt;</td>
<td>$1,329</td>
<td>2.28</td>
<td>7.4 lbs</td>
</tr>
<tr>
<td>Colorado</td>
<td>$3,190 &lt;sup&gt;n=3,722&lt;/sup&gt;</td>
<td>$1,430</td>
<td>2.23</td>
<td>3.0 lbs</td>
</tr>
<tr>
<td>California</td>
<td>$3,453 &lt;sup&gt;(AIC est.)&lt;/sup&gt;</td>
<td>$1,495</td>
<td>2.31</td>
<td>12.9 lbs</td>
</tr>
<tr>
<td>Arizona</td>
<td>$3,614 &lt;sup&gt;n=3,144&lt;/sup&gt;</td>
<td>$2,404</td>
<td>1.50</td>
<td>7.1 lbs</td>
</tr>
<tr>
<td>Nevada</td>
<td>$3,695 &lt;sup&gt;n=1,850&lt;/sup&gt;</td>
<td>$2,425</td>
<td>1.52</td>
<td>6.6 lbs</td>
</tr>
</tbody>
</table>

<sup>1</sup> Source: Priceofweed.com retail user survey, data current as of 23 December 2016. Medium quality assumed. AIC’s own assumptions used for California.


<sup>3</sup> Ratio of retail price to the cost of raw goods.

<sup>4</sup> Weighted averages.

<sup>5</sup> “n=” refers to number of observations in each state.

### 10.2 Washington State

Washington State’s history of cannabis regulation has much in common with California’s, beginning with medical legalization in 1998 (vs. 1996 in California) and 14 years (vs. 22 in California) of state-unregulated operation of the medical cannabis industry. The history of legal cannabis policy in Washington can be partitioned by the following three changes: the initial legalization of medical cannabis in 1998, the legalization and regulation of adult-use cannabis in 2012, and the restructuring of the cannabis tax system in 2015 so as to regulate medical cannabis similarly to adult-use cannabis. At each stage, the treatment of medical cannabis was impacted, and each will be examined in turn.

Medical cannabis possession and use was decriminalized by ballot initiative in 1998. The policies in the initiative failed to establish any regulatory structure, and the medical
cannabis industry functioned as a gray market similar to the one that has been in place in California to date, with only local regulations governing firm behavior. There were no state regulations to govern the establishment of dispensaries or to regulate providers of medical cannabis cards. In 2000, legislation was passed that would have established a regulatory system, but the majority of the law was vetoed by the governor.\footnote{In Washington, the governor may line-item veto, and in this case, the law was still enacted, but most of the legislation pertaining to cannabis regulation did not actually go into effect.}

Initiative 502 legalized adult-use cannabis use in 2012, but ignored the established medical cannabis system. This meant that adult-use cannabis and medical cannabis existed in parallel. The initiative included a three-tiered tax structure for adult-use cannabis, but medical cannabis was exempted from any taxation. This created competition between the regulated adult-use system and the unregulated medical system, and because of the tax advantages in and ease of access to the medical system, some consumers continued to purchase medical cannabis. In March of 2015, there were 123 licensed adult-use dispensaries and approximately 1,100 state-unregulated medical dispensaries (Washington Office of Financial Management 2016).

To address the disparity in the regulatory system, and to simplify the tax structure, Washington SB 5052 was passed in 2015 to restructure both the adult-use and medical cannabis systems into one regulatory structure.\footnote{All of the specific information in Section 10.2 is drawn from the Washington Governor’s Office (2016) website: “Frequently Asked Questions - Cannabis Patient Protection Act (SB 5052).”} The medical system was not phased out, but the same licensing system now governs adult-use and medical dispensaries. Medical cannabis products can be purchased by any consumer now, whether a medical cardholder or not, but there is also an additional medical endorsement that dispensaries may obtain.

Despite this, there are still key differences between adult-use consumers and medical consumers. Medical cardholders may possess larger quantities of cannabis, may purchase higher-THC products, may grow cannabis at home or participate in a growing cooperative, and are exempted from any taxation on cannabis. (This tax break is only offered to cardholders.) Under the new regulatory structure, medical cards are now issued by the state, with a voluntary registration database similar to California’s.
Following is a review of specific characteristics of the Washington medical and adult-use regulations, so that economic results in Washington can be interpreted in consideration of those factors, especially insofar as they differ from the proposed regulations in California.

Cannabis products in Washington are labeled in three ways: General Use, High-CBD, and High-THC. The definitions and limitations are as follows:

- **General Use**
  - Any approved cannabis product may be packaged in servings containing up to 10 mg of THC, but may not exceed 10 servings or 100 mg of THC
  - May be purchased by anyone over 21 or anyone holding a recognition card
  - May be sold by any licensed retail outlet

- **High-CBD cannabis**
  - May be any approved cannabis product except usable cannabis intended for smoking
  - Servings must contain no more than 2 percent THC concentration by weight and at least 25 times more CBD concentration
  - May be purchased by anyone over 21 or anyone holding a recognition card and may be sold by any licensed retail outlet

- **High-THC cannabis**
  - A cannabis product containing more than 10, but no more than 50, mg of THC per serving
  - The only products that qualify as High THC are capsules, tinctures, transdermal patches, and suppositories
  - May only be purchased by patients holding a recognition card, and may only be sold by medically endorsed licensed retail establishments

A consumer must obtain a state-registered medical card in order to participate in the Washington medical cannabis system, which enables the consumer to buy medical cannabis under a set of rules that have certain advantages over the adult-use rules: including a lower minimum age of legal purchase and consumption (18), and order-of-magnitude-higher concentration and quantity allowances.

Participation in the medical segment requires completion of two-page authorization form by healthcare practitioner. The healthcare practitioner may be a medical doctor, physician assistant, osteopathic physician or assistant, naturopathic physician, or an advanced registered nurse practitioner. Provider may recommend that the patient be
allowed to grow more than the number of plants allowed by law, up to 15. The form allows for identification of a designated provider (a person whom the patient authorizes to purchase their cannabis product or grow their cannabis plants).

A medical card can be acquired by a person of any age, but a patient under 18 must be registered in the authorization database. The authorization form requires the patient or designated provider’s name and address, and the name, license number, and contact information of the medical practitioner listed. The healthcare practitioner must also indicate the diagnosis that allows for the authorization. The authorization form expires after one year.

Once the authorization form is completed, the patient may join the medical cannabis authorization database and receive a medical cannabis recognition card. This requires the patient to visit a licensed and medically endorsed cannabis store and contact the medical cannabis consultant on staff. The consultant will then enter the patient’s information into the database and create the new medical cannabis recognition card.

The patient must pay a one-dollar fee for the creation of the card (the fee is transferred to the Washington Department of Health). As of December 5, 2016, a total of 15,536 recognition cards have been created, with 47 issued to minors under 18.

- Benefits of a medical recognition card:
  - Buy products at medically endorsed retail stores sales tax free;
  - Buy up to three times the current limits (see below for these levels) at medically endorsed retail stores;
  - Buy High-THC products;
  - Grow in their home or as a member of a cooperative:
    - 6 plants for personal medical use; and
  - Possess up to 8 oz usable cannabis produced from their plants.
  - Protection against arrest (if not registered in the database, patients only have an affirmative defense).

- Current purchase limitations:
  - Authorized medical patients entered into the state database are permitted to possess exactly three times the amounts permitted for adult-use consumers, plus the right to cultivate small amounts of cannabis:
    - 3 oz usable cannabis;
    - 48 oz cannabis-infused product in solid form;
    - 216 oz cannabis-infused product in liquid form;
    - 21 g cannabis concentrate;
o Grow in one’s home or as a member of a cooperative:
  ▪ 6 plants for personal medical use; and
  ▪ Possess up to 8 oz usable cannabis produced from their plants.

Medical-cannabis-endorsed stores must have a certified medical cannabis consultant on hand. Consultant may enter authorization form information into authorization database. There are currently 161 active medically endorsed retail stores (out of a total of 467 licensed retail locations in Washington). A medically endorsed retail store is defined as a store that has at least one certified medical cannabis consultant on staff.

Prior to July 2015, adult-use and medical producers, processors, and retailers paid an excise tax of 25%. This tax was in addition to state and local sales taxes and business and operation taxes. After July 2015, only retailers have paid excise tax, which was raised to 37%. The excise tax is collected by the Washington Liquor and Cannabis Board, while the Department of Revenue collects sales and B&O taxes.

- Adult-use cannabis is available to all individuals over the age of 21.
- Adult-use consumers are permitted to buy and possess:
  o 1 oz usable cannabis;
  o 16 oz cannabis-infused product in solid form;
  o 72 oz cannabis-infused product in liquid form;
  o 7 g cannabis concentrate.
- Adult-use consumers are permitted to buy and possess high-CBD cannabis products.
- Adult-use consumers are not permitted to buy or possess high-THC cannabis products.

Information from the Washington Department of Revenue tax collection data are summarized graphically in Figure 10.1, and the data are reported in Tables 10.3–10.5. Figure 10.1 paints a stark picture of the medical cannabis segment losing 89% of the legal market after the introduction of adult-use cannabis in 2013, as detailed in Table 10.1. In October 2014, medical cannabis loses its majority share, and medical revenues begin to fall precipitously in July 2015.
Figure 10.1. Monthly sales of medical and adult-use cannabis,


Source: Washington Department of Revenue data.
Table 10.3. Washington medical cannabis taxes for fiscal years 2015 and 2016^1,2

<table>
<thead>
<tr>
<th>Month of Sales Activity</th>
<th>Taxable Retail Sales</th>
<th>State Retail Sales Tax Due</th>
<th>State Business &amp; Occupation Tax Due</th>
<th>Local Retail Sales Tax Due</th>
<th>Implied Tax Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jul-2014</td>
<td>7,478,171</td>
<td>486,081</td>
<td>38,953</td>
<td>199,188</td>
<td>0.070</td>
</tr>
<tr>
<td>Aug-2014</td>
<td>7,346,693</td>
<td>477,535</td>
<td>38,298</td>
<td>192,169</td>
<td>0.070</td>
</tr>
<tr>
<td>Sep-2014</td>
<td>8,597,641</td>
<td>558,847</td>
<td>50,291</td>
<td>244,816</td>
<td>0.070</td>
</tr>
<tr>
<td>Oct-2014</td>
<td>7,597,259</td>
<td>493,822</td>
<td>39,986</td>
<td>235,881</td>
<td>0.070</td>
</tr>
<tr>
<td>Nov-2014</td>
<td>7,526,287</td>
<td>489,209</td>
<td>39,182</td>
<td>190,601</td>
<td>0.070</td>
</tr>
<tr>
<td>Dec-2014</td>
<td>12,405,007</td>
<td>806,326</td>
<td>87,933</td>
<td>324,655</td>
<td>0.070</td>
</tr>
<tr>
<td>Jan-2015</td>
<td>10,237,454</td>
<td>665,435</td>
<td>62,151</td>
<td>266,680</td>
<td>0.070</td>
</tr>
<tr>
<td>Feb-2015</td>
<td>9,868,715</td>
<td>641,467</td>
<td>58,817</td>
<td>254,938</td>
<td>0.070</td>
</tr>
<tr>
<td>Mar-2015</td>
<td>11,366,900</td>
<td>741,985</td>
<td>70,441</td>
<td>371,598</td>
<td>0.070</td>
</tr>
<tr>
<td>Apr-2015</td>
<td>11,451,376</td>
<td>744,340</td>
<td>69,432</td>
<td>298,760</td>
<td>0.070</td>
</tr>
<tr>
<td>May-2015</td>
<td>11,844,387</td>
<td>769,885</td>
<td>72,394</td>
<td>307,258</td>
<td>0.070</td>
</tr>
<tr>
<td>Jun-2015</td>
<td>12,181,480</td>
<td>791,568</td>
<td>75,506</td>
<td>336,761</td>
<td>0.069</td>
</tr>
<tr>
<td>FY 2015 Totals</td>
<td>117,901,369</td>
<td>7,666,500</td>
<td>703,383</td>
<td>3,223,303</td>
<td>0.070</td>
</tr>
</tbody>
</table>

<p>| Jul-2015                | 8,184,880            | 532,017                    | 78,955                             | 208,521                   | 0.070           |
| Aug-2015                | 7,755,748            | 504,124                    | 76,926                             | 197,800                   | 0.070           |
| Sep-2015                | 7,553,969            | 491,008                    | 100,731                            | 244,654                   | 0.070           |
| Oct-2015                | 7,155,186            | 465,087                    | 78,412                             | 179,608                   | 0.070           |
| Nov-2015                | 6,725,384            | 437,150                    | 72,884                             | 171,567                   | 0.070           |
| Dec-2015                | 7,388,484            | 553,995                    | 72,912                             | 196,490                   | 0.081           |
| Jan-2016                | 5,337,565            | 346,942                    | 54,557                             | 140,740                   | 0.070           |</p>
<table>
<thead>
<tr>
<th>Month</th>
<th>Taxable Retail Sales</th>
<th>State Retail Sales Tax Due</th>
<th>State Business &amp; Occupation Tax Due</th>
<th>Local Retail Sales Tax Due</th>
<th>Implied Tax Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jul-2014</td>
<td>2,578,241</td>
<td>167,586</td>
<td>31,125</td>
<td>52,679</td>
<td>0.070</td>
</tr>
<tr>
<td>Aug-2014</td>
<td>4,954,243</td>
<td>322,026</td>
<td>46,673</td>
<td>108,469</td>
<td>0.070</td>
</tr>
<tr>
<td>Sep-2014</td>
<td>6,208,687</td>
<td>403,565</td>
<td>62,140</td>
<td>139,183</td>
<td>0.070</td>
</tr>
<tr>
<td>Oct-2014</td>
<td>7,838,338</td>
<td>509,492</td>
<td>81,054</td>
<td>182,596</td>
<td>0.070</td>
</tr>
<tr>
<td>Nov-2014</td>
<td>9,053,929</td>
<td>588,505</td>
<td>94,701</td>
<td>212,475</td>
<td>0.070</td>
</tr>
<tr>
<td>Dec-2014</td>
<td>11,560,057</td>
<td>751,404</td>
<td>97,899</td>
<td>271,983</td>
<td>0.070</td>
</tr>
<tr>
<td>Jan-2015</td>
<td>13,864,329</td>
<td>901,181</td>
<td>103,626</td>
<td>324,943</td>
<td>0.070</td>
</tr>
</tbody>
</table>

Source: Washington Department of Revenue data.

1 Data contain adjusted amounts as of August 12, 2016. This includes adjusted data for the most current month, as well as any adjustment made to previous months. These figures do not include assessments.

2 These data come from 269 registered medical cannabis retailers who have reported retail sales, retail sales taxes and other excise taxes. There may be other medical cannabis sellers who have also properly remitted excise taxes, but who have not been identified as such by the Washington Department of Revenue.

3 Month of Sales Activity represents the month purchased from a retailer.

4 The retail sales tax and the state business and occupation tax (B&O tax) represent the major taxes paid by these taxpayers with other taxes being trivial.
<table>
<thead>
<tr>
<th>Month</th>
<th>Tax Revenue</th>
<th>Excise Revenue</th>
<th>Licenses &amp; Fees</th>
<th>Total Revenue</th>
<th>Sales Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feb-2015</td>
<td>15,915,997</td>
<td>1,034,540</td>
<td>119,232</td>
<td>371,655</td>
<td>0.070</td>
</tr>
<tr>
<td>Mar-2015</td>
<td>20,699,013</td>
<td>1,372,534</td>
<td>157,671</td>
<td>483,891</td>
<td>0.071</td>
</tr>
<tr>
<td>Apr-2015</td>
<td>23,790,464</td>
<td>1,546,380</td>
<td>185,190</td>
<td>561,581</td>
<td>0.070</td>
</tr>
<tr>
<td>May-2015</td>
<td>29,210,099</td>
<td>1,898,656</td>
<td>216,663</td>
<td>688,782</td>
<td>0.070</td>
</tr>
<tr>
<td>Jun-2015</td>
<td>31,931,700</td>
<td>2,075,561</td>
<td>243,550</td>
<td>751,860</td>
<td>0.070</td>
</tr>
</tbody>
</table>

**FY 2015 Totals** | **177,605,098** | **11,571,430** | **1,439,523** | **4,150,099** | **0.070** |

<table>
<thead>
<tr>
<th>Month</th>
<th>Tax Revenue</th>
<th>Excise Revenue</th>
<th>Licenses &amp; Fees</th>
<th>Total Revenue</th>
<th>Sales Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jul-2015</td>
<td>31,822,630</td>
<td>2,068,471</td>
<td>260,069</td>
<td>747,756</td>
<td>0.070</td>
</tr>
<tr>
<td>Aug-2015</td>
<td>34,976,812</td>
<td>2,273,493</td>
<td>287,489</td>
<td>824,443</td>
<td>0.070</td>
</tr>
<tr>
<td>Sep-2015</td>
<td>37,443,163</td>
<td>2,433,806</td>
<td>321,116</td>
<td>887,877</td>
<td>0.070</td>
</tr>
<tr>
<td>Oct-2015</td>
<td>37,533,721</td>
<td>2,439,692</td>
<td>321,989</td>
<td>904,438</td>
<td>0.070</td>
</tr>
<tr>
<td>Nov-2015</td>
<td>35,178,194</td>
<td>2,286,583</td>
<td>299,310</td>
<td>861,753</td>
<td>0.070</td>
</tr>
<tr>
<td>Dec-2015</td>
<td>39,657,987</td>
<td>2,587,874</td>
<td>336,215</td>
<td>972,630</td>
<td>0.070</td>
</tr>
<tr>
<td>Jan-2016</td>
<td>34,316,151</td>
<td>2,230,550</td>
<td>322,273</td>
<td>865,698</td>
<td>0.070</td>
</tr>
<tr>
<td>Feb-2016</td>
<td>36,490,730</td>
<td>2,371,897</td>
<td>327,316</td>
<td>882,626</td>
<td>0.070</td>
</tr>
<tr>
<td>Mar-2016</td>
<td>40,156,970</td>
<td>2,610,203</td>
<td>367,116</td>
<td>973,085</td>
<td>0.070</td>
</tr>
<tr>
<td>Apr-2016</td>
<td>42,666,562</td>
<td>2,773,327</td>
<td>386,681</td>
<td>1,051,718</td>
<td>0.070</td>
</tr>
<tr>
<td>May-2016</td>
<td>44,704,504</td>
<td>2,905,793</td>
<td>396,306</td>
<td>1,101,269</td>
<td>0.070</td>
</tr>
<tr>
<td>June-2016</td>
<td>46,709,764</td>
<td>3,036,135</td>
<td>424,332</td>
<td>1,155,568</td>
<td>0.070</td>
</tr>
</tbody>
</table>

**FY 2016 Totals** | **461,657,187** | **30,017,823** | **4,050,212** | **11,228,861** | **0.070** |

*Source: Washington Department of Revenue.*

1. Includes taxes paid by producers, processors, and retailers.

2. Data contain adjusted amounts as of August 12, 2016. This includes adjusted data for the most current month, as well as any adjustments made to previous months.

3. Month of Activity represents the month in which a producer and/or processor sold product to a retailer or a consumer purchased from a retailer.
\(^4\) The retail sales tax and the state business and occupation tax (B&O tax) represent the major taxes paid by these taxpayers with other taxes being trivial.

**Table 10.5. Washington adult-use cannabis sales revenue and excise tax for calendar year 2016**

<table>
<thead>
<tr>
<th>Month</th>
<th>Sales (Shelf Price)(^1)</th>
<th>Excise Tax Due</th>
<th>Implied Tax Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan-2016</td>
<td>77,962,150</td>
<td>14,643,661</td>
<td>0.2313</td>
</tr>
<tr>
<td>Feb-2016</td>
<td>81,081,943</td>
<td>15,659,135</td>
<td>0.2394</td>
</tr>
<tr>
<td>Mar-2016</td>
<td>91,340,974</td>
<td>17,356,284</td>
<td>0.2346</td>
</tr>
<tr>
<td>Apr-2016</td>
<td>95,063,638</td>
<td>18,156,968</td>
<td>0.2361</td>
</tr>
<tr>
<td>May-2016</td>
<td>95,171,114</td>
<td>18,149,800</td>
<td>0.2356</td>
</tr>
<tr>
<td>Jun-2016</td>
<td>106,762,250</td>
<td>20,012,239</td>
<td>0.2307</td>
</tr>
<tr>
<td>Jul-2016</td>
<td>121,494,961</td>
<td>23,547,274</td>
<td>0.2404</td>
</tr>
<tr>
<td>Aug-2016</td>
<td>134,635,800</td>
<td>25,003,323</td>
<td>0.2281</td>
</tr>
<tr>
<td>Sep-2016</td>
<td>139,621,291</td>
<td>26,002,289</td>
<td>0.2289</td>
</tr>
<tr>
<td>Oct-2016</td>
<td>141,031,391</td>
<td>25,623,780</td>
<td>0.2220</td>
</tr>
<tr>
<td>Nov-2016</td>
<td>136,778,617</td>
<td>24,828,041</td>
<td>0.2218</td>
</tr>
<tr>
<td>Dec-2016(^2)</td>
<td>21,960,275</td>
<td>4,397,984</td>
<td>0.2504</td>
</tr>
</tbody>
</table>

**Calendar Year 2016 Totals**

<table>
<thead>
<tr>
<th>Sales (Shelf Price)(^1)</th>
<th>Excise Tax Due</th>
<th>Implied Tax Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,242,904,404</td>
<td>233,380,778</td>
<td>0.2312</td>
</tr>
</tbody>
</table>

*Source: Washington Department of Revenue.*

\(^1\) Shelf price = sales price + tax

\(^2\) December 2016 includes sales as of December 12, 2016.

**10.4 Testing and the Oregon market**

On November 30, 2016, Whitney Economics LLC released a white paper on the two-month impact of new state testing standards on the Oregon cannabis market, whose results were widely reported in the Oregon and cannabis media. This is the most up-to-date empirical data set currently available on the economic effects of testing standards similar to those in the proposed regulation.
As for the results we quote earlier from ArcView and other private industry research firms and think-tanks that have published white papers or research reports, we must approach these data with caution due to the fact that they are compiled by analysts who have vested interests in the success of certain types of startup ventures over others.

Due to this and a wide array of other biases inherent to the questionnaire and response bias effects, we cannot rely on the Whitney survey to make economic estimates. Instead, we use it for rough comparison purposes only; and when we do reference the survey, we make additional qualifications about internal and external validity as necessary.

Legislative changes in Oregon may be poised to lessen some of these burdens through a dramatic policy shift. This situation has continued to develop as we have been compiling the SRIA, and in the last three months of 2016, policies have been fluctuating on a weekly or monthly basis. The following material is quoted from a report in the Oregonian report from December 15, 2016 (Harbarger, 2016):

Oregon this week continued to tweak its cannabis testing rules, hoping to ease a backlog and get flowers, oils and cannabis-infused snacks and treats into the medical and adult-use markets. The Oregon Health Authority issued yet another set of revised rules Wednesday that in essence reduce the number of required tests for potency, solvents and pesticides. The rules don’t change the type of tests required, though Jeff Rhoades, a senior adviser to Gov. Kate Brown, told a panel of lawmakers this week that the state is considering replacing the pesticide testing system in favor of a looser approach used in agricultural crops. Apples, grapes and hops, for instance, undergo random sampling for pesticides before they land on grocery store shelves.

"That is the approach we are looking to take eventually with cannabis," said Andre Ourso, manager of the medical cannabis program at the health authority. Under Oregon’s standards now, cannabis is subjected to frequent and comprehensive testing at multiple stages, from flower to oils. The state will re-examine its testing requirements early next year, Ourso said.

Norris Monson, CEO of Cultivated Industries, a Portland-based cannabis producer, processor and retailer, said he’s experienced long delays getting his products back from labs. He said he’s begun to spend more for expedited testing so he can move his flower and extracts more quickly. He figures he gets three to four calls a day from shops desperate for products. “A lot of them have nothing on their shelves anymore,” he said.
11. Brief historical review of alcohol control in the United States, with potential lessons for the impact of cannabis regulations

The United States has a long history of legislation designed to control alcohol consumption. From 1919 through 1934, the commercial production and distribution of beverage alcohol was illegal, and alcohol control is the subject of both the 18th and 21st Constitutional amendments (Pinney, 2005). Issues surrounding how to incorporate alcohol into society are not dissimilar to those facing state and local governments as they move to license, regulate and label medical cannabis in California (Mendelson, 2009). Beverage alcohol and medical cannabis are, of course, very different products, but issues of licensing, taxation, separation of producer from retailer, local control of production and sales and labeling are similar for beverage alcohol and medicinal cannabis. Alcohol is a heavily regulated product and such regulation adds costs that in turn effect both demand and supply. A review of alcohol regulation in the United States, and particularly in California, may have lessons for the regulation of medical cannabis.

11.1 Prohibition

National prohibition of alcohol was quite different from the criminalization of cannabis. The Eighteenth Amendment prohibited the production, distribution, and sale of most alcoholic beverages. However, it did not criminalize the possession or consumption of alcohol. Individuals with private cellars stocked with pre-Prohibition alcohol could legally consume those beverages at home and serve them to guests, although they could not legally transport the beverages to another location.

Nor were all forms of alcohol illegal to produce. The Volstead Act, which was the congressional legislation designed to enforce the 18th Amendment, allowed for the production of “non-intoxicating” fruit juices produced from apples and grapes. Up to 200 gallons of wine per family could legally be produced each year and consumed on-site and shared with guests. Unlike wine and hard cider, the production of beer and distilled spirits was illegal, and it was these two forms of beverage alcohol that were produced or smuggled into the country and sold.

Some of the legally-produced wine for home consumption was likely diverted into the illegal distribution system, just as some medical cannabis is probably resold to
individuals without medical cannabis cards, but the volume is unknown and wine was not the focus of government enforcement, which centered on distilled spirits (Mendelson, 2009; Pinney, 2005).

The legality of home wine production had a curious effect that may have parallels with medical cannabis, in that it spurred grape production. Because wine was the major legal form of alcohol during Prohibition, demand for wine, and for wine grapes, increased. Grapes that had sold for $30 per ton in 1919 were sold for $100 per ton the following year. The high prices sparked a winegrape planting boom, and winegrape acreage in California almost doubled from 98,500 acres in 1920 to 188,000 acres in 1930. The high prices only lasted for a few years, until quantity produced from the new plantings met quantity demanded, at which point winegrape prices fell to pre-Prohibition levels.

However, as is often the case in agricultural booms, the actual acreage of new vineyards exceeded the acreage needed to meet demand, and prices fell to $18 per ton by the late 1920s (USDA, 2014). Even after the repeal of Prohibition, low grape prices caused low profitability among growers, although not so low as to cause vineyard removals.

By 1938, low prices led the winegrape industry to mandate the distillation of 45% of the 1938 crop in an effort to stabilize winegrape prices (Pinney, 2005). Of course, winegrapes are perennial crops and, once planted, will produce for many years, whereas cannabis is an annual crop and growers can more quickly adjust supply relative to demand. However, investments in indoor growing facilities or land represent real costs that will only be recouped if used. Such investment may cause growers to continue to produce crop even at low prices. As growers respond to an increased demand that may follow the regularization of medical cannabis, limitations on the size of cannabis farms may result in an increased number of individual firms entering the industry, rather than the expansion of existing firms.

11.2 Repeal and taxation

Although by 1930 many Americans had concluded that Prohibition was a failure, more than a quarter of the states wished to continue some form of alcohol business ban and could thus block the Constitutional amendment that was necessary in order to repeal
the 18th Amendment. The political compromise that was reached in the form of the 21st amendment was that each state was given the right to control production and distribution of alcoholic beverages.

As a consequence, the United States effectively became 50 countries, each controlling alcohol in different ways and taxing at different rates. Some states, such as Oklahoma and Mississippi, maintained Prohibition for many years. Others, such as Utah and Pennsylvania, became what is termed “control states” and created a system in which the state was the importer, wholesaler and retailer of alcoholic beverages. Most states created a system in which private firms were licensed by the state to perform specific functions, such as production, wholesaling or retailing, generally separating retailing from other activities. This system, often referred to as the “three-tier” system, is addressed in greater detail later in this report (Mendelson, 2009).

One key point of State control was and is taxation. Each state taxes various alcoholic beverages at differing rates, often based on the concentration of the alcoholic beverage. In California, for example, distilled spirits under 100 proof (50% concentration) pay an excise tax of $3.30 per gallon; beer, wine and hard cider, on the other hand, pay $0.20 per gallon. The economic Law of Demand stipulates that all other things being equal, price increases will decrease the quantity consumed of a good. If price decreases, on the other hand, consumption will go up. In 1890, the Federal government eliminated the $0.90 a gallon excise tax on brandy used in fortifying wine for the production of dessert wines. Prior to 1890, fortified wine constituted about 5% of California’s total wine production. Without excise taxes, fortified wine prices fell and fortified wine quickly became the least expensive form of beverage alcohol available to consumers. By the early 20th century, fortified wine accounted for over 40% of California’s total wine production (West, 1935).

Taxes do change consumer behavior. There are numerous examples of consumers crossing state borders to purchase goods in a low-tax state. A 2011 study of consumer behavior in West Virginia concluded that consumers close to Kentucky and Ohio, whose tax rates on alcohol were lower than those of West Virginia, sometimes traveled out of state to purchase alcohol, resulting in lower sales and tax revenue for West Virginia counties adjoining Kentucky or Ohio (Nesbitt and King-Adzima, 2011). Conversely, the West Virginia counties bordering Virginia, whose alcohol tax rates are higher than
those of West Virginia, benefited from Virginia consumers crossing the border into West Virginia to purchase alcohol.

Anecdotal examples of consumers crossing borders to purchase alcohol and illegally smuggling their purchases back into their home state abound. In 2009 a Massachusetts legislator who had voted for a tax increase on alcohol was arrested smuggling alcohol purchased in New Hampshire, where alcohol taxes were lower (Henchman, 2009). Pennsylvania, which has a state monopoly on alcohol sales, and thus higher prices for similar products than in New Jersey or Delaware, has actively enforced searches of cars entering the state in an attempt to reduce liquor smuggling (Patch Staff, 2013).

Given observed behavior of consumers of alcohol, some cannabis consumers may travel from a high-cost area to a low-cost area for cannabis. Since this would occur intra-state, it would be legal from a state perspective, but it would reduce the volume of sales in the high-cost area. These effects may be considered by municipalities and counties when setting local requirements for cannabis licensing, but it is of course impossible for us or for the Bureau to predict the future actions of local municipalities with respect to the taxation of cannabis.

11.3 Three-tier distribution

Prior to Prohibition, a major concern of temperance advocates was the so-called "tied house" where a producer or supplier also owned the retail establishment, generally a saloon. The concerns were that vertical integration reduced alcohol prices, thus encouraging consumption, and that vertical integration tended to create large-scale enterprises that dominated independent retailers. Mendelson (2009) reports that by 1900, perhaps 80 percent of saloons in the United States were owned by brewers or distillers. Following the repeal of Prohibition, the Federal government and most states adopted what were called "tied-house" laws, which prohibited a supplier or wholesaler from also being a retailer. Although the original issue had been with on-sale establishments such as saloons or bars, most tied-house laws enacted after Prohibition included off-sale retail stores as well.

States differ in how rigorously they apply separation of licenses. Some states separate each tier and restrict the number of licenses that can be owned by a single entity. Colorado, for example, only allows one license per individual or company. Colorado
requires an importer’s license for companies bringing alcohol into the state. The importer pays state excise taxes and can only sell to a wholesaler. The wholesaler buys product from in-state producers or from importers and can only sell to retailers. Colorado retailers may only buy from wholesalers, can sell only to consumers and can only hold a retail license for one location—thus Whole Foods can sell wine and beer at only one of its supermarkets in the state. Colorado’s restrictions on license ownership are unusually severe, but most other states attempt to separate production from distribution and retail (Lapsley, Alston and Sambucci, 2016).

Other states use pricing mechanisms in addition to the three-tier system to control prices and availability of alcoholic beverages. Some use “price posting” in which the producer or importer posts with the state agency minimum prices at which the product can be sold at wholesale, thus eliminating volume discounts to retailers.

Ohio, for example, requires that suppliers publicly “post” their price to wholesalers in a document filed with the Ohio Division of Liquor Control. Under Ohio law, wholesalers and retailers must use minimum markups, thus assuring that no discounts for volume purchases by retailers are allowed and that retailers will sell the same good for the same price across the state. The general rationale for such systems is that no single retailer or wholesaler can dominate or control the marketplace (Mendelson, 2009). The practical result is that Ohio consumers pay higher prices than in neighboring states (Conlon and Rao, 2015).

Until 1980, California had a similar system of price posting for wine, which was overturned by the California Court of Appeals in the Midcal-Aluminum decision (Mendelson, 2009). Alcoholic beverage retailing changed dramatically in California following the 1980 decision as firms such as Liquor Barn appeared on the California retail scene, offering lower prices and wider selections.

California generally uses the three-tier system, but, as the dominant U.S. producer of wine, has allowed wineries special privileges under the California Winegrower license since Repeal. The Winegrower license combines the rights found in several different licenses. A holder of a Winegrower license can crush and ferment grapes, produce wine, buy and sell bulk wine, import and export bulk and bottled wine, sell wine to wholesalers and retailers in state, sell its produced wine directly to consumers either at the licensed facility or via direct shipping, pour wine for consumers, and charge for the
pour—but cannot own a retail establishment that sells alcoholic beverages produced by other manufacturers. Thus the holder of a California Winegrower license can act as a producer, importer, wholesaler, retailer, and bar, but is limited to only being able to sell its own products.

One of the stated goals of the three-tier system and tied-house laws was to prevent a single firm from dominating alcohol sales. In 2014, there were 4,286 licensed wineries in California. But most production and California sales was made by the three largest wine firms: Gallo, Constellation, and the Wine Group, which collectively account for approximately 50% of U.S. sales. The top ten U.S. producers account for approximately 80% of all production and imports. Similar consolidation has occurred at the wholesale level, where the top 5 national wholesalers accounted for more than 50% of all sales by value in 2014.

The average small winery is quite small, producing perhaps 5,000 gallons of wine (Lapsley, Alston and Sambucci, 2016). Small wineries generally have difficulty in acquiring three-tier distribution, and many survive partly on the strength of direct sales to consumers who visit their winery or join their wine clubs. For these firms, the provision in the California Winegrower’s license that allows direct sales to consumers is key to business success. In retrospect, there seems to be little data to indicate that tied-house laws and three-tier distribution have limited producer or retail consolidation. One consistent pattern is that in states in which retailers cannot purchase directly from producers or where price posting is maintained, consumers do pay higher prices (Conlon and Rao, 2015).

11.4 Local option and licensing

Although some states allow so-called “local option” at the county or city level for the retailing of alcoholic beverages, local option for alcohol retailing has not been allowed in California since Repeal. However, California has, in a sense, allowed de facto local option for medical cannabis, as the proposed regulations do not allow applicants to obtain state licenses until they have first been granted the permission to operate by their local counties or municipalities. Local option allows individual communities to decide whether or not they wish to allow cannabis cultivation and retailing in their county or city, but it also creates additional regulations and costs for firms, which should result in higher prices than if statewide regulations only are applied.
For a medical cannabis user located in a “dry” city or county, local option may also add cost in time and travel expense for the individual to visit a dispensary in a community where sales are allowed. 34 states currently allow local option at the county level for alcohol control, and it is estimated that approximately ten percent of counties, mostly in the Midwest and the South, ban the sale of alcohol. However, the general trend seems to be toward allowing alcohol sales. A 2014 study of 152 dry counties in the South and Midwest showed 40 changes in local option elections during the period from 1994-2001, all moving toward allowing sale of alcoholic beverages (Billings, 2014).

Given the local option for medical cannabis sales, the lack of clear state-wide guidelines for issuing cultivation and dispensary permits may create complexities for firms. The California Department of Alcoholic Beverage Control was created by a State Amendment in 1954, taking control of licensing from the State Board of Equalization, members of which had engaged in “selling” of licenses (California, 2005). The California Alcoholic Beverage Control Board’s system of retail licensing linked to population density and type of license offers an objective and fair way to license retailers, while still considering local opinions.

11.5 Testing and labeling

Testing for alcohol concentration in wine is straightforward, relatively inexpensive, and easily performed in a winery laboratory. Federal law requires that wineries have some means to determine alcohol concentration, and the typical instrument is an ebulliometer, a device that calculates alcohol concentration of a liquid by measuring the liquid’s boiling point relative to the boiling point of water. Ebulliometers cost about $1,000 and the test takes perhaps 10 minutes.

Two of the main reasons that the Federal government requires producers to test alcohol concentration in wine are that (1) wine is taxed differently depending upon alcohol concentration; and (2) wine labels must state alcohol concentration within the range of plus or minus 1.5% of observed alcohol. The testing does not need to be performed by an accredited third-party laboratory, and the process does not add appreciably to producer cost. The only check on label accuracy is performed by the Federal Tax and Trade Bureau (TTB) of the Department of Treasury, which conducts random product integrity audits that include testing of alcohol concentration.
Generally speaking, the incidence of label fraud with regard to state alcohol seems quite low for wine. Alston (2015) compared more than 91,000 alcohol label claims with alcohol levels analyzed by the Liquor Control Board of Ontario and found that the average actual alcohol concentration was 13.30% while the average alcohol content reported on the label was 13.16%.

Wine labels have evolved significantly from 1934, when a wine label might simply bear the name of the bottler, a semi-generic description of type such as “California Burgundy” or “New York Champagne,” and a statement of alcoholic content. Today, most wines are labeled with the name of the grape variety and the location of where the grapes were grown. Such labeling was made possible by the TTB, which issued new labeling regulations in response to consumer demand for more information.

Under the 1978 regulations, wines can carry a varietal designation if at least 75% of the wine was produced from the named grape variety. Wines may carry a geo-political designation, such as “Napa County,” if 75% of the grapes came from the named geo-political region. The 1978 regulations also allowed the creation of “American Vineyard Appellations” (AVAs). AVAs can be large, covering several states, or very small, nestled within a county. “Napa Valley” is probably the best known AVA (Lapsley, 1996). For a wine to bear an AVA on its label, 85% of the grapes must come from the named AVA.

Appellation has become an important factor in price and profitability for wine grapes, with the location of production being more important economically than the variety. Using Cabernet Sauvignon as an example, the average price for Cabernet from Fresno was under $500 per ton, while the average price of the same variety grown in Napa was over $5,000 a ton—an order-of-magnitude difference. Such factors should be considered in greater depth if the proposed regulations are eventually extended to include rules governing location-of-origin labeling.

11.6 Conclusions

The commercial production of alcohol was been banned from 1919 to 1934, and it has taken decades since Repeal to determine how alcohol should be assimilated into American society and what levels of control are necessary. Indeed, the discussion of the place of alcohol is still debated and the types and levels of control and taxation vary from state to state, and within state. The regulation of medical cannabis is still very
much in its infancy, but lessons may be learned by examining how alcohol production, distribution, and sales have evolved in California and other states.

12. Health, safety, community, and environmental benefits

12.1 Potential medical benefits of medical cannabis

Clinical trials on the benefits of medical cannabis find mixed results (Grant et al. 2012; Crippa et al. 2009; Wang et al. 2008). Medical cannabis may be an option for treating certain conditions, such as pain or nausea. Part of the reason cannabis works to relieve pain and quell nausea is that, in some people, it is reported to improve mood and/or act as a sedative. Grant et al. (2012) observes that medical cannabis may be effective in the treatment of psychiatric disorders or neuropathic pain.

Some findings in the medical literature suggest that using cannabis carries psychiatric risks including addiction, anxiety, and psychosis, while other findings suggest that cannabis is an effective treatment for those same conditions. In general, the literature is sparse, especially in top-tier scientific journals. In this SRIA, we do not attempt to evaluate or compare the relative technical merits of conflicting medical opinions in an area of neuropsychiatric research that is still in its early stages of development.

12.2 Product safety for medical users

Product safety may be one of the most important benefits of legalizing and regulating medical cannabis. Pesticide use in agriculture is common, but pesticides and pesticide residues are regulated. Allowable pesticides and residue levels on food crops are restricted by the U.S. Environmental Protection Agency, and the monitoring of the levels of residues are carried out by the Federal Drug Agency and U.S. Department of Agriculture. However, pesticide use in medical cannabis cultivation is not regulated. There are no approved pesticides or application limits established for use on cannabis crops.

Cannabis cigarettes and other common smoking devices often do not include filtration mechanisms, which may be likely to increase the intake of pesticide residues compared with tobacco smoking. Sullivan et al. (2013) investigated the presence of chemical residues on cannabis and the transmission of those residues into the user, and
evaluated the presence and extent of 10 different chemical residues using three different smoking devices. Sullivan et al. observed differences between the smoking devices, but they found that the portion of pesticide recovery was generally high enough to be a serious concern (over 50% of residues except in a water pipe with filters).

Given that medical cannabis is intended for consumption by medical patients, the intake of toxic substances may cause further health complications for medical users. Sullivan et al. (2013) also suggests that chemical residues found in cannabis may be the result of obtaining the cannabis products from unregulated product supply chains.

Under the legalization and regulation of the medical cannabis market, product testing is an important part of the governance system. A well-executed regulatory approach will help reduce the public health and safety risks that may arise from pesticide exposure or other forms of contamination.

### 12.3 Benefits to community residents

As is detailed in Chapters 7 and 8, our simulations predict that a regulated medical cannabis market is likely to reduce the size of the illegal market. A diminished illegal market will benefit California residents and improve their overall quality of life. The benefits from a reduction in illegal cannabis transactions will be potentially more explicit for California residents residing in urban low-income areas where drug dealing is more widespread. However, the magnitude of potential effects depends on the substitution effects between medicinal and illegal cannabis, which in part also depends on how the actual regulations are administered. The greater the extent to which regulations are able to incite previously illegal medical buyers to migrate into the legal medical market, the greater the reduction in the size of the illegal market and the greater the benefits to California residents.

### 12.4 Environmental effects

The potential environmental impacts of regulated cannabis can be discussed relative to the possible environmental impacts of unregulated cannabis.
It has been reported that unregulated cannabis has been cultivated in national parks and forests and associated with illegal deforestation (Caulkins 2010; National Drug Intelligence Center 2009). Unfortunately, there are no hard data on the extent of cannabis cultivation on public land. However, it is logical to expect that the current level of encroachment and resulting environmental damage on public lands could be greatly diminished or eliminated if regulation shifted cultivation to privately owned land. Private ownership of land used for cannabis cultivation acts as an incentive to preserve the land quality and maintain the long-term productivity.

Illegal outdoor cannabis cultivation sites may have harmful impacts on the environment. Illegal cannabis cultivation is associated with illegally diverted water, soil contamination, the presence of hazardous wastes, and the use of banned fertilizers and pesticides (Drug Enforcement Administration 2016; Wilkey 2013). The Drug Enforcement Administration (DEA) reports that rodenticide and insecticide toxicants that are detrimental to wildlife are frequently discovered on unregulated cannabis cultivation sites (DEA 2016). The DEA also reports that over 110,000 acres of land in California have been destroyed since 2006 due to fires associated with unregulated cannabis cultivation, costing taxpayers more than $55 million.

A significant share of cannabis is cultivated indoors. Indoor cultivation is a carbon-intensive endeavor that consumes huge amounts of energy. Mills (2012) finds that cannabis energy use costs about $6 billion annually and that indoor cannabis production may account for 1% of the entire country’s electricity consumption.

Specific energy uses by indoor cultivation operations include high-intensity lighting, dehumidification to remove water vapor, space heating during non-illuminated periods and drying, preheating of irrigation water and ventilation and air-conditioning to remove waste heat (Mills 2012). Substantial energy inefficiencies arise from air cleaning, noise and odor suppression, and use of inefficient electric generators to avoid conspicuous utility bills. One-third of the energy used by indoor growing operations comes from the lighting; the rest is devoted to ventilation, heating, dehumidification, and air conditioning (Mills 2012; Bullis 2014).

One reason for the current proliferation of indoor cultivation operations is also that they are the more inconspicuous to authorities. Insofar as state regulation enables and compels cultivators to be openly licensed and monitored by state authorities, the risk-
reduction incentives to run warehouse growing operations in situations where they are less efficient are eliminated. Thus regulation may further push investment in legal cannabis production toward more efficient greenhouse operations that use less energy inputs. This effect will likely by amplified by the increased availability of investors willing to participate in capital-intensive projects like greenhouse construction. Of course, these cultivation impacts are not the direct focus of the analysis in this appendix.

The nexus of movement toward greenhouse cultivation resulting from the proposed regulations is likely to reduce the negative environmental impact of indoor artificial-light cultivation, as well as reducing carbon emissions and more efficiently allocating and thus conserving public resources such as water and farmland.

13. A primer on IMPLAN methodology

13.1 Introduction

The most common and widely accepted methodology for measuring the economic impacts of specific industries is input-output (I-O) analysis, a subset of a family of methods called social accounting models (Shaffer, et al. 2004; Hewings 1986).

Input-output models are helpful to describe an array of economic transactions between various sectors in a defined economy for a given period, typically one year. These models not only provide researchers with estimates of the scalar multipliers but also support a detailed decomposition of the multipliers.

Like any economic model, the one presented in this SRIA is an abstraction of the real world and depends on assumptions that may be imperfect. Studies that document the economic impact of industries or changes in industries seldom discuss these limitations.

Input-output models are used descriptively and analytically to demonstrate the relative importance of a business, industry, or sector, such as the California almond industry (Sumner et al. 2014, Sumner et. al. 2015), and to estimate the economic responses from alternative actions such as the establishment of a new regulatory structure for the California medical cannabis industry.
Input-output analysis is attractive in part because it provides fairly straightforward results. Another appeal of I-O analysis is that it uses multiplier effect to calculate the total impact, which is broader than simple direct effects.

### 13.2 Using IMPLAN to project economy-wide impacts from wholesale and retail industries

In I-O analysis, one common source of misleading impact estimation is the inclusion of the value of goods sold in sectors that serve as intermediaries between the producer and the consumer. Wholesale and retail are examples of sectors that work with margins, which are calculated as sales receipts less the cost of the goods sold, plus sales taxes and excise taxes that are collected by the trade establishment (Day et al., 2012).

To account for economic impacts of wholesale and retail properly, it is necessary to conduct the analysis considering only the margins of these sectors, and to model the value of goods sold as part of their production processes. In correctly applied margins, the direct effect is distributed among all contributing sectors to reflect each sector’s proportion of the total sales value. This not only correctly distributes the sales value, but also ensures the appropriate total effects on the region. Under this approach, separate impacts from production, transportation, wholesale, and retail can be added up, avoiding double counting of the value of the vertical chain between farm and end consumer.

Running impact analysis using margins is often applied for various settings including vineyards and wine (Michaud et al. 2016), retail sales (Sullivan et al. 2012), and food (Jablonski et al. 2016). Crompton et al. (2015) discusses double counting and other issues involved in conducting impact analyses.

### 13.3 Input-output methodology

An I-O model offers a “snapshot” of the economy, detailing the sales and purchases of goods and services between all sectors of the economy for a given period of time within a conceptual framework derived from economic theory. The activities of all economic agents (industry, government, households) are divided into a specified number of production sectors.
The transactions between the sectors are measured in terms of dollars and segmented into two broad categories: non-basic, which includes transactions between local industries, households and other institutions; and basic, which includes transactions between industries, households, and other institutions outside the economy being modeled (i.e., imports and exports). One can think of an I-O model as a large "spreadsheet" of the economy where columns represents buying agents in the economy.

These agents include industries within the economy buying inputs into their production processes; households and governments purchasing goods and services; and industries, households, and governments that are located outside the region of analysis. The last group represents imports into the economy.

Economic agents can import goods and services into the regional economy for two reasons. First, the good or service might not be available and must be imported. Second, local firms might produce or supply the imported good or service, but the local prices or specifications might not meet the needs of the purchasing economic agents. The columns represent economic demand. The rows of the “spreadsheet” represent selling agents in the economy or supply. These agents include industries selling goods and services to other industries; and households, governments, and consumers outside the region of analysis. The latter group represents exports out of the economy. Households that sell labor to firms are also included as sellers in the economy.

A key assumption in the construction and application of input-output modeling is that supply equals demand. In the framework of the “spreadsheet of the economy” outlined above, the row total (supply or industry revenue) for any particular industry equals the column total (demand or expenditures): the “spreadsheet of the economy” must be balanced. This framework enables analysis of how changes in one part of the economy affect the whole of the economy.

In this analysis, for example, the introduction of regulations to the medical cannabis industry might increase demand for cannabis products. To meet this new, higher level of demand, cannabis supply must increase. Increasing production requires the purchase of additional flowers, the purchase of additional equipment from manufacturing, purchase of additional professional services, and/or more use of labor.
These other sectors must also increase production, and their corresponding inputs, to meet the new level of demand created by an increase in manufactured cannabis products. The new labor hired has higher levels of income, part of which is in turn spent in the regional economy. The increased demand for cannabis products creates a ripple or “multiplier” effect that can thus be measured across the whole economy and applied to the impact assessment.

13.4 Input-output multipliers

In the input-output model “spreadsheet of the economy,” any change ripples across the entire economy. By manipulating the empirical I-O model, it is possible to compute a unique multiplier for each sector in the economy.

These multipliers provide insight in the analysis of policy regulations of the California medical cannabis industry and are used to estimate the economic impact of alternative regulatory policies to the economy. In addition, the multipliers can identify the degree of structural interdependence between the medical cannabis industry and the rest of the economy. The sector output multiplier described here is among the simplest input-output multipliers available. By employing a series of fixed ratios from the input-output model, researchers can create a set of multipliers ranging from output to employment multipliers, as shown in Table 13.1.

The income multiplier represents a change in total income (employee compensation plus proprietary income) for every dollar change in output in any given sector. The value-added multiplier measures change in total income and profit minus business taxes for every dollar in additional output by the sector. The employment multiplier represents the total change in employment resulting from the change in output in any given sector. Thus, changes in economic activity can be estimated in four ways.
Table 13.1. Understanding multipliers

<table>
<thead>
<tr>
<th>Type</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Output multiplier</td>
<td>The output multiplier for an industry measures the sum of direct and indirect requirements from all sectors needed to deliver an additional dollar-unit of output of that industry to final demand.</td>
</tr>
<tr>
<td>Income multiplier</td>
<td>The income multiplier measures the total change in income throughout the economy from a dollar-unit change in final demand for any given sector.</td>
</tr>
<tr>
<td>Value added multiplier</td>
<td>The value added multiplier measures the total change in labor income and profit minus business taxes throughout the economy from a dollar-unit change in final demand for any given sector.</td>
</tr>
<tr>
<td>Employment multiplier</td>
<td>The employment multiplier measures the total change in employment due to a one-unit change in the employed labor force of a particular sector.</td>
</tr>
</tbody>
</table>

13.5 Initial, indirect, and induced effects

Construction of the multipliers allows us to decompose the multiplier effect into three parts: (1) the direct effects; (2) the indirect effects; and (3) the induced effects. Direct effects represent the initial change in the industry in question (e.g., in the industry itself). Indirect effects are changes in inter-industry transactions when supplying industries respond to increased demands from the directly affected industries (e.g., impacts from non-wage expenditures). Induced effects reflect changes in local spending that result from income changes in the directly and indirectly affected industry sectors (e.g., impacts from wage expenditures).

The initial effect is associated with the scenario that creates the impact on the economy. In the medical cannabis example, this is the increase in medical cannabis sales. To produce the additional output, the firm or industry must purchase additional inputs.
The inputs take two forms: purchases from other businesses, and labor. Purchases from other businesses creates the indirect effect. Labor creates the induced effect. For a particular producing industry, multipliers estimate the three components of total change within the region of interest.

Comparing and contrasting the indirect and induced effects can offer important insights. Under the input-output framework assumptions, industries that are more labor-intensive will tend to have larger induced effects and smaller indirect effects. Industries that tend to pay higher wages and salaries will also tend to have larger induced effects. Decomposing the multiplier into its induced and indirect effects can provide a better understanding of the industry under examination and its relationship to the larger economy.

Although input-output analysis is a useful economic tool for examining the impacts on an economy from changes in a particular industry, it does have some limitations in its assumptions. For example, I-O analysis assumes that production technology and returns to scale are constant. In other words, production technology does not vary across industries and does not evolve. These assumptions lead to the model being static. There is no allowing for adjustments due to advancements in technology or industry practices.

### 13.6 Modeling system

The input-output modeling system used in this study is IMPLAN (Impact M for Planning), originally developed by the USDA Forest Service. A product of the Rural Development Act of 1972, IMPLAN is a system of county-level secondary data input-output models designed to meet the mandated need for accurate, timely economic impact projections of alternative uses of U.S. public forest resources. IMPLAN is now operated by the Minnesota IMPLAN Group (MIG).

At the heart of the IMPLAN model is a national input-output dollar flow table called the Social Accounting Matrix (SAM). Unlike other static input-output models, which only measure the purchasing relationships between industry and household sectors, a SAM is an organized matrix representation of all transactions and transfers between different production activities, factors of production, and institutions (households,
corporate sector, and government) within the economy and with respect to the rest of the world.

A SAM is thus a comprehensive accounting framework within which the full circular flow of income—from production to factor incomes to household income to household consumption and back to production—is captured. All the transactions in the economy are presented in the form of a matrix in a SAM. Each row of the SAM gives receipts of an account, and the column gives the expenditure. Using the SAM allows IMPLAN to model transfer payments such as unemployment insurance.

Another advantage of the IMPLAN system is its design allows users the ability to alter the underlying structure of the data, the model, or means of assessing impact. The combination of the detailed database, flexibility in application, and open-access philosophy has made IMPLAN one of the most widely used and accepted economic impact modeling systems in the United States. To assess the economic impact of medical cannabis segments, we employed IMPLAN 2014 at the county level using the most recently available IMPLAN database.
Cited references and other consulted materials


Budwig, J., 2011. The Potential Economic Impact to Humboldt County if Marijuana is Legalized. The Humboldt Institute for Interdisciplinary Marijuana Research. Lecture available at: https://www.youtube.com/watch?v=Z0Gxt0uPnBw.


City Attorney, City of Oakland. 2016. Correspondence with Oakland Public Safety Committee: Oakland Municipal Code Chapters 5.80 and 5.81.

City of Oakland, Public Safety Committee. 2016. Correspondence re: Amending Ordinances 5.80 and 5.81.

Colorado Department of Revenue, 2014. Market Size and Demand for Marijuana In Colorado. Available at: https://www.colorado.gov/pacific/sites/default/files/Market%20Size%20and%20Demand%20Study,%20July%2024%20%20%202014%5B1%5D.pdf


Marijuana Travels, 2016. Israel Available at: www.marijuanatravels.com/countries/isr


New Frontier: see “Arcview Market Research.”


National Survey on Drug Use and Health (NSDHA), 2013: see “U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality, 2013.”


PerfectPrice. 2016. In Which Cities are Dispensary Prices Most Expensive Compared to Street Prices. Available at: http://www.perfectprice.io/blog


Revenue Division (Bureau of Revenue and Financial Services), City of Portland, Oregon, 2014. Marijuana Tax Revenue Estimates.


State of California Office of Administrative Law. 2015. Correspondence re: SRIA.


West, C., 1935. Economic Aspects of the Wine Industry in the United States. Undated manuscript (circa 1935) written for the Farm Credit Administration


